

## Medical Control Board

Treatment Protocols

## for

# EMS System for Metropolitan Oklahoma City & Tulsa

Revised 5/10/2023





#### Preface

Patients for whom EMS is summoned, EMS professionals providing life-sustaining and life-saving care, EMS professionals supporting field care through dispatch, education, quality improvement, and administrative leadership, and EMS physicians supporting all aspects of EMS through clinical leadership all deserve the finest clinical treatment protocols available. This protocol set was developed in that exact spirit to achieve that exact mission.

While no single set of EMS protocols can prove exhaustive, this particular compilation of protocols reflects essential care for the wide spectrum of patient ages, conditions, and acuities encountered by EMS professionals in metropolitan Oklahoma City and Tulsa. For 2022, we continue to incorporate an analysis of the peer-reviewed, published medical research within the past year so that our protocols remain current and evidenced-based. This set reflects that even the research of note over the past 12 months doesn't mandate tangible changes at this time, though additional advances are certainly on the horizon. This 2022 set continues to include every protocol identified as essential by the National Association of State EMS Officials.

Protocols are sectioned in easy to anticipate groupings (e.g. airway, cardiac arrest, trauma) and are formatted for brevity whenever possible. When appropriate, flowchart algorithms are utilized for easy to read care directives. Extensive use of pictures and diagrams are included in procedural protocols to promote clarity of understanding and accuracy of performance. Scopes of practice by EMS certification/licensure are clearly designated and use of color coding by scope of practice is consistent throughout all protocols.

With the exception of non-traumatic cardiac arrest, wherein patient return of spontaneous circulation is most often dependent upon effective, immediate interventions on scene, transport should be initiated as soon as possible.

EMS professionals should never perform emergency medical care outside of their individual scope of practice established by professional medical training, certification/licensure, and as credentialed by the Medical Control Board/Office of the Medical Director. When encountering patient conditions requiring care unspecified in these protocols, seek appropriate direction from on-line medical control, always delivering care with prudence and reasonable regard for safety of the patient, peers, and the public.

When possible, medication alternatives are indicated in these protocols in light of current and anticipated future medication supply shortages affecting EMS systems throughout the United States.

The Medical Control Board/Office of the Medical Director protocols development team has taken exhaustive efforts in developing and reviewing these protocols for accuracy. Despite every human effort, unintended typographical errors may persist. EMS professionals are directed to always deliver care with the highest regard for patient safety and when questions arise to care directives, care sequences, and/or medication selections and dosages, answers should be sought via on-line medical control during real-time patient care and via the Chief Medical Officers/OMD personnel during protocol training and review events.

In addition to this "Reference Edition" of these protocols, a "Field Edition" can be found at the Medical Control Board/Office of the Medical Director website (www.okctulomd.com). The Field Edition excludes the extensive medical literature references organized by individual protocol that reflect the evidence-based medicine used in protocol development in an effort to make the field edition more usable as a real-time clinical care resource.

It is the sincere hope that these protocols will guide EMS professionals serving metropolitan Oklahoma City and Tulsa in achieving the best clinical outcome possible for each and every patient receiving their dedicated care.



## Index of Protocols



## SECTION 1 GENERAL ASSESSMENT & GENERAL SUPPORTIVE CARE

- 1A Medical General Assessment Adult & Pediatric
- 1B Trauma General Assessment Adult & Pediatric
- 1C General Supportive Care Adult & Pediatric
- 1D Trauma and Hypovolemic Shock Supportive Care Adult & Pediatric
- 1E Neonatal Resuscitation- Pediatric

#### SECTION 2 AIRWAY

- 2A Airway Assessment Adult & Pediatric
- 2B Airway Establishment/Obstruction Management Adult & Pediatric
- 2C Airway Suctioning Adult & Pediatric
- 2D Bag Valve Mask (BVM) Management Adult & Pediatric
- 2E Supraglottic Airways– Adult & Pediatric
- 2F Oral Intubation Adult
- 2G Medication Assisted Intubation Adult
- 2H Nasal Intubation Adult
- 2I Cricothyrotomy Adult
- 2J Confirmation of Endotracheal Airway Placement Adult & Pediatric
- 2K Stoma/Tracheostomy Management Adult & Pediatric

#### SECTION 3 PULMONARY/RESPIRATORY

- 3A Respiratory Arrest Adult & Pediatric
- 3B Dyspnea Uncertain Etiology Adult & Pediatric
- 3C Dyspnea Asthma Adult & Pediatric
- 3D Dyspnea Chronic Obstructive Pulmonary Disease (COPD) Adult
- 3E Dyspnea Congestive Heart Failure (CHF) Adult & Pediatric
- 3F Dyspnea Brief Resolve Unexplained Event (BRUE) Pediatric
- 3G Pulse Oximetry Adult & Pediatric
- 3H Waveform Capnography Adult & Pediatric
- 3I Oxygen Administration Adult & Pediatric
- 3J Nebulization Therapy Adult & Pediatric
- 3K Non-Invasive Positive Pressure Ventilation (NIPPV) Adult
- 3L Mechanical Ventilation Adult
- 3M Acute Dyspnea Croup Pediatric





## Index of Protocols

## SECTION 4 CARDIAC ARREST

- 4A Resuscitation (CPR) Adult & Pediatric
- 4B Resuscitation Team Roles Adult & Pediatric
- 4C Automated External Defibrillation (AED) Adult & Pediatric
- 4D Manual Defibrillation Adult & Pediatric
- 4E Double Sequential External Defibrillation Adult
- 4F Asystole– Adult & Pediatric
- 4G Ventricular Fibrillation/Pulseless Ventricular Tachycardia Adult & Pediatric
- 4H Pulseless Electrical Activity (PEA) Adult & Pediatric
- 4I Specific Causes of Cardiac Arrest Adult & Pediatric
- 4J Post Cardiac Arrest Treatment Adult & Pediatric
- 4K "Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation &Termination of Resuscitation – Adult & Pediatric
- 4L Intra-Arrest Wakefulness Adult
- 4M Active Compression Decompression CPR Adult
- 4N EleGARD Head UP CPR Adult

## SECTION 5 CARDIAC (NON-ARREST)

- 5A Chest Pain Uncertain Etiology Adult & Pediatric
- 5B Acquiring & Transmitting 12-Lead ECGs Adult & Pediatric
- 5C Acute Coronary Syndrome Adult
- 5D Bradycardia Adult & Pediatric
- 5E Transcutaneous Pacing Adult & Pediatric
- 5F Tachycardia Stable Adult & Pediatric
- 5G Tachycardia Unstable Adult & Pediatric
- 5H Synchronized Cardioversion Adult & Pediatric
- 51 Implantable Pacemaker Management Adult & Pediatric
- 5J Implantable Cardioverter/Defibrillator (ICD) Management Adult & Pediatric
- 5K Premature Ventricular Contractions Adult & Pediatric
- 5L Hypertensive Emergency Adult & Pediatric
- 5M Ventricular Assist Device (VAD) Management Adult
- 5N Intra-Aortic Balloon Pump (IABP) Monitoring Adult
- 50 Zoll Lifevest Wearable Defibrillator

#### SECTION 6 NEUROLOGIC/ALTERED MENTAL STATUS

- 6A Stroke Adult & Pediatric
- 6B Altered Mental Status Adult & Pediatric
- 6C Glucometry (Blood Glucose Determination)
- 6D Seizure Adult & Pediatric



## Index of Protocols



## SECTION 6 NEUROLOGIC/ALTERED MENTAL STATUS (CONTINUED)

- 6E Syncope Adult & Pediatric
- 6F Dystonic Reactions Adult & Pediatric

#### SECTION 7 PSYCHIATRIC/BEHAVIORAL DISORDERS

- 7A Behavioral Disorder Adult & Pediatric
- 7B Physical Restraint Adult & Pediatric
- 7C Chemical Restraint Adult & Pediatric
- 7D Emergency Mental Hold Issues Adult & Pediatric

#### SECTION 8 TOXICOLOGIC/POISONINGS

- 8A Poisonings General Management Adult & Pediatric
- 8B Toxidromes Adult & Pediatric
- 8C Oklahoma Poison Control Center Use
- 8D Acute Allergic Reactions Adult & Pediatric
- 8E Snakebites Pit Vipers (Rattlesnakes, Copperheads, & Mocassins) (Crotalinae Envenomation) – Adult & Pediatric
- 8F Bee/Wasp Stings & Fire Ant Bites (Hymenoptera Envenomation) – Adult & Pediatric
- 8G Hazardous Materials Response
- 8H Hydrofluoric Acid Adult & Pediatric

#### SECTION 9 MEDICAL

- 9A Abdominal Pain/Nausea/Vomiting/Diarrhea Adult & Pediatric
- 9B Sepsis Adult & Pediatric
- 9C Epistaxis Adult & Pediatric
- 9D Pain Management (Acute Onset & Chronic Type) Adult & Pediatric
- 9E Dialysis-Related Issues Adult & Pediatric





## Index of Protocols

## SECTION 9 MEDICAL (CONTINUED)

- 9F Infectious Disease Precaution Recommendations EMS Professionals
- 9G Post-Exposure Prophylaxis Recommendations Adult & Pediatric
- 9H Vascular Access Intravenous Adult & Pediatric
- 9I Vascular Access Intraosseous Adult & Pediatric
- 9J Indwelling Central Vascular Device Management Adult & Pediatric
- 9K Medication Administration Adult & Pediatric
  - 9Ka Intravenous/Intraosseous Adult & Pediatric
  - 9Kb Intramuscular/Subcutaneous– Adult & Pediatric
  - 9Kc Intranasal Adult & Pediatric
  - 9Kd Sublingual/Oral Adult & Pediatric
  - 9Ke Intraocular Adult & Pediatric
  - 9Kf Intravascular Infusion Management Adult & Pediatric
- 9L Nasogastric/Orogastric Tube- Adult
- 9M Suspected Abuse/Neglect Adult & Pediatric

#### SECTION 10 TRAUMA

- 10A Head/Neck/Spine Injury Adult & Pediatric
- 10B Eye Injury Adult & Pediatric
- 10C Dental Injury/Pain Adult & Pediatric
- 10D Chest/Abdomen/Pelvis Injury Adult & Pediatric
- 10E Needle Thoracostomy (Tension Pneumothorax Decompression) Adult & Pediatric
- 10F Chest Tube Monitoring Adult & Pediatric
- 10G Extremity/Amputation Injury Adult & Pediatric
- 10H Tourniquet Adult & Pediatric
- 10I Hemostatic Agents Adult & Pediatric
- 10J Compartment Syndrome Adult & Pediatric
- 10K Crush Injury Syndrome Adult & Pediatric
- 10L Burns Adult & Pediatric
- 10M Conductive Energy Weapon Related Management Adult & Pediatric
- 10N "Less Lethal" Weapon Related Management Adult & Pediatric
- 100 Splinting of Injuries Adult & Pediatric
  - 100a Spinal Motion Restriction Adult & Pediatric
  - 100b Extremity Adult & Pediatric
- 10P Blast Injury Adult & Pediatric
- 10Q Field Amputation





## Index of Protocols

## SECTION 11 ENVIRONMENTAL

- 11A Heat Illness Adult & Pediatric
- 11B Cold Illness/Injury Adult & Pediatric
- 11C Electrical/Lightning Injury Adult & Pediatric
- 11D Water Submersion Events Adult & Pediatric
- 11 E Heat Stroke Athletic Participants with Field Cooling Capabilities On-Site at Events

## SECTION 12 FIREGROUND-RELATED

- 12A Fireground Rehabilitation Concepts Adult
- 12B Smoke Inhalation Adult & Pediatric
- 12C Carbon Monoxide Adult & Pediatric
- 12D Hyperbaric Oxygen Therapy Considerations Adult & Pediatric
- 12E Cyanide Adult & Pediatric

## SECTION 13 OBSTETRIC/GYNECOLOGIC

- 13A Childbirth Routine
- 13B Childbirth Complicated
- 13C Vaginal Bleeding/Discharge Adult & Pediatric
- 13D Complications of Pregnancy Adult
- 13E Pelvic Pain Adult & Pediatric
- 13F Alleged Sexual Assault Adult & Pediatric

#### SECTION 14 RESPONSE, SCENE ISSUES & PATIENT TRANSPORTATION

- 14A Staging Considerations
- 14B Actions to Preserve Crime Scenes
- 14C Other Health Care Professionals on Scene
- 14D Informed Patient Consent/Refusal
- 14E On-Line Medical Control Physicians
- 14F Helicopter EMS (HEMS) Considerations
- 14G Patient Prioritization
- 14H Radio Report Communications
- 14I Interhospital Transfers
- 14J Scene Coordination





## Index of Protocols

## SECTION 15 MASS CASUALTY/DISASTER/TERRORIST EVENTS

- 15A Multiple Patient Scenes/Mass Casualty Event Concepts
- 15B Regional EMS System (REMSS) Activation Procedure
- 15C Chemical Weapons
- 15D ChemPack Deployment Activation Procedure
- 15E Nerve Agents
- 15F Biological Weapons
  - 15Fa Suspicious Powder Response Procedure
- 15G Radiological Weapons
- 15H Nuclear Weapons

#### SECTION 16 FORMULARY

- 16A Activated Charcoal
- 16B Adenosine (Adenocard®)
- 16C Albuterol (Proventil<sup>®</sup>, Ventolin<sup>®</sup>)
- 16D Amiodarone (Cordarone<sup>®</sup>, Nexterone<sup>®</sup>)
- 16E Aspirin
- 16F Atropine Sulfate
- 16G Calcium Chloride
- 16H Dextrose (50% as D50 and 25% as D25 and 10% as D10)
- 16I Diazepam (Valium<sup>®</sup>)
- 16J Diltiazem (Cardizem<sup>®</sup>)
- 16K Diphenhydramine (Benadryl<sup>®</sup>)
- 16L Dopamine (Intropin<sup>®</sup>)
- 16M DuoDote<sup>®</sup> Auto-Injector
- 16N Epinephrine 1:1,000 & 1:10,000
- 160 Epinephrine Auto-Injector (Epipen<sup>®</sup>, Auvi-Q<sup>®</sup>)
- 16P Etomidate (Amidate<sup>®</sup>)
- 16Q Fentanyl (Sublimaze<sup>®</sup>)
- 16R Glucagon
- 16S Glucose (Oral)
- 16T Haloperidol (Haldol<sup>®</sup>)



## Index of Protocols



## SECTION 16

## FORMULARY (CONTINUED)

- 16U Hydralazine (Apresoline<sup>®</sup>)
- 16V Hydromorphone (Dilaudid®)
- 16W Hydroxocobalamin (CyanoKit<sup>®</sup>)
- 16X Ipratropium Bromide (Atrovent<sup>®</sup>)
- 16Y Labetalol (Normodyne<sup>®</sup>, Trandate<sup>®</sup>)
- 16Z Lidocaine 2% Intravascular (Xylocaine<sup>®</sup>)
- 16AA Lidocaine Viscous Gel (Xylocaine<sup>®</sup>)
- 16BB Lorazepam (Ativan<sup>®</sup>)
- 16CC Magnesium Sulfate
- 16DD Methylprednisolone (Solu-Medrol<sup>®</sup>)
- 16EE Midazolam (Versed<sup>®</sup>)
- 16FF Morphine Sulfate
- 16GG Naloxone (Narcan<sup>®</sup>)
- 16HH Nitroglycerin Nitroglycerin (Nitrolingual®, Nitromist<sup>®</sup>, Nitrostat<sup>®</sup>, Nitroquick<sup>®</sup>, Tridil (IV Infusion), Nitro-Bid<sup>®</sup> Dermal)
- 16II Norepinephrine (Levophed<sup>®</sup>)
- 16JJ Ondansetron (Zofran<sup>®</sup>)
- 16KK Phenylephrine 2% (NeoSynephrine<sup>®</sup>)
- 16LL Pralidoxime Chloride (2-PAM)
- 16MM Sodium Bicarbonate
- 16NN Calcium Gluconate

#### SECTION 17 RESERVED FOR AGENCY SPECIFIC USE

- 17A MCB: Destination Determination
- 17B MCB: Table: Categorization of Hospitals
- 17C MCB: EMS Diversion from Hospitals
- 17D MCB: "No Fly Zones"
- 17E MCB: Advanced Airway Management: Pediatric Oral Intubation
- 17F MCB: Medication-Assisted Intubation Pediatric
- 17G MCB: Confirmation of Endotracheal Airway Placement Pediatric
- 17H MCB: Helmet Removal
- 17I MCB: Controlled Substance Handling & Documentation Field Paramedics
- 17J MCB: Seasonal Influenza Vaccine Administration
- 17K MCB: Tranexamic Acid (TXA) Formulary
- 17L MCB: Positive End Expiratory Pressure (PEEP)
- 17M MCB: Blood Sample Collection For Law Enforcement Adult & Pediatric
- 17N MCB: Interim Guidance for Covid-19 Vaccine Administration
- 170 MCB: Low Titer O+ Whole Blood (LTOWB) Metropolitan Oklahoma City





## Index of Protocols

## SECTION 18 RESERVED FOR AGENCY SPECIFIC USE – PILOT PROGRAMS/RESEARCH


## SECTION 19 APPENDICES

- 19A Approved Abbreviations
- 19B Oklahoma State Department of Health Communicable Disease Risk Exposure Report, OSDH - 207
- 19C Oklahoma Model Trauma Triage Algorithm, Adult & Pediatric
- 19D Sample Fireground Rehabilitation Policies Tulsa Fire Department; Oklahoma City Fire Department





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



In general, approach the assessment of medical (non-trauma) patients, in A-B-C order:

**Airway**: Evaluate the patency and mechanics of the airway. Is the patient able to oxygenate and ventilate? Rapid intervention may be required during the assessment phase if airway patency and protection is compromised.

**Breathing:** Expose the chest as required to accurately assess the mechanics of respiration (taking into account patient privacy/modesty if in public location). Note the rate, depth, and pattern of respirations and if any degree of respiratory distress or effort. Auscultate breath sounds bilaterally.

Liberally obtain pulse oximetry readings and in patients with respiratory difficulties, waveform capnography readings (if equipped, \*\*Mandatory use if the patient is intubated).

**Circulation:** The adequacy of a patient's circulation is best assessed first by evaluating their level of consciousness and mental status. Next assess the location, rate, and character of the pulse. Then check a blood pressure – preferably, manually for at least the first reading. Apply the cardiac monitor (if equipped) liberally.

Cardiac Arrest is an exception to the above order. Aggressively initiate chest compressions and search for shockable rhythms at the appropriate intervals per Section 4 protocols.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 1A: Medical General Assessment – Adult & Pediatric, cont.

Many treatment decisions regarding airway management involve calculating the adult patient's Glasgow Coma Scale score using the following table:

Eyes Open		Best Motor Response E		Best Verbal Response	
Spontaneously	4	Obeys verbal orders	6	Oriented, conversant	5
To command	3	Localizes painful stimuli	5	Disoriented, conversant	4
To pain	2	Withdraws	4	Inappropriate words	3
No response	1	Painful stimulus, flexion	3	Inappropriate sounds	2
		Painful stimulus, extension	2	No response	1
		No response	1		
				Maximum 15 points	

# After addressing the A-B-C order in most medical patients, including evaluating and addressing any life-threatening conditions, minimize scene time and initiate timely transport to an appropriate emergency department in any setting of a time-sensitive medical condition.

Complete a head-to-toe assessment of the patient if the patient is relatively medically stable. Obtain relevant history of past and current medical problems, medications, allergies, and physicians/hospitals used in care plans to help guide further assessment.

Reassess patients frequently, typically at least every 10 minutes, and more often if critical illness is discovered and being treated. In the situations of an unstable patient, vital signs should be assessed every 5 minutes, especially if hemodynamic changes are occurring.

Assess and treat per symptom or illness specific protocols that follow in this protocol set.

#### Pediatric ("Pediatric" equals less than 18 years of age for all protocols unless specified) Assessment Comments:

1. Pediatric respiratory distress may look just like adult respiratory distress, presenting with:

slowing respirations accessory muscle use nasal flaring retractions – intercostal or subcostal tachypnea mottling cyanosis pallor lethargy/listlessness irritability stridor grunting





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 1A: Medical General Assessment – Adult & Pediatric, cont.

2. Vital signs vary with age. In general, the younger the patient, the faster the respiratory rate, the faster the heart rate, and the lower the blood pressure:

AGE	HEART RATE (BPM)	RESP. RATE (BPM)	SYSTOLIC BP (mmHg)
Premature	100-190	40-60	1
Neonate	90-190	30-60	50-70
6 months	80-180	25-40	60-110
1 year	80-150	20-40	70-110
3-4 years	80-140	20-30	80-115
5-6 years	70-120	20-25	80-115
7-8 years	70-110	20-25	85-120
11-12 years	60-110	15-20	95-135

The average normal systolic BP can also be estimated by:  $80 + (2 \times age)$  in years. Lower limits of normal systolic BP can also be estimated by:  $70 + (2 \times age)$  in years.

3. The following table can be used to calculate Glasgow Coma Scale scores in pediatric patients, especially those under 4 years of age. Most pediatric patients above the age of 4 years will be able to be assessed for Glasgow Coma Scale scores using the adult table.


Points*	Best eye	Best verba	Best Motor	
6				obeys
5	-	smiles, oriented to sound, interacts	localizes pain	
-		Crying	Interaction	the second second second
4	spontaneous	consolable	inappropriate	withdraws to pain
3	to speech	inconsistently consolable	moaning	flexion (decorticate)
2	to pain	inconsolable	restless	extensor (decerebrate)
1	none	none	none	none

\* Range of total points: 3 (worst) to 15 (normal)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Before entering any trauma scene, ensure your personal safety. Do not attempt patient contact until hazards can be appropriately mitigated. In addition to scene safety, factor mechanisms of injury, number of patients, and special equipment/extrication needs.

All trauma patients should be assessed utilizing primary, secondary, and reassessment surveys.

The **primary survey** is to be conducted on all trauma patients. It is designed to rapidly identify lifethreatening or potentially life-threatening injuries. The primary survey should be completed within 2 minutes of patient contact. THE PRIMARY SURVEY IS ONLY INTERRUPTED FOR LIFE-THREATENING ARTERIAL BLEEDING, AIRWAY OBSTRUCTION, OR RESPIRATORY/CARDIAC ARREST. The following are the steps of the **primary survey**:

- 1) Manually stabilize the cervical spine while assessing the airway and level of consciousness.
- 2) Evaluate breathing present? rapid? normal? slow? shallow?
- 3) Evaluate circulation carotid and radial pulses? Control external hemorrhage.
- 4) Exam the head for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS").
- 5) Exam the neck for deformity, contusions, abrasions, penetrations, burns, lacerations, swelling ("DCAP-BLS"), or subcutaneous emphysema.
- 6) Exam the chest for deformity, contusions, abrasions, penetrations, burns, lacerations, swelling ("DCAP-BLS"), or paradoxical movement.
- 7) Auscultate the chest for breath sounds in the mid-axilla bilaterally present? equal?
- 8) Exam the abdomen and pelvis for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS").
- 9) Exam the extremities for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS"), and pulse, movement, sensation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## Protocol 1B: Trauma General Assessment – Adult & Pediatric, cont.

Primary survey interventions include airway management (See Section 2 Protocols – Airway), sealing open chest wounds, needle thoracostomy for suspected tension pneumothorax (See Protocol 10E – Needle Thoracostomy), oxygen administration and controlling any obvious external hemorrhage. Remember to expose the patient as needed to conduct an appropriate exam.

Any trauma patient with altered level of consciousness, abnormal respiration, abnormal circulation, or signs/conditions likely to lead to shock (distended abdomen, pelvic instability, bilateral femur fractures) should be rapidly immobilized and transported after completing the primary survey. These are "LOAD & GO" patients.

The **secondary survey** is always done enroute on critical patients. If no critical conditions are found in the primary survey, the secondary survey may be conducted on the scene and should be completed within 5 minutes after the primary survey is completed. The following are the steps of the **secondary survey**:

- 1) Obtain vital signs (pulse, respiratory rate, blood pressure, pulse oximetry)
- 2) Obtain history of traumatic event and pertinent patient medical history (allergies, medications, past illness/injury, last oral intake)
- 3) Head to toe exam look for "DCAP-BLS" in every body area. Calculate GCS score
- 4) Perform indicated bandaging and splinting

The **reassessment survey** is an abbreviated exam after interventions and done at least every five minutes for critical patients (and approximately every ten minutes for non-critical patients). The following are the steps of the **reassessment survey**:

- 1) Repeat the primary survey
- 2) Repeat vital signs
- 3) Repeat GCS score calculation
- 4) Check every intervention proper placement of intubation? Proper placement of IV/IO?
- 5) Check results of every intervention improved oxygenation/ventilation? Improved blood pressure?

Pediatric ("Pediatric" equals less than 18 years of age for all protocols unless specified) trauma assessment mirrors adult strategies above.




EMERGENCY MEDICINE

UNIVERSITY OF OKLAHOMA

**EMS SECTION** 

Approved 9/14/22, Effective 1/16/23, replaces all prior versions



dyspnea. Move and package the patient for transport with safety considerations for all involved.


3. Maximum pediatric medication dosing equals standard adult dosing.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 1D - TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE ADULT & PEDIATRIC




2. Maximum pediatric medication dosing equals standard adult dosing.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



In general, approach the resuscitation of the newborn or infant within the first 30 days of life focusing on basic life support interventions. Invasive, advanced procedures are rarely warranted and are rarely more effective than simple, yet important basic interventions.

**Warmth (Body Temperature Conservation):** Due to high surface to body weight ratios, the neonate rapidly loses body heat which can lead to respiratory and circulatory distress. Keep the neonate warm and minimize skin exposures unless absolutely warranted during care events.

**Airway**: Evaluate the patency and mechanics of the airway. Is the patient able to oxygenate and ventilate? Simple positioning intervention may be required during the assessment phase if airway patency and protection is compromised.

**Breathing:** Briefly expose the chest as required to accurately assess the mechanics of respiration. Note the rate, depth, and pattern of respirations and if any degree of respiratory distress or effort. Auscultate breath sounds bilaterally in the axilla to avoid confusing breath sounds from the other side of the chest. Gentle tactile stimulation (e.g. rubbing of the back, flicking the soles of the feet) may be required early in the assessment and often proves very effective in improving breathing activity.

Liberally obtain pulse oximetry readings and in patients with respiratory difficulties, waveform capnography readings (if equipped with neonatal sized equipment, \*\*Mandatory use if the patient is intubated).





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 1E: Neonatal Resuscitation – Pediatric, cont.**

**Circulation:** The adequacy of a neonate's circulation is best assessed first by evaluating their level of activity and general body warmth. Next assess the rate and character of the brachial pulse. Pulse rates less than 100/minute are abnormal and a cause for concern of impending cardiovascular collapse. Pulse rates less than 60/minute indicate cardiovascular collapse and chest compressions should be initiated.

Cardiac Arrest is an exception to the above order. Aggressively initiate chest compressions, while still conserving warmth and initiating supplemental oxygenation and ventilation.

# After addressing the Warmth-A-B-C order in most neonates, including evaluating and addressing any life-threatening conditions, minimize scene time and initiate timely transport to an appropriate emergency department.

Reassess patients frequently, typically at least every 5 minutes, and more often if critical illness is discovered and being treated. Assess and treat per symptom or illness specific protocols.

#### **Neonatal Assessment Comments:**

1.	1. Respiratory distress may or may not look just like adult respiratory distress, presenting with:				
	slowing or increasing respirations	cyanosis			
	accessory muscle use	pallor			
	nasal flaring	lethargy/listlessness			
	retractions – intercostal or subcostal	grunting			
	tachypnea	mottling			

- 2. Vital signs vary with age. In general, the younger the patient, the faster the respiratory rate, the faster the heart rate, and the lower the blood pressure. In most neonates, blood pressure is difficult to measure and often unreliable in attempts to do so in the field. Rather than focus extended time on blood pressure measurements, evaluate perfusion by overall activity level, skin temperature/color, capillary refill (normally < 3 seconds), and muscular tone.</p>
- 3. Use APGAR scoring at 1 and 5 minutes post-birth, continue every 5 mins if APGAR < 7:


APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 2A – AIRWAY ASSESSMENT ADULT & PEDIATRIC



The following principles should be followed to allow optimum assessment and care of the airway without unnecessary intervention.

- 1. Use the least invasive method of airway management appropriate to the patient.
- 2. Use a method of airway management with which you are procedurally comfortable.
- 3. Use meticulous suctioning to keep the airway clear of debris.
- 4. Monitor continuously to be sure that oxygenation/ventilation is as effective as intended and as needed.
- 5. Understand the difference between these various aspects of airway management:
  - A. Patency: how open and clear is the airway, free of foreign substances, blood, vomitus, and tongue obstruction?
  - B. Ventilation: the amount of air the patient is able to inhale and exhale in a given time, promoting exhalation of carbon dioxide. Use waveform capnography if equipped.
  - C. Oxygenation: the amount of oxygen the patient is able to convey to the circulation for tissue/organ perfusion. Use pulse oximetry when available.

Although the dynamics of EMS care often dictate rapid decisions in critical skill performance, assessment for difficult airway characteristics should precede intubation attempt(s). Several methods of evaluating airway-related anatomy exist. One commonly used mnemonic in emergency airway care is "LEMON", which stands for:

Look externally (Heavy perioral facial hair? Mis-shaped or missing dentition?)

**E**valuate 3-3-2 (Can at least three fingers be placed in the vertical axis of the mouth? Can at least three fingers be placed in the space between the chin apex and the top of the neck? Can at least 2 fingers fit between the top of thyroid cartilage and the top of the neck? Three "yes" answers predicts lesser anatomical difficulty in establishing intubation.)

**M**allampati scoring – see Images A and B (View of posterior pharyngeal structures correlated to anticipated laryngeal view.)

**O**bstructions (Oral or upper neck masses? Large tongue?)

Neck mobility (Unable to assess if concerns of cervical spine injury.)






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 2A - Airway Assessment - Adult & Pediatric, cont.

Mallampati Scoring:



The LEMON criteria, including Mallampati scoring, is easiest to apply to compliant patients without acute respiratory distress and without need for emergent intubation. By nature, these are NOT the patients that EMS professionals are tasked with managing. However, the concepts expressed in these criteria can help in predicting more difficult invasive airway management. EMS professionals should always work in developing "Plan B" approaches in airway management to anticipate and be capable of effective care when facing obstacles to usually successful airway management methods.

The following directives guide the approach to typical medical and trauma-related airway problems. They assume the treating EMS professional is skilled in the various procedures appropriate for their scope of practice. Advanced procedures should only be attempted if clinically indicated after less invasive measures fail or are futile to attempt. Individual cases may require modification of these protocols. Airway management decisions and actions should always be thoroughly documented in the patient care report.

Medical Respiratory Arrest:

- 1. Open airway using head tilt-chin lift.
- 2. Oxygenate/ventilate with Bag-Valve-Mask (BVM) with supplemental O<sub>2</sub> near 100% FiO<sub>2</sub>.
- 3. Insert nasopharyngeal airway(s) and/or oropharyngeal airway as needed for patency.
- 4. Suction as needed.
- Intubate per applicable protocols. If unable to successfully intubate or intubation is not within the scope of practice of available EMS professionals, place supraglottic airway per Protocol 2E – Supraglottic Airways.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 2A - Airway Assessment - Adult & Pediatric, cont.

Trauma Respiratory Arrest:

- 1. Open airway using jaw thrust maneuver with another EMS professional applying in-line stabilization of cervical spine.
- 2. Oxygenate/ventilate with Bag-Valve-Mask (BVM) with supplemental O<sub>2</sub> near 100% FiO<sub>2</sub>.
- 3. Insert nasopharyngeal airway(s) only if no head/facial trauma and/or oropharyngeal airway as needed for patency.
- 4. Suction as needed.
- Intubate per applicable protocols. If unable to successfully intubate or intubation is not within the scope of practice of available EMS professionals, place supraglottic airway per Protocol 2E – Supraglottic Airways.

Medical Respiratory Insufficiency (Oxygenation, Ventilation, or Both):

- 1. Establish patency either spontaneously by patient, patient positioning, or with nasopharyngeal airway(s).
- 2. Suction as needed.
- 3. Apply supplemental O<sub>2</sub> by nasal cannula, non-rebreather mask, BVM, or if EMT license or higher, NIPPV if patient condition indicates need for oxygenation assist.
- 4. Assist ventilations by BVM, or if EMT license or higher, NIPPV if patient condition indicates need for ventilation assist.
- 5. If actions in steps 1-4 do not achieve needed oxygenation/ventilation AND if licensed as EMT-I85 or higher, intubate.

Trauma Respiratory Insufficiency (Oxygenation, Ventilation, or Both):


- 1. Establish patency either spontaneously by patient, patient positioning, or if no head/facial trauma with nasopharyngeal airway(s).
- 2. Suction as needed.
- 3. Apply supplemental O<sub>2</sub> by nasal cannula, non-rebreather mask, BVM as patient condition indicates need for oxygenation assist.
- 4. Assist ventilations by BVM as patient condition indicates need for ventilation assist.
- 5. If actions in steps 1-4 do not achieve needed oxygenation/ventilation AND if licensed as EMT-I85 or higher, intubate.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 2B - AIRWAY ESTABLISHMENT / OBSTRUCTION MANAGEMENT ADULT & PEDIATRIC








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

2C - AIRWAY SUCTIONING ADULT & PEDIATRIC



#### Indications:

- 1. Trauma to the face and/or upper airway, with potential or actual airway obstruction.
- 2. Vomitus, food boluses or other liquid foreign material in airway.
- 3. Excess secretions or pulmonary edema fluid in upper airway (or lungs with endotracheal tube in place).
- 4. Amniotic fluid in naso/oropharynx of newborn with obvious obstruction to spontaneous breathing or who require positive-pressure ventilation.
- 5. Meconium in naso/oropharynx of non-vigorous newborn.

#### Contraindications:

- 1. Airway patency effective without additional suctioning assistance.
- 2. Amniotic fluid or meconium in naso/oropharynx of vigorous, non-dyspneic newborn.

#### <u>Technique:</u>

- A. Open airway and inspect for visible foreign material.
- B. Turn patient on side if possible to facilitate clearance of liquid foreign material.
- C. Remove large or obvious foreign particulates with gloved hands. Sweep finger ACROSS posterior pharynx and clear material out of mouth in adults or if visible material in pediatrics.
- D. Power on suction machine.
- E. Suction of oropharynx:
  - 1. Attach suction catheter (or use open end of suction tubing for large amounts of debris).
  - 2. Oxygenate and ventilate the patient prior to the procedure as needed.
  - 3. Insert tip into oropharynx under direct vision, with sweeping motion.
  - 4. Continue intermittent suction interspersed with active oxygenation by mask. Use positive pressure ventilation if needed.
  - 5. If suction becomes clogged, dilute by suctioning water or normal saline to clean tubing. If suction clogs repeatedly, use connecting tubing alone, or manually remove large debris.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## **PROTOCOL 2C:** Airway Suctioning – Adult & Pediatric, cont.

#### Technique, cont.:

- F. <u>Catheter suction of endotracheal tube</u>:
  - 1. Attach suction catheter to tubing of suction device (leaving suction end in sterile container).
  - 2. Ventilate patient 4 5 times for pre-suction oxygenation.
  - 3. Detach bag from endotracheal tube and insert sterile tip of suction catheter <u>without</u> suction.
  - 4. When catheter tip has been <u>gently</u> advanced to estimated carina depth, apply suction and withdraw catheter slowly.
  - 5. Rinse catheter tip in sterile water or normal saline.
  - 6. Ventilate patient before each suction attempt.

#### Precautions:

- 1. Suctioning, particularly through endotracheal tubes, always risks suctioning the available oxygen as well as the fluid from the airway. In most situations, limit the suction time to a few seconds while the catheter is being withdrawn. This precaution should NOT be followed when vomitus or other material continues to well up and completely obstruct airway. Then suctioning must be continued until an airway is reestablished, with intermittent oxygenation and ventilation performed to avoid prolonged lack of oxygen.
- 2. Use equipment large enough for the job at hand. Large, solid matter will not be cleared out with suction catheters. Large amounts of particulate matter require open-ended suction using connecting tubing and physical removal with a gloved hand (using bite precautions) or use of Magill forceps.
- 3. The catheter and tubing will require frequent rinsing with water or normal saline to permit continued suctioning. Have a container of water or normal saline at hand before you begin. Use gauze to remove large material from the end of the catheter.
- 4. Do not <u>insert</u> a suction catheter with the suction functioning. Suction only on <u>withdrawal</u> of the catheter.

#### Complications:


- 1. Hypoxia due to excessive suctioning time without adequate ventilation between attempts.
- 2. Persistent obstruction due to inadequate tubing size for removal of debris.
- 3. Lung injury from aspiration of stomach contents due to inadequate suctioning.
- 4. Asphyxia due to recurrent obstruction if airway is not monitored after initial suctioning.
- 5. Trauma to the posterior pharynx from forced use of equipment.
- 6. Vomiting and aspiration from stimulation of gag reflex.
- 7. Induction of cardio-respiratory arrest from vagal stimulation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

2D - BAG VALVE MASK (BVM) MANAGEMENT ADULT & PEDIATRIC



#### Indications:

- 1. Respiratory arrest.
- 2. Inadequate oxygenation/ventilation not improved by non-positive pressure methods or immediately obvious that will not improve by non-positive pressure methods.

#### Contraindications:

- 1. Acute dyspnea of lesser severity able to be managed without BVM management
- 2. Active or suspected impending emesis

#### Technique:

Utilize the following mnemonic to guide correct BVM management:

- **C** Hold mask by **c-clamp** (now referred to as EC-clamp) formed by one, preferably both hands
- O Use an oropharyngeal and/or nasopharyngeal airway(s)
- **P** Place in a sniffing position to open the airway (\*\*\*unless spinal injury suspected)
- E Elevate the jaw to additionally open the airway
- **S** Seal the mask over the mouth and nose without excessive downward force
- **S** Use **Sellick maneuver** if indicated (**BURP** = backward, upward, rightward pressure) on the cricoid cartilage to partially occlude the esophagus in the unconscious patient. Do not utilize if ventilations are effective and without onset of gastric distention. Be ready for emesis when releasing Sellick maneuver.
- **O** Use 100% **oxygen** concentration (FiO2 = 1.0) to start and titrate down as indicated
- **S** Squeeze the bag slowly and smoothly (over 1 second ventilation periods) delivering adequate ventilation volume (approx. 6-8 mL of air/kg if respiratory/cardiac arrest or shock; 8-10 mL of air/kg up to 1000 mL if non-shock hemodynamics) and provide adequate exhalation time.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 2D: Bag Valve Mask (BVM) Management – Adult & Pediatric, cont.

BVM technique that promotes optimal oxygenation/ventilation takes two, sometimes three EMS professionals to achieve.

Utilization of the above technique will promote improved oxygenation/ventilation, while reducing potential for gastric insufflation, vomiting, and aspiration. For gastric insufflation in adults compromising BVM ventilations, utilize a nasogastric/orogastric tube per Protocol 9L – Nasogastric/Orogastric Tube.

Utilize the flowchart below to guide BVM management ventilation rates. Use of an adjustable rate metronome can promote delivery at the indicated rate(s).









Approved 9/14/22, Effective 1/16/23, replaces all prior versions



#### Indications:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management.
- 2. Airway protection to reduce aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score < 8.
- 3. Three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nare. Attempts are counted per patient not per intubator. It is not necessary to first attempt intubation if a difficult airway is anticipated or visualized. A supraglottic airway may be used as the first–line airway in these cases.

#### Contraindications:

- 1. Ability to maintain oxygenation and ventilation by less invasive methods, such as Bag-Valve-Mask ventilation.
- 2. Intact gag reflex
- 3. Known esophageal disease

PARAMEDIC

- 4. Ingestion of caustic substance (e.g. lye, acids) or extensive airway burns
- 5. Tracheotomy or laryngectomy
- 6. Suspected Foreign Body Airway Obstruction
- 7. <u>(Relative Contraindication)</u>: Patient size outside of manufacturer recommended range for airway size used. The supraglottic airway may be utilized in such patients if the fit of the airway allows for appropriate oxygenation and ventilation of the patient.

#### Precaution:

Medical literature indicates concerns regarding reduction in cerebral arterial flow and impedance of cerebral venous return due to pressure effects of supraglottic airways. Supraglottic airways should not be utilized when other methods of airway management are capable of achieving needed oxygenation/ventilation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2E: Supraglottic Airways – Adult & Pediatric, cont.** 

## Technique (I-gel™):

Patient Size	I-gel™ Size	Color	Nasogastric Tube Size
Neonate 2-5 kg	1	Pink	N/A
Infant 5-12 kg	1.5	Light Blue	10
Small Pediatric 10-25 kg	2	Grey	12
Large Pediatric 25-35 kg	2.5	White	12
Small Adult 30-60 kg	3	Yellow	12
Medium Adult 50-90 kg	4	Green	12
Large Adult 90+ kg	5	Orange	14



Illustration of Correct Placement I-gel<sup>™</sup> Airway (Size 4 Shown)


To prepare the I-gel<sup>™</sup> Airway:


- Open the package and take out the protective cradle containing the device.
- Remove the accessory pack containing the lubricant and airway support strap from the protective cradle and place the support strap aside.
- Open the lubricant and place a small amount in the OG suction port and the remainder in the cradle. **Preload OG tube into suction port.**
- Grasp the I-gel<sup>™</sup> along the integrated bite block and lubricate the back, sides and front of the cuff with a thin layer of lubricant.
- When lubricant is applied take care to avoid the introduction of lubricant in or near the ventilation portal in the airway.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2E: Supraglottic Airways – Adult & Pediatric, cont.** 









Grasp the lubricated I-gel<sup>TM</sup> along the integrated bite block (tube portion of the device). Position the device so that the I-gel<sup>TM</sup> cuff outlet is facing toward the chin of the patient. (**Figure 1**)

The patient should be in the "sniffing" position, with head extended and neck slightly flexed forward. If cervical injury is suspected, use modified "jaw thrust" instead of any flexion at the neck. The chin should be gently pressed down/inferior before proceeding to insert the I-gel<sup>™</sup>.

Introduce the leading soft tip into the mouth of the patient in a direction toward the hard palate. Glide the device downwards and backwards along the hard palate with a continuous, but gentile push until a definitive resistance is felt. (**Figure 2**)

WARNING: Do not apply excessive force on the device during insertion It is not necessary to insert your fingers or thumbs into the oral cavity of the patient during insertion of the device. If there is resistance during insertion, a 'jaw thrust' and slight rotation of the device is recommended.

At this point, the tip of the device should be located into the upper esophageal opening and the cuff should be located against the laryngeal framework. The incisors should be resting on the integrated bite block. (**Figure 3**)

Confirm proper position by auscultation of epigastrium and chest and observing physiologic changes. Waveform capnography is not required though strongly recommended for ongoing ventilation and perfusion assessment.

Once I-gel<sup>TM</sup> is in place advance OG to appropriate position, apply suction to decompress the stomach and secure the tube with strap provided. (**Figure 4**)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2E: Supraglottic Airways – Adult & Pediatric, cont.** 


#### Removal of the I-gel<sup>™</sup> Airway:

- 1. Ensure suctioning equipment is ready, roll patient onto left side
- 2. Carefully remove I-gel<sup>™</sup> airway with gentle, but firm traction. Suction as needed.
- 3. Insert an oropharyngeal or nasopharyngeal adjunct, as needed Protocol Title: I-gel<sup>™</sup> Airway Placement Procedure
- 4. Continue ventilations with a BVM at 10-15 LPM flow, as needed or place on non-rebreather mask at 10-15 LPM
- 5. Document time of removal and ongoing vitals

## Additional Information:

- 1. If unable to place an I-gel<sup>™</sup> Airway in three attempts, utilize BVM ventilation.
- 2. Ventilation portal of the I-gel<sup>™</sup> Airway must align with the laryngeal inlet for adequate oxygenation and ventilation. Insertion depth should be adjusted to optimize ventilation.
- 3. Preload the correct size OG tube prior to insertion. (OG will need to be lubricated prior to loading into I-gel<sup>™</sup>).
- 3. Most unsuccessful insertion attempts relate to the failure to keep the tube in a midline position during insertion.
- 4. Do not force the tube during insertion; this may result in trauma to the airway or esophagus.
- 5. Document any complications as well as all methods used to ensure appropriate placement of the I-gel<sup>™</sup> Airway including auscultation of absence of epigastric sounds and presence of lung sounds, physiologic changes (chest rise and fall, improved oxygenation, condensation in I-gel<sup>™</sup> Airway with exhalations), and waveform capnography readings (if applied).
- 6. Assess and document placement verification of the I-gel<sup>™</sup> Airway after patient movement and periodically throughout care and transportation.
- 7. Alternative method of securing as shown below. (Figure 5)
- 8. If strap is unavailable use tape as pictured (Figure 6)









Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 2F – ORAL INTUBATION ADULT

EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

#### Indications:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management.
- 2. Airway protection to minimize aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score <8.
- 3. Impending airway edema in the setting of respiratory tract burns or anaphylaxis.

#### Contraindications:

- 1. A total of three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nostril. Attempts are counted per patient not per intubator.
- 2. Waveform capnography not immediately available.

#### Technique:

- 1. Throughout the period pre-, during, post-intubation the patient must be continually monitored for hypoxia, bradycardia, or hypotension. Corrective measures, including BVM oxygenation should take priority over continuing the current intubation attempts.
- 2. In pulsatile (non-cardiac arrest) patients, provide supplemental oxygenation throughout the intubation process with nasal cannula oxygen delivery at 15 lpm flow. While this flow rate is much higher than typical nasal cannula oxygen flow rates, the additional force of 15 lpm will help to reduce intra-intubation oxygen desaturation/hypoxia.
- 3. Walk the laryngoscope down the tongue to avoid placing the laryngoscope in the esophagus.
- 4. If unable to lift the mandible with the laryngoscope, place your left forearm on the pt's head for leverage.
- 5. If the vocal cords are poorly visualized in any patient, manipulate the thyroid cartilage with your right hand until appropriate visualization is achieved. Have a colleague hold the thyroid cartilage in this place while you finish intubating. This technique is referred to as "bimanual laryngoscopy" and works much more reliably than cricoid pressure.
- 6. If the vocal cords are still poorly visualized in obese patients without suspected spinal injury, elevate their head/neck/shoulders. Place blankets or pillows under the head/neck/shoulders until the patient's chin or nose is level with the chest.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2F: Oral Intubation – Adult, cont.** 

- 7. If ambient light inhibits visualization of the larynx, block this light by any means possible, including a blanket stretched over your head and the patient's head and neck.
- 8. In adult patients of appropriate size, strong preference is given for using the 8.0 mm endotracheal tube for orotracheal intubation. Use of this sized tube enables inpatient pulmonary care unable to be performed with smaller sized tubes.
- 9. It is strongly recommended the Flex-Guide<sup>™</sup> introducer be used during any second intubation attempt.
- 10. It is required the Flex-Guide<sup>™</sup> introducer be used during the third intubation attempt.

#### The Flex-Guide<sup>™</sup> Introducer (also known as the Gum Elastic Bougie):

The Flex-Guide<sup>™</sup> Introducer is a single patient use, semi-rigid plastic rod with an angled tip, promoting glottic passage when the vocal cords are incompletely visible during laryngoscopy. A 1 cm wide black band is located along the Flex-Guide<sup>™</sup> to help determine correct placement depth. The Flex-Guide<sup>™</sup>shape and elasticity allow the intubator to feel a "washboard" sensation as the anteriorly-angled tip is advanced down the tracheal rings. Failure to feel a "washboard" sensation indicates inadvertent esophageal placement and the Flex-Guide<sup>™</sup> must be fully withdrawn before reattempting placement. The Flex-Guide<sup>™</sup> length allows it to be advanced to the carina where resistance is met, also a means of confirming tracheal rather than esophageal placement. Avoid storing the Flex-Guide<sup>™</sup> coiled, as it works best in these regards when it is straight. The Flex-Guide<sup>™</sup> is contraindicated in patients ≤ 16 years of age.



Flex-Guide<sup>™</sup> Introducer Technique:

- 1. Advance the angled tip facing anteriorly, with continual visualization by laryngoscopy. Anytime resistance is met, stop advancing and reassess placement forceful passage can result in perforation of soft tissues.
- 2. Stabilize the Flex-Guide<sup>™</sup> when in place, while maintaining laryngoscopy





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 2F: Oral Intubation – Adult, cont.

- 3. Direct a colleague to slide the endotracheal tube over the Flex-Guide<sup>™</sup>. He or she stabilizes the proximal end of the Flex-Guide<sup>™</sup> as it emerges from the sliding endotracheal tube.
- 4. Take control of the endotracheal tube, sliding it down the Flex-Guide<sup>™</sup> length, while being careful to avoid Flex-Guide<sup>™</sup> migration. Once the endotracheal tube has passed to an appropriate estimated endotracheal depth, stabilize it while your colleague withdraws the Flex-Guide<sup>™</sup> prior to laryngoscope removal

#### Confirmation of Oral Endotracheal Placement:

The following sequence is to be used (and its use documented) to verify and maintain correct oral endotracheal placement without fail:

- 1. Visualization of endotracheal tube passage between the vocal cords.
- 2. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H-Capnography for discussion of EtCO<sub>2</sub> values.
- 3. Auscultation. Auscultate the epigastrum. If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to mid axillary lines. If breath sounds are present on the right and absent on the left, this suggests a right main stem intubation. Withdraw the endotracheal tube 1cm and repeat auscultation. If necessary, the tube may be withdrawn an additional 1-2cm.
- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress or failure.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2F: Oral Intubation – Adult, cont.** 

5. Secure the endotracheal tube with a tube holder and place a cervical collar.

When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, you must either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.

#### Post-Endotracheal Intubation Additional Care:

Place a nasogastric or orogastric tube to intermittent suction in order to alleviate gastric air/distension. This will improve oxygenation/ventilation and decrease risk of aspiration.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 2G - MEDICATION ASSISTED INTUBATION ADULT

#### TREATMENT PRIORITIES

1, Oxygenation/Ventilation support

#### EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

ЕМТ

EMT-INTERMEDIATE 85

ADVANCED EMT

PARAMEDIC

PARAMEDIC
MEDICATION-ASSISTED INTUBATION IF INDICATED FOLLOW PROTOCOL 2F – ORAL INTUBATION FOR TECHNIQUE & CONFIRMATION OF INTUBATION
FOR FACILITATING ORAL INTUBATION: ADULT: ETOMIDATE 0.3 mg/kg IVP/IOP SINGLE DOSE OR
ADULT: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg_IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg
FOR POST-ORAL INTUBATION SEDATION TO PREVENT EXTUBATION (IF INDICATED):
ADULT: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg_IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg
OR ADULT: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg OR
ADULT: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg
CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 2H – NASAL INTUBATION ADULT

EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

#### Indications:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management, including refractory to NIPPV.
- 2. Airway protection to minimize aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score <8.
- 3. Impending airway edema in the setting of respiratory tract burns or anaphylaxis.
- 4. Patients more compliant with intubation attempts in a sitting position.
- 5. Oral anatomy, injury, or jaw clenching preventing indicated orotracheal intubation.

#### Contraindications:

- 1. Apnea.
- 2. Pediatric patients (age  $\leq 12$  years).
- 3. Suspected basilar skull fracture.
- 4. Mid-facial injuries with bony instability.
- 5. Combativeness preventing patient compliance.
- 6. Anticoagulant use (Warfarin/Coumadin, Plavix, or Aspirin) Relative contraindication orotracheal intubation preferred to minimize bleeding complications.
- 7. Three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nostril. Attempts are counted per patient not per intubator.
- 8. Waveform capnography not immediately available.

#### Technique:

- 1. Apply two sprays of phenylephrine 2% in each nostril to induce local vasoconstriction. This will enlarge the nostril and decrease epistaxis complications.
- 2. Apply lidocaine 2% gel to the endotracheal tube cuff.
- 3. Insert the well-lubricated tube along the floor of the most patent nostril, bevel side facing inward toward the septum. This positioning will prevent a turbinate from being trapped in the tube and subsequently being sheared off as the tube is advanced. Pass the tube straight back (not angulated upward) with constant, gentle pressure. Do not use an endotracheal stylet in nasotracheal intubations.
- 4. As the tube is advanced, there is a loss of resistance as the tube passes from the nasopharynx into the oropharynx. Continue advancing the tube.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 2H: Nasal Intubation – Adult, cont.

- 5. As the tube nears the glottis, guide the tube by listening at the adaptor. The awake patient should be instructed to deeply inspire to help guide the tube through the vocal cords and into the trachea. Correct endotracheal placement may also be assisted by rotating the tube 90 degrees so that the bevel is up and facing the glottis.
- 6. Once the tube has been placed, the patient should not be capable of phonation. The ability to speak after "nasotracheal intubation" actually denotes "nasoesophageal intubation." In such cases, the tube is to be slightly withdrawn and correct placement reattempted. The Flex-Guide<sup>™</sup> may NOT be used for difficult nasotracheal intubations.

#### Confirmation of Nasal Endotracheal Placement:

The following sequence is to be used (and its use documented) to verify and maintain correct nasal endotracheal placement without fail:

- Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid down stroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values.
- 2. Auscultation. Auscultate the epigastrum. If epigastric sounds are heard, intubation is to be reattempted. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to mid axillary lines. If breath sounds are present on the right and absent on the left, this suggests a right main stem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.
- 3. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress or failure.
- 4. Secure the endotracheal tube with tape and place a cervical collar.

When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid down stroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 1-4 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, you must either re-verify by this sequence or reattempt correct endotracheal placement.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 2H: Nasotracheal Intubation – Adult, cont.

#### Confirmation of Nasal Endotracheal Placement (cont.):

While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 2I – CRICOTHYROTOMY ADULT


#### PARAMEDIC

#### Indications:

1. Upper airway obstruction (eg. facial or neck trauma occluding airway patency, foreign body unable to be removed, angioedema) and inability to adequately oxygenate and ventilate using less invasive methods.

#### Contraindications:

- 1. Ability to oxygenate and ventilate using less invasive methods.
- 2. Infant and younger pediatrics airway anatomical size not conducive to successful cricothyrotomy in EMS care. Contact OLMC for direction in these ages.
- 3. Older pediatrics airway anatomical size MAY not be conducive to successful cricothyrotomy in EMS care. Contact OLMC for direction in these ages.
- 4. Suspected fractured larynx and/or cricoid cartilage.
- 5. Suspected tracheal transection with retraction of the trachea into the chest.
- 6. Inability to find anatomical landmarks







Approved 9/14/22, Effective 1/16/23, replaces all prior versions


#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™):

- A. Position patent supine and identify the cricothyroid membrane.
- B. Stabilize the thyroid cartilage with the non-dominant hand (illustration shows the right hand as non-dominant). The dominant hand rests on the sternum, holding the device, with the scalpel oriented horizontal, across the neck at the cricothyroid membrane (illustration shows the left hand as dominant). (Figure 1)



C. Inserting the scalpel to its depth safety hub, make a horizontal incision through both the skin and the underlying cricothyroid membrane. (Figure 2)








Approved 9/14/22, Effective 1/16/23, replaces all prior versions


#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™), cont:

D. Slide the included tracheal hook down the handle with the thumb placed at the knob, advancing the tip of the hook into the incision made in Step C/Figure 2. (Figure 3)



E. Free the tracheal hook from the handle by sliding it fully down the handle and transfer control of the hook to the non-dominant hand. The tracheal hook should now be able to stabilize movement of the trachea as it is pulled in a controlled force and manner, with the hook under the inferior edge of the thyroid cartilage. (Figure 4)







Approved 9/14/22, Effective 1/16/23, replaces all prior versions


#### **PROTOCOL 2I:** Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™), cont:

F. Insert the Cric-Key<sup>™</sup> through the cricothyroid membrane incision. Confirm placement by moving the Cric-Key<sup>™</sup> introducer along the anterior wall of the trachea to feel for the tracheal rings as partial confirmation of correct placement. (Figure 5)



G. Remove the Cric-Key<sup>™</sup> introducer. (Figure 6) Inflate the cuff until resistance is met. Confirm placement with continuous waveform capnography. See also Protocol 3H: Waveform Capnography – Adult & Pediatric.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™), cont:

G. Secure the cricothyrotomy airway with the included stabilizing strap. (Figure 7)



Surgical Technique (6.0 endotracheal tube and tracheal hook):

- A. Establish adequate space and lighting. Do not attempt cricothyrotomy in poorly visualized conditions.
- B. If rapidly available, clean anterior neck with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or alcohol wipe.
- C. Definitively locate the following landmarks: thyroid cartilage ("Adam's apple") and cricoid cartilage. The cricothyroid membrane lies between these cartilages.
- D. Using the non-dominant hand, spread the overlying skin taut with the thumb and fingers, and slightly depress the skin over the cricothyroid membrane with the index finger to mark the site of cricothyrotomy. Do not release the non-dominant hand from the neck until the procedure is complete! Once the anatomy is found and defined, avoid movement of the anatomy to promote proper cricothyrotomy airway placement.
- E. Stabilization of the anatomy requires assistance from a second EMS professional, preferably licensed as a paramedic as well.
- F. Ask second EMS professional to aspirate all air from the endotracheal tube cuff.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 2I:** Emergency Cricothyrotomy – Adult, cont.

Surgical Technique, cont.:

- G. Using a sterile scalpel, make a vertical incision in the mid-line of the neck extending from just above the lower edge of the thyroid cartilage to the middle of the cricoid cartilage. Make the depth of this incision sufficient to extend through the skin and fatty tissue underneath.
- H. Using sterile hemostats, spread the incision open horizontally to expose the cricothyroid membrane. Instruct the second EMS professional to hold the hemostats in this position.
- I. Using the same scalpel as in Step G, now make a short horizontal incision in the middle of the cricothyroid membrane. There is a small artery running vertically on each side of the cricothyroid membrane. Keeping the horizontal incision less than ½ inch (approx. 1 cm) will decrease bleeding that may occur.
- J. Pass the 6.0 mm endotracheal tube through the horizontal incision in the cricothyroid membrane, angling the tube inferior and posterior along the tracheal anatomy. A "washboard" sensation may be felt as the tube slides along the tracheal wall. Avoid excessive pressure in placing the endotracheal tube, but a moderate degree may be required to first pass the endotracheal tube through the cricothyroid membrane. If significant resistance is encountered (without suspicion of lower respiratory tract foreign body), the hemostats used in Step H may be used to spread the cricothyroid membrane incision vertically while the endotracheal tube is passed through it and/or use of the tracheal hook may better stabilize the anatomy to overcome resistance to airway passage.
- K. Inflate the endotracheal cuff and verify airway placement per Protocol 2J Confirmation of Artificial Airway Placement.
- L. Secure the airway using a cloth tie or commercial endotracheal tube restraint while continuing oxygenation and ventilation. Artificial ventilation will generally be easier if the endotracheal tube is cut to a shorter length. Be careful to cut the upper aspect of the endotracheal tube above the insertion site of the cuff inflation portal to avoid irreversible cuff deflation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.**

#### Modified Non-Surgical Technique (Control-Cric™):

In patients with neck edema, subcutaneous air, or fat/obesity preventing necessary tactile identification of anatomical landmarks to perform standard non-surgical cricothyrotomy, utilize the following modification:


A. Using the included scalpel, make a single, vertical, mid-line incision in the skin overlying the area that is estimated to contain the thyroid cartilage, cricothyroid membrane, and cricoid cartilage. When making the incision, make an incision approximately 2 inches (5 cm) in length and deep enough that the subcutaneous fat can be visualized. Using a gloved index finger palpate the structures through the incision and when identified, proceed as per standard non-surgical cricothyrotomy.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions


### 2J – CONFIRMATION OF ENDOTRACHEAL AIRWAY PLACEMENT ADULT



The following sequence is to be used (and its use documented) to verify and maintain correct endotracheal artificial airway placement without fail:

- 1. Visualization of endotracheal tube passage between vocal cords oral intubation only. (Figure 1)
- 2. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values and waveforms. (Figure 2)
- 3. Auscultation. Auscultate the epigastrium. (Figure 3) If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to midaxillary lines. If breath sounds are present on the right and absent on the left, this suggests a right mainstem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.












Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 2J: Confirmation of Endotracheal Artificial Airway Placement – Adult** 

- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress/failure.
- 5. Secure the endotracheal tube with a tube holder and place a cervical collar. (Figure 4)



When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequences performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.

Upon delivery of the patient at treatment destination or at subsequent transport (eg. helicopter transport), a waveform capnograph will be obtained and documented after the patient has been physically transferred onto the destination's/subsequent transport's stretcher/bed/operating table to show confirmed, continued correct endotracheal tube placement at EMS transfer of patient care.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 2K – STOMA/TRACHEOSTOMY MANAGEMENT ADULT & PEDIATRIC

EMT

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

PARAMEDIC

**Emergency Management:** 

- The majority of adults and children with tracheostomies are dependent on the tube as their primary airway. Cardio-respiratory arrest most commonly results from tracheostomy obstructions. Obstruction may be due to thick secretions/mucous plug, blood clot, foreign body, or kinking or dislodgement of the tube. Work expeditiously and deliberately to re-establish airway patency and support oxygenation/ventilation.
- Early warning signs of obstruction include tachypnea, tachycardia, and desaturation. Cyanosis, bradycardia and apnea are late signs - do not wait for these to develop before intervening.

#### Complications:

- Airway obstruction
- Aspiration
- Blocked tube
- Bleeding
- Tracheal trauma
- Pneumothorax
- Subcutaneous and mediastinal emphysema
- Respiratory and cardiovascular collapse
- Dislodged tube
- Tracheo-esophageal fistula
- Infection

#### Endotracheal Suctioning:

Endotracheal suctioning is necessary to remove mucus, maintain a patent airway, and avoid tracheostomy tube blockages. Indications for suctioning include:

- Audible or visual signs of secretions in the tube
- Signs of respiratory distress
- Suspicion of blocked or partially blocked tube
- Inability to clear the tube by coughing out the secretions
- Increases in required ventilation pressures (in ventilated patients)
- Request by patient for suction





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 2K: Stoma/Tracheostomy Management– Adult & Pediatric, cont.

Endotracheal Suctioning, cont.:

- Tracheal suctioning should be carried out regularly for patients with a tracheostomy. The frequency varies between patients and is based on individual assessment.
- Tracheal damage may be caused by suctioning. This can be minimized by using the appropriate sized suction catheter and only suctioning within the tracheostomy tube.

Table 1: recommended suction cath	neter s	sizes								
Tracheostomy tube size (in mm)	3.0	3.5		4.5	5.0	6.0mm	7.0mm	7.5mm	8.0mm	9.0mm – 10mm
	mm	mm	mm	mm	mm					
Recommended suction catheter size (Fr)	7	8	8	10	10	10-12	14	14-16	14-16	16

- The suction depth is determined by the estimated length of the tracheostomy tube.
- The depth of insertion of the suction catheter needs to be determined prior to suctioning to avoid trauma.
- Using the patient's spare tracheostomy tube of the same size (if available) to estimate needed depth of suctioning.
- The pressure setting for tracheal suctioning (suction machine pressure for small children 50-100 mmHg, for older children/adults 100-120 mmHg) to avoid tracheal damage.
- In most circumstances, it is best to limit the duration of suctioning (including passing the catheter and suctioning the tracheostomy tube) to 5-10 seconds.
- Routine use of normal saline is not necessary although there is anecdotal evidence it may thin secretions. In situations where this may be of benefit, only 1-2 mL is usually needed.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions


#### PROTOCOL 2K: Stoma/Tracheostomy Management– Adult & Pediatric, cont.

#### Tracheal Suctioning Procedure:

- 1. Inform pt of intended action.
- 2. Maintain appropriate PPE throughout procedure.
- 3. Assemble needed suction equipment and power on suction device.
- 4. Instill small volume of sterile normal saline into the tracheostomy tube if needed for thick or dry secretions. Excessive use of saline is not recommended. Use saline only if the mucus is very thick, hard to cough up or difficult to suction. Recommended amount per instillation is approximately 1-2 mL.
- 5. Gently insert catheter into the tracheal tube without applying suction, passing to the previously estimated needed depth.
- 6. Put thumb over opening in catheter to create suction and use a circular motion (twirl catheter between thumb and index finger) while withdrawing the catheter so that the mucus is removed well from all areas. Avoid suctioning longer than 10 seconds because of oxygen loss. Suction normal saline from a container if needed to clear catheter.
- 7. For tracheostomy tubes with cuffs, it may be necessary to deflate the cuff periodically for suctioning to prevent pooling of secretions above tracheal cuff.
- 8. Let patient rest and breathe, then repeat suction if needed until clear (trying to allow about 30 seconds between suctioning).
- 9. Oxygenate/ventilate as needed.


#### Tracheostomy tube tie changes:

- There is a potential risk for tracheostomy tube dislodgment when attending to tie changes, therefore two personnel who are competent in tracheostomy care should undertake tracheostomy tie changes.
- During the tracheostomy tie change one person is to maintain the airway by securing the tracheostomy tube in place and not removing the hand until the new tracheostomy ties are applied. The other person is to change the ties and attend to stoma care.
- If the tie becomes loose, make it is a priority to re-secure the tracheostomy tube before it can become dislodged.













### Approved 5/10/23, Effective 7/1/23, replaces all prior versions

#### **3B – DYSPNEA – UNCERTAIN ETIOLOGY ADULT & PEDIATRIC** EMERGENCY MEDICAL DISPATCHER **TREATMENT PRIORITIES** EMD EMERGENCY MEDICAL RESPONDER 1. Vital signs ADVISE TO AVOID PHYSICAL EXERTION (including EtCO2, if equipped) OR ENVIRONMENTAL STRESS (TEMP EXTREMES) 2. Oxygenation support EMT ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS ➢ O₂ by NC, NRB (eg. ALBUTEROL INHALER) BVM, Bi/CPAP, ETT if indicated **EMT-INTERMEDIATE 85** IF PREVIOUSLY PRESCRIBED FOR SIMILAR SYMPTOMS 3. Ventilation support BVM, Bi/CPAP, ETT if indicated 4. Nebulization therapy ADVANCED EMT > Albuterol PARAMEDIC **EMR** EMT GENERAL SUPPORTIVE CARE OBTAIN VITAL SIGNS O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped) ADULT: OBTAIN 12-LEAD ECG & TRANSMIT TO RECEIVING EMERGENCY DEPARTMENT (if equipped) ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable) **EMT OR HIGHER LICENSE:** MEASURE END-TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped) ADULT: APPLY Bi/CPAP IF INDICATED (if equipped) ADULT & PEDIATRIC WEIGHT ≥15 kg: NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg PEDIATRIC WEIGHT <15 kg: NEBULIZED ALBUTEROL 2.5 mg OR LEVALBUTEROL 1.25 mg MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 1 AS NEEDED PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE **EMT-185** AEMT ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS IV ACCESS ADULT: IV NS TKO IF SYS BP ≥ 100 mmHq WITHOUT HYPOTENSIVE SYMPTOMS ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA PARAMEDIC

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






#### Approved 5/10/23, Effective 7/1/23, replaces all prior versions EMERGENCY MEDICAL **3C – DYSPNEA – ASTHMA** DISPATCHER **ADULT & PEDIATRIC EMERGENCY MEDICAL** TREATMENT PRIORITIES RESPONDER 1. Vital signs EMT (including EtCO2, if equipped) EMD 2. Oxygenation support O<sub>2</sub> by NC, NRB **EMT-INTERMEDIATE 85** > BVM, Bi/CPAP, ETT if indicated ADVISE TO AVOID PHYSICAL EXERTION 3. Ventilation support OR ENVIRONMENTAL STRESS (TEMP EXTREMES). BVM, Bi/CPAP, ETT if indicated ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS **ADVANCED EMT** (eg. ALBUTEROL INHALER) 4. Nebulization therapy AS PREVIOUSLY PRESCRIBED FOR ASTHMA SYMPTOMS Albuterol, Ipratropium bromide PARAMEDIC **EMR** EMT GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped) ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable) **EMT OR HIGHER LICENSE:** MEASURE END-TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped,\*\*Mandatory use if pt intubated) ADULT: APPLY Bi/CPAP IF INDICATED (if equipped) ADULT & PEDIATRIC WEIGHT ≥15kg: NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg & IPRATROPIUM BROMIDE 0.5 mg PEDIATRIC WEIGHT <15kg: NEBULIZED ALBUTEROL 2.5 mg OR LEVALBUTEROL 1.25 mg & IPRATROPIUM BROMIDE 0.25 mg MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 2 AS NEEDED FOR SEVERE ASTHMA REFRACTORY TO NEBULIZATION: ADULT: EPINEPHRINE 1mg/mL (1:1000) 0.3 mg (0.3 mL) AUTOINJECTOR INTRAMUSCULAR INJECTION IN THIGH PEDIATRIC: EPINEPHRINE 1mg/mL (1:1000) 0.15 mg (0.15 mL) AUTOINJECTOR INTRAMUSCULAR INJECTION IN THIGH OLMC ORDER ONLY FOR EPHINEPHRINE IF PT ≥50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE >140/90 mmHg PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE **EMT-185** AEMT ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS IV ACCESS ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS **PEDIATRIC:** IV NS TKO IF SYS BP $\geq$ (70 + 2x age in years) mmHg PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA **AEMT OR HIGHER LICENSE:**

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA FOR SEVERE ASTHMA REFRACTORY TO NEBULIZATION: ADULT: EPINEPHRINE 1mg/mL (1:1000) at 0.3 mg (0.3 mL) IM PEDIATRIC: EPINEPHRINE 1mg/mL (1:1000) at 0.01 mg/kg (0.01 mL/kg) NOT TO EXCEED 0.3 mg (0.3 mL) IM OLMC CONSULT FOR EPHINEPHRINE IF PT ≥50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE >140/90 mmHg PARAMEDIC ADULT: METHYLPREDNISOLONE 125 mg IVP OR DEXAMETHASONE 10 mg IVP, MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED. PEDIATRIC: METHYLPREDNISOLONE 2 mg/kg NOT TO EXCEED 125 mg IVP OR DEXAMETHASONE 0.6 mg/kg NOT TO EXCEED 10 mg IVP MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED. ADULT: MAGNESIUM SULFATE 1 gram VERY SLOW IVP OVER 10 MINS AVOID/STOP IF HYPOTENSION OR KNOWN RENAL FAILURE ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Approved 5/10/23, Effective 7/1/23, replaces all prior versions



METHYLPREDNISOLONE 125 mg IVP OR DEXAMETHASONE 10 mg IVP, MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED.

MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






## Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3E – DYSPNEA – CONGESTIVE HEART FAILURE (CHF)

#### **ADULT & PEDIATRIC**




TREAT PER PROTOCOL 5C - ACUTE CORONARY SYNDROME AND/OR DYSRHYTHMIA PROTOCOL(S) AS INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S) TRANSPORT ASAP PER DESTINATION PROTOCOL





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 3F – DYSPNEA – BRIEF RESOLVE UNEXPLAINED EVENT (BRUE) PEDIATRIC LESS THAN 1 YEAR OF AGE








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3G – PULSE OXIMETRY ADULT & PEDIATRIC



#### Indications:

- 1. Medical General Assessment/General Supportive Care.
- 2. Trauma General Assessment/Trauma & Hypovolemic Shock Supportive Care.
- 3. Acute Dyspnea (Uncertain Etiology, Asthma, COPD, CHF, BRUE).
- 4. Cardiovascular Disorders (Chest Pain, Acute Coronary Syndrome, Dysrhythmias).
- 5. Neurologic Disorders/Altered Mental Status (Stroke, Seizure, Syncope).
- 6. Toxicologic/Poisonings (Altered Mental Status, Dyspnea).
- 7. Trauma (Head, Face, Neck, Chest Injuries).

#### Contraindications: None

#### Technique:

- A. Power on the pulse oximeter (may be included with monitor/defibrillator).
- B. Select an appropriate site for measurement.
  - 1. Best skin color on hand (or foot/ear if pediatric).
  - 2. Not distal to acute suspected orthopedic injuries.
- C. Place the infrared sensor on the patient.
- D. Read the pulse rate and oximetry reading (SpO<sub>2</sub>).

#### Precautions:

- A. Pulse oximetry values may be inaccurate in hemodynamically compromised patients (shock), patients with peripheral vascular constriction, carbon monoxide poisonings/smoke inhalations, and any conditions that may cause methemoglobinemia or sulfhemoglobinemia. Always correlate the patient's clinical condition with SpO<sub>2</sub> readings.
- B. Trends prove more informative than a single measurement. At least two measurements should be performed and documented when using pulse oximetry. In the setting of artificial airway placement, pulse oximetry should be utilized continuously.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3H – WAVEFORM CAPNOGRAPHY ADULT & PEDIATRIC

EMT

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

PARAMEDIC

Indications:

- 1.Medical General Assessment/General Supportive Care.
- 2.Trauma General Assessment/Trauma & Hypovolemic Shock Supportive Care.
- 3.Acute Dyspnea (Uncertain Etiology, Asthma, COPD, CHF, BRUE).
- 4.Confirmation of Endotracheal Airway Placement EARLY USE INDICATED; SEE PROTOCOL 2J.
- **5.Mechanical Ventilation**
- 6.Termination of Resuscitation; SEE PROTOCOL 4K
- 7.Neurologic Disorders/Altered Mental Status (Stroke, Seizure, Syncope).
- 8. Toxicologic/Poisonings (Altered Mental Status, Dyspnea).
- 9. Trauma (Head, Face, Neck, Chest Injuries).

Contraindications: None

Technique:

(Physio-Control LifePak® 12/15) to Monitor EtCO2:

- 1. Make sure the monitor is ON.
- 2. Select the appropriate  $EtCO_2$  accessory for the patient.
- 3. Open the CO<sub>2</sub> port door and insert the FilterLine<sup>®</sup> connector; turn connector clockwise until tight.
- 4. Verify that the CO<sub>2</sub> area is displayed. The EtCO<sub>2</sub> monitor performs the autozero routine as part of the initialization self-test.
- 5. Display  $CO_2$  waveform in Channel 3 on the LifePak screen.
- 6. Connect the CO<sub>2</sub> FilterLine<sup>®</sup> set to the patient.
- 7. Confirm that the  $EtCO_2$  value and waveform are displayed.



**Note:** Do not connect the FilterLine<sup>®</sup> set to the patient/ventilation system until the EtCO<sub>2</sub> monitor has completed its self-test and warm-up.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

Critical Comment:

When  $CO_2$  is **<u>NOT</u>** detected, four factors must be quickly assessed:

- 1. Loss of airway apnea? esophageal endotracheal tube placement/migration? obstruction?
- 2. Circulatory collapse cardiac arrest? massive pulmonary embolism? exsanguination?
- 3. Equipment failure disconnected or malfunctioning bag-valve or ventilator?
- 4. Adjust EtCO2 scale to 0-20 and print 6 second strip to verify waveform capnography.


#### Interpreting Capnography:

The figure below shows a normal capnography waveform display. There are 4 phases of the waveform that require analysis. The flat  $\mathbf{A} - \mathbf{B}$  baseline segment (Respiratory Baseline) represents the beginning of exhalation of  $CO_2$  – free gas that is contained in dead space from the conduction airways (trachea, bronchi). This value normally is zero. The  $\mathbf{B} - \mathbf{C}$  segment (Expiratory Upstroke), a sharp rise, represents exhalation of a mixture of dead space gases and alveolar gases. The  $\mathbf{C} - \mathbf{D}$  segment represents the alveolar plateau, characterized by exhalation of mostly alveolar gas. Point  $\mathbf{D}$  is the end-tidal (EtCO<sub>2</sub>) value that is recorded and displayed by the monitor, (peak concentration of  $CO_2$  occurring at the end of expiration). The  $\mathbf{D} - \mathbf{E}$  segment (Inspiratory Downstroke), a sharp fall, reflects the inhalation of gases that are  $CO_2$  – free (room air or supplemental oxygen). Alterations of the normal capnograph or EtCO<sub>2</sub> values are the result of changes in metabolism, circulation, ventilation, or equipment function.

A normal range for  $EtCO_2$  is **35 – 45 mmHg**, similar to the range of  $CO_2$  in arterial blood.

Normal Waveform:

Normal Capnography Waveform






Approved 9/14/22, Effective 1/16/23, replaces all prior versions



#### **PROTOCOL 3H:** Waveform capnography – Adult & Pediatric, cont.

#### Abnormal Waveforms:




Possible Causes:

#### 1.Endotracheal tube in esophagus.

#### 2.Apnea.


- 3. Endotracheal tube or supraglottic not connected to capnography detector.
- 4. Total obstruction/mucus plugging.
- 5.Capnography malfunction if abnormal waveform persists with change in capnography adaptor, the endotracheal tube or supraglottic MUST be withdrawn and intubation or supraglottic placement reattempted.

# Sustained low ETCO<sub>2</sub> with good alveolar plateau:



Possible Causes:

- 1. Hyperventilation (due to underlying illness/injury or excessive assisted ventilations).
- 2. Hypothermia (Decrease in Metabolism).



Possible causes:

- 1. Bronchospasm of asthma or COPD exacerbation.
- 2. Incomplete obstruction/mucus plugging.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions


### PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

Abnormal Waveforms:



Possible causes:


- 1. Hypoventilation (due to underlying illness/injury or inadequate assisted ventilations).
- 2. Hyperthermia, pain, shivering (Increase in Metabolism).



Possible causes:

- 1. Hypoventilation (due to underlying illness/injury or inadequate assisted ventilations).
- 2. Rising body temperature, increasing pain (Increasing Metabolism).

### Exponential decrease in ETCO2:



Possible causes:

- 1. Cardiopulmonary arrest.
- 2. Pulmonary embolism.
- 3. Sudden hypotension, massive blood loss, cardiopulmonary bypass.




Approved 9/14/22, Effective 1/16/23, replaces all prior versions




#### **PROTOCOL 3H:** Waveform capnography – Adult & Pediatric, cont.

Abnormal Waveforms:



Cardiogenic oscillations are caused by changes in thoracic volume secondary to expansion and contraction of the myocardium with each heartbeat. They are usually seen in patients with small tidal volumes and slow respiratory rates, and are of little physiologic consequence.



Spontaneous breathing efforts may be evident on the CO2 waveform display. The patient on the top demonstrates poorer quality spontaneous breathing effort than the patient on the bottom.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.** 

Troubleshooting Tips for EtCO2 monitoring:


Observation/Message	Possible Cause	Corrective Action		
ALARM APNEA	No breath has been detected for 30 seconds since last valid breath	Check the patient, then ventilation equipment for leaks/disconnected tubing		
CO2 FILTERLINE OFF	FilterLine <sup>®</sup> , or any other CO2 accessories disconnected or not securely connected to the LifePak <sup>®</sup> EtCO2 connector	Connect FilterLine <sup>®</sup> , or any other CO2 accessories, to input connector or tighten connection		
CO2 FILTERLINE BLOCKAGE	FilterLine <sup>®</sup> is twisted or clogged. The message appears after 30 seconds of unsuccessful purging	Check the FilterLine <sup>®</sup> and if necessary replace it		
	Airway Adapter clogged	Check the Airway Adapter and necessary, replace it		
CO2 FILTERLINE PURGING	FilterLine <sup>®</sup> tube twisted or clogged with water	Check the FilterLine <sup>®</sup> and if necessary, untwist or reconnect it		
EtCO2 values erratic	A leak in the tubing Assisted ventilated patient breaths spontaneously	Check for connection leaks and line leaks to patient and correct if necessary		
EtCO2 values are	Physiological cause	Check patient (pulse?)		
consistently higher or lower than expected	Ventilator/Assisted ventilation error	Check ventilator &/or assisted ventilation rate		
		Adjust EtCO2 scale to 0- 20mmHg to reflect lower than anticipated value		
		Print 6 second strip for verification of waveform		
<b>XXX</b> appears in place of EtCO2 value	CO2 module not calibrated successfully	Notify appropriate supervisor/materials agent of critical		
	CO2 module failed	equipment failure		





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

3I – OXYGEN ADMINISTRATION ADULT & PEDIATRIC



Indications:

Use in chronic conditions to include:

COPD – chronic bronchitis or emphysema Chronic lung disease – lung cancer, sarcoidosis, pulmonary fibrosis, pulmonary hypertension.

EMS administration of  $O_2$  may be at usual concentrations (e.g. nasal cannula flow at 2-3 liters per minute) or at higher concentrations than usual during acute dyspnea episodes (e.g. non-rebreather mask flow at 12 liters per minute) if the chronic pulmonary disease patient exhibits more than typical dyspnea or more than typical hypoxemia.

Use in acute conditions to include:

Respiratory arrest Dyspnea – uncertain etiology, asthma, COPD, CHF, BRUE, acute allergic reaction Cardiac arrest Acute coronary syndrome (if associated with dyspnea or pulse oximetry< 94%) Stroke (if associated with dyspnea or pulse oximetry< 94%) Multi-systems trauma

EMS administration of  $O_2$  should be goal-directed to achieve oxygen saturation levels, based on pulse oximetry, with a target level of 94–98% in most patients, or 88–92% in COPD patients.

#### Precautions:

Excessive oxygen levels can impair the respiratory drive in chronic pulmonary disease patients and paradoxically contribute to as much tissue disease as hypoxemia. Multiple studies show that **hyper**oxemia in certain ischemic tissue disease events (e.g. cardiac arrest, stroke) can lead to worse outcomes than normal oxygen levels. Treat hypoxemia, but avoid excessive oxygen levels that are unneeded in addressing patient symptoms of dyspnea or signs of respiratory failure (e.g. low pulse oximetry readings).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 3I: Oxygen Administration – Adult & Pediatric, cont.** 

#### Supplemental oxygen concentration capabilities of different devices:

Via nasal cannula (NC) at 1 - 6 liters per minute (lpm), yields 24-44% concentration of inhaled oxygen (FiO<sub>2</sub> of 0.24 – 0.40). Typically, each additional liter flow will increase the concentration of inhaled oxygen by 4%. With higher lpm flows (5-6 lpm) via NC, nasal irritation and drying of mucosa can occur without use of humidified O<sub>2</sub>.

There are a number of face mask options, such as the simple face mask, often used between 6 and 12 lpm, resulting in a concentration of oxygen to the patient between 40% and 50%. This is closely related to the more controlled air-entrainment masks, also known as Venturi masks, which can accurately deliver a predetermined oxygen concentration in a range of 24 - 50%.

In some instances, a partial rebreathing mask can be used, which is based on a non-rebreather mask, but with the values over the exhalation ports removed. The partial rebreathing mask can provide oxygen concentration in the 40 - 70% using up to 15 lpm flow.


Non-rebreather masks draw oxygen from an attached reservoir bag, with one-way valves that direct exhaled air out of the mask. When properly fitted and used at flow rates of 10-15 LPM or higher, they deliver 60 - 80% oxygen concentrations and occasionally higher, depending upon mask/face interface and valve function. Minimum lpm flow through a non-rebreather (even when using for presumed psychogenic hyperventilation) should be 10 lpm.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3J – NEBULIZATION THERAPY ADULT & PEDIATRIC



#### Indications:

- 1. Dyspnea Uncertain Etiology
- 2. Dyspnea Asthma
- 3. Dyspnea Chronic Obstructive Pulmonary Disease (COPD)
- 4. Acute Allergic Reactions
- 5. Bronchospasm from toxic inhalations

#### Contraindications:

1. Non-bronchospastic respiratory distress (e.g., clear presentation of CHF)

#### Technique:

- A. Assemble nebulization device.
- B. Fill nebulization chamber with medication to be nebulized.
- C. Initiate 6-10 lpm O<sub>2</sub> flow if using hand-held nebulization device or via face mask.
- D. Place nebulization chamber "in-line" with respiratory circuit if using nebulization via NIPPV, supraglottic airway or endotracheal tube. Use continuing pre-nebulization lpm flow of O<sub>2</sub> to deliver nebulized medication through the respiratory circuit.


Repeat steps B – D as patient condition indicates per applicable protocol(s).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3K – NON-INVASIVE POSITIVE PRESSURE VENTILATION (NIPPV) ADULT & INTER- FACILITY PEDIATRIC



#### Indications:

- 1. Dyspnea Uncertain Etiology Adult.
- 2. Dyspnea Asthma Adult.
- 3. Dyspnea Chronic Obstructive Pulmonary Disease (COPD) Adult.
- 4. Dyspnea Congestive Heart Failure (CHF) Adult.
- 5. Acute Allergic Reactions Adult (Dyspnea).
- 6. Water Submersion Event Adult (Dyspnea).
- 7. Pediatric Dyspnea Inter-Facility Continuation of Care.

#### Contraindications:

- 1. Apnea.
- 2. Pediatric dyspnea- Non-Inter-Facility/Non-Continuation of Care.
- 3. Adult dyspnea of lesser severity able to be managed without NIPPV.
- 4. Adult dyspnea of greater severity requiring invasive airway management.
- 5. Altered mental status preventing patient cooperation with NIPPV.
- 6. Active or suspected impending emesis.
- 7. High risk of aspiration/Impaired gag reflex.
- 8. Facial trauma/features impairing a tight NIPPV mask-face seal.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 3K: Non – Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

**Bi-Level/CPAP** Ventilation Algorithm



Monitor closely for nausea/impending emesis – be prepared to quickly remove facemask to avoid aspiration of emesis






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 3K: Non – Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

#### Technique (ZoLL Z Vent):

#### Circuits:



- 1. Zoll Z ventilator circuits feature a low dead space design that minimizes CO2 rebreathing.
- 2. Note: dead space (circuit and HME) should never be greater than <u>25%</u> of the patient's tidal volume (set or spontaneous.
- 3. The 2 standard ventilator circuits cover the range of patient from infant through adult.


Pediatric/adult – patients 20 kg through adult, minimum tidal volume 200mL.

\*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

Infant/pediatric – 5 through 30 kg, maximum tidal volume 300 mL. \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

Connections - check the ventilator for proper operation before connecting to patient:

<u>Step 1</u>: Connect ventilator circuit (use test lung whenever possible) oxygen hose to 55 psi regulated output.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 3K: Non - Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

Step 2: Power



Zoll Z then begins operation using the default settings. AUTO-CAL is performed every 5

minutes thereafter or when an altitude or temperature change is detected.

Unit performs a Self-Check and AUTO-CAL of the internal


Start-up settings may be changed during operation at any time.

#### Factory Defaults:

transducers.

•	FiO2:	21%
•	High PIP Limit:	35 cm H2O
•	PEEP:	5 cm H2O
•	Vt:	450 ml
•	RPM	12

- ВРМ: 12
- 1:3 I:E
- Mode: AC (V)



- 1. Current value is highlighted.
- 2. Turn rotary encoder to desired value.
  - Adult
  - Pediatric
  - > NIPPV
  - Custom (Cardiac) Arrest)
  - Last setting

Remember: "Touch, Turn, Confirm"™


3. Press select " $\sqrt{}$ " to accept new value





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 3L – MECHANICAL VENTILATION ADULT & INTER-FACILITY PEDIATRIC



Indications:

- 1. Respiratory/Cardiac Arrest Adult.
- 2. Any Medical Etiology of Dyspnea or Airway Management Requiring Intubation Adult
- 3. Any Trauma Etiology of Dyspnea or Airway Management Requiring Intubation (except suspected pneumothorax) Adult.
- 4. Pediatric Dyspnea Requiring Intubation Inter-Facility Continuation of Care.

Contraindications:

- 1. Pediatric Dyspnea Non-Inter-Facility/Non-Continuation of Care.
- 2. Adult dyspnea of lesser severity able to be managed without mechanical ventilation.
- 3. Suspected or impending pneumothorax/tension pneumothorax.

#### Technique (Zoll Z Vent):








Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.** 


### Circuits:



- 1. Zoll Z ventilator circuits feature a low dead space design that minimizes CO2 re-breathing.
- Note: dead space (circuit and HME) should never be greater than <u>25%</u> of the patient's tidal volume (set or spontaneous).
- 3. The 2 standard ventilator circuits cover the range of patient from infant through adult.
  - Pediatric/adult patients 20 kg through adult, minimum tidal volume 200 mL; \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*
  - Infant/pediatric 5 through 30 kg, maximum tidal volume 300 mL.
     \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

Connections- check the ventilator for proper operation before connecting to patient:

<u>Step 1</u>: Connect ventilator circuit (use test lung whenever possible) oxygen hose to 55 psi regulated output.








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.

### Step 2: Power:



Step 3: Changing a Primary Parameter:



- Zoll Z then begins operation using the default settings.
- AUTO-CAL is performed every 5 minutes thereafter or when an altitude or temperature change is detected.
- Start-up settings may be changed during operation at any time.

### Factory Defaults:

FiO2:	21%
High PIP Limit:	35 cm H2O
PEEP:	5 cm H2O
Vt:	450 ml
BPM:	12
I:E	1:3
Mode:	AC (V)
	FiO2: High PIP Limit: PEEP: Vt: BPM: I:E Mode:

- 1. Current value is highlighted.
- 2. Turn rotary encoder to desired value.
  - > Adult
  - > Pediatric
  - > NIPPV
  - Custom (Cardiac Arrest)
  - Last setting

Remember: "Touch, Turn, Confirm"™







Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.

"Custom" (For Adult Cardiac Arrest ONLY): (Figure 1)

- 100% Fi02: 25 cm H2O (Max
- PIP:
  - 50 cm H2O) 3 cm H2O
- PEEP:
- 400-500 ml (titrate Vt: PIP to keep tidal volume within this range.)
- BPM: 10
- I:E 1:3
- Mode: SIMV (P)

Once Ventilator Powered On;

- Select "Custom" from Start Menu
  - Press select " $\sqrt{}$ " green check twice (double tap) at startup
  - Confirm Correct Pre-programmed Settings
  - o Titrate only PIP, other settings remain as specified above




### Safety notes:

- Α. Initial airway management and ventilation must not be compromised while preparing mechanical ventilation equipment.
- B. If problems arise during Zoll Z vent use or if there is uncertainty about the adequacy of oxygenation and ventilations with the Zoll Z vent, then STOP and ensure oxygenation and ventilation with the usual methods.
- C. Using the Zoll Z vent mechanical ventilation device will give the ability to determine early changes in pulmonary compliance, such as may be detected using a bag-ventilation technique.
- D. The incidence of a pneumothorax is increased in the presence of chest trauma with any form of positive pressure ventilation.
- E. Gastric distention can cause resistance to mechanical ventilation. Gastric distention should be suspected in patients with an acutely distended abdomen after non-intubate positive pressure ventilation. Relieve gastric distention impairing respiratory mechanics with either a nasogastric or orogastric tube with low suction until distention is relieved.
- F. Continuous waveform capnography is indicated for mechanical ventilation utilizing the Zoll Z. If transporting a patient with a home ventilator that remains on baseline settings the use of continuous waveform capnography is optional.






### Approved 5/10/23, Effective 7/1/23, replaces all prior versions



**PEDIATRIC**: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 17F CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)










Approved 9/14/22, Effective 1/16/23, replaces all prior versions



consult OLMC when indicated by protocol

communicates with family/bystanders if

indicated



- apply AED/manual defibrillator 0
- analyze rhythm (by AED or paramedic) defib if indicated (by AED or paramedic) with 0
- compressions during AED or manual defib charging. Clear for defib. maintain compressions and analyze rhythm by AED
- or paramedic every 2 minutes (with defib if indicated as above) until additional help arrives

4B.1


patient upper left to P5 location





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 4C – AUTOMATED EXTERNAL DEFIBRILLATION (AED) ADULT & PEDIATRIC



Indications:


Adults and pediatrics that are unresponsive, apneic or agonally breathing, and pulseless.

### Contraindications:

None, though futile in obvious death (decapitation, rigor mortis, dependent lividity, and/or decomposition).

### Technique (Physio-Control LifePak®1000):

- 1. Turn ON AED. (Figure 1)
- 2. Apply AED. Follow illustration for correct defibrillation pad placement. (Figure 2)
  - a. Avoid air spaces/incomplete skin contact under pads.
  - b. Avoid placing pads over suspected implanted pacemakers and/or implanted defibrillators.
  - NOTE (Pediatric): If victim is less than 8 years old or under 25 kg (55 lbs), connect the Infant/Child Reduced Energy Defibrillation Electrodes to the AED and proceed to STEP 3. If Infant/Child Reduced Energy Defibrillation Electrodes are unavailable, place pads in anterior left chest and posterior left chest position when using a standard AED.
  - d. **NOTE (Infant <1 year of age):** Manual defibrillation preferred. Follow STEP 2c if manual defibrillation/paramedic unavailable.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 4C: Automated External Defibrillation (AED) – Adult& Pediatric, cont.

- 3. Follow AED visual and voice prompts.
  - a. If cardiac arrest duration estimated >4 minutes and without good quality bystander CPR, perform CPR for 2 minutes prior to AED analysis for defibrillation determination.
  - b. If cardiac arrest duration estimated ≤4 minutes, immediate AED analysis for defibrillation determination.
- 4. Follow all AED manufacturer recommendations for safe, effective, and accurate rhythm analysis and defibrillation.
- 5. Restart chest compressions while the AED is charging. **DO NOT CONTINUE TO PROVIDE** CHEST COMPRESSIONS WHEN THE AED IS DISCHARGING / DEFIBRILLATING.
- 6. Resuscitate victims of cardiac arrest per applicable protocol(s), minimizing pauses in chest compressions (see Protocol 4B Resuscitation Team Roles).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 4D – MANUAL DEFIBRILLATION ADULT & PEDIATRIC

### PARAMEDIC

Indication:


Ventricular Fibrillation/Pulseless Ventricular Tachycardia

Contraindications:

Spontaneous pulse. All cardiac rhythms except ventricular fibrillation/pulseless ventricular tachycardia.

### Technique:

- 1. Power **ON**. (Figure 1)
- 2. Connect the therapy electrodes (defibrillation pads) to the therapy cable and confirm cable connection to the monitor/defibrillator. (Figure 2)
- Prepare the patient's skin and apply therapy electrodes to the patient in anterior left chest and posterior left chest position. (Figure 3)
- Confirm desired energy is selected, or press ENERGY SELECT or rotate the SPEED DIAL to select the desired energy. (Figure 4)







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 4D: Manual Defibrillation, Adult & Pediatric, cont.

- Press CHARGE. While the monitor/defibrillator is charging, a charging bar appears and a ramping tone sounds, indicating the charging energy level. When the monitor/defibrillator is fully charged, the screen displays available energy. (Figure 5).
- 6. Make certain all personnel, including the operator of the monitor/defibrillator, are physically clear of the patient, stretcher, bed and any equipment connected to the patient.
- 7. Confirm ECG rhythm of ventricular fibrillation or pulseless ventricular tachycardia. Confirm available energy.
- 8. Press the 🥝 (shock) button on the monitor/defibrillator to defibrillate the patient. (Figure 6)
- 9. NOTE: To disarm (cancel the charge), press the SPEED DIAL. The monitor/defibrillator disarms automatically if shock buttons are not pressed within 60 seconds, or if the energy selection is pressed after charging begins. IF DEFIBRILLATION NOT INDICATED UPON A RHYTHM CHECK, DISARM (CANCEL THE CHARGE) BEFORE RESUMING CHEST COMPRESSIONS TO PREVENT INADVERTANT ELECTRICAL EXPOSURE TO EMS PERSONNEL.
- 10. Repeat procedure starting from Step 4, when indicated.

### PEDIATRIC PATIENT:

If patient is less than 4 years of age and/or under 15 kg weight, connect the Quik-Combo<sup>®</sup> Pediatric Electrodes to the monitor/defibrillator and proceed to Step 3. **NOTE**: Pediatric: Initial defibrillation 2 joules/kg with second and subsequent defibrillations at 4 joules/kg. Prior to determining manual defibrillation settings count prior AED defibrillations.

### **DEFIBRILLATION CLINICAL PEARLS:**

- In an emergency resuscitation setting that requires defibrillation, if unfamiliar with monitor/ defibrillator available, look for 1-2-3 sequence (Figure 7) that all monitor/defibrillators are labeled with by industry practice. 1 turns on the device; 2 selects energy; 3 charges the device. Typically, immediately next to 3 is the shock or discharge button.
- 2. In an emergency resuscitation setting that requires defibrillation, do not interrupt or pause chest compressions unless absolutely necessary. Continue to provide chest compressions while a monitor/defibrillator operator is powering on the monitor/defibrillator, selecting energy and charging the device.

### 3. DO NOT CONTINUE TO PROVIDE CHEST COMPRESSIONS WHEN THE MONITOR/ DEFIBRILLATOR IS DISCHARGING / DEFIBRILLATING.











Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 4E – DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION ADULT

### PARAMEDIC

Indication:


Adult refractory Ventricular Fibrillation/Pulseless Ventricular Tachycardia. See also Protocol 4G - Ventricular Fibrillation & Pulseless Ventricular Tachycardia.

### Contraindications:

Spontaneous pulse. All cardiac rhythms except ventricular fibrillation/pulseless ventricular tachycardia

### Technique:

- 1. If two LifePak12 or 15 monitor/defibrillators are available, power the second one ON.
- 2. Connect therapy electrodes (defibrillation pads) to therapy cable and confirm cable connection to monitor/defibrillator per Protocol 4D.
- Prepare the patient's skin and apply second set of therapy electrodes (defibrillation pads) to the patient, in the right parasternal and cardiac apex positions next to, but NOT overlapping the anterior pad of the first set of therapy electrodes (defibrillation pads). (Figure 1)



4. Proceed to charge each defibrillator to 360J. Once fully charged, have either one paramedic discharge both defibrillators or if using two

paramedics, using a 3-2-1 verbal countdown, discharge the defibrillators sequentially using a very specific count of "one thousand one" between the discharge of defibrillator one and the discharge of defibrillator two. FAILURE TO ALLOW A ONE SECOND PAUSE BETWEEN SEQUENTIAL DEFIBRILLATIONS CAN IRREVERSIBLY HARM A DEFIBRILLATOR, RENDERING IT PERMANENTLY INOPERABLE.

5. Throughout the use of double sequential external defibrillation, follow all standard safety measures as with routine defibrillation as outlined in Protocol 4D.


### CLINICAL PEARLS:

DO NOT CONTINUE TO PROVIDE CHEST COMPRESSIONS WHEN THE MONITOR/ DEFIBRILLATOR IS DISCHARGING / DEFIBRILLATING.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions




#### PARAMEDIC

VASOPRESSOR ADMINISTRATION: **ADULT:** EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3 – 5 MINUTES **PEDIATRIC:** EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES





### Approved 9/14/22, Effective 1/16/23 replaces all prior versions




PARAMEDIC
MANUAL DEFIBRILLATION: PAUSE CPR FOR A SINGLE SHOCK. LIMIT DEFIBRILLATION COMPRESSION PAUSE TO MAXIMUM OF 10 SECONDS. ADULT: IF PT ESTIMATED WEIGHT < 100 kg ESCALATING DEFIBS AT 200J, 300J, 360J FOURTH & SUBSEQUENT DEFIBS UTILIZING DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION PER PROTOCOL 4E
ADULT: IF PT ESTIMATED WEIGHT ≥ 100 kg FIRST DE FIB AT 360 JOULES SECOND & SUBSEQUENT DEFIBS UTILIZING DOUBLE SEQUENTIAL EXTERNAL DE FIBRILLATION PER PROTOCOL 4E
<b>PEDIATRIC</b> : INITIAL DEFIB 2 JOULES/kg, SECOND & SUBSEQUENT DEFIBS 4 JOULES/kg COUNT AED DEFIBRILLATIONS PRIOR TO DETERMINING MANUAL DEFIBRILLATION SETTING
VASOPRESSOR ADMINISTRATION: ADULT: EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3-5 MINUTES. MAXIMUM CUMULATIVE DOSE 3mg PEDIATRIC: EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES
ANTIARRHYTHMIC ADMINISTRATION: ADULT: AMIODARONE 300 mg IVP/IOP. REPEAT AT 150 mg IVP/IOP IN 5 MINUTES. MAXIMUM CUMULATIVE DOSE 450 mg. EPINEPHRINE 1 mg IVP/IOP WITH EVERY AMIODARONE ADMINISTRATION
ADULT: MAGNESIUM SULFATE 1 gram IVP/IOP IF TORSADES (POLYMORPHIC PULSELESS VENTRICULAR TACHYCARDIA)
<b>PEDIATRIC:</b> AMIODARONE 5 mg/kg IVP/IOP SINGLE DOSE. EPINEPHRINE 0.01 mg/kg (1:10,000. 0.1 mL/kg) WITH AMIODARONE ADMINISTRATION.
IF SUCCESSFUL CONVERSION TO SUSTAINED PULSATILE RHYTHM (RETURN OF SPONTANEOUS CIRCULATION): ADULT: AMIODARONE 150mg IVPB (ADD TO 100mL NS BAG, INFUSE OVER 10 MINUTES) PEDIATRIC: OLMC CONSULT

4G.1





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



PARAMEDIC


VASOPRESSOR ADMINISTRATION:

ADULT: EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3 – 5 MINUTES PEDIATRIC: EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



FIND POSSIBLE CAUSES OF CARDIOPULMONARY ARREST & TREAT WHERE APPROPRIATE:

HYPERKALEMIA – CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram) & SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq) TOXINS/DRUG OVERDOSE – SUSPECTED TRICYCLIC ANTIDEPRESSANT - SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq) TOXINS/DRUG OVERDOSE – SUSPECTED BETA BLOCKERS ADULT: GLUCAGON 1 mg IVP/IOP PEDIATRIC: GLUCAGON 0.5 mg IVP/IOP TOXINS/DRUG OVERDOSE – SUSPECTED CALCIUM CHANNEL BLOCKERS - CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram)


TENSION PNEUMOTHORAX - NEEDLE THORACOSTOMY (CHEST DECOMPRESSION)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 4J - POST CARDIAC ARREST TREATMENT ADULT & PEDIATRIC







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

4K - "Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation, & Termination of Resuscitation Adult & Pediatric



### "Do Not Resuscitate" & Advanced Directive Orders

Emergency Medical Responders, EMTs and Paramedics shall follow a physician's written Do-Not-Resuscitate (DNR) order, an Oklahoma DNR Consent Form, or an Advanced Health Care Directive accompanied by a written statement from two physicians that the patient is a "qualified" patient.

In many instances of advanced directives/DNR wishes communicated by the patient's family or caregivers, DNR paperwork is missing or incomplete. In such circumstances, contact the Chief Medical Officer or Assistant Chief Medical Officer early in resuscitation (within 2-3 minutes of initiating resuscitation) to review the situation. In most of these situations, the Chief Medical Officer or Assistant Chief Medical Officer will be able to determine further resuscitation is NOT warranted and will be able to cease further resuscitation in concordance with the patient's/family's wishes.

In any of the above confirmed situations, cease or withhold BVM ventilations, advanced airway placement, defibrillation, CPR, and antiarrhythmic and/or vasopressor medication administration. Provide all other appropriate care in accordance with applicable treatment protocols and procedures if the patient is not in respiratory or cardiac arrest, specifically addressing non-cardiopulmonary arrest conditions and maintaining appropriate comfort care for the patient.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Futility of Resuscitation Initiation

CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, and paramedics in the following clinical conditions representing "obvious death" (regardless of cause of cardiac arrest):

No pulse AND No spontaneous respirations AND Pupils fixed (unreactive to light) AND One or more of the following: Rigor mortis. Decomposition. Decapitation. Dependent lividity.

# PROTOCOL 4K: "Do Not Resuscitate" Advanced Directive Orders, Futility of Resuscitation, & Termination of Resuscitation – Adult & Pediatric, cont Futility of Resuscitation Initiation, cont.

In <u>blunt traumatic cardiac arrest</u>, CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, and Paramedics in the following clinical conditions:

No pulse AND No spontaneous respirations AND No shockable rhythm AND No organized ECG activity, i.e., (patient is asystolic or PEA <40 beats per minute)

In <u>penetrating traumatic cardiac arrest</u>, CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, & paramedics in the following clinical conditions:

No pulse AND No spontaneous respirations AND Pupils fixed (unreactive to light) AND No spontaneous movement AND No organized ECG activity (asystole or PEA <40 beats per minute)

Unless the above death criteria are clearly met, CPR and other resuscitative efforts should be initiated and aggressively delivered to promote the best chance of patient survival. In cases involving relative hypothermia (often involved in water submersion situations), ensure full resuscitative efforts are delivered as outlined in Protocol 11B - Cold Illness/Injury. In cases of lightning strike (without signs of "obvious death" as previously listed in this protocol), ensure full resuscitative efforts.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# PROTOCOL 4K: "Do Not Resuscitate" Advanced Directive Orders, Futility of Resuscitation Initiation, & Termination of Resuscitation – Adult & Pediatric, cont.

### Termination of Resuscitation

Evidence-based medicine supports the practice of field CPR termination in the following:

Adult, non-traumatic cardiac arrest patients who have not responded to full resuscitative efforts delivered consistent with the 2023 Medical Control Board Treatment Protocols in the following circumstance in which Paramedic (or higher level) care is available within 20 minutes of first EMS contact with the patient:

An adult patient who has a **non-EMS witnessed**, <u>**non-traumatic cardiac arrest</u>** and is **found in asystole or PEA upon Paramedic arrival** may be considered a candidate for field termination of resuscitation if they do not respond to full resuscitation efforts AND:</u>

- 1) Location of cardiac arrest is a private residence or healthcare facility (e.g. nursing home).
- 2) ALS resuscitative efforts (CPR, successful placement of advanced airway, successful vascular access – IV or IO, and medication administration) have been continuously performed for at least 20 minutes without return of spontaneous circulation (ROSC) or conversion of asystole or PEA to Ventricular Fibrillation/Ventricular Tachycardia at any time during the 20+ minutes of advanced life support.
  - 3) End-tidal carbon dioxide <20 mmHg at time of resuscitation termination.
- 4) The cardiac arrest did not occur in absolute or relative hypothermia.
- 5) The cardiac arrest did not occur due to apparent toxic agent exposure.

# Adult, non-traumatic cardiac arrest patients who have not responded to full resuscitative efforts delivered consistent with the 2023 Medical Control Board Treatment Protocols in the following circumstance in which Paramedic (or higher level) care is <u>NOT</u> available within 20 minutes of first EMS contact with the patient:

An adult patient who has a **non-EMS witnessed**, <u>**non-traumatic cardiac arrest</u>** and is **found in a non-AED shockable rhythm upon first care arrival** may be considered a candidate for field termination of resuscitation if they do not respond to full resuscitation efforts AND:</u>

- 1) Location of cardiac arrest is a private residence or healthcare facility (e.g. nursing home).
- 2) BLS/ALS (non-Paramedic level) resuscitative efforts (CPR, and the possible inclusion of successful placement of advanced airway, successful vascular access IV or IO, and limited medication administration) have been continuously performed for at least 20 minutes without return of spontaneous circulation (ROSC) or conversion of a non-AED shockable rhythm to an AED-shockable rhythm at any time during the 20+ minutes of resuscitation.
  - 3) The cardiac arrest did not occur in absolute or relative hypothermia.
- 4) The cardiac arrest did not occur due to apparent toxic agent exposure.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions


### Termination of Resuscitation, cont.

To be perfectly clear, only after <u>ALL</u> of the above criteria are met, then an online medical control physician or the patient's personal physician may be consulted for field termination of cardiac arrest resuscitation. The physician's order may be either by direct voice communication or in writing if the physician is present at the scene. The order is based upon the physician's decision that the patient's condition is terminal, cardiovascular unresponsiveness has been established despite optimal out-of-hospital ALS emergency medical care, and biologic death has occurred. The EMS professional's decision to stop the resuscitation then shall be based on this physician's order, though such order cannot contradict the conditions specified for termination of resuscitation.

In the event that all of the above field termination criteria are not met, and on scene personnel identify extenuating circumstances that could supersede the stated criteria, the Office of the Medical Director shall be contacted for consultation.

Prior to field termination of resuscitation order requests, logistical factors should be considered such as family expectations, safety of crew and public if resuscitation is halted on scene, factors inhibiting safe patient movement, non-English-speaking family/cultural barriers, private physician order to continue resuscitation and transport, possible correctable causes of cardiac arrest yet untreated. EMS providers on-scene should consider the family member(s) access to resources including clergy, crisis workers, social workers, and other necessary personnel to ensure field termination of resuscitation can be achieved in an efficient, humane manner. Additionally, Oklahoma legal requirements for unattended death must be follow.










Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Indication:

Adult non-traumatic cardiac arrest.

### Contraindications:

Spontaneous circulation/pulse. Traumatic cardiac arrest (hanging/strangulation is NOT considered traumatic in this context). Sternotomy less than estimated 6 months time.

### Technique:

- 1. The correct compression/decompression rate is 80 cycles/minute when using the ResQPUMP<sup>®</sup>. Either the built-in two-tone metronome or an external metronome set to 80 should guide the rate.
- 2. The correct compression depth is 2 inches in adults when using the ResQPUMP<sup>®</sup>. Excessive depths can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 3. The correct compression force is whatever occurs at no more than 2 inches of depth in adults when using the ResQPUMP<sup>®</sup>. In many adults, this will be at or very near 40kg of force as measured on the device's force gauge (which should read as 0kg of force when pulled out for patient use), but let the depth determine the force. Do not start out trying to achieve a certain force regardless of depth. Excessive force can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 4. Any compression with the ResQPUMP<sup>®</sup> should be directly midline of the sternum. Avoid placing the ResQPUMP<sup>®</sup> laterally to the sternum. Improper placement can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 4M: Active Compression Decompression CPR, Adult, cont.

Technique (cont):


- 5. The correct compression technique with the ResQPUMP<sup>®</sup> involves the compressor's shoulders being over and in line with the sternum, producing a direct down (compression) and up (decompression) cycle. Even slight lateral movements of the ResQPUMP<sup>®</sup> can cause loss of suction between the device and the patient's chest, losing the active decompression advantage of the ResQPUMP<sup>®</sup>.
- 6. The correct decompression force of the ResQPUMP<sup>®</sup> is at 10kg as measured on the device's force gauge. Additional decompression force is unnecessary and could lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 7. Avoid any ResQPUMP<sup>®</sup> use when standing. All ResQPUMP<sup>®</sup>-assisted compressions should be performed when kneeling immediately next to the patient's side.
- 8. Avoid any ResQPUMP<sup>®</sup> use when the patient is in motion. This includes during movement of the patient to the ambulance for transport. This includes during ambulance transport of the patient to an Emergency Department.
- If unable to achieve consistent chest wall suction and active decompression with the ResQPUMP<sup>®</sup>, discontinue its use and revert to manual chest compressions at 110 compressions/minute. Strategies to improve chest wall suction include wiping away any moisture on the chest and avoiding placement of therapy electrodes (defibrillation pads) in the compression/decompression site.







## Approved 9/14/22, Effective 1/16/23, Replaces All Prior Versions



Indication:

Adult non-traumatic cardiac arrest (includes isolated hanging or strangulation)

Contraindications:

Spontaneous circulation Traumatic cardiac arrest Patient size/body habitus prevents correct positioning Sternotomy less than 6 months old – by history or best estimate if history unconfirmed

### Technique:

- 1. Move patient to area allowing approximately 3 feet of space in all directions (if applicable).
- 2. Position EleGARD® near the patient's head. DO NOT apply c-collar when using EleGARD®
- 3. Power on EleGARD<sup>®</sup> device by depressing the #1 button.
- 4. 'Coordinate lifting the patient's torso (to no more than approximately 45 degrees) and sliding the lower edge of EleGARD<sup>®</sup> under the patient until that edge comes to the approximate line of the patient's tailbone, with the patient's head being cradled within the head rest of EleGARD<sup>®</sup>.
- 5. Lower the patient and EleGARD<sup>®</sup> together, aligning the patient with their armpits above the compression backplate (yellow board) ensuring the neck rest is at the base of the neck. This may involve pulling EleGARD<sup>®</sup> back while lowering to ensure proper alignment. While not always possible, the goal for completion of steps 4 & 5 is within 10 seconds.
- Place a superglottic airway with a ResQPOD<sup>®</sup> and continue ResQPUMP<sup>®</sup> CPR. Once ResQPOD<sup>®</sup> is in place on the airway, press #2 button and continue with 2 minutes of CPR. Begin manual CPR if the ResQPUMP<sup>®</sup> is either not available or not effective.





Approved 9/14/22, Effective 1/16/23, Replaces All Prior Versions

### Protocol 4N: EleGARD<sup>®</sup> Head Up CPR, Adult, (cont.)

### Technique (cont.):

- 7. Adjust patient position as necessary. DO NOT stop CPR until the timer flashes indicating the end of the 2-minute CPR cycle.
- 8. Activate the head/neck/upper trunk elevation sequence by depressing the #3 button. The sequence is automatic once the #3 button is depressed and will take 2 minutes. The battery lights will illuminate in an upward cascade as the head/neck/upper trunk are being elevated. Limit any interruptions in compressions while EleGARD<sup>®</sup> is elevating. Continue standard resuscitative measures.
- 9. In instances of ROSC and a mean arterial blood pressure of 65mmHg or greater or a systolic blood pressure of 90mmHg or greater, the head of the patient should remain elevated in the head-up device. In instances where the mean arterial pressure is below 65mmHg or systolic BP below 90 mmHg, the head-up device should be lowered to the lowest position in the device.
- 10. If transporting, lift EleGARD<sup>®</sup> horizontally just enough to slide a Mega Mover under the patient's torso. Lift the patient's legs to assure Mega Mover extends the complete length of the patient. Before and after any patient move, check patient positioning for correctness in EleGARD<sup>®</sup>.
- 11. When patient transfer of care occurs or termination of resuscitation occurs, EleGARD<sup>®</sup> is lowered to its resting position by depressing the gray "DOWN" button.
- 12. Complete decontamination of EleGARD<sup>®</sup> and ready its next use following departmental/OMD instructions.






# **4N - RESUSCITATION TEAM ROLES**




# EleGARD<sup>®</sup> HEAD UP CPR-ADULT



4N – EleGARD<sup>®</sup> HEAD UP CPR ADULT












Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 5B – ACQUIRING & TRANSMITTING 12–LEAD ECGs ADULT & PEDIATRIC



### Indications:

- 1. Respiratory Arrest
- 2. Dyspnea Uncertain Etiology
- 3. Dyspnea Chronic Obstructive Pulmonary Disease
- 4. Dyspnea Congestive Heart Failure
- 5. Dyspnea Apparent Life-Threatening Event
- 6. Post Return of Spontaneous Circulation from Cardiac Arrest
- 7. Chest Pain Uncertain Etiology
- 8. Acute Coronary Syndrome
- 9. Bradycardia
- 10. Tachycardia Stable
- 11. Tachycardia Unstable
- 12. Premature Ventricular Contractions
- 13. Hypertensive Emergency
- 14. Stroke
- 15. Syncope
- 16. Poisonings
- 17. Conductive Energy Weapon Related Management
- 18. "Less Lethal" Weapon Related Management
- 19. Lightning/Electrical Injury

### Contraindications:

If transferring facility has already obtained 12-Lead ECG confirming STEMI prior to EMS arrival, transport is not to be delayed in an effort to obtain additional 12-Lead ECG by arriving EMS professionals. Serial 12-Lead ECG(s) for transmission to receiving facilities is/are to be obtained during transport.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5B: Acquiring & Transmitting 12–Lead ECGs – Adult & Pediatric, cont.** 

### Technique (applicable to all 12-Lead ECG devices):

- 1. Prepare skin for electrode application. This may include hair removal with razor and/or rubbing the skin with a gauze (sterile or non-sterile) to remove oil and sweat. Both actions contribute to better electrode adhesion, leading to better quality 12-Lead ECGs.
- 2. For standard 12-Lead ECG, apply leads/electrodes as follows (Figures 1 & 2):
  - a. RA lead on right upper extremity, preferably distal on the extremity near the wrist on the palm side.
  - b. LA lead (mirror image of RA) on the left upper extremity, preferably distal on the extremity near the wrist on the palm side.
  - c. RL lead on the right lower extremity, preferably distal on the extremity near the ankle on the outside of the leg.
  - d. LL lead (mirror image of RL) on the left lower extremity, preferably distal on the extremity near the ankle on the outside of the leg.
  - e. V1 lead to the right of the sternum in the 4<sup>th</sup> intercostal space.
  - f. V2 lead (mirror image of V1) to the left of the sternum in the 4<sup>th</sup> intercostal space.
  - g. V4 lead is placed next and in the mid-clavicular line in the left 5<sup>th</sup> intercostal space.
  - h. V3 lead in the middle of the line now created between leads V2 and V4.
  - i. V5 lead in horizontal line with V4 at anterior axillary line of the left axilla.
  - j. V6 lead in horizontal line with V5 at mid-axillary line of the left axilla.
- 3. For a "right-sided" 12-lead ECG to evaluate for right ventricular myocardial infarction in the setting of suspected left ventricular inferior wall ST segment elevation myocardial infarction, simply apply four additional electrodes on the right chest, mirroring V3, V4, V5, and V6. Then move the leads off of V3-V6 and place on their right-sided mirror electrode to create V3R, V4R, V5R, and V6R (Figure 2).








Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5B: Acquiring & Transmitting 12–Lead ECGs – Adult & Pediatric, cont.** 


Technique (Physio-Control LifePak® 15):

- To acquire and transmit a 12-lead ECG:
- 1. Press ON. (Figure 4)
- 2. Insert the lead attachments into the main cable. (Figure 5)
- 3. Insert the cable connector into the monitor's green ECG connector. (Figure 6)
- 4. Prepare patient's skin as described above.
- 5. Apply leads/electrodes as described above.
- 6. Instruct patient to remain still as possible during 12-Lead ECG acquisition to reduce movement artifact (to improve quality of 12-Lead ECG sent to emergency department).
- Press 12-LEAD to acquire ECG and enter patient demographic information of last name, first name, age, sex (gender), incident number (if applicable) using the speed dial. (Figures 7 & 8)
- 8. Once 12–Lead ECG acquired, press **TRANSMIT**. (Figure 9)
- 9. In the TRANSMIT window, select 12-Lead **REPORT** to be sent. (Figure 10)
- 10. In the TRANSMIT window, select SITE.
- 11. In the SITE window, select desired transmission destination, typically a hospital's emergency department. (Figure 11)
- 12. In the TRANSMIT window, select **SEND**. (Figure 12)
- 13. The Physio-Control LifePak<sup>®</sup>15 should connect to the selected destination.
- 14. Once the transmission is completed a transaction message is automatically printed.
- 15. If the transmission fails, make at least one additional attempt at transmission.

















5B.3





### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5B: Acquiring & Transmitting 12–Lead ECGs – Adult & Pediatric, cont.**

**NOTE:** There are limitations with transmitting data by telecommunications. Successful transmission depends on the access to public or private network services that may or may not always be available. This is especially true for cellular communication that is influenced by many factors, such as:


- Geography
- Location
- Weather
- Cellular service activity load (volume of active users)
- Cellular service availability

Treatment protocols take into account the fact that data transmissions cannot be assured with the use of cellular communications. Therefore, early voice communication with the receiving facility is an essential contingency plan for interrupted data transmissions.

Multiple methods of transmitting 12-Lead ECG data exist (proprietary cellular/satellite network systems, data fax transmission, cellular transmission of images, e.g. photographs of the 12-Lead ECG sent via smartphone). Check with local EMS administration officials and medical oversight physician(s) to ensure local practices are understood and follow all applicable laws relating to protected health information.

























Approved 9/14/22, Effective 1/16/23, replaces all prior versions

5E – TRANSCUTANEOUS PACING ADULT & PEDIATRIC

### PARAMEDIC

Indications:

- 1. Symptomatic 2nd Degree AV Block-Type II (Classic)
- 2. Symptomatic 3rd Degree AV Block (Complete)
- 3. Symptomatic Bradycardia in Acute Coronary Syndrome in preference to atropine use
- 4. Symptomatic Bradycardia unresponsive to non-electrical interventions
- 5. Symptomatic Bradycardia in pediatric patients (when approved by OLMCP consultation)


### Contraindications:


1. Asymptomatic Bradycardia

Technique: (Physio-Control LifePak<sup>®</sup> 15):

- 1. Maintain standard ECG monitoring using electrodes/cable.
- 2. Apply Quik–Combo<sup>™</sup>pads in anterior/posterior chest wall location illustrated in (Figure 1). Excessive diaphoresis may require drying and/or excessive chest hair may require partial removal to achieve appropriate pad-chest wall adhesion.
- 3. Connect Quik-Combo<sup>™</sup> pad set to LifePak<sup>®</sup> monitor/defibrillator via attached cable.
- 4. Advise patient of impending therapy. Administer sedation if patient condition allows, adults to receive 2-5 mg midazolam IVP as individual patient weight and hemodynamics dictate.
- 5. Power on the pacing function by pressing the "PACER" button (Figure 2).
- 6. Confirm ECG rhythm is sensed by Quik-Combo<sup>™</sup> pads, looking for triangular "sense markers" marking QRS complexes (Figure 3). If sense markers do not appear, check for correct Quik-Combo<sup>™</sup> pad attachment to LifePak monitor/defibrillator. If sense markers are inconsistently tracking QRS complexes and/or tracking T waves, adjust ECG size or select alternate monitoring lead to achieve correct QRS complex tracking.













Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **PROTOCOL 5E:** Transcutaneous Pacing, Adult & Pediatric, cont.

### Technique (cont):

- 7. Set pacing rate at 60 paces per minute (adults) either by pressing the "RATE" switch up arrow to increase rate or down arrow to decrease rate or by rotating the "SPEED DIAL" knob (Figure 4). The "RATE" switch will allow changes in 10 paces per minute increments; the "SPEED DIAL" knob will allow changes in 5 paces per minute increments.
- 8. Set pacing current at minimum level achieving electrical AND mechanical capture. Deliver electrical pacing current either by pressing the "CURRENT" switch up arrow to increase milliAmp (mA) current or down arrow to decrease mA current or by rotating the "SPEED DIAL" knob (Figure 5). The "CURRENT" switch will allow changes in 10 mA increments; the "SPEED DIAL" knob will allow changes in 5 mA increments.
- 9. Pressing the "PAUSE" button will cause the set pacing rate to decrease by 25% (eg. rate of 60 paces per minute changes to rate of 45 paces per minute) while it is being depressed. This function should not be used without directive from OLMC.
- 10. If pacing therapy termination is required, power off the pacing function by pressing the "PACER" button (Figure 2).





### Pacing-Related Considerations: (Physio-Control LifePak<sup>®</sup> 15):

- 1. In the event of ventricular fibrillation or pulseless ventricular tachycardia, pressing the yellow "CHARGE" button will automatically stop the pacing function. Proceed with defibrillation.
- If the monitor displays "ECG LEAD OFF" during transcutaneous pacing, pacing automatically switches to non – demand and continues at the fixed rate until the ECG lead(s) is reattached. During non – demand pacing, the pacemaker delivers pulses at the set pace rate regardless of any intrinsic beats that the patient may have. The monitor continues to display the pacing rate and the current. To reestablish demand pacing, reattach the ECG lead(s).
- 3. If the Quik-Combo<sup>™</sup> electrodes detach during pacing, the monitor will display "CONNECT ELECTRODES" and "PACING STOPPED" messages and sound an alarm. The set pacing rate is maintained, but the current resets to 0 mA. Reattaching the Quik-Combo<sup>™</sup> electrodes silences the alarm and removes the messages. The current remains at 0 mA until manually adjusted as described above.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 5E: Transcutaneous Pacing, Adult & Pediatric, cont.

### Pacing-Related Considerations (cont):


- Proper electrical capture is displayed by depolarization of the ventricles, reflected as a wide QRS, followed by a distinct, broad T wave (Figures 6 & 7). Absence of these findings immediately following pacing spikes generally indicates failure of consistent electrical and mechanical capture (Figures 8 & 9).
- With transcutaneous pacing, it may be difficult to see the paced QRS complex due to washout from the pacing stimulus. It is imperative to confirm capture by a physiologic measure such as a pulse.








#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions







#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 5H – SYNCHRONIZED CARDIOVERSION ADULT & PEDIATRIC

#### PARAMEDIC

### Indication:

Unstable, symptomatic tachycardia (adult heart rate > 150 beats per minute; afebrile pediatric heart rate > 180 beats per minute) AND hemodynamic compromise adult systolic blood pressure <100 mmHg; pediatric systolic blood pressure < (70 + 2x age in years) mmHg.


#### Contraindications:


- 1. Stable tachycardia (Treatment per Protocol 5F Stable Tachycardia)
- 2. Normal sinus rhythm
- 3. Bradycardia
- 4. Ventricular fibrillation/pulseless ventricular tachycardia

#### Technique (Physio-Control LifePak® 15):

- 1. Power **ON**. (Figure 1)
- 2. Attach patient ECG cable and ECG electrodes. ECG electrodes and cable must be used to monitor the ECG when paddles are used for synchronized cardioversion.
- 3. Select lead with the greatest QRS complex amplitude positive or negative deflection. (Figure 2)
- 4. Press **SYNC**. The **SYNC MODE** message appears in the message area when **SYNC** is active. (Figure 3)
  - a. **NOTE:** To deactivate **SYNC MODE** when not synchronized cardioverting, press **SYNC** again.













Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5H: Synchronized Cardioversion, Adult & Pediatric, cont.** 


Technique (cont):


- Observe the ECG rhythm. Confirm that a triangle sense marker (▼) appears near the MIDDLE of each QRS complex. (Figure 4)
  - a. If the sense markers DO NOT appear or are displayed in the wrong location (for example on the T wave) adjust ECG SIZE or select another lead. It is normal for the sense marker location to vary *slightly* on each QRS.
- Connect the therapy electrodes to the therapy cable and confirm cable connection to the monitor/defibrillator. (Figure 5)
- Prepare the patient's skin and apply therapy electrodes to the patient in the anterior-posterior chest wall position. (Figure 6)
- Press ENERGY SELECT or rotate the SPEED DIAL to select the desired energy. (Figure 7) Per Protocol 5G – Tachycardia – Unstable, for adult synchronized cardioversion, begin at 100 joules energy. If unstable tachydysrhythmia persists, repeat synchronized cardioversion at escalating energy settings of 200 joules, 300 joules, 360 joules. For pediatric synchronized cardioversion, consult on-line medical control for treatment plan and energy settings.
- Press CHARGE. While the monitor/defibrillator is charging a charging bar appears and a ramping tone sounds, indicating the charging energy level. When the monitor/defibrillator is fully charged, the screen displays available energy. (Figure 8)

















Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5H: Synchronized Cardioversion, Adult & Pediatric, cont.** 

Technique (cont):

- 10. Make certain all personnel, including the operator, stand clear of the patient, bed, and any equipment connected to the patient.
- 11. Confirm ECG rhythm. Confirm available energy. <u>Prior to</u> <u>delivering synchronized cardioversion, it is paramount to</u> <u>ensure that the **SYNC MODE** message continues to</u> <u>appear. Failure to deliver a "synchronized" cardioversion</u> <u>in this setting could cause ventricular fibrillation cardiac</u> <u>arrest in the patient.</u> (Figure 9)
- 12. Press and hold the *(shock)* button on the monitor/defibrillator until the **ENERGY DELIVERED** message appears on the screen. (Figure 10)
  - a. **NOTE:** To disarm (cancel the charge), press the SPEED DIAL. The energy disarms automatically if shock buttons are not pressed within 60 seconds, or if the energy selection after charging begins.
- 13. Observe patient and ECG rhythm. Repeat procedure starting from Step 4, if necessary.









Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 5I - IMPLANTABLE PACEMAKER MANAGEMENT ADULT & PEDIATRIC

#### PARAMEDIC

### **Clinical Pearls:**

- 1. Correlate electrical pacing activity with mechanical heart activity (eg. pulses).
- 2. If electrical pacer spikes seen on the ECG monitor are not consistently and immediately followed by electrical activity of atrial, ventricular, or both atrial and ventricular depolarization, then the pacemaker may be intermittently functioning. This may be normal if the patient's heart rate is above 60 beats per minute, since most pacemakers will be set to a demand mode (pacing only when needed). Alternately, if the patient is bradycardic, the pacemaker may be non-functional (eg. battery failure).
- 3. The "sensor function" of a pacemaker attempts to anticipate increased metabolic needs and raises heart rate. The most commonly used sensor is an accelerometer which raises pacing rate when motion is detected. Thus, physical motion of the patient (including motion created by riding on the ambulance stretcher enroute to the hospital) can stimulate increasing rates of pacing. If the paced rate is noticeably higher than usual set rates of 60-80 beats per minute, attempt to minimize the patient's physical motion and observe if pacing rates decline.
- 4. Due to the variety of pacemaker types and settings, pacemaker manufacturers supply patients with a card to be carried (usually in wallet or purse) that identifies the pacemaker by manufacturer, type, and date of implantation.
- 5. Specific types of pacemaker malfunction include the following:
  - a. Failure to pace/output no pacing spikes seen in a bradycardic patient. (example, oversensing of myopotentials, dead battery)
  - b. Failure to sense pacing becomes asynchronous. (example, patient's heart voltage too low for pacer to sense)
  - c. Failure to capture pacing spikes seen without capture. (examples, lead becomes dislodged from myocardium or breaks)
  - d. Overpacing or "runaway pacing" pacemaker pacing at fast rates without clear reason. (examples, sensor-driven pacing from motion, pacemaker-mediated tachycardia)
- 6. In the setting of sustained, symptomatic rapid pacing suspected to be related to overpacing (see Item 4 above) tachycardia may be able to be controlled by placing a doughnut-shaped medical magnet over the generator.
- 7. In the setting of cardiac arrest, treat per usual resuscitation, but avoid placing defibrillation pads over the pacemaker generator.
- 8. Consult on-line medical control early in the course of suspected pacemaker management issues for further guidance.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 5J - IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR (ICD) MANAGEMENT ADULT & PEDIATRIC

#### PARAMEDIC

**Clinical Pearls:** 

- 1. Correlate ICD activity with ECG rhythm ventricular fibrillation/tachycardia?
- 2. Due to the variety of ICDs, manufacturers supply patients with a card to be carried (usually in wallet or purse) that identifies the ICD by manufacturer, type, and date of implantation.
- All ICDs have pacemaker function. Some patients have pacing indications and may have normal or abnormal pacemaker function (see 5I – Pacemaker Management) associated with their ICD. Many patients with ICDs, however, do not have a pacemaker indication.
- 4. Specific types of ICD malfunction include the following:
  - a. Inappropriate ICD shocks Patient is shocked without evidence of arrhythmia (examples, lead fracture, oversensing of t-waves)
  - Failure to shock ventricular tachycardia/fibrillation (examples, undersensing of small fibrillatory waves, slow ventricular tachycardia below the ICD's programmed VT zone)
- 5. If the patient is hemodynamically stable, acquire and transmit a 12-Lead ECG prior to attempting any change in ICD function.
- 6. In the setting of oversensing, especially if multiple apparently inappropriate ICD discharges occur, the ICD may be temporarily deactivated by placing a doughnut-shaped medical magnet over the ICD generator. Depending upon the exact model of ICD, a beep or sustained tone may be heard with successful magnet application.
- 7. While the magnet is applied to the ICD, no therapies will be delivered even when needed for life-threatening arrhythmias. Therefore, PRIOR TO DEACTIVATING AN ICD WITH A MAGNET, THE PATIENT MUST BE ON CONTINUOUS ECG MONITORING AND A DEFIBRILLATOR MUST BE IMMEDIATELY AVAILABLE.
- 8. In the setting of cardiac arrest, treat per usual resuscitation, but avoid placing defibrillation pads over the ICD generator.
- 9. Consult on-line medical control early in the course of suspected ICD management issues for further guidance.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **5K - PREMATURE VENTRICULAR CONTRACTIONS ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. O2 via NC or NRB if indicated 2. 12-Lead ECG
- 3. Rhythm Analysis

#### UNSTABLE (SYMPTOMATIC) premature ventricular contractions are defined by any of the following symptoms:

1. Dyspnea

- 2. Chest pain
- 3. Weakness
- Altered mental status 4.
- Hypoxemia
   Pulmonary
- Pulmonary edema

EMERGENCY MEDICAL DISPATCHER **EMERGENCY MEDICAL** RESPONDER

EMT

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

PARAMEDIC

#### PARAMEDIC

ASYMPTOMATIC PVCs DO NOT REQUIRE ANTI-DYSRHYTHMIC MEDICATION.

TREAT IF UNSTABLE WITH SYMPTOMS AND ADULT SYS BP < 100 mmHg

DO NOT PHARMACOLOGICALLY SUPPRESS PVCs IN 2<sup>nd</sup> / 3<sup>rd</sup> DEGREE HEART BLOCKS ADULT: AMIODARONE 150mg VERY SLOW IVP/IVPB OVER 10 MINUTES.

PEDIATRIC: OLMC CONSULT





Removed by MCB September 11, 2013

5L - HYPERTENSIVE EMERGENCY ADULT & PEDIATRIC




### EMS System for Metropolitan Oklahoma City and Tulsa 2023 Medical Control Board Treatment Protocols Approved 9/14/22, Effective 1/16/23, replaces all prior versions



5M – VENTRICULAR ASSIST DEVICE (VAD) MANAGEMENT


ADULT



A **Ventricular Assist Device**, or **VAD**, is a mechanical device used to support circulation in a patient with significant cardiac ventricular dysfunction. The VAD, most commonly, is used to support the left side of the heart and provide extra cardiac output to the body. This device is called an LVAD or left ventricular assist device. An LVAD can be placed for short term use to bridge patients until they can receive a heart transplant (bridge to transplant) or long term use for those patients that are not candidates for heart transplant (destination therapy). A destination therapy patient will live for months to years at home with the device in place. A VAD is <u>not</u> a total artificial heart (TAH), which completely supports circulation in a patient whose native heart has been removed.

VADs can assist either the right (RVAD) or left (LVAD) ventricle, or both at once (BiVAD). The choice of device depends on underlying heart disease and the function of the right side of the heart. The most common type of device used is an LVAD.

In Oklahoma the most common VAD in use is the HeartMate<sup>®</sup> II LVAD. The Heart Mate<sup>®</sup> II uses a continuous flow pumping action to produce forward circulation. Because of the continuous flow nature of the pump, a patient with a HeartMate II<sup>®</sup> may not have a palpable pulse even though they are alive. The lack of pulse can also make it difficult, or impossible to obtain a blood pressure.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.** 

Hospital Resources in Oklahoma for Patients with a VAD and TAH:

Integris Baptist Medical Center in Oklahoma City is the only VAD/TAH surgical implant site in Oklahoma at the time of this protocol's release.

Upon arrival to the scene, contact a VAD coordinator for assistance with VAD/TAH related questions. An RN coordinator is available 24-hours a day.

### 24-hour Integris Baptist Medical Center VAD/TAH phone number: 405-713-7040

#### Cardiac Arrest Care in Patients with a VAD:

Follow same BLS and ACLS protocols (including defibrillation and cardioversion).

Perform chest compressions only after all other treatments have been applied.

Because of the assistance from the LVAD, patients may not be symptomatic with ventricular arrhythmias. Be sure to assess the patient first prior to intervention.

The LVAD does NOT interfere with the patient's heart rhythm. The native rhythm will appear on the monitor.

#### Non-Cardiac Arrest Care in Patients with a VAD:

Emergencies in a patient with a VAD can arise due to:

- Problems directly related to the VAD:
  - → Power Failure
  - ↔ Suspected mechanical malfunctions characterized by frequent alarms emitting from the system controller, an increase or decrease in flow rates
- Focus on switching out the system controller. (see directions below)
- Illness/Injury not related to the VAD treat per applicable protocol. (i.e. stroke, bleeding, etc.)

#### Power Failure of a VAD - EMS Assessment & Care:

- A patient experiencing a power failure with their VAD system will present with signs and symptoms of circulatory collapse (dyspnea, hypoxemia, hypotension, dysrhythmias, altered mental status).
- Focus on restoring power to the VAD by switching batteries in the battery pack, connecting to an AC power source, or switching out the system controller.



EMERGENCY MEDICINE UNIVERSITY OF OKLAHOMA

Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.

### TROUBLESHOOTING: Heart Mate<sup>®</sup> II

### When the Pump Has Stopped

- Check the connections between the controller and the pump and the power source and fix any loose connections.
- If the pump does not restart and the patient is connected to batteries replace the current batteries with a new, fully-charged pair.
- If pump does not restart, change controllers.

### Changing Controllers:









- 1. To insert the driveline, slide the safety tab back to unlock and expose the red button
- 2. Align the arrow on the controller to the arrow on the driveline cable until they connect, and firmly insert the driveline until it snaps into place
- 3. Be sure to slide the safety tab back over the red button, locking the driveline in place.
- 4. Tug gently on the metal portion of the driveline to ensure it is fully engaged.





Button

User

Interface Screen

HeartMatell'

Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.** 

### **Alarms: Emergency Procedures**

Low Battery Alarm	The red low battery symbol illumina battery power remain (applicable o battery-powered operation).		
	This is a <b>Hazard</b> alarm. When the immediately replace the depleted be switch to the Power Module.		
Yellow Wrench Alarm	The yellow wrench symbol illuminates when the System Controller detects a mechanical, electrical, or software issue with the system.		
and the second s	This is an <b>Advisory</b> alarm. When the screen for troubleshooting instru	the yellow wrench illuminates, check ctions.	
Red Heart Alarm	The red heart symbol illuminates wh problem that could cause serious in		
<b>9</b>	This is a <b>Hazard</b> alarm. When the screen for instructions and take imm	red heart illuminates, check the ediate action to resolve the problem.	
Cable	Battery Button	Pump Running	
Disconne	et /	Symbol	

Status Symbols Silence Alarm Button

 $\boxtimes$ 

0



Approved 9/14/22, Effective 1/16/23, replaces all prior versions




### **PROTOCOL 5M:** Ventricular Assist Device (VAD) Management – Adult, cont.

#### TROUBLESHOOTING: Heart Mate® II

#### **Changing Batteries**

- 1. Warning: At least one power lead must be connected to a power source at all times.
- 2. **DO NOT remove** both batteries at the same time or the pump will stop.
- 3. Obtain two charged batteries from patient's black bag.
- 4. Check the charge of the battery by pressing the battery gauge button on the end and top of the battery. (Figure 1)
- 5. Remove <u>only one battery</u> from the clip by pressing the tab on the battery clip to release the battery.
- 6. Controller will start beeping and flashing green lights.
- 7. Replace with new fully charged battery by lining up the arrows on the battery and the clip and pressing until you hear a "click."
- 8. Repeat previous steps with the second battery and battery clip. Remove only one battery from the clip by pressing the tab on the battery clip to release the battery.










Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.** 

# HeartMate II<sup>®</sup> LVAD Patient Assessment Protocol








Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.** 

### **Total Artificial Heart**

#### **Overview:**



**Basic Operations** 

- 1. Pump is connected to 2 drivelines (air lines) that are attached to the driver, which runs the pump
- 2. Do not kink the drivelines.
- 3. The electrical conduction system of the heart has been removed so a heart rhythm cannot be viewed on the ECG.
- 4. Batteries last approximately 2 hours for a set.
- 5. Plug the driver into an outlet as often as possible for power.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions



## PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult, cont.

**Total Artificial Heart** 

# When the Pump Has Stopped: <u>Immediately</u> switch to the back-up driver.

# **Changing to the Back-Up Driver**


- With the Wire Cutter Tool, cut the Wire Tie under the metal release button of the CPC Connector that secures the red TAH Cannula to the red Freedom Driveline. DO NOT DISCONNECT THE CANNULA FROM THE DRIVELINE YET.
- With the Wire Cutter Tool, cut the Wire Tie under the metal release button of the CPC Connector that secures the **blue** TAH Cannula to the **blue** Freedom Driveline. DO NOT DISCONNECT THE CANNULA FROM THE DRIVELINE YET.



CAUTION: Before disconnecting the Drivelines of the primary Freedom Driver, you must have the Drivelines of the backup Freedom Driver within reach. <u>The backup</u> <u>Driver must be turned on by inserting 2 batteries.</u> Perform steps 3 and 4 simultaneously.

- 3. Disconnect the **red** Cannula from the **red** Driveline of the primary Freedom Driver.
- 4. Press and hold down the metal release button. (Fig. 11)
- 5. Pull the **red** Cannula away from the **red** Driveline (Figure 12). **Immediately** insert the **red** Cannula into the new **red** Driveline from the backup Freedom Driver until you hear a click.
- 6. **Simultaneously** disconnect the **blue** Cannula from the **blue** Driveline of the primary Freedom Driver.
- 7. Press and hold down the metal release button.
- 8. Pull the **blue** Cannula away from the **blue** Driveline.
- **9. Immediately** insert the **blue** Cannula into the new **blue** Driveline from the back-up Freedom Driver until you hear a click.









Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**PROTOCOL 5M:** Ventricular Assist Device (VAD) Management – Adult, cont.

### Total Artificial Heart

Treatment Considerations:

- 1. External chest compressions cannot be performed on a patient with a Total Artificial Heart. Changing to the back-up driver is essential to maintaining circulation. There's no "handpump" to operate the Total Artificial Heart manually.
- 2. If the pump stops, a red fault alarm along with a continuous audio tone will sound.
- 3. All device settings are preset and cannot be changed in the field.
- 4. Since the electrical conduction system of the heart has been removed the underlying ECG rhythm will show asystole. The patient with a Total Artificial Heart should not be defibrillated.
- 5. If the driver pump is connected and functioning properly, the patient will have a pulse.
- 6. A measurable blood pressure is obtainable using a manual or automated blood pressure device.
- 7. Use alternative ways to assess the adequacy of perfusion such as pale vs. pink, dry vs. diaphoretic, and alert vs. confused.
- 8. Incorporate device into assessment.
- 9. General Supportive Care and initiate treatment per applicable protocol.
- 10. Listen just below the heart to hear if the device is running and assess for a palpable pulse.
- 11. If there is no palpable pulse detected, consider the following:
  - The device is not running: Troubleshoot the device and treat per protocol.
  - The device is running, but the patient is still unconscious or unstable:
    - Neurological evaluation: Possible Stroke
    - Expose the patient:
      - Be cautious with trauma shears; don't cut a driveline or cable exiting the patient's body that might be hidden under an article of clothing;
      - Assess the dressings over the driveline exit site (found in the abdominal area) for signs of infection.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 5N – INTRA-AORTIC BALLOON PUMP (IABP) MONITORING - ADULT

#### PARAMEDIC


#### Introduction:

Transfer of patients between hospitals is and will be an increasing demand due to an aging society and the increasing invasiveness of recommended therapies. Intra-aortic balloon pumps are used in mechanical circulatory support. The reduction in size and weight of the respective devices now allows an increasing number of interfacility transfers with continuing mechanical circulation support.

#### Indications for Intra-Aortic Balloon Pump (IABP):

IABP counter-pulsation support is a recommended option for patients with cardiac failure, mainly due to coronary artery disease or congestive heart failure. Early IABP support is used to accompany acute percutaneous coronary intervention (PCI) or cardiac surgery. In addition, IABP support may function as a bridge prior to invasive procedures if these specialties are unavailable at the initial hospital of admission. If in such a situation inter-hospital transfer is mandatory, IABP support must be maintained in clinical settings that may include refractory unstable angina, impending or acute myocardial infarction, ventricular failure, acute valvular disease, and cardiogenic shock.

#### Objective of the Transport Team:



**NOTE**: Paramedic may provide or assist in providing mechanical circulatory support during interfacility transport only if they have completed special additional training in the use of IABP including appropriate continuing education and are properly credentialed by the appropriate local medical oversight physician(s) to operate or assist with IABP.









Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

### Before transport of the patient:

- 1. Together with physician, nurse, or cardiovascular technical staff (as appropriate), ensure that intra-aortic balloon catheter is properly secured, check intra-aortic balloon insertion site for bleeding or drainage, confirm adequacy of distal pulses and perfusion, and record pre-transport intra-aortic balloon pump settings.
  - NOTE: IT MAY BE NECESSARY TO USE A DOPPLER STETHOSCOPE TO CONFIRM PULSATILE FLOW IF CARDIOGENIC SHOCK IS SEVERE.
- 2. Measure and record augmented systolic, mean, and diastolic blood pressure in addition to standard vital signs.
- 3. If the transport is not accompanied by a physician or nurse, obtain written order for intraaortic balloon pump settings to be used enroute.
  - NOTE: IF YOU ARE NOT FAMILIAR WITH THE TYPE OF INTRA-AORTIC BALLOON PUMP BEING USED, OR DO NOT FEEL COMFORTABLE WITH THE INTRA-AORTIC BALLOON PUMP SETTINGS PRESCRIBED BY THE SENDING PHYSICIAN, DO NOT ATTEMPT TRANSPORT. CONTACT ON-LINE MEDICAL CONTROL FOR FURTHER INSTRUCTIONS.
- 4. Ensure that the intra-aortic balloon pump being used is properly functioning, that an acceptable ECG trigger is present, and that all settings are correct.

#### During transport of the patient:

- 1. Connect IABP power cable to the ambulance power supply during transport. The battery gauge of the IABP is in the right lower corner of the console screen.
- 2. Continuously monitor augmented systolic, mean, and diastolic blood pressure in addition to standard vital signs.
- 3. In the event of mechanical failure, and the patient remains stable, attempt to identify and correct the problem.
- 4. In the event of a clinical emergency, and a physician, nurse practitioner, or physician surrogate IS present, assist with intra-aortic balloon pump management on request, and contact on-line medical control (or duly authorized agent) as soon as possible (without compromising patient safety).
- 5. In the event of a clinical emergency, and a physician, nurse practitioner, or physician surrogate is **NOT** present, proceed with cardiopulmonary resuscitation as indicated, and contact on-line medical control as soon as possible (without compromising patient safety).

• **NOTE**: CARDIOPULMONARY RESUSCITATION AND DEFIBRILLATION MAY BE PERFORMED WHILE THE INTRA-AORTIC BALLOON PUMP IS FUNCTIONING.

#### After transport of the patient:


Record type and model of intra-aortic balloon pump used, settings employed in-transport, and augmented systolic, mean and diastolic blood pressures obtained post-transport, as well as any changes in patient condition, modifications in intra-aortic balloon pump settings, and unusual incidents occurring enroute.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.** 

Troubleshooting the Maquet CS300<sup>™</sup> IABP – (see protocol Special Note):







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

### Troubleshooting the Maquet CS 300<sup>™</sup> IABP, cont:

Augmentation Below Lin	mit Set	Autofill Failure		
116 AUG. 120 ANG ALARM				
Probable Cause	Corrective Action	Probable Gause	Corrective Action	
Hemodynamic status has changed: ↑HR, ↓SV, ↓MAP.	Treat patient, adjust alarm limit as appropriate.	IAB disconnected.	Attach IAB catheter.	
Alarm limit set too high.	Press AUG. ALARM key,	Helium tank is closed.	Open helium tank.	
	change limit.	Helium tank is empty.	Change helium tank.	
		Incorrect IAB catheter extender tubing length.	Ensure only one IAB catheter extender tubing is connected from IAB to pump.	
ALARMS Check IAB Catheter		IAB Disconnected		
		IAB Disconnected		
Check IAB Catheter	Corrective Action	IAB Disconnected	Corrective Action	
Check IAB Catheter	Corrective Action	Probable Cause IAB catheter or extender tubing is	Corrective Action Reattach IAB, press START.	
Check IAB Catheter	Corrective Action Relieve kink if possible, press START.	Probable Cause	Reattach IAB,	
Check IAB Catheter	Corrective Action Relieve kink if possible, press START. Manually inflate and	Probable Cause IAB catheter or extender tubing is	Reattach IAB,	





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

### Troubleshooting the Maguet CS300<sup>™</sup> IABP, cont:


Prolonged Time in St	andby	Rapid Gas Loss or Le	eak in IAB Circuit
IAB STATUS		- aheck tubing for blood	
Probable Gause	Corrective Action	Probable Cause	Corrective Action
IABP has been in STANDB' mode for an extended peri of time.	· · · · · · · · · · · · · · · · · · ·	Gas loss has been detecte in IAB circuit.	d If blood observed - STOP pumping. Prepare for removal of IAB.
			If blood is not observed. verify connections are leak-free.
			With Rapid Gas Loss, resume pumping by pressing START key.
			With Leak in IAB Circuit, press IAB FILL key for 2 seconds to initiate an AUTOFILL, then resume
ALARMS			pumping by pressing START key.
ALARMS	AB Optical Sensor	IAB Optical Sensor C	pumping by pressing START key.
Unable to Calibrate I			pumping by pressing START key.
	AB Optical Sensor Corrective Action When patient's pulse pressure improves, press ZERO PRESSURE key for 2 seconds while the IABP is assisting. Provide alternate A.P. source (i.e.: radial).	Probable Cause A calibration update has been intentionally post- poned because either patient's mean arterial pressure may be too low to pause assist or less than 15 minutes have	alibration Expired Corrective Action Assess patient to determine If a brief pause in assist would be toler- ated, and if so, press ZERO PRESSURE key for 2 seconds while IABP is assisting.
Unable to Calibrate M Probable Cause Patient's pulse pressure is	Corrective Action When patient's pulse pressure improves, press ZERO PRESSURE key for 2 seconds while the IABP is assisting. Provide alternate A.P. source	Probable Cause A calibration update has been intentionally post- poned because either patient's mean arterial pressure may be too low to pause assist or less	alibration Expired Corractive Action Assess patient to determine if a brief pause in assist would be toler- ated, and if so, press ZERO PRESSURE key for 2 seconds while IABP is
Unable to Calibrate M Probable Cause Patient's pulse pressure is	Corrective Action When patient's pulse pressure improves, press ZERO PRESSURE key for 2 seconds while the IABP is assisting. Provide alternate A.P. source (i.e.: radial). Relieve restriction.	Probable Cause A calibration update has been intentionally post- poned because either patient's mean arterial pressure may be too low to pause assist or less than 15 minutes have elapsed since last calibration. Pump is either in STANDBY or the IAB FILL	alibration Expired Corractive Action Assess patient to determine if a brief pause in assist would be toler- ated, and if so, press ZERO PRESSURE key for 2 seconds while IABP is assisting. Provide alternate A.P.
Unable to Calibrate I/ Probable Cause Patient's pulse pressure is inadequate for calibration.	Corrective Action When patient's pulse pressure improves, press ZERO PRESSURE key for 2 seconds while the IABP is assisting. Provide alternate A.P. source (i.e.: radial).	Probable Cause A calibration update has been intentionally post- poned because either patient's mean arterial pressure may be too low to pause assist or less than 15 minutes have elapsed since last calibration. Pump is either in	alibration Expired Corractive Action Assess patient to determine if a brief pause in assist would be toler- ated, and if so, press ZERO PRESSURE key for 2 seconds while IABP is assisting. Provide alternate A.P. source (i.e. : radial). Verify that IAB FILL mode





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.** 

### Troubleshooting the Maguet CS300<sup>™</sup> IABP, cont:








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 50-ZOLL LIFEVEST WEARABLE DEFIBRILLATOR



The following will help guide you through your assessment and care of the Zoll LifeVest.

- 1. The LifeVest wearable cardioverter defibrillator is worn by patients at risk for sudden cardiac arrest, providing protection during their changing condition and while permanent sudden cardiac arrest risk has not been established.
- Before delivering a treatment shock, the LifeVest tests to see if a patient is conscious by providing the patient an opportunity to press the response buttons to prevent a treatment shock. It is important that only the patient press the response button.
- 3. The LifeVest therapy pads release a Blue gel prior to a treatment shock to both improve shock conduction and mitigate burning. The gel should remain on the patient as long as the patient is wearing the LifeVest in case additional treatment shocks are required. If you choose to remove the LifeVest from the patient and monitor the patient with external equipment, the gel can be removed with water.
- 4. After the LifeVest detects a treatable arrhythmia, the time to treatment will be between 25 and 60 seconds depending on the type and rate of the arrhythmia and whether the patient presses the response buttons.
- 5. No one should touch the patient while a shock is delivered. The LifeVest will warn bystanders with a tactile vibration alarm, a two tone siren alert and a voice command stating "electrical shock possible, do not touch patient," or "bystanders do not interfere" before a shock is delivered.
- 6. The monitor should be disconnected from the electrode belt prior to delivering an external defibrillation. The garment and belt do not need to be removed.
- 7. Never do CPR with the LifeVest turned on. Pull the battery out of the monitor to turn the device off. The garment can be opened from the front if CPR needs to be performed.
- 8. The tactile vibration alert, the two tone alarm, the voice prompts, and the display on the monitor screen are part of the LifeVest consciousness test, which requires the patient to press the response buttons to avoid a shock. It is important that only the patient press the response buttons.
- 9. Look at the monitor display if the LifeVest is giving gong alerts. Follow the prompts on the monitor screen. No treatment will be given for gong alerts.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 50: Zoll Lifevest Wearable Defibrillator – Cont.

- 10. The patient should always bring the LifeVest system, the wireless modem / battery charger, and the extra external battery to the hospital. This will allow the patient to download any stored event data from the monitor and change the battery as required.
- 11. If the LifeVest needs to be turned off, remove the battery from the end of the black monitor. Removing the battery will shut the system off. To turn the system back on, put the battery back in and press the response button to activate device.
- 12. It is best to leave a patient in their LifeVest if at all possible. Do not remove the LifeVest unless absolutely necessary.
- 13. This device is a patient belonging and should be treated as a patient valuable. It is a rented durable medical equipment item that must be returned to Zoll and the patient is held liable for missing components. Please keep components in a personal belonging bag and make sure the equipment is kept with the patient or a family member.

Contact Zoll LifeVest to report where the patient was transported and if the patient had alarms or was defibrillated.

# 1-800-543-3267





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 50: Zoll Lifevest Wearable Defibrillator – Cont.

Photo 1:

(Boxed in red) is the monitor worn in a holster around the waist and collects ECG data from the sensing electrodes which can later be sent to a doctor via modem.





Photo 2:


(Circled in red) Dry, non-adhesive sensing electrodes on this electrode belt continuously monitor patient's heart.

(Boxed in green) These dry therapeutic electrodes will automatically deploy conductive gel prior to delivering a shock.






#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions







#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions



PARAMEDIC


ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED AMS ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE FOR HYPOGLYCEMIA OR NARCOTIC/OPIATE ETIOLOGY CONSULT OLMC IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN OF AMS





Approved 9/14/22, Effective 1/16/23, replaces all prior versions





### Indications:

- 1. Suspected stroke (as part of Los Angeles Prehospital Stroke Screen)
- 2. Altered mental status unclear etiology
- 3. Seizure
- 4. Known or suspected diabetes

Contraindications: None

#### Technique:

- 1. Calibrate the meter per manufacturer instructions.
- 2. Use only manufacturer approved test strips.
  - a. Run a control test every time a new box of test strips is used.
  - b. Store unused test strips in original container and do not use **EXPIRED** test strips.
  - c. Do not apply blood to the test strip before inserting the test strip into the meter. If the meter displays a result before applying blood **DO NOT** use that result.
  - d. Do not reuse test strips. Once blood is applied to test strip discard it.
  - e. If another glucometry reading is required, use a new test strip.
  - f. Do not expose strips to heat outside the recommended range, moisture or humidity.


#### Determining Blood Glucose:

- 1. Using universal precautions, power on the meter.
- 2. Insert a test strip into the meter per manufacturer instructions.
- 3. Position hand palm-side up; choose whichever finger is least calloused.
- 4. Apply intermittent pressure to the finger to help the blood to flow.
- 5. Clean the fingertip with alcohol. Start in the middle and work outward to prevent contaminating the area. Allow area to dry.
- 6. Hold the finger and firmly place a new, sterile lancet <u>off-center</u> on the fingertip and firmly press the lancet to puncture the fingertip.
- 7. Wipe away the first drop of blood with a sterile gauze pad, then apply blood to test strip.
- 8. Properly dispose of all contaminated supplies





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions







Approved 9/14/22, Effective 1/16/23, replaces all prior versions **6E - SYNCOPE** EMERGENCY MEDICAL **ADULT & PEDIATRIC** DISPATCHER TREATMENT PRIORITIES EMERGENCY MEDICAL EMD RESPONDER 1. Vital signs KEEP PATIENT FREE FROM INJURY HAZARDS 2.  $O_2$ AVOID PLACING ANYTHING IN MOUTH EMT 3. Dextrose for hypoglycemia ADVISE TO AVOID PHYSICAL EXERTION 4. Benzodiazepine for OR ENVIRONMENTAL STRESS (TEMP EXTREMES) sustained, active seizure **EMT-INTERMEDIATE 85** PLACE IN RECOVERY POSITION/POSITION OF COMFORT (refer to 6D Seizure if applicable) EMR ЕМТ 5. BVM prior to administration of ADVANCED EMT Naloxone GENERAL SUPPORTIVE CARE; OBTAIN VITAL SIGNS PARAMEDIC **Evaluate differential diagnosis** O2 VIA NC, NRB, OR BVM AS APPROPRIATE DETERMINE BLOOD GLUCOSE of Syncope & treat per protocol(s): FOR PATIENT ABLE TO SWALLOW ADULT & PEDIATRIC WEIGHT ≥25 kg HYPOGLYCE MIA CARE: IF GLUCOSE <50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO Acute Coronary Syndrome PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE: Cardiac Dysrhythmia IF GLUCOSE <50 mg/dL, 1/2 tube ORAL GLUCOSE (7.5 grams) PO Hypotension (Shock) Hypoxemia (Shock) TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE ADDRESS OXYGENATION AND VENTILATION (SP02 ≥ 94%) BEFORE ADMINSTRATION 0 Head Injury Stroke OF NALOXONE APNEIC/AGONALLY BREATHING 0 Seizure 0 ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE Infection (Sepsis/ PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg INEFFECTIVE BREATHING ACTIVITY Meningitis) Medication/Alcohol 0 ADULT & PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg USE NALOXONE TO RESTORE EFFECTIVE BREATHING; Heat or Cold Illness 0 • Psychogenic/Emotion AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped) TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT EMT OR HIGHER LICENSE MEASURE END-TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE EMT-185 AEMT

IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCESS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS:

GLUCAGON: IF PT WT 225 kg, 1mg IM; 25 kg, 0.5 mg IM ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

ADULT: INTUBATE IF INDICATED; DO NOT INTUBATE PATIENTS WITH RAPIDLY REVERSIBLE AMS ETIOLOGY (eg. HYPOGLYCEMIA, OPIATES) ADVANCED EMT OR HIGHER LICENSE:

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC/AGONALLY BREATHING

ADULT: NALOXONE 2 mg IVP/IOP/IN MAY REPEAT ONCE

PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - INEFFECTIVE BREATHING ACTIVITY

ADULT & PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg


USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

#### PARAMEDIC

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED AMS ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE FOR HYPOGLYCEMIA OR NARCOTIC/OPIATE ETIOLOGY CONSULT OLMC IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN OF AMS








CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE







CONSULT OLMCP IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN FOR PSYCHIATRIC PROBLEM OR IF ADDITIONAL RESTRAINT MEASURES NEEDED


CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

7B – PHYSICAL RESTRAINT ADULT & PEDIATRIC



#### Indications:

- 1. Reducing likelihood of patient doing harm to self.
- 2. Reducing likelihood of patient doing harm to others (including EMS professionals).
- 3. Reducing likelihood of patient disrupting medically necessary interventions.
- 4. Patient requires/required chemical restraint per Protocol 7C.

Alternatives to physical restraint as outlined below are to be utilized so as to minimize the use of physical restraints. However, if alternatives to physical restraints are unsuccessful, then physical restraints will be applied in an effective and compassionate manner. Throughout the use of alternatives to physical restraint and physical restraint, the patient and the patient's concerned parties (family, friends, co-workers, etc.) shall be treated with respect and informed of the need for these procedures. This protocol is not intended to place EMS professionals at higher risk for injury. If personal safety is compromised or threatened during the course of patient care, appropriate law enforcement personnel should be summoned for assistance. If at any time questions arise as to appropriateness of using alternatives to physical restraint or physical restraint, OLMC should be consulted for direction.

### Contraindications:

- 1. Patient (or patient's legal guardian or medical power of attorney) possesses medical decision making capacity and is refusing evaluation, treatment, and/or transport (in the absence of threatened or actual harm to self or others).
- 2. Patient is compliant with medically necessary interventions.
- 3. Reducing likelihood of patient doing harm to self and/or others and reducing likelihood of patient disrupting medically necessary interventions can be successfully accomplished with alternatives to physical restraint in the best judgment of the EMS professional(s) treating the patient.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 7B:** Physical Restraint – Adult & Pediatric, cont.

#### Technique:

The following steps shall be taken and documented in determining the need for physical restraints:

- 1. **Assessment of mental status** Observe for uncontrolled agitation, combativeness, threats of violence to self or others, disorientation, altered mental status impeding medically necessary interventions, or pulling at necessary medical interventions (eg. oxygen, IV lines, endotracheal tubes).
- 2. Alternatives to physical restraint- Reassurance, support of concerned parties (family, friends, coworkers, etc.), reorientation, diversionary activity, explanation of illness, injury, and medically necessary interventions.
- 3. **Justification for physical restraint** Failure of alternatives to physical restraint, reduce likelihood of patient harm to self, reduce likelihood of patient harm to others, enable medically necessary interventions per EMS protocols.
- 4. Inform patient and concerned parties of physical restraint use.

#### 5. Apply physical restraints.

Restraints are to be soft and are not to impede airway patency, respiratory mechanics, or circulation. Patients will not be restrained prone unless an impaled object or airway patency necessitates such positioning. Restraints will be applied in an effective, yet compassionate manner. Every effort should be made to avoid injury to the patient during application of physical restraints.

Humane restraints that reduce potential for patient injury from the restraints are those made from roll gauze, soft leather, and those designed as single-patient use, disposable foam with cloth ties. Restraints are to be non-locking unless applied by law enforcement officers in appropriate circumstances and able to be released rapidly if patient condition mandates.

During treatment and transport of a patient in law enforcement-instituted restraints (including handcuffs), EMS professionals should monitor for and advocate for change in restraints that compromise airway patency, respiratory mechanics, or circulation. Patients will not be transported with wrists cuffed to ankles either directly or indirectly (also referred to as "hog-tying"). These positions have been shown to impair respiratory mechanics and pose significant obstacles to definitive airway management if required enroute. During transport of patients in law enforcement-instituted locking restraints, a law enforcement officer should either accompany the patient in the ambulance or provide the treating EMS professionals means to unlock the restraints. This policy allows rapid restraint release should the patient deteriorate to a condition requiring restraint release to properly treat.

Patients restrained using this protocol should generally be restrained to a backboard. This facilitates patient transfer in the emergency department and in the case of airway secretions or vomiting, enables rapid positioning of the patient to reduce aspiration. Patients will not be transported "sandwiched" between two backboards; this positioning impedes patient care and increases risk of aspiration.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 7B:** Physical Restraint – Adult & Pediatric, cont.

Once physical restraints are applied, they will be left in place until the patient is transferred to emergency department personnel. This policy prevents recurrent harm to self, harm to others, and disruption of intact medical devices and treatment. Despite assurance from the patient that they will comply with treatment, restraints are to be left in place unless a direct order from OLMC is given to release the physical restraints. Such an order must be clearly documented on the patient care form.












Approved 9/14/22, Effective 1/16/23, replaces all prior versions





EMS professionals should utilize this protocol and its principles and directives to promote and protect the safety of mentally ill patients, drug or alcohol dependent patients, and other involved parties who may be endangered by the patient's disturbed or altered psychological state to the extent of being subject to an immediate likelihood of serious harm.

#### Definitions:

- "Drug Dependent Patient" for the purpose of this protocol means: A patient who is using a controlled substance as presently defined in Section 102 of the Federal Controlled Substances Act and who is in a state of psychic or physical dependence, or both, arising from administration of that controlled substance on an intermittent or continuous basis.
- 2. "Alcohol Dependent Patient" for the purpose of this protocol means: A patient who uses alcoholic beverages to an extent that it impairs mental or physical health, family life, occupational life, and potentially compromises the health and safety of the community.
- 3. "Mentally III Patient" for the purpose of this protocol means: A patient afflicted with a substantial disorder of thought, mood, perception, psychological orientation or memory that significantly impairs judgment, behavior, capacity to recognize reality or ability to meet the ordinary demands of life. Mental illness may be reflected in a sustained altered mentation secondary to chronic medical condition or prior physical injury.
- 4. "Immediate likelihood of serious harm" posed by patients either to self or others for the purpose of this protocol means:
  - a) a substantial risk of physical harm to self, manifested by active threats of, or attempts at, suicide or intentional bodily harm; **OR**
  - b) a substantial risk of physical harm to others manifested by active threats of, or attempts at, homicide or intentional bodily harm; **OR**
  - c) actively placing others in reasonable fear of imminent violent behavior or serious physical harm; **OR**





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 7D: Emergency Mental Hold Issues – Adult & Pediatric, cont.

d) causing a prudent EMS professional to believe with reasonable certainty that without immediate medical treatment, severe physical impairment or injury would be sustained by the patient or other involved party as a result of the patient's apparent inability to prevent suicidal activity, homicidal activity, or significant risk of harm to self or others through distorted reality (eg. driving while acutely psychotic or clinically intoxicated).

#### Emergency Mental Hold Procedures:

- 1. Upon dispatch to and/or subsequent assessment of a patient representing, in the EMS professional's best judgment, "immediate likelihood of serious harm", the EMS professional should notify dispatch to immediately request the appropriate law enforcement authority. It is the duty of the responding law enforcement officer(s) to determine if the affected person appears to be mentally unstable, alcohol dependent or drug dependent to a degree that immediate emergency action is necessary to prevent the patient from harming self or others. If the law enforcement officer determines that immediate emergency action is necessary, under Oklahoma law, the law enforcement officer must take the person into protective custody. The law enforcement officer(s) can base their decision upon personal observation of the actions of the patient or upon the statement of either EMS professionals or other parties deemed credible.
- 2. If EMS professionals at the scene believe the patient to be actively mentally ill, alcohol dependent, and/or drug dependent to the extent of being subject to an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement, the primary assessing EMS professional shall fill out the "Individual's Affidavit for Emergency Detention" and submit to the law enforcement officer(s) at the scene as may be required to effect such detention.
- 3. If EMS professionals and the law enforcement officer(s) at the scene cannot reach agreement whether the patient is actively mentally ill, alcohol dependent, and/or drug dependent to the extent of representing an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement, the appropriate EMS supervisor(s) and corresponding law enforcement supervisor(s) should be contacted. Supervisor presence at the scene could be required to achieve consensus of actions that promote the patient's and others' safety.
- 4. If the EMS supervisor determines the patient is actively mentally ill, alcohol dependent, and/or drug dependent to the extent of representing an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement and therefore is in need of immediate medical attention, this shall be conveyed to the appropriate law enforcement supervisor. If the law enforcement supervisor does not subsequently place the patient on mental hold, notify the appropriate receiving hospital's On-Line Medical Control Physician (or the System EMS Chief Medical Officer) for formal physician consultation, complete an agency-specified Incident Report, and submit it to the Chief Medical Officer for review.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 7D: Emergency Mental Hold Issues – Adult & Pediatric, cont.


5. If it appears that the affected person is mentally ill or suffers chronic altered mentation and does not require emergency medical attention, EMS personnel will stay on scene only until it can be reasonably determined that the person does not suffer from an apparent serious physical condition, illness, or injury requiring emergency medical attention and/or until the law enforcement officers at the scene indicate that they no longer require assistance from EMS.

#### Emergency Detention (previously referred to as Emergency Order of Detention or EOD) Issues:

- 1. An affidavit that is completed by anyone (including an EMS professional) who is concerned about the patient's safety or who witnessed concerned behavior that could impact the safety of others, that details the observations and impressions that serve as the basis for involuntary detention of the patient in the safety interests of the patient and others has been commonly referred to as an "EOD" or "Emergency Order of Detention". This is no longer used as a legal term. The correct terminology is a "third party statement" and the statement form as displayed in state documents can be found immediately following this protocol.
- 2. The "third party statement" must have sufficiently detailed information to justify placing the patient, at least temporarily, into law enforcement custody. (eg. "suicidal" is not enough). A law enforcement officer can refuse to take a patient into custody if he or she determines there is insufficient written evidence contained within the "third party statement".
- 3. The "third party statement" is the legally recognized documentation that compels a patient to be placed into Emergency Detention (ED) in the safety interests of self and others until emergency psychiatric assessment (and stabilization when applicable) can be conducted. Medical facilities in Oklahoma that can conduct emergency psychiatric assessment and stabilization are referred to as "Emergency Detention (formerly EOD) designated facilities".
- 4. A patient that is under Emergency Detention by use of a "third party statement" cannot refuse transport to receive an appropriate physician evaluation. EMS professionals treating and transporting patients under Emergency Detention should not let the patient flee from EMS care and supervision, unless the patient poses an immediate, serious physical threat to the EMS professional(s). Utilize law enforcement officers, physical restraint, and if licensed as a paramedic, chemical restraint, as warranted to prevent patients under Emergency Detention from fleeing.
- 5. Once an appropriate physician, typically a psychiatrist, has evaluated the patient under Emergency Detention through use of a "third party statement", he or she may validate continued involuntary detention of the patient or may release the patient from further involuntary medical detention.
- 6. EMS professionals should work with their system Chief Medical Officer, local medical professionals, and local law enforcement officers to review applicable emergency mental hold issues and resources.











Approved 9/14/22, Effective 1/16/23, replaces all prior versions

8B - TOXIDROMES ADULT & PEDIATRIC

EMERGENCY MEDICAL RESPONDER

ЕМТ

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

PARAMEDIC

#### Toxidromes as a Diagnostic Guide in Suspected Overdose


Toxidrome	Signs and symptoms	Vital sign	Classic agents
anticholinergic	delirium, flushed skin, dilated pupils, urinary retention, decreased bowel sounds, memory loss, seizures (mnemonic: "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter")	tachycardia hyperthermia hypertension	atropine antihistamines scopolamine tricyclic antidepressants
cholinergic	confusion, weakness, salivation, lacrimation, urination, defecation, gastrointestinal motility, emesis, diaphoresis, muscle fasciculations, miosis, seizures, "Killer Bs": bradycardia, bronchorrhea, bronchospasm	bradycardia hypothermia tachypnea	organophosphates carbamates
hallucinogenic	disorientation, hallucinations, visual illusions, panic reaction, moist skin, hyperactive bowel sounds, seizures	tachycardia tachypnea hypertension	phencyclidine lysergic acid diethylamide cannabis
opiate/narcotic	altered mental status, unresponsiveness, miosis, shock, decreased respiration	bradypnea bradycardia hypothermia hypotension	dextromethorphan opiates: morphine propoxyphene
sedative/hypnotic	coma, stupor, confusion, sedation, CNS dsyfunction	apnea	ethanol barbiturates benzodiazepines anticonvulsants
sympathomimetic	delusions, paranoia, diaphoresis, piloerection, mydriasis, hyperreflexia, seizures, anxiety	tachycardia hypertension hyperthermia	cocaine amphetamines methamphetamine phenylpropanolamine ephedrine pseudoephedrine





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 8C – OKLAHOMA POISON CONTROL CENTER USE



#### Indications:

- A. Real-time consultation on toxic severity of exposure/inhalation/ingestion/snakebites.
- B. Real-time consultation regarding no/minimal toxicity exposures for patient follow-up contact and self-treatment advice.
- C. Real-time consultation regarding needed hospital resources for patient toxicity.
- D. Identification of pills (using imprint letters/numbers on pills).
- E. Product ingredient identification and toxic severity potential.

#### Contraindications:

None

Technique:

To contact the Oklahoma Poison Control Center in Oklahoma City:

# Healthcare Professional Access Number: 1-877-271-6998

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient information and substance/exposure/snake information possible readily available to share with the poison center specialist.


The University of Oklahoma College of Pharmacy administers all operations of the Oklahoma Poison Control Center in cooperation with The Children's Hospital at OU Medical Center.

Calls are answered 24 hours a day by pharmacists and nurses intensively trained in clinical toxicology and designated as specialists in poison information.






Approved 5/10/23, Effective 7/1/23, replaces all prior versions




PEDIATRIC: \*\*EPINEPHRINE 0.1mg/mL 1:10,000, 0.01 mg/kg SLOW IV/IOP (OVER 3 MINUTES) NOT TO EXCEED 0.5 mg

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)










Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**8G – HAZARDOUS MATERIALS RESPONSE** 



This protocol contains generally accepted principles related to EMS response and activity relating to suspected or actual hazardous materials incidents. The overriding principle is safety, with an emphasis on minimizing, preferably preventing, further hazardous materials exposures and related illness.

Specific practices for individual hazardous material substances are beyond the capability of a general principle protocol and the EMS professional is directed to utilize hazardous material specialists within local fire services as well as hazardous material information found in resources such as:

- Emergency Response Guidebook (ERG 2012 edition if available), developed jointly by the US Department of Transportation (DOT), Transport Canada, and the Secretariat of Communications and Transportation of Mexico.
- 2) Wireless Information System for Emergency Responders (WISER), maintained at the US National Library of Medicine Specialized Information Services. The webpage for WISER is http://wiser.nlm.nih.gov/ and according to this website, "WISER is available for download as a standalone application on Microsoft Windows PCs, Apple iPhone and iPod Touch, Google Android devices, Windows Mobile devices, BlackBerry devices, Palm OS PDAs, and via WebWISER.

When responding to individuals in hazardous materials environment(s) and/or contaminated by hazardous materials, real danger exist that EMS professionals, public safety apparatus, and hospitals may be unable to effectively function if not protected from this contamination. Therefore, appropriate efforts must be made to protect the already apparent patient(s), responding public safety professionals, at-risk citizenry, and the emergency healthcare system from further contamination.

Treatment by unprotected or inappropriately protected EMS professionals should not be attempted until appropriate protective measures can be accomplished and the patient is decontaminated or otherwise determined non-toxic by appropriate authority (eg. Fire Department Hazardous Materials specialist, Oklahoma Poison Control Center specialist, and/or on-line medical control physician).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 8G: Hazardous Materials Response, cont.** 

#### Initial measures of protection for EMS professionals and equipment:

EMS professionals that are initially responding and arriving toward the incident location should perform the following:

- 1. Park in an anticipated safe area (typically upwind/uphill unless otherwise directed by Hazardous Materials specialists responding or already on-scene).
- 2. Determine and advise the appropriate communications center of the following (if not previously known):
  - a) The exact location of the incident.
  - b) The type of incident (transportation accident, fire, explosion, etc.).
  - c) Identification/nature of the hazardous materials, if known.
  - d) Environmental conditions (estimated wind direction and speed).
  - e) Recommended routes to and from the location.
  - f) Staging area.
  - g) Control line (perimeter) established or recommended to be established by fire service and/or law enforcement professionals.
  - h) Approximate number of patients (actual number preferred if known).
  - i) Number of ambulances needed (estimated transport resources).
- 3. **DO NOT** rush into a suspected hazardous/contaminated situation until appropriate safety measures are accomplished. If additional public safety professionals have not yet arrived, generally accepted safe practices include:
  - a) Do not drive any further into the area. Stay upwind and uphill.
  - b) Establish a control line at least 300 feet from the incident and stay outside of it.
  - c) Tell approaching persons to stop where they are.
  - d) Designate a refuge area for victims already inside the control line and direct those ambulatory to this refuge area.


#### Additional measures of protection for EMS professionals and equipment:

- 1. Whenever possible, use portable or disposable medical equipment for treating hazardous materials victims. Check with local policy, but in general a safe practice is to leave any potentially contaminated equipment with the Hazardous Materials team to coordinate decontamination of any potentially contaminated equipment.
- 2. Open any windows to the patient compartment of the ambulance. Dangerous concentrations of chemicals can develop when unintentionally contaminated victims or rescuers are in the unventilated patient compartment of an ambulance.
- 3. After decontaminated patients have been treated and/or transported to the emergency department, the EMS professionals should be formally evaluated by emergency health care providers at an emergency department if exhibiting unusual signs or symptoms consistent with hazardous materials exposure since participating in the incident.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions








Approved 9/14/22, Effective 1/16/23, replaces all prior versions


#### 9A ABDOMINAL PAIN/NAUSEA/VOMITING/DIARRHEA ADULT & PEDIATRIC







#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions




IF CLINICAL CONCERN FOR SEPSIS, NOTIFY RECEIVING ED OF POSSIBLE SEPSIS IN RADIO REPORT CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions




PARAMEDIC

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions







Approved 9/14/22, Effective 1/16/23, replaces all prior versions








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 9F – INFECTIOUS DISEASE PRECAUTION RECOMMENDATIONS EMS PROFESSIONALS



In the course of EMS care of a patient (from time of emergency services request through transport of the patient to the destination location), EMS professionals should be informed, aware, and proactive regarding practices that reduce their exposure to infectious diseases, with a goal of preventing transmission of those infectious diseases to and/or through EMS professionals.

The following recommendations are general guidelines that will assist in reducing exposure to infectious diseases in the commission of EMS treatment of patients.


- 1. Follow immunization recommendations from Centers for Disease Control Advisory Committee on Immunization Practices (ACIP) (eg. Hepatitis B and Flu vaccinations).
- 2. Always be prepared for isolation from body substances (blood, respiratory secretions, sputum, saliva, emesis, fecal matter).
- 3. Wear examination gloves (in most situations, non-sterile type) during patient care activities.
- 4. If patient conditions tolerate, reduce exposure of suspected infectious respiratory droplets by covering the patient's nose and mouth in oxygen administration (eg. non-rebreather mask) or with a face mask (eg. surgical type face mask) if oxygen administration is not required.
- 5. When providing airway assessment and management, maximize the functional distance between the patient's nose and mouth and the EMS professional's nose and mouth. The greater the possible distance, the lesser the risk of respiratory illness transmission.
- 6. Wear appropriate body substance isolation (eye splash protection, mask over nose/mouth, gloves as previously noted, gown to protect personal uniform contamination) as patient suspected illness/injury may dictate.
- 7. During treatment of the patient, avoid likely trajectories of bleeding, coughing, spitting, vomiting, defecating whenever possible.
- 8. Exercise extremely diligent action when handling or around the handling of contaminated sharps (eg. IV/IO needles, needle/syringe, glucometry lancets) and have appropriate sharps container readily present at patient side and on ambulance.
- 9. For all exposures, wash exposed area(s) as soon as possible with copious irrigation and/or antibacterial solution approved for that area(s) use.
- In the event of exposure, follow general principles as listed in Protocol 9G Post-Exposure Prophylaxis Recommendations as well as agency-specific policies. Do not delay in reporting and seeking treatment for an infectious disease/body substance exposure of concern.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 9G – POST-EXPOSURE PROPHYLAXIS RECOMMENDATIONS ADULT & PEDIATRIC



Preventing an exposure is always better than the "cure" for an exposure. Despite careful practices, EMS professionals can experience at least one concerning infectious disease exposure in a career.

Every EMS organization should have a pre-planned course of rapid, clinically-effective action steps (regardless of time of day, day of week) to be followed in the event of EMS professionals sustaining concerning occupational exposures to infectious diseases. The Chief Medical Officer should be involved in the planning of post-exposure evaluation and post-exposure prophylaxis (PEP) care.

The following recommendations are general guidelines that can assist in post-exposure evaluation and PEP care:

- 1. Wash exposed area(s) as soon as possible with copious irrigation and/or antibacterial solution approved for that area(s) use.
- Gather as much information about the exposure of concern as possible what body substance (eg. blood, saliva), what route of exposure, timing/amount of exposure, patient demographics, location of the exposure source (e.g. in the emergency department at "any town" hospital), and any related infectious disease medical history of the patient (eg. known HIV or Hepatitis C?).
- 3. Do not delay in reporting and seeking treatment for an infectious disease/body substance exposure of concern. Regardless of time of day or day or week, seek direction from the appropriate EMS supervisor and/or report to the employer's pre-designated PEP health care facility immediately after the patient's care can be transferred to other healthcare providers. Time to treatment (in hours) is of the essence to reduce transmission of infectious disease.
- 4. A national resource exists for real-time PEP care. This clinical resource is maintained at the University of California at San Francisco/San Francisco General Hospital. **Treating** physicians can access phone advice (PEP line) at 1-888-448-4911 in the evaluation and treatment for occupational events concerning for exposure to HIV, hepatitis, and other blood-borne pathogens. The PEP line is answered from 0800-0100 Central Standard Time except on holidays. Messages left during unanswered hours are returned during the next operational morning.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 9G: Post-Exposure Prophylaxis Recommendations – Adult & Pediatric, cont

- 5. Additional information on PEP care can be obtained at the following website: http://www.nccc.ucsf.edu/clinical-resources/prep-guidelines-and-resources/
- 6. The Oklahoma State Department of Health has a policy and reporting form for EMS professional use in the event of an occupational exposure to infectious disease of concern. The information and form can be accessed at the following website: https://www.ok.gov/health2/documents/HIV-CommunicableDiseaseRiskExposureReport.pdf A copy of this form (OSDH Form 207) can be found in Section 19 of these protocols.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 9H - VASCULAR ACCESS - INTRAVENOUS ADULT & PEDIATRIC



#### Indications:

- 1. Vascular access for intravenous administration of crystalloid fluids in hypotension and/or volume insufficiency.
- 2. Vascular access for intravenous administration of medications for a multitude of medically indicated effects.
- 3. Vascular access in a patient with an increased potential for needing either of the above indications.

#### Contraindications:

- 1. None absolute, though despite aseptic technique and using sterile angiocatheters, there is always a risk of introducing infection when the skin integrity is violated. Do not establish IV access unless directed by applicable treatment protocol(s) or the patient meets one of the indications above.
- 2. Venous sites distal to a fracture.
- 3. Venous site underlying cellulitis/abscess.

#### Technique:

- A. Extremity:
  - 1. Apply IV tourniquet proximal to proposed vascular access site.
  - 2. Clean insertion site with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or alcohol prep.
  - 3. Stabilize vein in place by applying gentle traction on vein distal to point of entry.
  - 4. Puncture the skin with the bevel of the needle upward about 0.5 1 cm from the vein and enter the vein from the side or from above.
  - 5. Note blood return and advance the catheter over the needle.
  - 6. Remove needle and connect IV line. Note: venous blood for laboratory work may be drawn with syringe before connecting IV line.
  - 7. Release IV tourniquet.
  - 8. Open IV tubing clamp full to check flow and placement, then slow rate to TKO or as indicated by applicable treatment protocol.
  - 9. Secure catheter and tubing with tape or commercial device in a manner that reduces traction upon the catheter.
  - 10. Anchor with an arm board or splint if the catheter is likely to be dislodged.
  - 11. Recheck IV patency periodically to minimize occurrence of unrecognized fluid/medication extravasation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 9H: Vascular Access - Intravenous – Adult & Pediatric, cont.

#### Technique:

- B. External Jugular Vein for peripheral venous access in a patient in extremis only.
   Anatomical landmarks, including the vein, must be visible no "blind" sticks.
   Avoid multiple attempts and avoid attempts on both sides use IO access prn.
  - Position the patient supine, head down (this may not be necessary or desirable if congestive heart failure or respiratory distress present). Turn patient's head to opposite side from procedure. (Maintain cervical spine alignment if cervical spinal injury suspected; do not attempt external jugular vein cannulation in suspected cervical spine injury patients.)
  - 2. Expose vein by having patient bear down if possible, and "tourniquet" vein with finger pressure just above clavicle.
  - 3. Clean insertion site with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or alcohol prep.
  - 4. Stabilize vein in place by applying gentle traction on vein distal to point of entry.
  - 5. Align the cannula in the direction of the vein, with the point aimed toward the shoulder on the same side.
  - 9. Puncture skin over vein first, then puncture vein itself. Use other hand to traction vein near clavicle to prevent rolling.
  - 10. Proceed as with extremity vein. Do not wrap any tape/retaining device around the circumference of neck to stabilize IV catheter/line.

#### Complications:

- 1. Local: hematoma formation, infection, thrombosis, phlebitis.
- 2. Systemic: bacteremia/sepsis, catheter fragment embolus.

#### Additional Notes:

- A. Antecubital veins are useful access sites for patients in shock, but if possible, avoid areas near joints (or splint well!).
- B. The point between the junction of two veins is more stable and often easier to use.
- C. Start distally and, if successive attempts are necessary, make more proximal attempts.
- D. The most difficult problem with IV insertion is to know when to try and when to stop trying. If the procedure is not accomplished after two attempts or two minutes, the EMT – I85 or higher licensed EMS professional must consider expediting other care, including transport to the emergency department, with further attempts enroute. This does not pertain to the trauma patient where rapid transport is advised with IV's performed enroute to the hospital.
- E. Renal dialysis fistulas and surgically implanted ports should not be used for vascular access. Use IO access in critical patient situations otherwise.
- F. Saline locks may be utilized in place of crystalloid infusions/IV lines in conditions less likely to require rapid administration of IV fluid.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 9I - VASCULAR ACCESS - INTRAOSSEOUS ADULT & PEDIATRIC



#### Indications:


- 1. First-choice access in cardio/pulmonary arrest (unless IV access can be achieved as timely).
- 2. Second-choice access in dynamic, life-threatening shock or respiratory failure (if IV access cannot be achieved in clinically needed time).


#### Contraindications:

- 1. Inability to locate anatomical landmarks (blind insertion contraindicated).
- 2. Suspected cellulitis at insertion site.
- 3. Suspected acute or non-healed fracture proximal to foot in same leg (proximal tibial insertion) or proximal to forearm in same arm (humeral head insertion).
- 4. Suspected total knee arthroplasty/replacement (proximal tibial insertion).
- 5. Suspected markedly poor circulation extremity (history of amputation, gangrene, bypass).

#### Technique (EZ-IO® System):

- A. Assemble following materials:
  - Driver with Needle Set based on patient size and weight: 15mm 3-39 kg (PINK); 25mm 40 kg and greater (BLUE); 45mm 40 kg and greater (excessive tissue) (YELLOW).
  - 2. EZ-Connect<sup>®</sup> 90 degree connection set.
  - 3. Alcohol wipe (or ChloraPrep<sup>®</sup> or equivalent if available).
  - 4. Saline flush syringe.
  - 5. 1 mg/kg Lidocaine (up to 40mg) for intraosseous push if patient responsive.
  - 6. Pressure infuser.
  - 7. EZ-IO®Stabilizer (optional if proximal tibia insertion; required if humeral head insertion).
- B. Locate insertion site:
  - 1. Proximal tibia site (Figure 1).
  - 2 Palpate patella (1). Palpate tibial tuberosity (2) approximately two fingers widths below patella in adults and adolescents, or one finger width below patella in smaller pediatrics. Insertion (3) at one finger width medial to tibial tuberosity in the tibial plateau.










Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.** 

- B. Locate insertion site (cont.)
  - 3. Humeral head site. Extra precision should be taken when utilizing this site. The anatomy proves more difficult to locate, the insertion area is smaller, and the IO needle is more prone to dislodgement due to a thinner bony cortex and higher likelihood of inadvertent EMS provider contact with the IO line.

Position arm in 90 degree flexion, with elbow kept to side of trunk (Figure 2). This position helps to gain maximal "exposure" of the humeral head.

Palpate and identify the mid-shaft humerus and continue palpating with a thumb proximal toward the humeral head. Near the shoulder, note a small protrusion. This is the base of the greater tubercle insertion site. With the opposite hand "pinching" the anterior and inferior aspects of the humeral head, confirm the identification of the greater tubercle in the midline of the humerus. (Figure 3).




- C. Clean insertion site with alcohol wipe, or preferably with ChloraPrep<sup>®</sup> or equivalent swab.
- D. Access the intraosseous space.
  - 1. Stabilize anatomy near the insertion site with non-dominant hand.
  - Position driver at insertion site with needle at 90 degree angle to the surface of the bone. Use driver to insert needle through the skin at the insertion site until you feel the needle tip encounter bone. Allow the driver to perform its function of progressively inserting the needle. Avoid strong, downward pressure on the needle and maintain constant driver drilling speed. (Figure 4 next page – proximal tibia insertion site depicted)
  - 3. Once the bone cortex feels encountered, ensure use of proper sized needle by checking for visualization of at least one 5 mm mark line (solid black circumferential line on the needle). If at least one 5mm mark line is not visible, a longer needle will be required to achieve useable intraosseous access. (Figure 5 next page)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.** 




- 4. Resume use of driver to insert a properly-sized needle through the bony cortex and into the bony marrow (evident with a sudden decrease in resistance to needle insertion), maintaining the 90 degree angle to the surface of the skin. Most typically, properly-sized needles will have their hub resting on the skin surface at the time the needle tip is correctly in the marrow space.
- E. While stabilizing the needle hub with a thumb and an index finger, disengage the driver from the needle in a gentle, upward motion.
- F. While still stabilizing the needle hub with a thumb and an index finger, remove the stylet by rotating it counterclockwise until disengaged.
- G. Do NOT attempt aspiration of blood or marrow via the catheter. Pulling marrow into the catheter may clog the catheter and prevent its use for needed fluid and/or medication administration. Do confirm proper EZ-IO<sup>®</sup> catheter placement using a combination of the following signs:
  - a. IO catheter rests at 90 degree angle and feels firmly in bone when grasping hub.
  - b. Blood-tinged marrow oozes spontaneously from hub (may often be absent, yet the catheter is still correctly placed).
  - c. Fluid and medication administration is possible without significant resistance and without extravasation.
- H. When using the proximal tibia insertion site, use of the EZ-Stabilizer<sup>®</sup> (Figure 6 next page) is optional and its use is determined by the EMT-Intermediate's or EMT-Paramedic's judgment. When using the humeral head insertion site, use of the EZ-Stabilizer<sup>®</sup> is required to reduce the chances of inadvertent dislodgement (refer to earlier discussion of humeral head insertion site). If the EZ-Stabilizer<sup>®</sup> is used, it must be applied prior to connecting the 90 degree connector set to the catheter hub.





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.**



- The EZ-Connect<sup>®</sup> 90 degree connector set (also seen in Figure 6) is used to prevent excessive pressure on the catheter when infusing fluids or administering medications. Failure to use the 90 degree connector set can cause inadvertent dislodgement due to excessive pressure down the catheter. Flush the EZ-Connect<sup>®</sup> set with Normal Saline prior to attaching it to the catheter hub and then flush the line to flush the catheter with 10mL Normal Saline if patient unresponsive or Lidocaine 2% 1 mg/kg up to 40mg slow intraosseous push if the patient is responsive and clearly able to sense pain. If using Lidocaine as directed, follow with 10mL Normal Saline flush.
- J. Medication administration is given in the same dosing as with IV administrations.
- K. Fluid administration will require the use of a pressure infuser on the IV fluid bag. Due to the increased pressure of the marrow space, IV fluid will not infuse without assistance of the pressure infuser. Inflate pressure infuser until IV fluid is seen infusing with constant flow. Monitor for extravasation and monitor for need to reinflate pressure infuser. Fluid delivery rate may be as high as 1 liter per hour at tibial site and up to 5 liters per hour at humeral head site.
- L. In determining the site for IO access, consider knowledge of the anatomy, prior training and comfort in accessing that particular site, and how IO access at that site may or may not interfere with other care events (eg. use of the humeral head site for medication administration in cardiac arrest could disrupt the continuity of chest compressions).

#### Complications of intraosseous line placement attempts:

Through and through bone penetration – avoid by using correct needle and insertion technique. Extravasation – avoid by using correct needle and insertion technique. Monitor ongoing use and stop at early signs of extravasation. Fracture of bone – avoid by using correct insertion technique (avoid excessive pressure). Infection – avoid by using aseptic technique and do not insert through suspected cellulitis. Growth plate injury in pediatrics – avoid by choosing correct insertion site.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

9J – INDWELLING CENTRAL VASCULAR DEVICE MANAGEMENT ADULT & PEDIATRIC

PARAMEDIC

#### Indications:

Use and/or monitoring of indwelling central venous devices.

#### Contraindications:

- 1. Central venous ports easily permanently damaged with wrong needle or infected.
- 2. Suspected infection in the indwelling central venous devices.
- 3. Easy peripheral venous access available or already established.

#### Technique:

Indwelling central venous devices may become irreversibly damaged if wrong needles and techniques occur. In general, avoid the use of indwelling central venous devices unless already in use (during an interfacility transfer) or in the case of a peripherally inserted central catheter (PICC) line, peripheral venous access is not readily available or already established.

In the setting of interfacility transfer, indwelling central venous device(s) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel prior to conducting the interfacility transfer. Potential complications during transfer should be discussed and contingency plans reviewed.

During packaging, patient movement, and throughout the interfacility transfer, perform periodic inspection and assessment of indwelling central venous devices and take precautions to avoid inadvertent dislodgement of such devices.

If the need arises to access a PICC line, clean the port with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or an alcohol wipe. Aspirate 4 - 5 mL of fluid and discard (to remove any anticoagulant in the line) prior to infusing fluid or administering medication. Flush 10 mL of saline in the PICC line after administering a medication. Maintain aseptic technique throughout all handling of the PICC line.

If a closed cap on the line is required to be removed to access the indwelling central venous device, make sure the line is clamped to avoid introduction of an air embolus.

Contact OLMC early for any needed advice or direction in the use of an indwelling central venous device.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 9K – MEDICATION ADMINISTRATION ADULT & PEDIATRIC

Prior to all medication administrations, assure the "5 Rights" are reviewed:

- 1. Right Patient
- 2. Right Route
- 3. Right Dose
- 4. Right Time
- 5. Right Medication

If any one of these "rights" is "wrong", stop and do not administer the medication!

Specific routes of medication administration:

EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

<u>9Ka: Intravenous / Intraosseous – Adult & Pediatric:</u>


- 1. Assure that the IV / IO line is patent.
- 2. Cleanse the access port nearest the IV / IO site with alcohol prep.
- 3. Eject any air from syringe and insert needle or adapter into access port.
- 4. Pinch the IV /IO line above the medication port. This prevents the medication from traveling toward the IV bag, forcing it instead toward the patient.
- 5. Inject the medication as specified per appropriate treatment protocol.
- 6. Remove the needle or adapter and release the tubing.
- 7. Open the flow regulator to allow 10 20 mL fluid flush.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 9K:** Medication Administration – Adult & Pediatric, cont.



<u>9Kb: Intramuscular/Subcutaneous Injection – Adult & Pediatric:</u>

- 1. Use a 1 inch to 1.5 inch long 21 to 25 gauge needle on a syringe.
- 2. Select injection site (if IM, deltoid, lateral thigh, or upper/outer quadrant of gluteus; if SubQ, arm or lateral thigh).
- 3. Cleanse the injection site with alcohol prep.
- 4. Eject any air from syringe.
- 5. If IM, stretch skin over injection site and insert needle 90 degrees to skin surface, through skin into muscle, aspirate and if no blood return, inject medication.
- 6. If SubQ, pinch skin in a fold over injection site and insert needle 45 degrees to skin surface, through skin into subcutaneous fatty tissue, aspirate and if no blood return, inject medication.
- 7. Remove needle and put bandage over the injection site.



<u>9Kc: Intranasal – Adult & Pediatric, technique:</u>

- 1. Use a medication nasal atomization device on a syringe.
- 2. Eject any air from syringe.
- 3. Place the atomizer tip approximately 1.5 cm within the nostril.
- 4. Briskly compress the syringe plunger to spray atomized solution into the nasal cavity/onto the nasal mucosa (gently pushing the plunger will not result in atomization).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 9K:** Medication Administration – Adult & Pediatric, cont.

EMERGENCY MEDICAL DISPATCHER
EMERGENCY MEDICAL RESPONDER
ЕМТ
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

#### <u>9Kd: Sublingual/Oral – Adult & Pediatric:</u>

1. Instruct, assist, or place the tablet or spray under the tongue (sublingual) or in the mouth (oral)/on the tongue (oral dissolving).

PARAMEDIC

9Ke: Ocular - Adult & Pediatric:

- 1. Don't touch the tip of the medication container to any part of the eye or face.
- 2. Pull the lower eyelid down while avoiding any ocular (eyeball) pressure.
- 3. Instill eye drop(s) in the space between the eyelid and the eyeball.

PARAMEDIC

9Kf: Intravascular Infusion Management - Adult & Pediatric:


- 1. Assure that the IV / IO line is patent.
- 2. Cleanse the access port nearest the IV / IO site with alcohol prep.
- 3. Flush any air from infusion line/set and insert needle or adapter into access port.
- 4. Unless simultaneously giving an IV fluid bolus, close off the IV line above the medication port. This prevents the medication from traveling toward the IV bag, forcing it instead toward the patient.
- 5. Infuse the medication as specified per appropriate treatment protocol.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 9L - Nasogastric/Orogastric Tube – Adult & Pediatric



#### Indications:

- 1. I-gel<sup>™</sup> placement only.
- 2. Decompression of ventilated air in stomach (reduction of gastric distension) in the cardiac arrest patient.
- 3. Decompression of ventilated air in stomach (reduction of gastric distension), compromising oxygenation/ventilation in the unconscious, I-gel<sup>™</sup> patient.

#### Technique:

- 1. Choice proper NG tube size from chart in protocol 2E.1 (page 2E.2).
- 2. Lubricate NG tube prior to insertion into I-gel<sup>™</sup> NG tube portal.
- 3. Place NG tube through the I-gel<sup>™</sup> NG tube portal into the stomach.
- 4. Confirm correct gastric placement of gastric tube by injecting 10 to 20 mL of air while auscultating over the stomach for a "swoosh" or "burping/bubbling" indicating the gastric tube tip lies within the stomach. Confirm absence of similar sounds in the lungs by auscultating in the mid-axillary line bilaterally while repeating the injection of small mL volumes of air.
- 5. Attach gastric tube to low pressure suction and observe for gastric decompression.


#### PARAMEDIC

#### Indications:

- 1. Decompression of ventilated air in stomach (reduction of gastric distension) in the cardiac arrest patient. (may be placed pre or post intubation)
- 2. Decompression of ventilated air in stomach (reduction of gastric distension), compromising oxygenation/ventilation in the unconscious, intubated patient.

#### Contraindications:

- 1. Suspected basilar skull fracture
- 2. Suspected mid-facial fractures
- 3. Known or suspected actively bleeding esophageal varices







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Technique:

- 1. Select correct size gastric tube. Adult patients typically require size 16 to 18 French gastric tubes.
- 2. Measure length of gastric tube to pass by starting with tip just at xiphoid process, then using distance to earlobe and over to tip of nose (Figure).
- 3. Mark the measured length of tube with a piece of tape.
- 4. Lubricate tip of tube with water soluble lubricant if inserting nasally.
- 5. Nasal insertion: direct gastric tube along the floor of nostril to the posterior nasopharynx, then feed the gastric tube through the oropharynx down the esophagus and into the stomach, stopping when taped mark nears nostril.
- 6. Oral insertion: direct gastric tube along tongue to posterior oropharynx, then feed the gastric tube down the esophagus and into the stomach, stopping when taped mark nears lips.
- 7. Confirm correct gastric placement of gastric tube by injecting 10 to 20 mL of air while auscultating over the stomach for a "swoosh" or "burping/bubbling" indicating the gastric tube tip lies within the stomach. Confirm absence of similar sounds in the lungs by auscultating in the mid-axillary line bilaterally while repeating the injection of small mL volumes of air.
- 8. Tape the tube in place on the nose or on around the mouth. Alternatively, some commercial types of endotracheal tube holders can be used to secure gastric tubes if passed orally.
- 9. Attach gastric tube to low pressure suction and observe for gastric decompression.

#### Troubleshooting:


- 1. Abort gastric tube passage attempts if unsuccessful in three attempts.
- 2. Repetitive coughing indicates the gastric tube is erroneously passing down the trachea. Tracheal/bronchial stimulation in gastric tube passage will typically provoke strong coughing reflex. Promptly withdraw tracheally placed gastric tubes to avoid aspiration. An endotracheal tube will not prevent inadvertent passage of a gastric tube down the trachea.
- 3. Avoid lavage or medications via gastric tube. Use is for gastric decompression.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

9M – SUSPECTED ABUSE/NEGLECT ADULT & PEDIATRIC



Indications:

- 1. Concern for child abuse and/or neglect.
- 2. Concern for adult/elder abuse and/or neglect.

Contraindications:

None

In the course of EMS care of a patient (from time of emergency services request through transport of the patient to the destination location), EMS professionals that become concerned regarding actual or perceived abuse and/or neglect occurring to persons of any age should directly inform any receiving health care professionals and/or involved law enforcement officers of the concerns. If the concerns are regarding abuse and/or neglect of the patient, document such concerns in the patient care report, including specific comments that the receiving health care professional(s) and/or law enforcement officers were directly informed of such concerns in appropriate detail.

If EMS professionals believe an adult or child is being abused or neglected, and/or have concerns regarding the imminent safety of an adult or child due to possible abuse or neglect, there is a legal responsibility to report the beliefs and/or concerns.


## Oklahoma Department of Human Services Abuse and Neglect Hotline (Calls Answered 24 Hours a Day/7 Days a Week)

## 1-800-522-3511

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient/person information and situational/observation information possible readily available to share with the abuse and neglect hotline specialist.
































Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 10E – NEEDLE THORACOSTOMY – TENSION PNEUMOTHORAX DECOMPRESSION ADULT & PEDIATRIC

PARAMEDIC

Indications:

Suspected tension pneumothorax

Clinical signs of tension pneumothorax:

Increasing respiratory insufficiency in a susceptible patient:

- 1. Spontaneous pneumothorax
- 2. CPR with appearance of PEA, increased difficulty bagging patient
- 3. Sucking chest wound which has been covered and which has not responded to removal of the seal/dressing
- 4. Chest trauma with suspected pneumothorax AND

Adult systolic blood pressure less than 100 mmHg (or pediatric systolic blood pressure less than 70 + (2 x age in years) mmHg **AND** Three or more of the following:

- 1. "Air Hunger"
- 2. Cyanosis
- 3. Decreased breath sounds on affected side(s)
- 4. Jugular venous distension
- 5. Tracheal shift away from affected side extremely late sign do not wait as indication for needle thoracostomy if other signs are developing

Etiologies of tension pneumothorax include:

- 1. Trauma (blunt or penetrating) disruption of either visceral or parietal pleura; often associated with rib fractures (rib fractures not necessary for tension pneumothorax to occur)
- 2. Barotrauma secondary to positive-pressure ventilation, especially when using high amounts of positive end-expiratory pressure (PEEP)
- 3. Unsuccessful attempts to convert an open pneumothorax to a simple pneumothorax in which the occlusive dressing functions as a 1-way valve
- 4. Chest compressions during cardiopulmonary resuscitation

#### Contraindications:

No absolute contraindications. Do not place a needle thoracostomy through an area of suspected cellulitis, using instead an approved alternative site.






#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 10E: Needle Thoracostomy -Tension Pneumothorax Decompression - Adult** & Pediatric, cont.

#### Precautions:

- A SIMPLE pneumothorax causes some degree of respiratory distress and chest pain, and MAY be associated with decreased or absent breath sounds on the side of the collapse and with subcutaneous air if the cause is traumatic. TENSION pneumothorax is associated with progressive respiratory distress, dropping BP, "drum-like" hyperexpanded chest, distended neck veins, and patient deterioration. Tracheal shift may be present but is a late sign and needle decompression should be accomplished before waiting for the appearance of tracheal shift.
- 2. Pneumothorax rarely presents with tension on initial assessment. Be particularly suspicious with deterioration during transport, and with patients requiring assisted ventilation.
- 3. In patients who are being ventilated by bag-valve mask or ventilator, caution should be exercised when performing needle decompression. If the presumptive diagnosis of a tension pneumothorax is incorrect, the insertion of the needle may create a pneumothorax, which may be converted into a tension pneumothorax by positive-pressure ventilation.
- 4. If a previously covered sucking chest wound is present, remove the seal and allow chest pressures to equilibrate. This should allow air to escape relieving the tension pneumothorax.

#### Technique:

- A. Expose the entire chest.
- B. Locate landmark on affected side(s), (figure 1)
  - a. Adult: fourth or fifth intercostal space-anterior axillary just superior to the lower rib
  - b. Pediatric: second intercostal space-midclavicular just superior to third rib
- C. Clean area of insertion with ChloraPrep®, Betadine®, or alcohol prep.
- D. Attach 10 mL or larger syringe to a 15 gauge Cook pneumothorax catheter or use a 10-gauge SPEAR catheter (no syringe).
- E. Decisively locate the insertion point.
- F. Insert the needle at 90 degrees through the skin and advance until tip of the needle hits the top of the rib below the intercostal space penetrated by the needle. Continue to advance angling over the top of the rib to avoid the neurovascular bundle running horizontally under the rib above the intercostal space is penetrated.
- G. Advance of the needle tip into the pleural space. A slight "pop" is usually felt when the needle pierces the outside pleural membrane, or parietal pleura.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 10E: Needle Thoracostomy - Tension Pneumothorax Decompression - Adult & Pediatric, cont.

#### Technique, cont .:

- H. When tension is present, syringe plunger will typically dislodge back out of syringe, or an immediate hiss of air escaping will be heard.
- I. If using the 10-gauge SPEAR catheter the plastic catheter should be separated after signs of proper placement. This is achieved after the needle has been inserted to an estimated depth of:
  - **a.** <1 y.o. =  $\sim \frac{1}{2}$  cm past the rib
  - **b.** >1 y.o <12 y.o. =  $\sim$ 1- 3 cm past the rib
  - **c.** 12 y.o Adult =  $\sim$ 3 cm past the rib
- J. Remove the syringe and needle and leave the catheter in the pleural space.
- K. If using the 10-gauge SPEAR catheter remove the one-way valve from the needle hub and attach it to the catheter hub.
- L. If recurrent decompensation of the patient occurs related to suspected redevelopment of tension pneumothorax, repeat the procedure next to the previously successful needle thoracostomy site.

#### Complications:

- 1. Creation of pneumothorax if none existed previously. This is an unfortunate occurrence if needle thoracostomy is done too aggressively. Do not hesitate to relieve a strongly suspected tension pneumothorax but perform an accurate assessment to validate the suspicion of tension pneumothorax.
- 2. Laceration of lung, which is rare, can cause significant pulmonary injury. Avoid excessive length needles.
- 3. Hemothorax from vascular injury. Avoid needle thoracostomy medial to the mid-clavicular line. Avoid needle thoracostomy just inferior to a rib, where the intercostal vessels run underneath the rib margin. Avoid needle thoracostomy inferior to the right 6<sup>th</sup> intercostal space to avoid the upper margin of the liver.
- 4. Infection. Minimize risk by clean insertion site and maintaining aseptic technique, using sterile catheters/needles.

#### Note:

Both the 2<sup>nd</sup> Intercostal space-midclavicular line and the 4<sup>th</sup> or 5<sup>th</sup> Intercostal space-anterior axillary line are effective in the release of tension pneumothorax. Utilize this alternate location if the preferred site does not improve the respiratory or hemodynamic conditions of a patient with a strongly suspected tension pneumothorax.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

10F – CHEST TUBE MONITORING ADULT & PEDIATRIC

#### PARAMEDIC

Indications:

Interfacility transfer of patient with chest tube thoracostomy.

#### Technique:

The chest tube thoracostomy-related device(s) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel prior to conducting the interfacility transfer. Potential complications during transfer should be discussed, such as in the possibility of recurrent pneumothorax, and contingency plans reviewed, such as releasing the occlusive dressing around the chest tube or performing a needle thoracostomy per Protocol 10E – Needle Thoracostomy. If the Paramedic feels unable to safely monitor and maintain the chest tube, he or she is to request appropriate resources from the transferring hospital to accompany the patient during transfer.

Under these conditions, EMS personnel will not begin the transfer until such request is accommodated.

During packaging, patient movement, and throughout the interfacility transfer, perform periodic inspection and assessment of the chest tube.


The chest tube may be attached to a one-way valve (Heimlich valve) that allows for air or fluid passage from the chest to the outside, often contained within a simple bag container. If a Heimlich valve is present, keep it attached to the chest tube.

The chest tube may alternatively be attached to a multi-chamber container that can be attached to low suction. This container can be used for collection of blood drainage from the chest for auto-transfusion and/or to measure how much blood or other fluid is being drained from the chest tube. The chamber connecting to the chest tube is for fluid collection. The second chamber contains a small volume of water, establishing a water seal, creating a one-way flow of air from the chest, and keeping the pressure in the chest less than atmospheric pressure. The third chamber is a suction chamber, designed to limit excessive wall suction effect on the chest. Keep the container upright to keep fluid collection measurement accurate and avoid any loss in function of the device.

Persistent bubbling in the chamber(s) indicates an air leak in the chest tube system. This may be due to a loose connection in the tube/chamber/suction circuit or due to a perforation in the airway (e.g. bronchiole). Check the visible connections of the chest tube system. If bubbling prior to transfer, discuss with transferring practitioner/physician.












Approved 9/14/22, Effective 1/16/23, replaces all prior versions





<u>Indication</u>: Life-threatening extremity hemorrhage unable to be controlled by direct pressure or immediately obvious that direct pressure alone will not provide control.

#### Contraindication: None

#### Technique (Combat-Application-Tourniquet<sup>®</sup> - C-A-T<sup>®</sup>):

The <u>C-A-T<sup>®</sup> (Figure 1)</u> windlass uses a free moving internal band to provide circumferential pressure to an injured and uncontrollably bleeding extremity. Once placed, keep the tourniquet secure, but uncovered so that the bleeding site can be clearly monitored as well as the tourniquet itself. The time of tourniquet application (Figure 6, e.g. TK 0145) is to be written on a piece of adhesive tape and secured to the tourniquet. Conscious patients may experience pain related to tourniquet use. In such instances, follow the pain management protocol if the patient is hemodynamically stable.



## Step 1 (Figure 2):

The <u>C-A-T<sup>®</sup></u> is applied over the extremity proximal to the bleeding site routing the self – adhering band around the extremity. Feed the strap through the buckle.





Approved 9/14/22. Effective 1/16/23. replaces all prior versions

## PROTOCOL 10H: Tourniquet, Adult & Pediatric, cont.

Step 3 (Figure 3 & 4):

Pull the self - adhering band, through the buckle, tight and secure the band back on itself with the Velcro adhesive strap.

#### Step 4 (Figure 4):

Twist the windlass until the bleeding has stopped. This will typically be at or less than 3 complete rotations of the windlass.

Step 5 (Figure 5):

Lock the rod in place with the windlass clip.

Step 6 (Figure 6):

Secure the rod with the strap by pulling it tight and adhering it to the opposite hook on the windlass hook. Indicate the time of tourniquet application on tape.















Approved 9/14/22. Effective 1/16/23. replaces all prior versions

## PROTOCOL 10H: Tourniquet, Adult & Pediatric, cont.

Using Generation 7 <u>C-A-T<sup>®</sup></u> tourniquets, all applications are made passing the self-adhering band through the single slit of the buckle.

If one tourniquet correctly applied does not completely control hemorrhage, in addition to direct pressure, an additional tourniquet may be applied just proximal to the first tourniquet.

Once bleeding has been controlled by a tourniquet, the usual and customary practice is to leave the tourniquet in place throughout the remainder of scene care and transport to an emergency department. In infrequent circumstances, if pain control becomes an issue, the tourniquet may be loosened to see if bleeding will stay controlled. If bleeding resumes, promptly re-tighten the tourniquet to its effective tightness.

#### Technique SWAT-T™

The <u>SWAT-T<sup>TM</sup> (Figure 1)</u> provides circumferential pressure to an injured and uncontrollably bleeding extremity. The SWAT-T<sup>TM</sup> can be used on children or adults with smaller extremities where the <u>C-A-T<sup>®</sup></u> is too large to control the hemorrhage. Once placed, keep the SWAT-T<sup>TM</sup> secure, but uncovered so that the bleeding site can be clearly monitored as well as the SWAT-T<sup>TM</sup> itself. The time of application is to be written on a piece of adhesive tape and secured to the SWAT-T<sup>TM</sup>. Conscious patients may experience pain related to tourniquet use. In such instances, follow the pain management protocol if the patient is hemodynamically stable. (Stretch-Wrap-Tuck)



Step 1 (Figure 2):


Wrap tightly while pulling tension (**Stretch**) on the <u>SWAT-T<sup>TM</sup></u>

Step 2 (Figure 3):

Continue to **Wrap** while pulling tension on the <u>SWAT-T<sup>TM</sup></u>


## Step 3 (Figure 4):

After <u>SWAT-T<sup>TM</sup></u> is tight & bleeding is controlled **Tuck** the <u>SWAT-T<sup>TM</sup></u> up into itself making it secure.



































Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 10L: Burns - Adult &Pediatric, cont,** 

## % Body Surface Area (BSA) Estimation Chart

Count only Second and Third Degree Burns when calculating estimated %BSA



An alternate method of calculating %BSA involvement is to use the size of the patient's entire hand equal to 1% of their BSA. This is a useful method when calculating smaller burn areas.






Wt (Kg)	Burn Surface Area %													
	20	25	30	35	40	45	50	55	60	65	70	75	80	
2	10	15	15	20	20	25	25	30	30	35	35	40	40	
4	20	25	30	35	40	45	50	55	60	65	70	75	80	
6	30	40	45	50	60	70	75	80	90	100	105	115	120	
8	40	50	60	60	80	90	100	110	120	130	140	150	160	
10	50	65	75	75	100	115	125	135	150	165	175	190	200	
12	60	75	90	105	120	135	150	165	180	195	210	225	240	
15	75	100	115	130	150	170	190	210	225	250	280	285	300	
17	85	110	130	150	170	190	215	235	255	275	300	320	340	
20	100	125	150	175	200	225	250	275	300	325	350	375	400	
22	110	140	165	200	220	250	275	300	330	360	385	415	440	
25	125	160	190	220	250	280	315	350	375	400	440	470	500	
27	135	170	200	240	270	300	340	370	405	440	470	500	540	
30	150	190	225	260	300	340	375	410	450	490	525	560	600	
35	175	220	260	300	350	400	440	480	525	570	610	660	700	
40	200	250	300	350	400	450	500	550	600	650	700	750	800	
50	250	315	375	440	500	560	625	690	750	810	875	940	1000	
60	300	375	450	525	600	675	750	825	900	975	1050	1125	1200	
70	350	450	525	620	700	800	875	1000	1050	1150	1225	1325	1400	
75	375	500	550	650	750	850	950	1050	1150	1200	1300	1400	1500	
100	500	625	750	875	1000	1125	1250	1375	1500	1625	1750	1875	2000	

Fluid resuscitation for 2nd and 3rd degree burns totalling greater than 20% BSA
Milliliters of fluid to be given during first hour based on Parkland Formula
4mL x kg x BSA% = Total Fuid over 24 Hrs
Half of total should be given over the first 8 Hrs













Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 10N – "LESS LETHAL" WEAPON RELATED MANAGEMENT ADULT & PEDIATRIC








Approved 9/14/22, Effective 1/16/23, replaces all prior versions



## 100 – SPLINTING OF INJURIES ADULT & PEDIATRIC



## 100a: Spinal Motion Restriction - Adult & Pediatric:

Many patients evaluated by EMS professionals are placed in a cervical collar and onto a long spine backboard based as much upon "tradition" that this practice is without risk and the benefit is without question. Like many medical practices scrutinized over time, evidence-based medicine reveals it is with risk (pain, tissue damage leading to pressure sores, and concerns about risks of aspiration and impaired breathing mechanics). Similarly, the benefit is not certain. Few "real" injuries are so unstable that the process of spinal motion restriction as performed in EMS is the difference-maker between paralysis and ambulation.

This protocol does not seek to avoid spinal motion restriction when clinically indicated. This protocol rather seeks to provide an evidence-based approach that directs the careful practice of spinal motion "restriction" in situations where history, exam findings, and/or patient interaction limitations make the possible benefit outweigh the risks. When the benefit does not outweigh the risks, patients should not incur clinically unnecessary collars and boards.

When applying spinal motion restriction, include the following:

- 1. Avoid traction being placed on the spine in any direction.
- 2. Correctly size the cervical collar to additionally avoid traction being placed on the spine.
- 3. Maintain the spinal column alignment integrity when rolling the patient onto a long back board, using a scoop stretcher, or placing/moving in any other spinal motion restriction device.
- 4. Secure the torso and extremities to the backboard first, the head/neck last.
- 5. Remove from the long spine backboard once on the stretcher, unless CPR is ongoing or anticipated during transport.


Documentation of spinal motion restriction should include a neurologic assessment before and after the process, which includes the application of a cervical collar, noting any movement using a backboard/scoop stretcher, and indicating prompt removal from the backboard/scoop stretcher unless CPR ongoing/anticipated. In the seated patient that is hemodynamically stable and requiring spinal motion restriction, assist the patient in pivoting and lying supine onto the stretcher and/or use a spinal motion restriction device to achieve the same, whichever involves less anticipated spinal motion.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions



**EMS SECTION** 





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



## PROTOCOL 100: Splinting of Injuries, cont.

10Oa - Spinal Motion Restriction - Adult & Pediatric, cont.

Comments regarding the Selective Spinal Motion Restriction Process:

- The process of EMS-performed selective spinal motion restriction constitutes a formal stepwise screening of individuals suffering from mechanisms of injury compatible with possible injury to the spine. This process, now increasingly widely adopted in EMS systems across the United States, is designed from research-verified assessments, identifying individuals that may be safely transported to an emergency department, without spinal immobilization, for further appropriate physician evaluation. IT DOES NOT CONSTITUTE FORMAL "CLEARING" OF THE SPINE.
- 2. When following the decision flowchart in this protocol, there is no validated benefit to applying a cervical collar to patients who do not have any indication for spinal motion restriction and risks of pain, skin trauma, and compromise of respiratory mechanics may result if placed and left on a long spine backboard.
- 3. The process of EMS-performed selective spinal motion restriction, while continuing to involve placement of a cervical collar, no longer requires continuous use of a long spine backboard. While the long spine backboard is one option to assist a patient supine onto a stretcher, in the absence of ongoing or imminent CPR, patients should be removed off the long spine backboard as soon after movement onto the stretcher as possible.
- 4. Patients with penetrating trauma have been shown to have worse outcomes with continuous use of the long spine backboard, in part due to prolonged scene times relating to extensive spinal motion restriction actions. Victims of penetrating trauma (stabbings, gunshot wounds) to the head, neck, and/or torso SHOULD NOT receive spinal motion restriction unless there is one or more of the following:
  - Obvious neurologic deficit to the extremities
  - Priapism
  - Neurogenic shock
  - Anatomic deformity to the spine secondary to injury
- 5. Patients with any form of trauma may experience reduction in pulmonary mechanics (ease of oxygenation/ventilation) when placed onto a long spine backboard. Continuous use of the long spine backboard should be limited to situations involving ongoing or imminent CPR.
- 6. Patients at age extremes are prone to unreliable history and physical assessments. Patients under the age of 12 years or over the age of 65 years, if they have suffered a mechanism of injury compatible with possible spinal injury, are to be placed in spinal motion restriction.
- 7. The designation of a Glasgow Coma Scale score of 15 includes an assessment that no neurological deficits exist. If a patient is complaining of motor and/or sensory loss following a mechanism of injury compatible with possible spinal injury, that patient is to be placed in a cervical collar with verbal reinforcement that they limit movement of their cervical spine, keeping the spine in natural/neutral alignment.



**EMS System for Metropolitan Oklahoma City and Tulsa 2023 Medical Control Board Treatment Protocols** Approved 9/14/22, Effective 1/16/23, replaces all prior versions



#### PROTOCOL 100: Splinting of Injuries, cont. 100a - Spinal Motion Restriction – Adult & Pediatric, cont.

Comments regarding the Selective Spinal Motion Restriction Process (cont):

- 8. At any point from sustaining an acute mechanism of injury compatible with possible spinal injury through EMS care, if the patient has a reported loss of consciousness or altered mental status, regardless of normal mental status upon EMS contact and assessment, that patient is to be placed in spinal motion restriction.
- 9. A language barrier exists if the EMS professional and the patient cannot fluently communicate. Fragmented communication ("broken" language) or the use of a family member or bystander to communicate with the patient does not constitute fluent communication. If the EMS professional has a language barrier with the patient following an injury involving a mechanism compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 10. Regardless of apparent "soberness" on assessment, if a patient has ingested ethanol or mental-status altering drugs (e.g. narcotics, benzodiazepines, barbiturates, marijuana, cocaine) within six hours prior to a mechanism of injury compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 11. Distracting pain or injury is best defined as an injury in which the patient is repetitively fixated upon to the extent the history and physical assessment is frequently interrupted to address that injury. The EMS professional must use his or her best judgment and anytime a concern exists that an injury may prove distracting to a patient with a mechanism of injury compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 12. In circumstances of acute vomiting and/or third trimester pregnancy, the patient is preferentially transported left lateral recumbent to reduce aspiration of emesis and when in advanced stages of pregnancy, to avoid compromising venous return to the chest.
- 13. If the supine positioning of the patient wearing a cervical collar is compromising respiratory mechanics and/or causing the patient to have dyspnea, the head of the stretcher may be elevated approx 15 degrees to assist respiratory status.
- 14. If a patient suffering a mechanism of injury compatible with possible spinal injury complains of pain in the spinal or paraspinal area anywhere from the base of the skull to the coccyx, that patient is to be placed in spinal motion restriction.
- 15. In the physical examination of a patient suffering a mechanism of injury compatible with possible spinal injury, if the EMS professional discovers spinal or paraspinal pain or deformity upon palpation or with patient flexion, extension, or lateral rotation of the neck or back, that patient is to be placed in spinal motion restriction.



EMS System for Metropolitan Oklahoma City and Tulsa 2023 Medical Control Board Treatment Protocols Approved 9/14/22, Effective 1/16/23, replaces all prior versions



PROTOCOL 100: Splinting of Injuries, cont. 100a - Spinal Motion Restriction – Adult & Pediatric, cont.

Comments regarding the Selective Spinal Motion Restriction Process (cont):

- 17. If the EMS professional judges a complicating factor (e.g. patient stress or anxiety, the energy or nature of the mechanism of injury) to be present or significantly concerning, that patient is to be placed in spinal motion restriction. If any doubt exists in the view of the EMS professional as to whether to spinal motion restrict the patient, that patient is to be placed in spinal motion restrict the patient, that patient is to be placed in spinal motion.
- 18. An instance may occur when a patient has been deemed safe for transport without spinal motion restriction using this protocol and the patient subsequently develops neck or back pain in the ambulance during transport to an emergency department. The EMS professional must use his or her best judgment factoring the degree of pain verbalized and the remaining transport route and time in deciding when to spinal motion restrict the patient. As a guideline, if the remaining route involves unusually rough highway or will be prolonged beyond several minutes duration, the EMS crew should temporarily stop transportation and apply spinal motion restriction to the patient in the ambulance unless the patient's condition is otherwise unstable and requires continued emergency transport. As a guideline, if the arrival at the destination emergency department is imminent, the patient may be spinal motion restricted upon hospital arrival. In each instance, the EMS professional should inform the receiving nurse or physician of the events and timing of spinal motion restriction and appropriately reflect the events in the patient care report.
- 19. Any utilization of the selective spinal motion restriction protocol should be clearly documented in the patient care report, with each requirement in this process denoted.
- 20. An instance may occur when a patient that is to be spinal motion restricted by this protocol absolutely refuses a cervical collar and other such movement limitations. These are, indeed, difficult circumstances. If repeated attempts to secure the cooperation of the patient fail, guidance from OLMC should be sought. If such a patient is transported without spinal motion restriction by the direction of the OLMC, detailed documentation of the spinal motion restriction attempts, OLMC consultation and direction, and subsequent actions is to be contained in the patient care report.
- 21. For pediatric patients found in car seats and involved in motor vehicle collisions, use the following if spinal motion restriction indicated:
  - Infants restrained in a rear-facing car seat may remain in and be extricated in the car seat if secure and his/her condition allows (no signs of respiratory distress or shock)
  - Children restrained in a car seat (with a high back) may remain in and be extricated in the car seat.
  - Children restrained in a booster seat (without a back) need to be extricated and cared for following standard spinal motion restriction procedures.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 100: Splinting of Injuries, cont.


#### 100b - Extremity - Adult & Pediatric:

When applying extremity splinting, include the following:

- 1. Assess and document the assessment of distal vascular (pulse) and nerve (motor/sensation) function, before and after splinting.
- 2. In general, immobilize the joint on either side of the suspected fracture area.
- 3. Pad splints whenever possible to avoid tissue pressure from splints.
- 4. In the setting of that an extremity is pulseless distal to a markedly angulated fracture, make one gentle attempt to place the angulated extremity in near-normal alignment. Document the distal vascular and nerve function before and after any such maneuver.
- 5. Prioritize timely transport to an appropriate emergency department for extremity injuries with pulselessness distal to the suspected fracture/injury.











Approved 9/14/22, Effective 81/16/23, new protocol issuance

10Q – FIELD AMPUTATION

## **Operational Procedure:**

- 1. The Surgical Emergency Response Team (SERT OU Trauma) is a resource for metropolitan Oklahoma City that can be activated for patients with entrapped extremities requiring surgical amputation procedures which exceed the capabilities of EMS system professionals.
- 2. SERT activation may occur when mutually agreed by the ranking fire officer and EMSA District Chief on-scene.
- 3. SERT activation is accomplished by contacting OUMC ED Trauma Side and requesting SERT mobilization to the indicated scene.
- 4. SERT transportation to and from the scene will be facilitated by the ranking fire officer and EMSA District Chief on-scene working together to determine the appropriate EMS system vehicle(s) to utilize for SERT members responding from OUMC.
- 5. SERT team composition may include trauma surgeon(s), orthopedic surgeon(s), surgical nurse(s), emergency nurse(s), surgical tech(s), and/or other deemed essential to specific patient care. SERT team composition is at the discretion of OU Trauma Services.

# SERT ACTIVATION ACCESS NUMBER OUMC ED - TRAUMA: 405-271-1623


## Contraindications:

- 1. Completed amputations
- Near-complete amputations with only soft tissues needing incision to complete contact OMD for amputation completion orders if any questions remain about limb salvage/viability.
- 3. Ability to extricate the patient without need for further amputation

<u>The instructions above apply only to metropolitan Oklahoma City.</u> For metropolitan Tulsa, contact a Chief Medical Officer or OMD Division Chief for surgical team activation and mobilization assistance.











Approved 3/1/23, Effective 5/1/23, replaces all prior versions

## Protocol 11A: Heat Illness Adult & Pediatric (cont.)

## **Rapid Cooling for Heat Stroke**

#### **PURPOSE**

Rapid, on-scene cooling is highly beneficial to survival from **environmental or exertional-induced heat stroke**. On-scene cooling is not intended for patients who have a non-environmental, non-exertional cause for elevated core temperature (such as fever from an infectious disease). The exact cooling method(s) chosen is often dependent upon scene location, available personnel, and available resources. The primary goal of rapid cooling for heat stroke is to provide **immersion cooling <u>before</u> transporting** to an emergency department. While on-scene cooling will involve extra minutes of care prior to transport, few if any destination hospitals have immersion cooling capabilities, particularly capabilities that can deployed as rapidly as within the EMS System for Metropolitan Oklahoma City and Tulsa. The extra time and effort in cooling before transporting can prove life-saving.

## PROCEDURE

In static settings, such as multi-hour fireground rehabs, and particularly in pre-planned static settings, such as summer outdoor football practices, cold water/ice bath immersion resources already on-scene should be identified and utilized.

For unplanned heat exposures leading to heat stroke, cold water deluge is the most practical application. As soon as potential heat stroke is identified, an emergency apparatus capable of establishing water supply from a fire hydrant should be dispatched. If a copious cold water supply or fire hydrant is not immediately available at the scene, it is acceptable to move the patient via ambulance to the nearest such copious cold water supply or fire hydrant to perform rapid cooling for heat stroke.

## **Cold Water Deluge:**

- 1. Place the patient in a cooling bag.
- 2. Place a minimum estimated 5 gallons of iced water on patient while fire hydrant source is established (if available/applicable).
- 3. Deluge water over the patient's chest and lower body continuously while protecting the patient's airway.
- 4. Deluge water until patient temperature is less than 102.2°F (39°C) or, if continuous temperature monitoring is not available, until the patient demonstrates improvement in mental status.
- 5. Do not initiate deluge while the patient is in an ambulance or on an ambulance stretcher due to electronics.
- 6. Unless hypotensive or other immediate need, prioritize rapid cooling in the setting of heat stroke, over IV access and other invasive procedures.





Approved 3/1/23, Effective 5/1/23, replaces all prior versions

## Protocol 11A: Heat Illness Adult & Pediatric (cont.)

#### Static Setting Cold Water/Ice Bath Immersion:

- 1. Utilize a tub designed to manage weight of patient and water.
- 2. Fill tub with ice and water to a level that will cover the patient's chest.
- 3. Ice the water to reach a temperature near 50°F.
- 4. Utilize a tarp or similar device to lower and lift the patient.
- 5. Utilize a blanket roll or similar device looped under the axillae to keep the patient's head (airway) above water.
- 6. Agitate the water while patient is immersed.
- 7. Immerse until patient temperature is less than 102.2°F (39°C) or, if continuous temperature monitoring is not available, until the patient demonstrates improvement in mental status.
- 8. Unless hypotensive or other immediate need, prioritize immersion cooling in the setting of heat stroke, over IV access and other invasive procedures.

#### ADDITIONAL CONSIDERATIONS

- Cooling bags should have handles to facilitate movement and oscillation of the patient during deluge or immersion. Webbing or sewed-on handles are preferred over less sturdy options. Handles cut into the material of the bag are more prone to leaks and failure.
- Rectal thermometers designed for continuous monitoring (if available) should be placed as soon as possible, even if after cold water deluge or cold water/ice bath immersion has been initiated.
- Fire hydrant water temperature may range between approximately 50°F to 70°F depending on time of year. Fire hydrant water is preferred over fire apparatus tank water due to more predictable temperature range.





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **11B - COLD ILLNESS/INJURY** EMERGENCY MEDICAL **ADULT & PEDIATRIC** DISPATCHER EMERGENCY MEDICAL RESPONDER TREATMENT PRIORITIES Warming therapy EMT 2. Vital signs 3. Modified cardiac arrest EMD **EMT-INTERMEDIATE 85** resuscitation (when applicable) PROTECT FROM COLD ADVANCED EMT REMOVE WET CLOTHING WARM WITHOUT RUBBING AFFECTED AREAS DO NOT GIVE ALCOHOL TO DRINK PARAMEDIC EMR EMT GENERAL SUPPORTIVE CARE REMOVE FROM COLD ENVIRONMENT REMOVE WET/RESTRICTIVE CLOTHING APPLY HEAT PACKS TO GROIN, NECK, AXILLA COVER PATIENT WITH BLANKETS TO EXTENT CLINICALLY POSSIBLE OBTAIN VITAL SIGNS O2 VIA NC, NRB, OR BVM AS APPROPRIATE (WARM & HUMIDIFIED O2 if equipped) APPLY CARDIAC MONITOR (if equipped) UNRESPONSIVE HYPOTHERMIA PATIENT STATUS? ASSESS BREATHING/PULSE FOR UP TO 45 SECONDS PERFORM CPR IF IN CARDIOPULMONARY ARREST IF DEFIBRILLATION ADVISED BY AED, LIMIT TO ONE DEFIBRILLATION UNTIL WARMED FROSTBITE? APPLY LOOSE STERILE DRESSINGS AND SPLINT INVOLVED EXTREMITIES **EMT OR HIGHER LICENSE:** MEASURE END - TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE EMT-185 AEMT ADULT: INTUBATE IF INDICATED IV ACCESS ADULT: IV NS (WARMED UP TO 43°C (109°F) if available) 500 mL BOLUS IF NO SIGNS OF PULMONARY EDEMA. ADULT: REPEAT UP TO 2 LITERS NS IF PT TEMP <30°C (<86°F), ALTERED MENTAL STATUS, &/OR HYPOTENSION < 100 mmHg PERSISTS

IF NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS 20 mL/kg BOLUS (WARMED AS PER ADULT if available) IF NO SIGNS OF PULMONARY EDEMA PEDIATRIC: REPEAT UP TO 60 mL/kg IF PT TEMP <30°C (<86°F), ALTERED MENTAL STATUS, &/OR HYPOTENSION < (70 + 2x age in years) mmHg PERSISTS IF NO SIGNS OF PULMONARY EDEMA

PARAMEDIC

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

HYPOTHERMIC CARDIAC ARREST?

ADULT/PEDIATRIC: WITH BODY TEMPERATURE <30°C (<86°F)

CONTINUE CPR, WITHHOLD MEDICATIONS, LIMIT TO A SINGLE DEFIBRILLATION FOR VENTRICULAR FIBRILLATION/PULSELESS VT


ADULT/PEDIATRIC: WITH BODY TEMPERATURE ≥30°C (≥86°F) CONTINUE CPR, ADMINISTER DYSRHYTHMIA APPLICABLE MEDICATIONS AT 10 MINUTE INTERVALS AS CORE TEMPERATURE RISES, DEFIBRILLATE PER NORMAL BODY TEMPERATURE INTERVALS

CONTINUE REWARMING MEASURES UNTIL ROSC OR OLMCP AUTHORIZES TERMINATION OF RESUSCITATION

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)










EMERGENCY MEDICINE

UNIVERSITY OF OKLAHOMA

**EMS SECTION** 








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 11E – HEAT STROKE – ATHLETIC PARTICIPANTS WITH FIELD COOLING CAPABILITIES ON-SITE AT EVENT



<u>Indication</u>: Life-threatening heat stroke by clinical assessment requiring rapid cooling of core body temperature

<u>Contraindication</u>: Cardiac Arrest Respiratory Arrest Unstable Airway Inability to Maintain Normal Oxygenation

#### Technique (Ice Bath Immersion or Commercially Produced Body Cooling Wraps):

Athletic trainers and sports medicine physicians most typically are able to identify athletes at increased risk of heat stroke, stopping their activity and initiating cooling measures before heat stroke occurs. Athletic trainers most typically know their assigned athletes well, work in consultation with sports medicine physicians, and are valuable resources on the scene of an athletic-related medical emergency.

Field cooling with ice bath immersion or using commercially produced body cooling wraps, typically performed in a training room area adjacent to the actual "field" of play, can lower core body temperature more rapidly than ice packs to the groin and axilla as traditionally used in EMS care or Emergency Department based care. The reality is that no local Emergency Department has measures that can lower core body temperature more rapidly than effective field cooling.

After initial Paramedic assessment of the patient, consult with an OMD physician (Dr. Goodloe or Dr. Knoles) or OMD paramedic (Duffy McAnallen, David Howerton, or Matt Cox) is mandatory to help guide efficient, effective patient management, including field cooling.

Essential steps in any field cooling include: rapid activation of 911-based EMS care, continuous attention to airway/breathing/circulation, organized ongoing assessment and care throughout cooling, ability to accurately and continuously measure core body temperature by rectal thermometry, and packaging/moving the patient for timely ambulance transport once field cooling has achieved core body temperature less than 103F (rectally).



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Heat Stroke – Athletic Participants with Field Cooling Capabilities On-Site at Event (cont.)

Appropriate hospital destinations for patients requiring emergent field cooling once cooled:

- Tulsa area: St. Johns Medical Center, Saint Francis Hospital, Hillcrest Medical Center, OSUMC
- Oklahoma City area: The Children's Hospital, Integris Baptist Medical Center, Integris Deaconess Hospital, Integris Southwest Medical Center, OU Medical Center, St. Anthony Hospital

#### Step 1 (Figure 1):

The patient will most likely be encountered immersed in an ice bath or within the commercial cooling wrap device. Rectal thermometry should already be in place as well. Initial assessment includes confirmation of pulse – best practice would be to have continuous access to one wrist, and effective breathing. Any patient requiring active airway management beyond positioning the head above the ice bath should be removed from cooling and transported as quickly as possible.



#### Step 2 (Figure 2):

The Paramedic should establish location near the patient's airway throughout cooling. Attach waveform capnography to continuously measure spontaneous circulation, respiratory rate, and ventilatory effects. Notify OMD for patient consultation of care.



#### Step 3 (Figure 3):

Cooling impact should be rapid, being able to see decrease in core body temperature on the rectal thermometer screen. Be prepared for sudden alertness, and often vomiting, once the core temperature approaches 103F. If initial temperature shows 107.9F, realize the actual temperature is likely higher, as most available rectal thermometers will only read to 107.9F.





EMERGENCY



Approved 9/14/22, Effective 1/16/23, replaces all prior versions



#### Heat Stroke – Athletic Participants with Field Cooling Capabilities On-Site at Event (cont.)


#### Step 4 (Figure 4):

Prior to patient alertness, pass a lifting tarp under the patient to assist in safely lifting the patient, particularly if immersed in an ice bath.



#### Step 5 (Figure 5):

Once a core body temperature of 103F is achieved, the patient should be removed from ice immersion and packaged on the EMS stretcher for timely transport to a destination identified in this guidance document. Any patient with emergent field cooling mandates an Emergency Department evaluation.








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### 12A – FIREGROUND REHABILITATION CONCEPTS ADULT



Indications:

Active fireground operations in which physiologic stress is exerted upon firefighters.

#### Contraindications:

None

Clinical Pearls:

- Fireground operations place significant physiologic stress upon firefighters. Even in seemingly "normal" weather (absence of temperature extremes, absence of precipitation) during operations on even terrain, conducted by ample numbers of firefighters, the elevated body temperatures and physical stress experienced from exertion while wearing heavy protective clothing should not be underestimated. Early and effective rehabilitation promotes desired firefighter safety on the fireground.
- 2. The "basics" of effective fireground rehabilitation include:
  - a. medical monitoring of fire fighters at rehab entry, during rehab, and at rehab release;
  - b. returning body temperatures to near normal (cooling in heat; warming in cold);
  - c. hydration and electrolyte replacement;
  - d. Incident Command support of preventing fire fighter return to fireground duty until medically appropriate.
- 3. Fireground rehabilitation operations conducted by EMS organizations should be performed in close cooperation with involved fire departments and with knowledge of the rehabilitation policies of those fire departments. Section 19 contains current fireground rehabilitation policies utilized by the Tulsa Fire Department as resource documents in assisting other EMS organizations and fire departments in Oklahoma (courtesy Tulsa Fire Department).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 12A: Fireground Rehabilitation Concepts, cont.

4. In addition to the medical literature references for this protocol, additional fireground rehabilitation resources are available through the US Fire Administration, National Fire Protection Agency, International Association of Fire Chiefs, and International Association of Firefighters. Suggested resources that may prove helpful in designing and conducting effective fireground rehabilitation operations include:


U.S. Fire Administration, Emergency Incident Rehabilitation, February 2008 https://www.usfa.fema.gov/downloads/pdf/publications/fa\_314.pdf


NFPA 1584: Standard on the Rehabilitation Process for Members During Emergency Operations and Training Exercises, 2015 Edition

www.firerehab.com














Approved 9/14/22, Effective 1/16/23, replaces all prior versions



ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA.

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

PARAMEDIC

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 12C: Carbon Monoxide, cont.** 

%SpCO	Expected Signs & Symptoms – * may not correlate w/ individual pt symptoms		
0-3%	None - Normal		
4-9%	Minor Headache (**Normal for Smokers)		
10-19%	Headache, Shortness of Breath		
20-29%	Headache, Nausea, Dizziness, Fatigue		
30-39%	Severe Headache, Vomiting, Vertigo, AMS		
40-49%	AMS, Syncope, Tachycardia		
50-59%	Seizures, Shock, Apnea, Coma		
60% +	Coma, Death		

### Technique (Masimo RAD-57<sup>™</sup> - see protocol Special Note):

### Fingertip Sensor Placement Using Light Shield:

- Using the light shield with correct placement of finger is <u>VERY IMPORTANT</u> for accuracy of reading.
- Clean and dry finger.
- Orient equipment and finger to replicate diagram.
- When possible, use ring finger, non-dominant hand (using the dominant hand of smokers has been shown to result in higher level readings that do not correlate with body-wide levels of CO).
- Insert finger until the tip of finger hits the stop block.
- Sensor should NOT rotate or move freely on finger.
- LED's (red light) should pass through mid-nail, not cuticle.
- Connecting cable should be on top (nail side).







0

S Masino

**S** Masino

**SMASINOSET** 

0

Rad 57

0

Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 12C: Carbon Monoxide, cont.

#### Startup Sequence:

- Place sensor on finger (clean/dry skin)
- Press "POWER" button
- Verify all LED's light up and a 1 second tone is heard
- Startup mode begins
- All preset configurations are displayed
- Scrolling zeroes 0 0 0 and flashes dashed lines
- May take up to 25 seconds
- Do not move sensor during startup
- When complete, reading is displayed
- Begin patient monitoring
- Defaults to pulse rate and oxygen saturation reading
- "PI" bar graph displays strength of arterial perfusion

Power Button. Press "ON", Hold for "OFF"

Each green LED window below Power Button that illuminates indicates 25% battery power

#### Operation / Pulse Oximetry & Pulse Rate:

- Displays after startup sequence described above
- Oxygen Saturation on top in red numbers
- Pulse Rate on bottom in green numbers
- Low Signal I.Q.<sup>®</sup> (SIQ) LED lit indicates poor pulse ox signal quality - evaluate finger/sensor, use alternate finger
- Press "DISPLAY" to display %spCO

Press "Bell" to silence alarms (if needed)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 12C: Carbon Monoxide, cont.** 

Operation / Carbon Monoxide (Carboxyhemoglobin) Measurement:

- Press "DISPLAY" button as described above to toggle display to show %SpCO reading (to toggle back to pulse oximetry and pulse rate mode, press "DISPLAY" again).
- Carboxyhemoglobin displayed in % on top in numbers.
- "CO" displayed on bottom confirming mode.
- Real-time SpCO indicator continuously reads SpCO.
- Confirm abnormal readings by taking several measurements on different fingers and average the readings.

#### Operation / Troubleshooting:

Error Messages:

- "NO Cbl" = cable not seated properly into device or defective cable
- "SEN OFF" = sensor off finger or misaligned
- "bAd CbL" = defective cable (cable most likely needs replaced)
- "CbL" = incompatible cable (change to appropriate cable)
- "bAd SEN" = defective sensor (sensor most likely needs replaced)
- "SEN" = unrecognized sensor (change to appropriate sensor)
- "Err" = return for service

Will not power on = check battery compartment and replace batteries.

Continuously in startup mode (Scrolling zeroes 0 - 0 - 0 and flashes dashed lines) = shield sensor from flashing lights, strobes or high ambient light with Light Shield (best accurate practice is to always use the Light Shield); try another finger.

Using Physio-Control LifePak® 15 with Masimo sensing to measure %SpCO:

- Power on, connect pulse oximetry cable to monitor/defibrillator and sensor, place sensor on patient..
- To display %SpCO, use the SPEED DIAL to select the pulse oximetry display area.
- Select PARAMETER from menu.
- Select SpCO. Selected value displays for 10 seconds. If %SpCO is elevated, an advisory event occurs and elevated value flashes and alarm tone sounds.








Approved 9/14/22, Effective 1/16/23, replaces all prior versions

12D – HYPERBARIC OXYGEN THERAPY CONSIDERATIONS ADULT & PEDIATRIC



Indications:

Carbon monoxide (CO) toxicity (as determined through Protocol 12C – Carbon Monoxide).

#### Contraindications:

Absence of carbon monoxide toxicity.


#### Clinical Pearls:

- 1. In the care of the suspected CO poisoned patient, exercise personal safety and avoid becoming CO poisoned.
- 2. The hallmarks of effective EMS care of the suspected CO poisoned patient include removal of the patient from the CO source and oxygenation with near 100% oxygen (via high flow through non-rebreather mask with good seal, non-invasive positive pressure ventilation, or through bag-valve-mask or bag-valve-artificial airway connected to an oxygen reservoir).
- 3. The vast majority (nearly all) of suspected CO poisoned patients may be appropriately transported to an emergency department that does not have direct access to hyperbaric oxygen (HBO) therapy.
- 4. Contact the nearest HBO capable facility's on-line medical control for EMS to discuss the advisability of transport for HBO therapy consideration if either of the following distinct clinical situations in which suspected/measured CO toxicity is the primary medical issue of concern:
  - a. Glasgow Coma Scale score ≤ 13
  - b. Pregnancy
- 5. Consultation and/or transport to a HBO-capable facility does not compel use of HBO therapy by the medical staff at that facility.
- 6. In Oklahoma, emergency facilities with direct access to HBO therapy (at least part-time) include:
  - a. Oklahoma City Integris Baptist Medical Center
  - b. Tulsa OSU Medical Center (cannot give HBO therapy to intubated patients)





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions



IV/IO ACCESS - START TWO LINES

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

**AEMT or HIGHER LICENSE:** 

FOR HYDROXOCOBALAMIN, USE SEPARATE LINE FROM ALL OTHER MEDICATIONS

ADULT: HYDROXOCOBALAMIN 5 grams IVPB IN 15 MINS - ADMINISTER WITHOUT DELAY


PEDIATRIC: HYDROXOCOBALAMIN 70 mg/kg IVPB TO A MAX OF 5 grams IN 15 MINS - ADMINISTER WITHOUT DELAY



ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)








APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions




ECLAMPSIA: MAGNESIUM SULFATE 1 gram IVP/IOP MAY REPEAT EVERY 2-3 MINUTES UNTIL SEIZURE ABATES MAXIMUM CUMULATIVE DOSE IS 4 grams

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)

APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING

































Approved 9/14/22, Effective 1/16/23; replaces all prior versions

14A – STAGING CONSIDERATIONS



The Medical Control Board firmly supports all appropriate operations designed to protect public safety professionals (law enforcement, fire, and EMS) from physical assault in the course of fulfilling their respective duties. While the vast majority of Medical Control Board Treatment Protocols focus upon patient care and beneficence, it is never their intent that public safety professionals purposefully compromise their personal safety in the commission of these protocols.

Enroute to a scene of threatened, alleged, or actual violence, non-law enforcement/tactical fire and EMS professionals are to stage an appropriately safe distance away and not to proceed to the patient(s) until the scene is declared safe by appropriate law enforcement professionals. In the event of structural fire, non-fire EMS professionals are to stage at a perimeter assigned by appropriate fire suppression professionals and to take further access as directed by fire suppression professionals when hazards are appropriately mitigated. In all cases involving staging pending hazard mitigation, dispatch should be notified when the scene has been declared safe to ensure timely information transmission to the assigned field professionals. Further specific details related to any hazard staging communication procedure should be the responsibility of centralized communications for each responding agency.

#### General Principles Regarding Threatened or Alleged Violent Scenes:

- A. While enroute to a scene where violence might be involved, check to see whether law enforcement officer(s) are also enroute to the scene. Responding EMS professionals should be advised by dispatch to stage when a known violent incident has not been declared safe for EMS entry by appropriate law enforcement professionals.
- B. While still an anticipated safe distance from the reported incident location, turn off all emergency warning devices if being used (emergency lights and sirens).
- C. Avoid crossing the line of sight of the reported incident address while responding and park out of sight of the address when staging.





Approved 9/14/22, Effective 1/16/23; replaces all prior versions **PROTOCOL 14A: Staging Considerations, cont.** 


- D. Advise dispatch of the staging location (exact address if known). First arriving unity should advise dispatch of an anticipated safe approach route to the area for all other incoming emergency responders.
- E. Anytime encountering a previously unidentified scene of threatened or alleged violence, rapidly promote personal safety and the safety of fellow emergency professionals. Advise dispatch for law enforcement assistance (emergency response/assistance if violence is ongoing). Withdraw to a position of safety until the scene can be appropriately secured by appropriate law enforcement. If the alleged assailant is reported to have left the scene use caution and gain access to the patient. If the patient condition is priority 1 begin transport without waiting for law enforcement to arrive. At all times use your best judgement for crew and patient safety, be constantly alert to the possibility of the assailant's return.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

14B - ACTIONS TO PRESERVE CRIME SCENES



This protocol has been developed to promote proper emphasis on patient care while simultaneously promoting law enforcement ability to conduct effective and thorough crime scene investigation.

- A. Only assigned EMS units should respond. Excess numbers of EMS professionals on scene may lead to inadvertent evidence destruction.
- B. When approaching a crime scene protected by law enforcement, EMS professionals should request entry into the area to determine life status of the individual. The highest licensed EMS professional (eg. Paramedic if on scene) is to enter in cases of probable irreversible death to minimize scene disturbance. Attempt scene entry and exit by same route to minimize scene disturbance.
- C. If law enforcement professionals refuse EMS access into the crime scene, do not become confrontational. Follow applicable operational procedures in consulting with an appropriate Supervisor.
- D. Refer to Protocol 4K "Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation & Termination of Resuscitation Adult & Pediatric for information regarding when to withhold resuscitation.
- E. To obtain an ECG tracing when the probable irreversibly dead patient is prone:

(If using a 4-lead cable) place the left arm electrode on the left arm or upper left back. Place the right arm electrode on the right arm or upper right back. Place the left leg electrode on the lower portion of the left back or on the left leg. Place the right leg electrode on the lower portion of the right back or on the right leg. Alternatively, use monitoring/defibrillation pads. Place the sternum electrode on the upper right back and the apex electrode on the lower left back.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14B:** Actions to Preserve Crime Scenes, cont.

- F. If the patient has signs of life, aggressive resuscitative efforts should be initiated. During scene resuscitation:
  - 1. Keep EMS professionals and medical equipment close to the victim.
  - 2. Keep out of any blood that has pooled.
  - 3. Minimize destruction of the patient's clothing. If the patient's clothing has a puncture, do not use the hole to start cutting and do not cut "through" the hole.
- G. In crime victim resuscitation, work to move the victim to the ambulance expeditiously.
- H. If the patient relates any information relating to the crime, report this information to the appropriate law enforcement professionals.


#### Special Notes:

- 1. **DO NOT** go through the victim's personal effects (if the victim has expired).
- 2. **DO NOT** cover the body with a sheet or other material (if the victim has expired).
- 3. **DO NOT** move or handle any object at the scene unless absolutely essential for lifesaving medical care. Inform law enforcement professionals of any such movement or handling, preferably before doing so.
- 4. **DO NOT** take any object from the scene unless absolutely essential for life-saving medical care (eg. impaled object).
- 5. **DO NOT** clean the body of blood, etc. (if the victim has expired)
- 6. **DO NOT** wander around the crime scene; return to the emergency vehicle.
- 7. **DO NOT** litter the crime scene with medical equipment, dressings, bandages, etc.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 14C – OTHER HEALTH PROFESSIONALS ON SCENES



Licensed EMS professionals must at all times act utilizing appropriate medical authority. Formats of appropriate medical authority include verbal physician medical orders, written physician medical orders, and standing orders in the form of the Medical Control Board Treatment Protocols. Licensed EMS professionals are authorized to accept medical directives from the following:

- 1. EMS System Chief Medical Officer.
- 2. Principles of accepted standard of care practice by EMS professionals, as defined by the Medical Control Board Treatment Protocols.
- 3. Verbal order from an On-Line Medical Control Physician (OLMCP) or approved designate (OLMC).
- 4. Verbal or written order signed by a physician (M.D. or D.O.) present with the patient in the medical office, clinic, or specialized treatment facility (eg. dialysis center).
- 5. Bystander physician that presents a valid M.D. or D.O. Oklahoma License Card.
- 6. Oklahoma Poison Control Center Specialists acting under the standing orders of the Physician Medical Director of the Oklahoma Poison Control Center.

#### Compliance with Physician's Verbal or Written Orders:

- 1. Verbal or written orders that are signed by the physician are acceptable.
- 2. If a physician (M.D. or D.O.) directs an EMS professional to provide treatment that is not clearly defined in the Medical Control Board Treatment Protocols that EMS professional may carry out the order to the best of his or her ability as long as the ordered treatment or procedure falls within his or her authorized scope of EMS practice.
- 3. If an EMS professional receives a physician order for care that he or she does not feel comfortable with, or feels the order does not represent the appropriate standard of care for the patient's assessed condition, he or she should advise the ordering physician of the Medical Control Board Treatment Protocols that he or she is required to uphold. Request to be allowed to continue further patient care under these standing orders. Should the ordering physician dissent to using these standing orders at that time, contact the appropriate OLMCP, brief the OLMCP on the situation, including the patient's assessed condition and the physician orders of





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **PROTOCOL 14C:** Other Health Care Professionals on Scene, cont.

Compliance with Physician's Verbal or Written Orders, cont.:

concern and allow the physicians to directly discuss further treatment of the patient. At no time should critical patient care as specified in these standing medical orders be delayed while resolution of the situation is occurring.

4. Poison Control Center Specialists are authorized to direct medical care related to the medical toxicology and/or hazardous material exposure aspects of patient care if contacted for directives.

General Principles for Working with Other Health Care Professional(s) On-Scene

- 1. Conduct all conversations and operations with the standards of professional demeanor and respectful attitude.
- 2. Make every reasonable effort to carry out orders within appropriate standards of care given by on-scene physician(s).
- 3. Orders by nurses, nurse practitioners, and physician assistants are not applicable to EMS professionals. Proceed with managing the patient according to established protocol.
- 4. If doubt exists as to whether the "physician" is indeed a validly licensed Oklahoma M.D. or D.O., ask to see the physician's registration card from the Oklahoma State Board of Medical Licensure and Supervision. If the physician cannot verify this status, EMS professionals are to proceed with managing the patient according to established protocol.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 14D – INFORMED PATIENT CONSENT/REFUSAL



- A. Competent adults are entitled to make decisions about their health care. They have the right to refuse medical care after they have been properly informed of the benefits, risks, and alternatives to the recommended care. This protocol defines the mechanisms by which a patient who summoned EMS care, or for whom EMS care was summoned, may refuse care and/or transport.
- B. To safely allow a patient (or their legal representatives) to exercise their rights while protecting yourself and your organization, you need to follow the following steps each and every time, with each patient who is ultimately not treated or transported:
  - 1. Perform a complete assessment, maintaining suspicion of serious illness or injury.
  - Evaluate the differential of possible medical conditions. Avoid tunnel-vision on only one explanation for the patient's condition. Assume worst case possibilities. You should be thinking of "ruling in" rather than "trying to explain away" worrisome findings. These worst case possibilities must be communicated clearly to the patient (or their legal representatives).
  - 3. Ascertain the patient's mental status. The patient must be alert and oriented to time, place, and events. You must determine the patient's ability to make an informed refusal, dependent upon their ability to evaluate choices, understand risks and benefits of those choices, and have the capacity to make rational decisions. Factors that could impede or impair comprehension and decision making capacity include clinical, physical, and emotional disturbances. If a patient's legal representative is making a refusal request, similar evaluation of that person's mental status must be accomplished.
  - 4. The patient (or their legal representatives) must be offered transport in a polite and unqualified manner. Discouragement of EMS transport, intentional or not, may represent a breach of duty.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 

- C. For the purpose of this protocol, legal representatives of patients (by legal custody or Durable Power of Attorney for Health Care), or parents of minor patients may refuse medical care if they:
  - 1. Have capacity to make medical decisions = able to understand the nature of the potential injury or illness and the consequences of refusing medical care and/or transportation to an emergency department.

#### AND

- 2. At least one of the following:
  - Adult = 18 years of age or older.
  - An emancipated minor = <18 years of age but living away from parents or guardians and financially responsible for self.
  - Married minor.
  - Minor in the military.

Pregnant minors must still have adult consent (unless the emergency medical care being requested or refused is directly related to the pregnancy) if they do not meet one of the above minor exceptions.

- D. At no time may a spouse or relative who is not the legal representative of the patient make a decision to refuse evaluation, treatment, or transportation of the patient.
- E. The following patients may be considered **NOT** to have capacity to make medical decisions:
  - 1. Altered level of consciousness, including, but not limited to alcohol/drug use or head injury.
  - 2. Attempted or threatened suicide (verbally or otherwise) recently and related to the call.
  - 3. Suspected cerebral hypoxia due to, but not limited to, head injury or prolonged seizure(s).
  - Adults with sustained severely altered vital signs (pulse >120 or <40; respirations >30 or <8 per min; pulse oximetry <85% if history of chronic respiratory illness or <90% if previously healthy; systolic BP >220mmHg or <90mmHg).</li>





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 

- 5. Children with sustained severely altered vital signs (pulse >160 or <40; respirations >45 or <12 per min; pulse oximetry <90%; systolic BP >140 mmHg or < 70 + 2 x years of age).
- 6. Hypoglycemia defined as blood glucose <50 mg/dL.
- 7. Making largely irrational decisions in the presence of an obvious life or limb threatening condition (e.g. near amputation, ST elevation acute myocardial infarction), including persons who are emotionally unstable.
- 8. Under mental hold (Emergency Detention) which has been invoked by a person authorized to invoke such a hold.
- 9. Known mental retardation or deficiency to the degree of being unable to care for self without constant assistance or supervision.
- F. An appropriate Supervisor or OLMC must be contacted for all incidents when:
  - 1. EMS has been requested; AND
  - 2. Patient contact has been established (occurs when EMS personnel are physically with the patient and inquire to the patient's well-being), the patient has evidence of acute medical condition (verbalized symptoms or physical exam findings), but further EMS assessment, treatment, and/or transport has been refused; AND
  - 3. Any one of the following:
    - a) Patient may NOT have medical decision making capacity to refuse (see E 1-9 immediately above); **OR**
    - b) Age < 2 years or > 65 years; **OR**
    - c) Minors (unemancipated or not in military) without ability to contact parent/guardian; **OR**
    - d) Communication barrier (language or handicap) to extent patient's understanding of condition and recommended treatment/transport cannot be verified; **OR**
    - e) Refusal of further assessment, treatment, and/or transport in the EMS professional's judgment places the patient at significant risk.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 

- G. After the EMS Supervisor and/or OLMC has been informed of the situation, the EMS Supervisor and/or OLMC should communicate directly with the patient, on a recorded line, to establish the patient's intent. To validate the refusal, the EMS Supervisor and/or OLMC should inform the patient or patient's legal representative of:
  - 1. The patient's condition to the extent EMS assessment allows, specifically noting that EMS assessment is limited in scope and not a replacement for physician evaluation.
  - 2. Given the apparent patient condition, the corresponding potential risks of refusal.
  - 3. EMS will transport the patient to an appropriate emergency department for further assessment and care regardless of the financial status of the patient.
  - 4. Alternate forms of treatment or transport that can be offered.
  - 5. A clear statement that the patient (or patient's legal representative) is voluntarily assuming all health risks that may result from the refusal for care at this time.
  - 6. A clear statement that EMS can be recalled anytime if medical assistance is desired.
- H. If the EMS Supervisor and/or OLMC cannot successfully intervene to affect further assessment, treatment, and transport in an obvious life or limb threatening condition (e.g. near amputation, ST elevation acute myocardial infarction), AND on-scene personnel believe physically restraining the patient at this juncture to be unsafe or otherwise illadvised, the EMS Supervisor and/or OLMC should consult the EMS System Chief Medical Officer or his/her designee for further consultative directives.
- I. If a patient is determined to NOT have medical decision making capacity, the patient should be treated by implied consent. If this patient continues to refuse assessment, treatment, and/or transportation, all reasonable measures, including law enforcement assistance and/or appropriate use of physical restraint should be used to assess, treat, and transport the patient. The Medical Control Board does not expect EMS professionals to place themselves in physical danger in this process. If a physical threat is imminent, withdraw to a position of safety, requesting additional appropriate resources, while attempting to leave the patient in the care of a responsible adult.
- J. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport must have the risks, benefits, and alternatives of their decisions explained to them by EMS personnel and demonstrate an understanding of this discussion. The reason(s) of refusal stated to EMS, benefits of recommended treatment and/or transport, alternatives to initially recommended care and/or transport, and risks of the refusal explained to the patient (or their legal representatives) and the reactions to this explanation must be documented in the patient care report in addition to the patient's chief complaint, vital signs and physical assessment.
- K. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport must be advised to seek further medical examination and care by a licensed physician (M.D. or D.O.). The limitations of EMS scope of assessment and practice must be explained. Document this information as it was explained.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 

- L. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport are to sign a refusal statement. A witness (preferably a friend or relative of the patient) is to countersign the refusal to verify its accuracy. The signature of release may or may not actually "release" an EMS professional or EMS organization from liability. One of the many purposes of using a release, however, is to further demonstrate good faith and diligence in meeting responsibilities to the patient. Together, with prudent actions, it helps to defend against assertions of abandonment. If the patient (or their legal representative) refuses to sign a valid refusal form, EMS professionals should also document the details of this encounter, including reasons for refusal to sign. EMS professionals should also document on the refusal form "Patient refused to sign." with at least one colleague signing as a witness.
- M. Leave the patient (or their legal representatives) any applicable medical care instruction sheets. Document in the patient care report what instruction sheet(s) were given.
- N. All dispatches not resulting in the transport of a patient require completion of the appropriate no transport information.

#### Additional Notes:

- 1. **DO NOT** ignore clues to potentially serious injuries or illnesses, such as abnormal vital signs, unconsciousness which may be followed by a transient lucid stage (head injury with epidural hematoma), concern of family members or witnesses, or inconsistencies in information obtained from different sources.
- A red flag needs to be raised anytime with thoughts such as "this patient is just a drunk", "it's not that bad, this patient can't afford an ambulance", or "an ambulance shouldn't be tied up on this type of call". These rationalizations encourage underestimating the patient's condition and treatment shortcuts, resulting in substandard patient care and patient endangerment.
- 3. Refusal of assessment, treatment, and/or transport situations are often emotionally and potentially legally charged situations. Maintain duty to act in the best interests of all patients by avoiding any potentially discouraging tone, language, or body positioning that conveys unwillingness to provide humane, compassionate patient care.
- 4. Every patient has a right to EMS full service and attention. While a perception of "system demands" may be commendable, it cannot supersede a patient's needs and rights unless in the most dire of disaster conditions. Take patients one at a time and give them the best care morally, ethically, and legally possible.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 


### **Special Considerations in Care of Minors**

- A. If a minor aged patient presents with life or limb threatening condition, but no parent or guardian is present, do not delay indicated care. Provide treatment and transport per applicable protocol(s) and assign other public safety colleagues the task of notifying the child's parent/legal guardian of the incident, any obvious illness/injury, and hospital to which the child was transported.
- B. If a minor needs medical treatment, but no parent or guardian is present, EMS professionals may treat per applicable protocol(s) if the parent or guardian cannot be reached after reasonable attempts and the minor gives verbal and physical consent.
- C. IF THE PARENT/GUARDIAN CANNOT BE REACHED AFTER REASONABLE ATTEMPTS AND THE MINOR REFUSES TREATMENT:
  - 1. Consult an appropriate EMS Supervisor for advice, which may include, but is not limited to:
    - Police assistance, taking the minor into their protective custody.
    - Utilization of family members outside the immediate parents/legal guardians.
    - Utilization of reliable adults with prior knowledge of the minor.
    - As a last resort, allowing the minor refusal of service under the same requirements and procedures as listed above for adult patients (or their legal representatives).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 14E – ON-LINE MEDICAL CONTROL PHYSICIANS



The Medical Control Board supports EMS professionals in the field having the availability of On-Line Medical Control Physicians (OLMCP). The OLMCP represents the Chief Medical Officer in "real-time" system operations.

The OLMCP is the resource available 24 hours per day for consultation contemporaneous with patient care.

OLMCP consultation, when desired or required, is to be made at the earliest appropriate point in the patient's assessment and treatment in order to facilitate appropriate patient care.

Radio reports to the OLMCP should follow Protocol 14H - Radio Report Communications. It is the responsibility of the consulting EMS professional to ensure a brief, yet pertinent report to meet the needs of the patient and the treating EMS professional(s). If the lead EMS professional is involved in performing critical interventions, other personnel may make the report under the guidance of the lead EMS professional as may be beneficial for accuracy. Communications should ideally be established via a recorded communication method.

Contact with OLMCP will be made in the following circumstances:

- All situations in which consultation is specifically required in these treatment protocols.
- Any situation in which the treating EMS professional(s) feel it is in the best interest of the patient to obtain physician consultation, ensuring the most accurate EMS care possible for the patient's condition.
- Any situation in which the EMS professional(s) feels extensive modification is required from the standard treatment and/or procedure protocols.
- All patients in whom a refusal of care and/or transport would, in the EMS professional's judgment, place the patient, the EMS professional, and/or the EMS system at risk after appropriate attempts fail to produce needed results..





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 14E: On-Line Medical Control Physicians, cont.


Acceptable modification to the sequence of drugs or procedures must be justified as being appropriate for field management of critically ill or injured patients in unusual circumstances and therefore, should be an uncommon event.

EMS providers complying with orders which exceed their level of licensure and/or authorized scope of EMS practice may be subject to disciplinary action by the Oklahoma State Department of Health (as well as locally applicable action) which may include, but is not limited to, indefinite suspension or permanent revocation of licensure and authorization to provide patient care.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 14F – HELICOPTER EMS (HEMS) CONSIDERATIONS



Medical literature to date demonstrates no significant survival benefit utilizing medical helicopter transport for patients in densely populated, urban settings. The Medical Control Board and the University of Oklahoma Department of Emergency Medicine EMS Section provide the following information regarding the clinically appropriate utilization of medical helicopters to maximize patient benefit and protect the safety of patients, aeromedical professionals, and ground EMS professionals.

### "No Fly" Patient Conditions

Medical helicopter utilization rarely affects outcome in already moribund patients or in the converse, stable patients without apparent serious illness/injury. A medical helicopter should NOT be utilized for the following patients:

- 1. Medical or Traumatic Cardiac Arrest without Return of Spontaneous Circulation;
- 2. Trauma Patients with minimal traumatic injury, without apparent risk of life/limb loss;
- 3. Patients with stable vital signs and without signs of serious illness/injury.

#### "No Fly" Zones

Medical helicopter utilization is very rarely indicated within an approximate 30 minute radius of an appropriate destination hospital unless there are extenuating circumstances. These "extenuating circumstances" include the following:

- 1. Hazardous or impassible road conditions resulting in significant ground transport delays for seriously injured or ill patients;
- 2. Multiple casualty incidents with high numbers of red/priority 1 patients, overwhelming available ground EMS units;
- 3. A combination of lengthy extrication and extended ground transportation (traffic conditions, weather conditions) of a priority 1 or priority 2 patient at the lead EMS professional's careful discretion.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14F: Helicopter EMS (HEMS) Considerations, cont.** 

#### Medical Helicopter Utilization:

At incidents greater than 30 minutes from the appropriate destination hospital, the decision to activate a medical helicopter response should be based upon an EMS professional's assessment of the patient's clinical condition, factoring in apparent and/or suspected illness or injury, mechanisms of injury – if applicable, anticipated scene time, and anticipated ground transport time to an appropriate destination hospital (eg. cardiac catheterization capable hospital or trauma center). Medical helicopters should not be activated until an EMS professional or medically-trained law enforcement officer has assessed the patient. Further utilization concepts include:

- 1. EMS professionals on scene may elect to activate a medical helicopter if flight time to the incident, flight scene time, and return flight time would still allow a critical patient to arrive at an appropriate destination hospital significantly faster by air.
- 2. If ground EMS transport capability is not on scene and a decision is being factored as to ground or air transport, the on scene EMS professionals should first request an ETA for the ground transport unit. If the on scene EMS professionals then judge transport time by ground will be detrimental to the patient clinical condition, a medical helicopter response can be activated. This decision should be communicated to ground EMS agency to keep all responding apparatus crews aware of scene and patient dynamics.
- 3. If uncertain whether medical helicopter activation is in the best interest of the patient, contact OLMC at the anticipated destination hospital for consultation and determination of transport mode and destination.
- 4. The primary determinant of helicopter transport mode is to achieve getting the critical patient to the most appropriate definitive care hospital in the shortest amount of time. The medical helicopter to be utilized is the medical helicopter appropriate for the patient's needs and closest to the incident location.

#### Cancellation of Medical Helicopter Activation:

An EMS professional may cancel a medical helicopter response after being activated if patient condition significantly improves or deteriorates to meet "no fly" criteria. Keep in mind, though, that once a medical helicopter is responding to the scene, it is generally unwise to cancel that response. EMS professionals should avoid requesting a medical helicopter response, canceling the response, and then having to request the helicopter again. Such a situation prolongs scene time and helicopter response time in addition to conveying indecisive patient care.

#### Landing Zone:

Appropriate fire or law enforcement personnel will be responsible for establishing and maintaining a safe landing zone.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14F: Helicopter EMS (HEMS) Consideration, cont.** 


#### Utilization Review:

All medical helicopter activations may undergo utilization review by the Chief Medical Officer and/or his/her designee and by the medical director of the aeromedical organization. This is to specifically promote optimal medical helicopter utilization and not to be interpreted as discouraging appropriate medical helicopter utilization per this protocol.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



While each patient will receive the best possible EMS care in a humane and ethical manner, proper patient prioritization ensures that patients most dependent upon rapid and critical medical interventions receive expeditious field treatment and that destination hospitals receive early notification.

**Red/Priority I:** Patient condition expected to require immediate intervention upon Emergency Department arrival. Examples include:

- Inability to successfully oxygenate and/or ventilate;
- Acute dyspnea in adults requiring NIPPV (use of red lights & sirens at paramedic discretion based upon patient stability and if markedly improving on NIPPV);
- Acute Myocardial Infarction with ST elevation on 12-Lead ECG;
- Acute Congestive Heart Failure with hypotension (Cardiogenic Shock);
- Acute Stroke with positive LAPSS with symptom onset < 23 hours in duration;</li>
- Status epilepticus;
- Deep penetrating trauma (e.g. gunshot wound) to head, neck, or trunk;
- Trauma in adults with systolic blood pressure <90 mmHg;</li>
- Trauma in pediatrics with systolic blood pressure < (70 + 2 X age in years) mmHg.

Red/Priority I patients are typically transported to the Emergency Department with red lights and sirens.

**Yellow/Priority II:** Patient condition expected to require intervention within 15 minutes upon Emergency Department arrival. Yellow/Priority II patients have potential time sensitive problems, are currently stable, but at risk for sudden deterioration. Examples include:

- Acute dyspnea in adults and pediatrics with normalizing vital signs;
- Acute non-traumatic chest pain in adults improving with protocol specified treatment;
- High force traumatic injuries with normal and stable vital signs.

Yellow/Priority II patients may be transported to the hospital red lights and sirens if time of transport would otherwise create marked risk to patient recovery. In most situations, though, the safety risk of red lights and sirens transport of these patients is unwarranted.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14G: Patient Prioritization, cont.** 

**Green/Priority III:** Patient condition expected to require routine timeliness of intervention upon Emergency Department arrival. Green/Priority III patients do not appear to require further emergent medical intervention and do not appear to have life/organ threatening conditions. Examples include:

- Asthma exacerbation dyspnea resolved with bronchodilator nebulization;
- Nausea/non-bloody vomiting with normal and stable vital signs;
- Isolated orthopedic injury with intact neurovascular function.

Green/Priority III patients should be transported to the hospital without red lights and without sirens. The safety risk of red lights and sirens transport of these patients is unwarranted.

**Black or Blue:** Obvious death or illness/injury severity incompatible with successful resuscitation given concurrent system demands (such as in multiple casualty responses).

Adult trauma patients are determined to be **Red/Priority I** by either vital signs and level of consciousness (systolic BP < 90 mmHg, sustained tachycardia, respiratory rate <10 or >29 breaths per minute, GCS  $\leq$  13, cool, diaphoretic skin) or any of the following anatomical injury:

- Penetrating injury of head, neck, torso, extremities proximal to elbow or knee;
- Amputation proximal to the wrist or ankle;
- Paralysis or suspected spinal fracture with neurological deficit;
- Flail chest;
- Two or more suspected proximal long bone fractures;
- Open or suspected depressed skull fracture;
- Unstable pelvis or suspected pelvic fracture;
- Tender and/or distended abdomen;
- Burns associated with other Priority I Trauma;
- Crushed, degloved, or mangled extremity, proximal to the wrist or ankle;
- Pulseless extremity.

Adult trauma patients are determined to be **Yellow/Priority II** from events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Adult trauma patients may also be determined to be Yellow/Priority II if exhibiting a single system injury as noted:

- High risk auto crash (intrusion > 12 inches in occupant site; intrusion > 18 inches in any site; ejection (partial or complete) from automobile; death in same passenger compartment);
- Auto v. pedestrian/bicyclist thrown, run over, or with significant ( >20 mph) impact;
- Motorcycle crash > 20 mph;
- Falls > 20 feet in height (one building story is 10 feet in height);
- Significant force alleged assault;
- Isolated closed head trauma with resolved altered mental status (Neuro System);
- Positive seatbelt sign or handlebar mark;
- Fractures/dislocation; lacerations/avulsions with extensive tissue damage;
- High voltage electrical injury;
- Pregnancy > 20 weeks.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 14G: Patient Prioritization, cont.

#### Adult Priority II Determining Criteria, cont.

Adult trauma patients are determined to be **Yellow/Priority II** from events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Adult trauma patients may also be determined to be Yellow/Priority II if exhibiting a single system injury as noted:

- Facial lacerations; fractured facial bones; avulsed teeth (Maxillofacial/Dental);
- Select & isolated hand injuries ("isolated" defined by the level of suspected injury involvement being no further proximal than the elbow).
  - Only certain hand injuries require rapid treatment to avoid unfavorable outcomes.
    - These "select" Priority II injuries include:
      - Vascular injuries that involve significant arterial hemorrhage;
      - Nerve injuries that cause loss of motor function;
      - Amputations;
      - High-pressure injection injuries;
      - Flexor tendon injuries of hand.

Adult trauma patients <u>may</u> be determined to be **Discretionary Red/Priority I or Yellow/Priority** If if clinical suspicion of significant injury <u>and</u> heightened by any single or particularly a combination of the following patient attributes:

- Age > 55;
- Anticoagulation, bleeding disorders and/or significant comorbidities;
- Time sensitive extremity injury.

Discretionary Red/Priority I or Yellow/Priority II adult trauma patient radio and care reports should clearly indicate to the receiving Trauma Center personnel the rationale for the Discretionary Red/Priority I or Yellow/Priority II assignment.

Level III Trauma Centers are intended to receive adult patients at risk for severe injury with normal, stable vital signs or patients with no significant anatomical injuries.

Adult trauma patients are determined to be **Green/Priority III** from events with normal and stable vital signs, without change in usual mentation or usual neurologic function, and without new or significant organ system dysfunction. Green/Priority III adult trauma may include:

- Single proximal or distal long bone fractures without dislocation;
- Minor puncture wounds/lacerations/abrasions;
- Isolated neck pain without new neurological deficit;
- Isolated extremity pain;
- Isolated abdominal pain.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14G: Patient Prioritization, cont.** 

Level IV Trauma Centers may receive adult patients <u>without</u> physiologic instability, altered mentation, neurological deficit or significant anatomical injuries and have also not been involved in a significant mechanism of injury incident for expected care at that facility. Patients in other categories (eg. with physiologic instability) should be expected to be transferred to a higher level trauma center after immediate care needs are addressed (eg. invasive airway management).

Pediatric trauma patients are prioritized **Red/Priority I** by either physiological criteria (systolic BP < (70 + 2 x age of patient in years) mmHg, sustained tachycardia >160 bpm, respiratory rate <12 or >40, pulse oximetry<95% without supplemental oxygen, or GCS ≤ 12)

- Penetrating injury of head, neck, torso, extremities proximal to elbow or knee;
- Amputation proximal to the wrist or ankle;
- Paralysis or suspected spinal fracture with neurological deficit;
- Flail chest;
- Unstable pelvis or suspected pelvic fracture;
- Crushed, degloved, or mangled extremity, proximal to the wrist or ankle;
- Pulseless extremity;
- Two or more open fractures.

Pediatric trauma patients are prioritized **Yellow/Priority II** from "high-energy" events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Pediatric trauma patients may also be determined to be Yellow/Priority II if exhibiting any of the adult trauma priority II single system injury criteria.

Pediatric trauma patients may be determined to be Discretionary Red/Priority or

**Yellow/Priority II** if clinical suspicion of significant injury warrants <u>and</u> is heightened by any of the following patient attributes:

- GCS of 13-14;
- Extrication time > 20 mins, \*death in same vehicle, speed >40 mph, rollover mechanism, vehicle external intrusion >20" or compartment intrusion >12";
- Fall criteria for pediatric trauma Red/Priority I is >10 feet or 2 3 times the height of the child;
- Two or more suspected proximal long bone fractures;
- Open or suspected depressed skull fracture;
- Tender and/or distended abdomen/positive seatbelt sign or handlebar mark;
- Suspected or known Non-Accidental Trauma in pediatric patients;
- Tenderness to spine with palpation;
- Isolated open fracture (excluding hand);
- Significant laceration or soft tissue injury;
- High voltage electrical injury;
- Anticoagulation and bleeding disorders and/or significant comorbidities.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14G: Patient Prioritization, cont.** 

Discretionary Red/Priority I or Yellow/Priority II pediatric trauma patient radio and care reports should clearly indicate to the receiving Trauma Center personnel the rationale for the Discretionary Red/Priority I or Yellow/Priority II assignment.

Pediatric trauma patients are determined to be **Green/Priority III** from events with normal and stable vital signs, without change in usual mentation or usual neurologic function, and without new or significant organ system dysfunction. Green/Priority III pediatric trauma may include any of the adult trauma Green/Priority III injury criteria as previously listed in this protocol.

- Single bone fractures from a same level fall;
- Minor puncture wounds/lacerations/abrasions;
- Isolated extremity pain;
- Abdominal pain without bruising;
- Back pain.

#### SEE ALSO SECTION 19 RESOURCE: OKLAHOMA MODEL TRAUMA TRIAGE ALGORITHM

Pediatric (Age < 16 years of age) general medical patients are determined **Red/Priority I** to be if the following organ system dysfunction is evidenced by acute symptoms or physical exam signs:

Pulmonary System:

- Respiratory arrest;
- Respiratory distress and inability to maintain  $O_2$  sat > 95% on 100% supplemental  $O_2$ ;
- Stridor with inability to phonate, weak cry, altered mental status, or pallor.

Cardiovascular System:

- Cardiac arrest (or history of pre-arrival CPR) or bradycardia requiring chest compression;
- <u>Multiple</u> shock signs (pallor, cool, slow capillary refill, weak pulse, altered mental status);
- Persistent tachycardia > 200/min or bradycardia < 80/min (without athletic fitness level).

Neurologic System

- Status epilepticus;
- Acute sustained altered mental status without apparent etiology;
- Acute focal neurological deficits.

Metabolic System/Toxicology (Overdose);

- Ingestion of a tricyclic antidepressant;
- Ingestion, inhalation, or contact exposure causing altered mental status, respiratory distress, or shock.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 14G: Patient Prioritization, cont.

Pediatric (Age  $\leq$  16 years of age) general medical patients are determined to be **Green/Priority III** if there does not appear to be an acute medical problem of life/organ threatening severity.

#### **Specialized Burn Care**

In Oklahoma, the following burn care specialty centers exist: Oklahoma City: Adult - Integris Baptist Medical Center Pediatric - OU Medical Center Childrens Adult/Pediatric - Hillcrest Medical Center

Patients with the following burn injuries (without additional trauma center criterion injuries) should either be transported directly to a burn care specialty center or be referred to such after initial emergency department evaluation:

- Partial thickness (second degree) burns >10% total body surface area (TBSA);
- Full thickness (third degree) burns;
- Partial or full thickness burns of the face, hands, feet, genitalia/perineum, or major joints;
- Electrical burns (includes lightning injury), inhalation burns, chemical burns;
- Burn injury in patients with preexisting medical disorders compromising healing and survival (cardiac disease, chronic respiratory illness, diabetes);
- Multisystem trauma with partial or full thickness burn as the predominant injury.


If the burn patient cannot be oxygenated or ventilated, transport the patient to the nearest appropriate emergency department for airway management.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

14H – RADIO REPORT COMMUNICATIONS



#### Radio Report Format:

- A. Identification (Apparatus ID, Personnel Last Name & Licensure) & Estimated Time of Arrival;
- B. Patient Priority Red/Priority 1; Yellow/Priority 2; Green/Priority 3;
- C. Objective of communication Notification of transport only or request for on-line medical control. Be specific in what orders will be requested from on-line medical control so that the physician (or designate) will be oriented to the request as he/she is listening to the report;
- D. Patient Information Age/Sex/Chief Complaint or Condition/Pertinent Past Medical History;
- E. Patient Condition LOC/Vital Signs/Exam Findings/ECG Interpretation;
- F. Treatment and response to treatment.


#### Notes:

- A. All communications should be brief and orderly. Radio reports should rarely take longer than one or two minutes per patient and should be made on a recorded line.
- B. Describe the patient condition in enough detail to explain treatment initiated and rationale for any request(s). Remember while the patient's condition may be visually obvious, the nurse or physician on the radio or phone is completely dependent on the EMS professional's ability to verbally "paint the picture of the patient".
- C. It is critical to notify the receiving emergency department at the earliest opportunity to describe the patient's illness/injury and condition so that emergency department personnel can be appropriately prepared for the patient's arrival, including preparing resources to ensure continuity of care (eg. respiratory care, cardiac pacing, trauma surgery notification). In many instances, the earliest opportunity for a radio report will occur even before discovering the full extent of illness or injury in the critical patient. It is important that the "lead EMS professional" or his/her designee make the report at this time, especially to report a STEMI Alert, Stroke Alert, or Trauma Alert rather than wasting several minutes of hospital pre-arrival notification trying to make a "more complete" report.
- D. Particularly critical objective findings, (eg. cardiac arrest, critically abnormal vital signs, gunshot wound to chest) need to take precedence in a radio report and should be reported after the identification/ETA and patient priority statements.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions
14I – INTERHOSPITAL TRANSFERS



A patient may require a transfer from one hospital to another hospital if:

- 1. Patient evaluation at the original hospital reveals care needs unavailable at that hospital.
- 2. Another hospital is preferred by the patient, the patient's legal representative, or the patient's established physician(s).

A hospital must agree to facilitate a patient transfer (regardless of patient's financial status) if the patient meets any of the above criteria.

Any interhospital transfer must be arranged as a practitioner/physician-to-physician transfer in accordance with Federal regulations.

Prior to any interhospital transfer, the EMS professional must receive appropriate transfer paperwork, including an adequate summary of the patient's condition, current treatment (including nursing and practitioner/physician evaluation notes, lab results, radiology results and films, possible complications that could occur during transfer, and any further medical information deemed necessary by the EMS professional or physician(s). Any anticipated interhospital transfer treatment orders are to be written and signed by the transfer initiating practitioner/physician.

Prior to any interhospital transfer, if the EMS professional is concerned that the patient is not stabilized to the extent possible for transport, the EMS professional shall review his /her concerns with the transferring practitioner/physician with a goal to ensure appropriate clinical care is performed to further stabilize the patient. In the **rare** instance in which the EMS professional and transferring practitioner/physician cannot agree on the stability of the patient and/ or further care necessary prior to the interhospital transfer, the EMS professional is to consult with the accepting physician at the receiving hospital to review these concerns. If in such situation the receiving hospital has automatically accepted the patient for care to the "emergency group/doctor", the EMS professional is to discuss concerns with the on-duty emergency physician at that hospital. If the EMS professional cannot rapidly resolve the situation with the transferring practitioner/physician and receiving physician, the EMS professional cannot rapidly resolve the situation with the transferring practitioner/physician and receiving physician, the EMS professional is to notify the Chief Medical Officer for intervention, ideally via a recorded line.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 14I: Interhospital Transfers, cont.

The overriding principle for all aspects of interhospital transfer is matching patient needs with adequate provider knowledge and skill, equipment and infrastructure that provide continued patient safety during transport.

# It is the professional and ethical responsibility of an EMS professional as well as of an EMS organization to not accept or perform an interhospital transfer that involves monitoring and treatment exceeding their scope of authorized practice, training, and/or ability.

An EMS professional must be licensed as an EMT – I85 or higher to verify patency of vascular access. IV fluid type and flow rate must be specified in written practitioner/physician orders and verified prior to interhospital transfer. Any IV fluid bag supplied must contain enough solution to accommodate the expected interhospital transport time.

Any IV infusion medications must be specified in written practitioner/physician orders and verified prior to transfer. The paramedic must be comfortable managing all medications ordered or anticipated to be given during the interhospital transfer. Questions to the contrary should be routed to the supervisor, with subsequent physician consultation as needed. There is a limit of 4 concurrent IV infusion medications for paramedic-only accompanied interhospital transfers.

All interhospital transfer patients with IV infusion medications will be continuously cardiac monitored, including monitoring pulse oximetry during transport. Waveform capnography should be utilized as indicated by appropriate protocols. Blood pressure monitoring will be at least as frequently as every 10 minutes with a minimum of two blood pressure recordings. The interhospital transfer orders may specify more frequent measurements.

During interhospital transfer, should the patient experience signs or symptoms of intolerance (significant side effects) to the IV infusion medication(s) or the IV infusion pump indicates an error not easily addressed by the paramedic, stop the infusion and consult the transferring hospital's on-line medical control for direction.

Mechanical ventilation settings must be confirmed with either the transferring practitioner/physician or a respiratory therapist. The paramedic must review and confirm ventilation rate, tidal volume, FiO2 (50% or 100%), and positive-end expiratory pressure (PEEP) settings. If at any time during interhospital transfer mechanical ventilation malfunctions, institute bag-valve assisted ventilations with 100% O2 while troubleshooting the mechanical ventilator and airway circuit. Ensure the patient receives appropriate oxygenation and ventilation continuously.

All indwelling devices and lines (e.g. chest tube(s), naso/orogastric tube, PEG/G/J-tube, surgical drain(s), intra-aortic balloon pump (IABP), ventricular assist device (VAD), wound vacuum) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel. Potential complications during transfer should be discussed and contingency plans reviewed. If the paramedic feels unable to safely monitor and maintain any indwelling device, he or she is to request appropriate nursing or ancillary personnel from the transferring hospital to accompany the patient during transfer.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14I: Interhospital Transfers, cont.** 

Under these conditions, EMS personnel will not begin the transfer until such request is accommodated.

\*\*\*For specialized patients not ordinarily transported by EMS professionals (e.g., high-risk obstetrical patients, neonates) or for any patient with a condition requiring interhospital assessment and/or treatment beyond expected EMS professional scope of practice, an appropriately trained healthcare professional is to accompany the transporting EMS professionals to best provide interhospital transfer care.

For acute stroke patients either having received alteplase (tPA<sup>®</sup>) just prior to interhospital transfer or that will be continuing to receive alteplase during interhospital transfer, specific documentation and treatment should include:

- 1. Vital signs prior to transport and every 10 minutes enroute. Verify that systolic blood pressure is less than 180 mmHg and diastolic blood pressure is less than 105 mmHg. If blood pressure exceeds these limits, the transferring hospital is to lower the blood pressure via anti-hypertensives for further vascular stabilization prior to transport.
- 2. Stroke neuro-exam at time of interhospital transfer, utilizing the Los Angeles Prehospital Stroke Screen.
- 3. Oxygen administration via NC or NRB if dyspnea or SpO2 <94% at room air.
- 4. Head of cot elevated at approximately 15 degrees if tolerated and low risk of aspiration.
- 5. Patient NPO status, including medications, to protect against aspiration.
- 6. Documentation of total dose and time of IV alteplase bolus (if dose is completed prior to transfer) and when infusion started (and completed, if applicable).
- 7. Infuse all alteplase from tubing by infusing saline through same tubing set following alteplase dose.
  - When bottle appears empty, there is still some alteplase left in the tubing which must be infused.
  - Remove the IV tubing connector from the bottle and attach it to a newly spiked bag of normal saline and re-start infusion at the previous rate used. This will ensure that the remainder of the alteplase is infused.
- 8. Anti-hypertensive therapy adjustment enroute:
  - If labetalol IV infusion started at sending facility: Increase infusion rate by 2 mg/min every 10 minutes (to maximum of 8 mg/min) until desired decrease in BP: Sys BP <180 mmHg and Dia BP <105 mmHg</li>
  - If nicardipine IV infusion started at sending facility: Increase infusion rate by 2.5 mg/hr every 10 minutes (to maximum of 15 mg/hr) until desired decrease in BP: Sys BP <180 mmHg and Dia BP <105 mmHg</li>
  - Discontinue anti-hypertensive infusion for any one of the following: Sys BP <140 mmHg, Dia BP <80 mmHg, or heart rate <50 per minute</li>





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14I: Interhospital Transfers, cont.** 

Common IV Medications During Interhospital Transfer (Infusions are continuation of infusions started at the transferring facility, not initiations)

#### **Class of Medication**

#### Significant Side Effects

Sedatives

Diazepam (Valium<sup>®</sup>) Diprivan (Propofol<sup>®</sup>) Lorazepam (Ativan<sup>®</sup>) Midazolam (Versed<sup>®</sup>) Respiratory depression, Hypotension

Respiratory depression, Hypotension

#### **Opiate Analgesics**

Fentanyl (Sublimaze<sup>®</sup>) Hydromorphone (Dilaudid<sup>®</sup>) Meperidine (Demerol<sup>®</sup>) Morphine Nalbuphine (Nubain<sup>®</sup>)

#### Hypertension Control Agents

Labetalol (Normodyne<sup>®</sup>, Trandate<sup>®</sup>) Nicardipine (Cardene<sup>®</sup>) Nitroprusside(Nipride<sup>®</sup>) Hypotension, Symptomatic bradycardia Symptomatic tachycardia, Ventricular dysrhythmias

#### **Acute Coronary Syndrome Agents**

Anti-platelet (Clot Inhibitors) Abciximab (ReoPro <sup>®</sup> ) Eptifibatide (Integrilin <sup>®</sup> )	Bleeding
<b>Anti-coagulant (Clot Inhibitors)</b> Heparin	Bleeding
<b>Thrombolytic ("Clot Buster")</b> Alteplase (tPA <sup>®</sup> ) Reteplase (Retavase <sup>®</sup> ) Tenectaplase (TNKase <sup>®</sup> )	Bleeding
Anti-anginal (Coronary Vasodilator) Nitroglycerin (Tridil <sup>®</sup> )	Hypotension





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14I: Interhospital Transfers, cont.** 

Common IV Medications during Interhospital Transfer, cont. (Infusions are continuation of infusions started at the transferring facility, not initiations)

#### **Class of Medication**

### Significant Side Effects

Symptomatic tachycardia,

Ventricular dysrhythmias

#### **Cardiac Anti-arrhythmics**

Amiodarone (Cordarone<sup>®</sup>, Pacerone<sup>®</sup>) Diltiazem (Cardizem<sup>®</sup>) Lidocaine Procainamide

#### Vasopressors (Hypotension Treatment)

Dobutamine (Dobutrex<sup>®</sup>) Dopamine (Intropin<sup>®</sup>) Epinephrine Norepinephrine (Levophed<sup>®</sup>) Phenylephrine (Neosynephrine<sup>®</sup>)

Hypertension, Symptomatic tachycardias Ventricular dysrhythmias

Hypotension, Symptomatic bradycardia

#### Volume Expanders (Hypovolemia Treatment)

Albumin Dextran Hetastarch (Hespan<sup>®</sup>) Plasma protein fraction (Plasmanate<sup>®</sup>) Allergic reactions ranging from itching only to more serious reactions of hives, (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis).

#### Blood Products (Anemia or Coagulopathy Treatment)

Cryoprecipitate Frozen Plasma (FFP) Packed Red Blood Cells (PRBC) Platelets Whole Blood	Allergic reactions ranging from itching only to more serious reactions of hives, (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis).
Gastrointestinal Bleeding Control Agents	
Esomeprazole (Nexium <sup>®</sup> – acid reducer) Octreotide (Sandostatin <sup>®</sup> –varices constrictor) Pantoprazole (Protonix <sup>®</sup> – acid reducer)	None
Acid-Base Metabolism Agents	
Sodium Bicarbonate	None





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 14I: Interhospital Transfers, cont.

Common IV Medications during Interhospital Transfer, cont. (Infusions are continuation of infusions started at the transferring facility, not initiations)

Class of Medication	Significant Side Effects
Hyperglycemia Control Agents	
Insulin	Hypoglycemia-related complications
Electrolyte Replacement	
Potassium chloride (KCL)	Ventricular dysrhythmias
Seizure Control Agent	
Fosphenytoin (Cerebyx <sup>®</sup> ) Magnesium (for eclampsia) Phenytoin (Dilantin <sup>®</sup> ) Phenobarbital	Respiratory depression, Hypotension, Symptomatic bradycardia
Bronchospasm Control Agents	
Aminophylline (Theophylline®)	Symptomatic tachycardias, Hypertension
Pregnancy - Related Agents	
Oxytocin (Pitocin <sup>®</sup> –stimulates uterine contraction Inducing labor and controls uterine bleeding)	Hypotension (if rapid infusion), Symptomatic tachycardias, Hypertension
Antimicrobials/Antibiotics	
Aminoglycosides (e.g. gentamicin) Antifungals (e.g. fluconazole) Anti-TB (e.g. isoniazid - INH) Anti-viral (e.g. acyclovir) Carbapenams (e.g. imipenem)	Allergic reactions ranging from itching only to more serious reactions of hives (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis). In some cases, a localized phlebitis (pain at infusion site with redness of

Cephalosporins (e.g. ceftriaxone) Macrolides (e.g. azithromycin) Penicillins (e.g. ampicillin; piperacillin) Quinolones (e.g. levofloxacin) Sulfonamides (e.g. TMP-SMX, Bactrim®) Other categories (e.g. clindamycin, vancomycin)

oitis (pain at infusion site with re vein) may occur due to irritation cause by the infusion itself. While the infusion is to be stopped, this usually is not a true allergy.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 14I: Interhospital Transfers, cont.** 

Priority and Timing for Interfacility Transfer Requests:

Priority 1 Clinical Condition – Immediate Life Critical Intervention at Receiving Hospital Facility Time Standard is 911 Call to Arrival = Response 10:59 or less with use of Red Lights & Sirens (RLS)

Once ambulance is assigned cannot be re-assigned unless closer unit and only one reassignment total

Acute ST Elevation Myocardial Infarct Transferring Facility - No Interventional Cardiology Receiving Facility – Interventional Cardiology/Cardiac Cath Lab Acute Thromboembolic Stroke Transferring Facility – No Interventional Neurology Receiving Facility – Interventional Neurology & Procedure Imminent Acute Aortic Dissection Transferring Facility – No Vascular Surgery Receiving Facility - Vascular Surgery & Surgery Imminent Acute GI Bleeding with Hemodynamic Instability Transferring Facility – No Gastrointestinal/Colorectal Capability Receiving Facility – Gastrointestinal/Colorectal Capability and Endoscopy Imminent Acute Amputation with Limb Salvage Attempt/Limb Ischemia/Arterial Occlusions Transferring Facility – No Vascular Surgery/Interventional Radiology Receiving Facility – Vascular Surgery/Interventional Radiology and Intervention Imminent Suspected or Confirmed Ectopic Pregnancy with Hemodynamic Instability Transferring Facility – No Obstetric Surgery Receiving Facility – Obstetric Surgery & Surgery Imminent Active Labor with Evidence for Complicated Delivery – Breech/Limb Position by Ultrasound Transferring Facility – No Obstetric Surgery Receiving Facility – Obstetric Surgery & Surgery Imminent Acute Angle Closure Glaucoma/Acute Retinal Artery Occlusion/Acute Vision Loss Imminent Transferring Facility – No Ophthalmology Receiving Facility – Ophthalmology & Intervention Imminent Level I/II Trauma with Hemodynamic Instability Transferring Facility – No Trauma Surgery/Capability Receiving Facility – Trauma Surgery/Capability





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

Priority 2 Clinical Condition – No Immediate Time Critical Intervention at Receiving Hospital Facility

Time Standard is 911 Call to Arrival = Response 24:59 or less without use of Red Lights & Sirens Once ambulance is assigned cannot be re-assigned unless Priority 1 Call and only one re-assignment total

Post Cardiac Arrest with Hemodynamic Stability Transferring Facility – No ICU and/or Cardiology Services Receiving Facility – ICU and Cardiology Services

Active Labor with Routine Delivery Planned Transferring Facility – No Obstetric Surgery Receiving Facility – Obstetric Surgery

Dialysis Required with Hemodynamic Stability Transferring Facility – No Dialysis Capability Receiving Facility – Dialysis Capability with Dialysis Imminent

Ground Component of Air Ambulance Transport Assist Estimated Landing Time 25 Mins or Less

Priority 3 Clinical Condition – No Immediate Time Critical Intervention at Receiving Hospital/Facility Time Standard is 911/non-911 Call to Arrival = Response 59:59 or less without use of Red Lights & Sirens

Once ambulance is assigned cannot be re-assigned unless Priority 1 or 2 Call and only two reassignments total

Hospital ED or Inpatient Transfer

Transferring Facility – Limit of Care Capabilities/Course of Treatment Reached Receiving Facility – Higher Care Capabilities/Ongoing Course of Treatment Possible

Hospital ED to Residence/Nursing Facility Post ED Evaluation and Treatment

Priority 4 Clinical/Logistic Condition – No Immediate Time Critical Intervention at Receiving Hospital/Facility

Time Standard is 911/non-911 Call to Arrival = 15 minutes within scheduled pick-up appointment time

Once ambulance is assigned cannot be re-assigned unless Priority 1, 2, or 3 Call and only four re-assignments total

Scheduled Outpatient Dialysis Care

Hospital Inpatient to Residence/Nursing Facility Post ED Evaluation and Treatment

Inpatient Bed Shortages and Hospital to Hospital or Facility to Facility Patient Movement Due to Bed Shortage






Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 14I: Interhospital Transfers, cont.

#### High Flow Nasal Cannula during Interhospital transfer

Nasal high flow creates breath and flow-dependent pressure, making inspiration easier and promoting slow, deep breathing on expiration, thereby increasing alveolar ventilation.



Any patient on High Flow Nasal Cannula (HFNC) requiring transfer to another facility or being discharged home with appropriate equipment in place may be transported utilizing the hospital's high flow system (if allowed by facility) or change out HFNC components as needed to allow for transport on the same settings.

Titrations can be made as needed during transport to maintain therapeutic oxygenation and ventilatory support.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## **14J - SCENE COORDINATION**

Emergency Medical Services in Metropolitan Oklahoma City and Tulsa are provided by several agencies that must interact cooperatively to achieve the goal of quality patient care. Interactions between on-scene personnel must be predictable and consistently professional. The following protocol has been developed to facilitate optimal scene coordination including transfer of care and timeliness of patient transport. Additional benefits include promoting a collaborative practice of EMS medicine and improved scene safety for patients and EMS professionals.

#### If a disagreement regarding patient care occurs, protocol, OMD or OLMC guidance is to be sought, avoiding any unnecessary delay in transport of critical patients.

The following guidelines are most commonly applicable to scenes involving a single or limited number of patients. Mass casualty incidents should be managed per Protocol 15A: Multiple Patient Scene/Mass Casualty Event Concepts.

- 1. The first arriving crew will bring all indicated mobile medical equipment to the patient side.
- The first arriving crew will relay information regarding current level of provider (EMT, EMT-I, AEMT, Paramedic), scene safety/staging, scene access, and equipment needs, as appropriate, to additional responding crews through 800 MHz radio systems, shared frequencies or relay through respective communication centers.
- 3. The transporting crew will bring all indicated mobile medical equipment and the stretcher to the patient side, unless otherwise notified by crew(s) on-scene.
- 4. The first on duty EMS provider on-scene will assume charge of and direct patient care. If a paramedic is not present, the officer or designated person in charge will brief the first arriving paramedic on assessment and treatment of the patient(s). The paramedic will verbally acknowledge receiving the patient-centered briefing, then assume charge of and direct patient care.
- 5. On arrival of the transporting unit, the officer or designated person in charge will brief the transporting paramedic on assessment and treatment of the patient(s). The transporting paramedic will verbally acknowledge receiving the patient-centered briefing, then assume charge of and direct patient care. In the event the transporting paramedic and an EMR paramedic arrive on scene simultaneously, the transporting paramedic will assume charge of and direct patient care.
- 6. If the transporting paramedic is first on-scene, as soon as it is clinically practical, the transporting paramedic will brief subsequent arriving providers on assessment and treatment of the patient(s) and assign tasks consistent with treatment protocols.
- 7. Avoid unnecessarily repeating questions to the patient that have been answered.
- 8. All personnel will assist each other in every possible way (i.e. moving/gathering of equipment, lifting and movement of stretcher).
- 9. Once charge of patient care is appropriately transferred, a confirmatory patient assessment by the transport paramedic may be necessary. As a routine practice, such reassessments should not delay ongoing care and/or timely transport. Transport should not be delayed or interrupted for patient care documentation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 14J: Scene Coordination, cont.

- 10. If a patient has been loaded into the ambulance prior to additional crew arrival(s), at least one additional crew will inquire with the transporting paramedic if they can be of assistance.
- 11. All personnel will work cooperatively and in a professional manner to ensure ongoing high quality of patient care. If any EMS personnel on-scene believes patient condition requires additional support, including accompanying the patient during transport, this shall be discussed with the transporting paramedic.
- 12. The transport crew will accept response cancellations from EMR crew's on-scene when clinically appropriate. Conversely if EMR personnel are informed by the on-scene transporting crew that no clinical assistance is required the EMR units will cancel their response, unless non-clinical scene characteristics dictate a continued response.
- 13. The EMS System for Metropolitan Oklahoma City and Tulsa supports the National Incident Management System guidelines, even in single patient encounters. Be familiar with NIMS (See Protocol 15A: Multiple Patient Scenes/Mass Casualty Event Concepts) and be able to utilize when indicated.

#### Special Note: ALS First On-Scene at 911 BLS Assigned Response


In the rare instance that a system credentialed ALS provider is first on scene of a 911 BLS assigned response, they should assess all patients and determine if there is a need for the response to be upgraded to an ALS level call. If ALS care is needed, the ALS provider will assume charge of and direct patient care, until transitioning ALS care to an ALS transport unitbased paramedic (if applicable). If the ALS provider determines that no ALS-only scope of practice patient care is required, the ALS provider can transition care to the 911 BLS EMTs. The transporting EMTs shall verbally acknowledge receiving transition of care, then assume BLS scope of practice patient care.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 15A – MULTIPLE PATIENT SCENES/ MASS CASUALTY EVENT CONCEPTS



A Multi-Patient Scene (MPS) occurs when an incident involves more than one patient, but less than 5 critical patients and less than 10 total patients.

A Mass Casualty Incident (MCI) occurs when an incident involves several patients, specifically including five or greater critical patients or ten or more total patients, regardless of patient priority composition.

Incident command at multiple patient scenes (MPS) or mass casualty incidents (MCI) will be assigned according to the National Incident Management System (NIMS) guidelines and a unified command team consisting of representatives of police, fire, and EMS should be rapidly assigned and coordinated to ensure safe, efficient, and effective operations.

#### Multi-Patient Scene Tasks:

- 1. Initial Size-up Actions: (these are the same for Mass Casualty Incidents)
  - a. Park initial arriving apparatus in safe location at scene perimeter to avoid loss of its availability/use.
  - b. Advise dispatch:
    - i. Incident location (if different from initial dispatch).
    - ii. Incident type (transportation accident, fire, etc. if different from initial dispatch).
    - iii. Estimated number of patients.
    - iv. Numbers & types of additional resources needed.
    - v. Any hazardous conditions (weather, electrical, structural, toxic chemicals, etc).
    - vi. Identify a "HOT ZONE"/"Immediate Danger Zone" if applicable.
    - vii. Best route & access to scene (if appropriate).
    - viii. Staging area location (if staging indicated).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Multi-Patient Scene Tasks, cont.:

- c. Check in with Incident Command to determine ICS role. The medical treatment and transport of injured patients will normally be done through the position of Medical Branch Director and subordinate positions headed by Group Supervisors. However, the Incident Commander will determine which positions, if any, he or she feels needs to be filled.
- 2. Medical Branch Director:
  - a. Reports to the Operations Section Chief.
  - b. Don identification vest for position.
  - c. Establishes Triage, Treatment, and Transport Areas (if indicated) and assigns individuals to the role of Group Supervisors (unit leader) for each area.
  - d. Maintains adequate span of control within Medical Branch.
  - e. Establish appropriate EMS communications with appropriate response elements (ie. Annex H, MERC, staging, logistics).
  - f. Establish and maintains communications with assigned Group Supervisors (unit leader).
  - g. Oversees the triage, treatment, transportation and accountability of patients created by incident.
  - h. Monitors the potential or actual effect of the incident on the existing medical infrastructure and communicates such with the Operations Section Chief, MERC, and/or Annex H.
  - i. Determines resource requirements to meet the medical needs of the incident and communicates needs to Operations Section Chief or designated response element.
  - j. Determines the need for specialized medical resources and processes requests for such elements through appropriate channels.
  - k. Provides situation updates and reports to the Operations Section Chief, MERC, and/or Annex H.
- 3. Group Supervisor (Unit Leader):
  - a. Establishes Area to perform assigned tasks.
  - b. Determine resource and staffing needs for Area of responsibility and communicates needs to Medical Branch Director.
  - c. Follows assigned duties as outline in Agency Plan, Task Cards, or Job Action Sheets.
  - d. Provides situational updates and reports to the Medical Branch Director.
  - e. Establish communications with the Medical Branch Directors and other needed response elements.
  - f. Monitors safety and welfare of patients and assigned personnel.
  - g. Ensures patient tracking and accountability of injured patients in assigned Area.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Triage Area Tasks:

- 1. Initial triage is at casualty locations unless hazards indicate that rapid extrication or casualty self-extrication should occur to a designated area safe for triage operations. In some instances, the use of priority-specific colored tape (red, yellow, green, black/blue) may be utilized to mark patients in the absence of readily usable triage tags.
- 2. Perform first pass (initial) triage. Do not perform any treatment in first pass triage other than very quick, simple and extremely urgent measures (i.e., open the airway by positioning). Move quickly to ensure all casualties are identified and triaged to minimize loss of life and limb.
- 3. Attach tag to patient using the string loop directly on their body. Over the head or on the upper arm works well. The left extremities should be utilized unless extremely injured. This will make it easier to utilize the triage tag during transport.
- 4. Use a reliable method to count the number of patients in each category. This information will need to be relayed to the Triage Group Supervisor (Unit Leader) officer, and in turn, the Medical Branch Director.
- 5. Direct ambulatory patients to the GREEN Treatment Area when it is established. Use discretion in allowing GREEN patients to assist in caring for the YELLOW and RED patients while those more serious casualties are awaiting extrication to the treatment areas. ALL persons involved in the incident are to be triaged and tagged those without apparent injuries should be tagged GREEN.
- 6. Report number of casualties in each category and in total to the Triage Group Supervisor (Unit Leader).
- 7. Repeat triage sequence when possible and note changes in any casualty's condition. Perform a more detailed assessment, provide treatment, and write-in information on the tag while casualties are being extricated to the Treatment Area.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Treatment Area Tasks:

- 1. Establish treatment area in consultation with the Medical Branch Director regarding location. Think BIG to allow adequate space to treat casualties. Ensure the location promotes relative ease of ambulance loading and egress.
- 2. Request, assign, utilize, and oversee appropriate clinical personnel caring for patients.
- 3. Assemble into crews of at least 2 personnel equipped with a backboard and straps for assignment by the treatment officer to perform BASIC packaging and extrication of triaged casualties into the Red, Yellow, and Green treatment areas. The treatment officer may choose to have separate personnel perform treatment once inside the Treatment Area, depending on the logistics of the particular call. All persons involved in the incident triaged Green due to very minor or no apparent injury are to be kept in the Green Treatment Area until more fully evaluated. These individuals will be released at an appropriate time by the Transport Group Supervisor (Unit Leader). Depending on the circumstances, the Green casualties may be transported early or in large groups using alternative transport means.
- 4. On the clinical side of the triage tag, circle injuries on the body diagram (if present), note the BP, pulse, and respirations. Note any IM or IV medication given and the time it was given. On the administrative side of the tag, note the time, date, patient name, address, city, state, and past medical history and prescriptions. Record the primary EMS caregiver.
- 5. If a casualty's condition worsens (e.g. Yellow to Red; Green to Yellow) inside the Treatment Area, apply a new triage tag indicating the more serious condition (leaving the original tag in place to indicate a change in condition occurred) and move the patient to the appropriate location in the Treatment Area. Notify the Treatment Group Supervisor (Unit Leader) of any change in casualty condition so that this may be recorded for overall patient accountability and reported to the Medical Branch Director.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Transportation Area Tasks:

- Establish patient loading zone. Consider proximity to treatment area and ambulance approach AND exit routes. Establish ambulance traffic routes that prevent ambulances from having to back-up to load patients. This makes for safer and more efficient transport operations. While multiple ambulances may be in staging, minimize the number of ambulances in the immediate load zone. This makes for more accurate and efficient transport operations. Work with staging to ensure at least 1 ambulance is always in the loading zone. Ensure vehicle operators stay with their ambulances to ensure as soon as patients are loaded, the ambulance leaves.
- 2. Assign Unit Leaders to appropriate needed subordinate roles such as tracking and communications. The Transportation Area will likely require the coordinated effort of several people and can quickly overwhelm one individual. Loss of patient accountability can be the result of an inadequately staffed Transportation Area.
- 3. Communicate with Treatment Group Supervisor (Unit Leader) when ambulances are available for transport. NO MORE THAN ONE CATEGORY RED PATIENT PER AMBULANCE. May take another patient if yellow/green in category.
- 4. Supervise the assignment and loading of patients into available transport.
- 5. Communicate with response elements (Annex H, MERC, Communications Center) to determine hospital capacity and appropriate destination of patients based upon clinical condition(s) and vehicle operator familiarity with destination.
- 6. Consider the use of alternate means of transportation if indicated (busses, specialty vans).
- 7. Before patient leaves the scene to destination, the accountability process should be completed by whatever means being used (triage tag identifier slip, patient log).
- 8. Notify the Medical Branch Director when all patients have been cleared from the scene and transported. Maintain and secure records for the Medical Branch Director and secure the patient loading area.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Staging Group Supervisor Tasks:

- 1. If not already established and/or determined by Incident Command, establish staging area for medical transportation resources. Staging area should be an area large enough to contain numerous transportation assets, be far enough away so units don't get caught in incident, but close enough to loading zone to allow for short drive times.
- 2. Select and communicate a desired travel route for resources assigned to the Staging Area. This route should allow for easy access, but should take units away from the impacted area.
- 3. Staging Area for medical assets may be co-located with staging for other response assets, or may be a stand-alone area, depending on the desire of the Incident Commander. If colocated with other response assets, ensure medical assets are grouped together for accountability and an accurate assessment of available resources.
- 4. The Staging Group Supervisor (Unit Leader) should coordinate an orderly arrangement of arriving apparatus to allow for ease of ambulance ingress to the transport loading zone. Medical equipment assets (cache, trailers) should also be organized to allow for rapid deployment upon request.
- 5. The Staging Group Supervisor (Unit Leader) or the officer's designee should maintain a log of available resources in staging and communicate with the Medical Branch Director resource levels as appropriate and as requested by the Medical Branch Director.
- 6. The Staging Officer or the officer's designee should assure ambulance or specialty transport crews stay with their assigned vehicles to assure rapid availability of the asset when requested at the transport loading zone.
- 7. Deliver equipment needed in the treatment area that is requested from staging in an organized cache with a minimum of personnel leaving the staging area to deliver this equipment. Alternatively, all the requested equipment may be sent to the treatment area on one designated vehicle.
- 8. Assign and deploy transportation assets to the loading zone(s) per the request of the Medical Branch Director or the Transportation Group Supervisor depending on the established communication pathways.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Mass Casualty Medical Communications:


- 1. Medical communications during a mass casualty incident, like all other incident communications, are of critical importance and often will determine the level of effectiveness and success of the operation. Basic communication principles should be used during an incident.
  - a. Use of interoperable radio channels so all agencies are able to communicate.
  - b. Following the overall incident communications plan established by the Incident Commander.
  - c. Establishing assigned, clear, and understood lines of communications; who will communicate with whom, for what reason, and by what method.
  - d. Use of multiple and redundant means of communications including, but not limited to, radio, data, phone, runners, face-to-face, and even hand signals.
  - e. Preparation for communications failure and immediately switching over to one of the established redundant communication means.
  - f. Ensuring communications sent receive a response of some manner to ensure the loop has been closed.
- 2. Medical communications from the scene of an MCI, depending on complexity and command structure, often involves up to three different levels of communications:
  - *i.* Communications (internal) with other Incident Command System elements
  - *ii.* Operations Section Chief or designee(s)
  - *iii.* Unified Command medical representatives
  - iv. Logistics, Planning, Admin/Finance if appropriate
  - b. Communications (internal) within the scene medical response infrastructure: *i.* Triage, Treatment, Transportation, Staging Group Supervisors
  - c. Communications (external) with local, county, or regional medical coordination entities:
    - *i.* Local Emergency Response Coordinator (LERC)
    - *ii.* County Public Health Annex H Representative
    - iii. Medical Emergency Response Center (MERC)
- 3. After assigning support positions, one of the first activities of the Medical Branch Director should be to establish redundant communications pathways with the ICS structure, subordinate Group Supervisors (Unit Leader), and other medical response elements by:
  - a. Obtaining the ICS Communication Plan (incident channels etc).
  - b. Determine reporting lines and redundant means of communication with Groups Supervisors (Unit Leader). Example: Transport requesting assets through Medical Branch or directly to Staging.
  - c. Establishing and communicating manner for all communications acknowledgments.
  - d. Establish communications via radio, e-mail, or phone with outside medical coordination entities.
  - e. Advise the ICS infrastructure of communication pathways for incorporation into updated ICS communication plan.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

15B – REGIONAL EMS SYSTEM (REMSS) ACTIVATION PROCEDURE



All requests for REMSS deployment will need to be validated through information provided on the request form contained within this protocol. The REMSS deployment request form can also be found within the Oklahoma REMSS Ambulance Strike Team (AST) Guidelines.

Medical Branch Request for REMSS Assistance is accomplished in the following sequence:

- 1. Before any REMSS assets can be requested, a functioning Incident Command Structure (ICS) with an identified Medical Branch will need to exist.
- 2. Depending upon local county emergency operational procedures, the Medical Branch can request REMSS assets through one of the following means:
  - a. through the ICS to the county Emergency Operations Center (EOC) and Annex H Health and Medical Representative (if EOC in operation)
  - b. through direct contact with Regional Medical Emergency Response Center (MERC) in Regions 1,3,5,6,7,8 or the Regional Multiple Agency Coordination Center (MACC) in Regions 2, 4
  - c. calling the Incident Resource Hotline at 1-800-800-2481 ("top down" method)
- 3. Any request for a REMSS team will need to be accompanied by:
  - a. Specific number/types of ambulances and trailers needed (Who/What needs to go?)
  - b. Reason for request (Why are they needed?)
  - c. Expected mission for REMSS team (What will they do?)
  - d. Staging location for REMSS team upon incident arrival (Where will they go?)
  - e. Known scene or access to scene hazards (What hazards do they need to expect?)
  - f. Contact name and phone number(s) for updates/requests for additional information (Who should be contacted during the REMSS response and upon arrival?)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Protocol 15B: Regional EMS System (REMSS) Activation Procedure:

Once a valid request, containing the above information, is received for REMSS deployment, the following sequence of actions occurs to effect the deployment:


- Oklahoma State Office of Emergency Management (OEM) receives a call from the Incident Resource Hotline (1-800-800-2481) for REMSS assistance. An OEM representative will give the request to the Emergency Support Function 8 - Public Health and Medical Services (ESF-8) desk at the State Operations Center (Oklahoma State Department of Health) and notify the Regional Response Coordinator from the Oklahoma Office of Homeland Security.
- 2. ESF-8 personnel will contact MERC in regions 1,3,5,6,7,8, or the MACC in regions 2, 4 for validation.
- 3. MERC/MACC professionals will contact the Medical Branch at the scene to validate the request for assets. That contact will also include the affected county's Annex H Representative if the county EOC has been activated.
- 4. Once the request is validated, MERC/MACC will contact REMSS regional representative in affected region to determine ability of REMSS team to respond based upon the parameters of a validated request.
- 5. If a REMSS team can be formed from within the affected region, it will respond to the validated request.
- MERC/MACC will notify state ESF-8 personnel and state Regional Response Coordinator of intra-regional response. ESF-8 will notify Oklahoma State Department of Health EMS Division and the County Health Administrator for the affected area.
- If the REMSS team from the affected region is already engaged or otherwise unavailable, ESF-8 personnel will be notified and will contact the MERC/MACC in the adjoining region.
- 8. The next involved MERC/MACC will repeat the contacting process and determination of an available team.
- 9. Once a REMSS team able to respond from another region has been identified, ESF-8 personnel will be notified, and in conjunction with the state Regional Response Coordinator, will dispatch that REMSS team as an inter-regional response asset. ESF-8 personnel will make notifications to Oklahoma State Department of Health EMS Division.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions





#### Communication Center Principles:

911 calls present the first opportunity to identify that a potential weapon of mass destruction (WMD) - chemical incident exists. Identifying the incident, relaying potential threat information, and advising precautionary measures to <u>all</u> of the responding public safety professionals may be a key to saving lives of responding public safety professionals.

#### Indicators of a Possible Chemical Weapons Incident:

- 1. Explosion with little or no structural damage;
- 2. Reports of a device that dispersed a mist or vapor;
- 3. Multiple casualties exhibiting similar symptoms (may be without apparent reason);
- 4. Reports of unusual odors, liquids, spray devices, or cylinders;
- 5. Dead animals;
- 6. Discarded personal protective equipment (PPE).

Potential Notifications (actual notification needed if chemical weapon event confirmed):

- 1. Local Law Enforcement
- 2. Local Federal Bureau of Investigation (FBI) office WMD Coordinator;
- 3. Local/State Office of Emergency Management (OEM);
- 4. Local Health Department

#### Initial Actions/On – Scene Arrival:

- 1. Approach upwind and uphill of the incident;
- 2. Stop at an apparent safe distance away from incident location;
- 3. Alert subsequent arriving responders;
- 4. Direct all personnel to use full PPE, including self-contained breathing apparatus (SCBA)
   a. At a minimum, respiratory protection;
- 5. Be aware of possible secondary devices;
- 6. Treat as a crime scene/Consider that alleged perpetrator may still be on the scene;
- 7. Avoid contact with liquids;
- 8. Request appropriate resources (HazMat specialists, law enforcement officers, etc.).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 15C: Chemical Weapons, cont.:** 

#### **Establishing Incident Command: (Follow Specific Directives of Incident Commander)**

Follow National Incident Management System (NIMS) practices as reflected in local policies. Utilize a Unified Command structure, promoting effective and efficient multi-agency

communications and operations.

Further information through NIMS courses can be accessed at this website: https://www.fema.gov/national-incident-management-system

#### **Casualty Rescue:** (Follow Specific Directives of Incident Commander)

As many ambulatory casualties as possible should be removed from the area without rescuers entering the incident site. It should be expected, though, that live, non-ambulatory casualties will be present at any chemical incident.

- 1. Use bull horns and vehicle public address (PA) system to give directions;
- 2. Be alert for secondary devices;
- 3. Determine if there are live victims in the contaminated area;
- Use PPE appropriate for safe rescue PPE level most likely determined by HazMat specialists advising the Incident Commander (IC). The IC evaluates the chemical threat, potential to save lives, risk to responders, and time constraints to achieve each level of responder protection before determining what level of PPE to use to perform rescue operations;
- 5. When safe and appropriate, assist/direct all victims to decontamination and triage area.

#### **Decontamination:** (Follow Specific Directives of Incident Commander)

The theories and procedures referred to by the Chemical Weapons Improved Response Program (CWIRP) are based on decontaminating victims using large volumes of water.

Establish decontamination location(s) upwind and uphill of the incident:

- 1. Decontamination personnel must wear appropriate PPE, likely to include SCBA;
- 2. Be alert for secondary devices, weapons, and perpetrators;
- 3. Avoid contact with unknown liquids;
- 4. Decontaminate (immediately) casualties with liquid contamination on their skin or clothing. For dry contamination, substance should be brushed off casualty immediately;
- 5. Clothing removal is often the most effective decontamination. Encourage victims to remove clothing at least down to their undergarments;
- 6. Prioritize asymptomatic, symptomatic, and non-ambulatory casualties:
  - a. Coordinate decontamination with EMS triage activities.
  - b. Establish separate technical decontamination for responders away from masscasualty decontamination.


The diagrams on the following page are provided to illustrate commonly recognized methods of mass "wet" decontamination. Follow the directives of the Incident Commander and HazMat specialists in charge of decontamination.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 15C: Chemical Weapons, cont.:** 

## LADDER PIPE DECONTAMINATION SYSTEM (LDS)



## EMERGENCY DECONTAMINATION CORRIDOR SYSTEM (EDCS)







Approved 9/14/22, Effective 1/16/23, replaces all prior versions **Protocol 15C: Chemical Weapons, cont.:** 

Types of Decontamination:

- a. Passive (clothing removal) often the simplest and effective method
- b. Dry agents
  - i. Dirt Flour
  - ii. Baking powder Sawdust
  - iii. Charcoal Silica gel
- c. Wet agents
  - i. Soap and water
  - ii. Water (only)
  - iii. Bleach (for equipment decontamination)
- d. Air decontamination (positive pressure ventilation [PPV]/portable fans)

#### EMS Principles: (Follow Specific Directives of Incident Commander)

One of the primary challenges facing EMS on a chemical weapons incident will be the number of casualties (eg. trauma and agent exposure) and segregating these casualties by severity of illness/injury as well as attempting to segregate the "worried well" from actual exposed victims.


Work with appropriate HazMat specialists to determine proper level of PPE and respiratory protection needed for EMS personnel and what areas are appropriate for EMS care activities.

- a. Be alert for secondary devices and perpetrators;
- b. Avoid contact with liquids other than non-contaminated water;
- c. Rapid prioritization of number of patients;
- d. Triage victims based on medical necessity, using MCI protocols;
- e. Establish patient identification and tracking.
- f. Establish:
- i. Communications with command post and hospitals;
- ii. Staging for EMS personnel, ambulances, supplies, and resources;
- iii. Transportation area avoid transporting any contaminated patient(s).





Approved 9/14/22, Effective 1/16/23, replaces all prior versions 15D – CHEMPACK DEPLOYMENT ACTIVATION PROCEDURE



If an incident appears to have the possibility of a nerve agent, organophosphate or radiological incident, the Incident Commander on the scene should notify the Oklahoma Poison Control Center (OPCC).

To contact the Oklahoma Poison Control Center in Oklahoma City:

## Healthcare Professional Access Number: 1-877-271-6998

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient information and substance information possible (may be limited in early phase of potential mass casualty incident) readily available to share with the poison center specialist.

Based on the outcome of the call, if it is a plausible chemical or radiological event, OPCC will activate the nearest CHEMPACK site and notify the appropriate Regional Medical Emergency Response Center (MERC) (also referred to as the Regional CHEMPACK Coordinator).

The Regional CHEMPACK Coordinator will assume coordination and determine additional support facilities, transport modes if needed (coordinating with local Emergency Management, medical facilities, the nearest CHEMPACK site and Oklahoma Highway Patrol), and contact the facilities to determine their level.

The selected site(s) can be placed on three (3) different levels: *Standby* - Level 1, *Alert* - Level 2 and *Activation* - Level 3. During *Activation* - Level 3, the cache site will open the container and access the material. If pre-defined at the time of container receipt from the CDC, the container contents will be separated and prepared for delivery to hospital emergency departments and/or EMS.

CHEMPACK assets are to be utilized as a second line of defense. It is expected that existing supplies of nerve agent antidotes will be utilized before opening CHEMPACK containers unless EMS and/or hospitals anticipate exhausting their existing cache of these agents, at which time CHEMPACK containers may be opened.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



EMERGENCY MEDICAL DISPATCH
EMERGENCY MEDICAL RESPONDER
EMT-BASIC
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

#### NERVE AGENT EXPOSURES

#### Comments

- Nerve agent exposure should be considered at multiple causality incidents in which patients are exhibiting the DUMBELS constellation of symptoms and signs. In particular, nerve agent exposure should be considered while responding to any reports of multiple casualties at a location of high occupancy (should malls, stadiums, etc), high visibility (crowds gathered for public speeches, protests, etc), or high political symbolism (places of worship, governmental offices, etc).
- 2. Immediate countermeasures to nerve agent exposure with developing DUMBELS symptoms and signs are administration of the DuoDote<sup>®</sup> auto-injectors, auto-injector-as indicated and evacuation from the exposure are for decontamination.
- 3. Any personnel exposed to a nerve agent and requiring treatment with the DuoDote<sup>®</sup> autoinjectors is restricted from providing patient care and should be promptly transported for emergency physician evaluation.
- 4. Atropine is utilized in nerve agent exposure treatment to dry secretions, reduce bronchospasm, and decrease gastrointestinal motility. If significant bronchorrhea continues after three DuoDote<sup>®</sup> auto-injector have been administered in the adult patient, further atropine may be given by paramedic as follows until the bronchorrhea subsides:

Adult – 1 mg atropine IVP every 3-5 minutes Adult – 2 mg atropine IM every 5 minutes

5. In the case of nerve agent exposure with bronchorhea, there is no maximum atropine dosing in the adult patient, though atropine should be withheld in the case of developing ventricular tachydysrhythmias. In this case, treat the ventricular tachydysrhythmia according to 5G Tachycardia – Unstable – Adult & Pediatric or 4G Ventricular Fibrillation/Pulseless Ventricular Tachycardia – Adult & Pediatric as applicable.






Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 15E: Nerve Agents, cont.** 

- DuoDote<sup>®</sup> is utilized in nerve agent exposure to reverse the nerve agent effect on acetylcholinesterase, the enzyme responsible for neurotransmitter regulation. Refer also to Protocol 16M for self/buddy care using DuoDote<sup>®</sup>.
- 7. Patients contaminated by vapor-only nerve agent exposures should be decontaminated by clothing removal (dry decon). Patients contaminated by liquid nerve agent exposures should be decontaminated by clothing removal and thoroughly washed with soap and water (wet decon).
- 8. In the absence of DUMBELS symptoms and signs, nerve agent exposure has not occurred. The DuoDote<sup>®</sup> auto-injectors are not authorized for patients not exhibiting DUMBELS symptoms and signs.
- 9. Pediatric patients (<25 kg) with DUMBELS symptoms and signs in the setting of suspected nerve agent exposures should be treated with one DuoDote<sup>®</sup> auto-injector kit and OLMCP should be contacted for further direction in relation to any further atropine and/or 2-PAM usage.
- 10. Patients treated with DuoDote<sup>®</sup> auto-injector kits should either have the auto-injector hooked to their clothing or a prominent vertical mark on their forehead for each kit administered to indicate to further healthcare providers the number of DuoDote<sup>®</sup> auto-injector kits the patient has received.



EMERGENCY MEDICINE UNIVERSITY OF OKLAHOMA

Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 15E: Nerve Agents, cont.** 



#### LOOK FOR "DUMBELS" SIGNS AND SYMPTOMS

- D: DIARRHEA
- U: URINATION
- M: MIOSIS (PINPOINT PUPILS)
- B: BRONCHOSPASM, BRONCHORRHEA (COPIOUS RESPIRATORY SECRETIONS)
- E: EMESIS (NAUSEA/VOMITING)
- L: LACRIMATION (TEARING)
- S: SALIVATION

Additional resources regarding nerve agents can primarily be accessed through the Centers for Disease Control at www.bt.cdc.gov/agent/nerve.

National Disaster Life Support training also includes nerve agent education in:

Basic Disaster Life Support (one day classroom course)

Advanced Disaster Life Support (two day classroom/practical exercise course)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 15F – BIOLOGICAL WEAPONS EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC

While a multitude of biological agents exist that have possibility in weapon use, the Centers for Disease Control categorizes these agents into priority of concern and probable use. Category A agents include organisms that pose a risk to national security due to easy dissemination or person to person transmission, high mortality rates, high impact upon public health, ability to cause public panic and social disruption, and require special action for public health preparedness.

Category A agents and their diseases include:

Bacillus anthracis – Anthrax Clostridium botulinum toxin – Botulism Yersinia pestis – Plague variola major – Smallpox Francisella tularensis – Tularemia filoviruses (eg. Ebola, Marburg); arenaviruses (eg. Lassa, Machupo) – Viral hemorrhagic fevers

Of particular concern among these agents is anthrax. While anthrax is a naturally occurring disease among animal skin handlers, the bacteria has already been successfully used in domestic terrorism in the United States. Concern about anthrax prompts responses by public safety agencies, including EMS in some locales, to investigate these concerns and in some cases, acute onset of symptoms, in response to exposure to "suspicious white powder". The following information serves as one resource in preplanning responses to such substances in efforts to protect EMS and other safety professionals.

Additional resources regarding biologic weapons can primarily be accessed through the Centers for Disease Control at www.bt.cdc.gov/bioterrorism.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 15F: Biological Weapons, cont.

Suspicious Powder Response Model Procedure - Follow Local HazMat Directives

#### Definitions:

Isolation Perimeter – The designated crowd control line surrounding the Hazard Control Zones. The isolation perimeter is always the line between the general public and the Cold Zone.

Field Test – A procedure that will be determined by on-scene FD Hazmat and PD personnel to check the presence of radiological, biological, chemical, and volatility (flammability) in or around a package.

ID Test – FD procedure to obtain information to identify a specific substance (i.e., salt, sugar, flour, etc) or chemical compound. Testing to identify a substance is more geared toward dry product or liquids without water content. The test signature of water overrides/masks the graph spikes preventing identification.

#### Procedures:


The following actions should be taken at incidents involving a package suspicious for anthrax:

- 1. Once law enforcement (LE) arrives on scene and decides that FD is needed, HazMat resource mobilization should be considered.
- 2. If the first arriving FD company is not a Hazmat Unit and receives information that the incident may be a potential chemical or biological threat, the OIC should:
  - a. Not make entry or attempt to mitigate the incident
  - b. Establish an isolation perimeter of at least 100 feet
  - c. Should keep all citizens on the outside of the isolation perimeter
  - d. Call for the Hazmat Team
  - e. Wait upwind until arrival of Hazmat Team
  - f. Operate in a support role for the Hazmat Team upon their arrival
- 3. The Hazardous Materials Team OIC will be either Command or Hazmat Branch as appropriate.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions PROTOCOL 15F: Suspicious Power Response Procedure, cont.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**15G – RADIOLOGICAL WEAPONS** 



- 1. Potential radiologic weapon devices in the United States include:
  - a. Simple radiation emitting devices (example would be dumping radioactive waste in a water supply typically NOT a significant threat due to dilution effect of large amount of water).
  - b. Conventional explosive device containing radiation ("dirty bomb") typically NOT a significant threat due to the fact that explosions are very inefficient in producing radioactive particles of a size that are easily inhaled.
- 2. Either of the above devices may be utilizing radioactive isotopes initially manufactured for medical use (eg. nuclear imaging).
- 3. Radiation types include the following:
  - a. Irradiation = gamma radiation passing through a body
  - b. External contamination = radioactive "dust" particles falling on a body
  - c. Internal contamination = radioactive "dust" particles being ingested or inhaled
- 4. Protection takes the simple format of:
  - a. Reducing time of exposure.
  - b. Increasing distance from exposure source biggest factor in protection. Radiation does not travel far, but contamination can.
  - c. Shielding device use to minimize exposure uptake. Airborne illness PPE protection is excellent for radiation protection as well). Think of radioactive particles as "dirt" that shouldn't be inhaled (wear N95 masks) and shouldn't be in contact with skin.
- 5. Three **myths** that can paralyze medical response:
  - a. "Radioactive contamination is highly dangerous & requires extraordinary protective measures." (see above)
  - b. "Decon is highest medical priority." Decon is actual very simple = remove clothing and shower. Most of radiation goes away with removal of clothing.
  - c. "Special skills are needed to handle radioactive patients." (see above)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 15G: Radiological Weapons, cont.

6. Multiple resources exist to aid in the understanding and response planning for radiological weapons. The following are suggested resources:

Radiation Emergency Medical Management www.remm.nlm.gov

National Alliance for Radiation Readiness (NARR) www.radiationready.org

Society of Nuclear Medicine and Molecular Imaging www.snmmi.org

Health Physics Society www.hps.org

National Disaster Life Support training Basic Disaster Life Support (one day classroom course) Advanced Disaster Life Support (two day classroom/practical exercise course)


Special acknowledgement to John C. White, CNMT, Radiation Safety Officer, The University of Texas Southwestern Medical Center at Dallas for material integral to this protocol's preparation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**15H – NUCLEAR WEAPONS** 



- 1. Potential nuclear weapon devices impacting the United States include:
  - a. Improvised nuclear device.
  - b. 1 kiloTon "suitcase nuke."
  - c. Tactical weapons of 5-50 kiloTons.
  - d. Electromagnetic pulse detonation = nuclear weapon detonation in atmosphere wherein gamma waves hit radio waves, causing phones, pagers, radios, etc go down.
  - e. Ballistic missile attack.
  - f. 250 kiloTon nuclear bomb = "city killer."
- 2. Nuclear detonation = 50% blast effect; 35% thermal effect; 10% fallout; 5% ionizing radiation effect.
- 3. Mass blindness is a concern due to retinal burns (non-thermal) from viewing detonation.
- 4. Radiation types include the following:
  - a. Irradiation = gamma radiation passing through a body.
  - b. External contamination = radioactive "dust" particles falling on a body.
  - c. Internal contamination = radioactive "dust" particles being ingested or inhaled.
- 5. Protection takes the simple format of:
  - a. Reducing time of exposure.
  - b. Increasing distance from exposure source biggest factor in protection. Radiation does not travel far, but contamination can.
  - c. Shielding device use to minimize exposure uptake. Airborne illness PPE protection is excellent for radiation protection as well). Think of radioactive particles as "dirt" that shouldn't be inhaled (wear N95 masks) and shouldn't be in contact with skin.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 15H: Nuclear Weapons, cont.** 

- 6. Three **myths** that can paralyze medical response:
  - a. "Radioactive contamination is highly dangerous & requires extraordinary protective measures." (see above)
  - b. "Decon is highest medical priority." Decon is actual very simple = remove clothing and shower. Most of radiation goes away with removal of clothing.
  - c. "Special skills are needed to handle radioactive patients." (see above)
- 7. Multiple resources exist to aid in the understanding and response planning for nuclear weapons. The following are suggested resources:

Radiation Emergency Medical Management www.remm.nlm.gov

National Alliance for Radiation Readiness (NARR) www.radiationready.org

Nuclear Regulatory Commission www.nrc.gov

Society of Nuclear Medicine and Molecular Imaging www.snmmi.org

Health Physics Society www.hps.org

Planning Guidance for Response to a Nuclear Detonation June 2010 – Second Edition www.remm.nlm.gov/PlanningGuidanceNuclearDetonation.pdf

National Disaster Life Support training Basic Disaster Life Support (one day classroom course) Advanced Disaster Life Support (two day classroom/practical exercise course)


Special acknowledgement to John C. White, CNMT, Radiation Safety Officer, The University of Texas Southwestern Medical Center at Dallas for material integral to this protocol's preparation.



EMERGENCY MEDICINE UNIVERSITY OF OKLAHOMA

Approved 9/14/22, Effective 1/16/23, replaces all prior versions





Actions/Pharmacodynamics: Activated charcoal is a liquid suspension that adsorbs many drugs and chemicals. It acts by binding / adsorbing toxic substances, thereby inhibiting their GI absorption, uptake into the liver, and thus, their presence in the bloodstream for action, also called "bioavailability". Activated charcoal has a tremendous surface area, allowing for a large amount of adsorption. The combined complex formed by the adsorption process is excreted from the body in the feces. It is a general purpose emergency treatment of poisoning by most drugs and chemicals, e.g., acetaminophen, aspirin, atropine, barbiturates, digitalis, glycosides, phenytoin, propoxyphene, strychnine, and tricyclic antidepressants, among many others.

Indications: Poisonings - General Management (8A)

**Contraindications:** Activated charcoal is contraindicated for treatment of poisoning by cyanide, mineral acids, caustic alkalis, organic solvents, iron, ethanol, and methanol. Activated charcoal may not be administered in patients with current or suspected imminent altered mental status, dysphagia, or vomiting to prevent elevated risk of aspiration of charcoal.

Pharmacokinetics: Nonabsorbed; onset immediate; peak, duration, and half - life: unknown.

**Side Effects:** GI: vomiting following rapid ingestion of high doses, abdominal cramping, abdominal bloating, constipation (diarrhea from sorbitol additive).

- Dosage: Poisonings General Management Adult & Pediatric (8A) 1 gram/kg PO (OLMC or OK Poison Center order required; Consult for order only if transport time estimated to exceed 30 mins)
- **How Supplied:** 25 grams of activated charcoal in aqueous suspension in bottle. (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** Activated charcoal, while historically often administered in the setting of ingested poisonings, is no longer utilized with frequency. The American Board of Medical Toxicology does not recommend administering activated charcoal to all suspected ingested poisonings. The purpose of OLMC or OK Poison Center order requirement is to prevent unnecessary use of activated charcoal and the side effects its use can create - especially vomiting and aspiration.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16B – ADENOSINE (ADENOCARD®)

#### PARAMEDIC

**Class:** Anti-Tachydysrhythmic (Purine Nucleoside)

**Actions/Pharmacodynamics:** Slows electrical conduction through the cardiac atrioventricular (AV) node, with ability to interrupt reentry pathways through the AV and sinoatrial (SA) nodes. Adenosine is administered to convert paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm.

 Indications:
 Tachycardia - Stable (5F) PSVT (sustained regular, narrow-complex tachycardia >150 bpm in adults) & systolic BP ≥ 100mmHg, failed valsalva maneuver.

 Contraindications:
 2<sup>nd</sup>/3<sup>rd</sup> degree AV Blocks (may induce asystole) Known Wolff-Parkinson-White Syndrome (may increase heart rate) Known Sick Sinus Syndrome (may induce asystole) Bradycardia (may induce symptomatic hypotension)

**Pharmacokinetics:** Onset of action within 10-20 seconds after IV administration. Very rapid metabolism (and duration of effect) within 10-20 seconds after IV administration.

**Side Effects:** Common, though transient, symptoms include chest pain, palpitations of irregular bradycardia, dyspnea, lightheadedness, numbness, and sweating. A constellation of these side effects may produce significant patient apprehension and/or sense of impending doom. The patient should be advised of these possibilities prior to adenosine administration and given reassurance such symptoms will be short-lived in duration of seconds. Transient asystolic or profound, irregular bradycardic rhythms may be observed on ECG monitoring.

Dosage: Tachycardia - Stable - Adult (5F) (PSVT as described above) 12 mg rapid IVP (1 – 2 seconds) followed rapidly by 10 mL saline flush. May repeat once at 12 mg.

\*\*OLMC Order Only for use in pediatric patients.

OLMC may direct use of adenosine in evaluating etiology of regular, monomorphic wide complex tachycardia.

**How Supplied:** 12 mg/4 mL in prefilled syringe. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16C – ALBUTEROL (PROVENTIL<sup>®</sup>, VENTOLIN<sup>®</sup>)



Class: Sympathomimetic Bronchodilator

Actions/Pharmacodynamics: Albuterol is a relatively selective beta<sub>2</sub> adrenergic stimulant. Albuterol causes relaxation of the smooth muscles of the bronchial tree thus decreasing airway resistance, facilitating mucus drainage, and increasing vital capacity. It exerts mild effects on beta<sub>1</sub> (heart) or alpha (peripheral vasculature) receptors. In therapeutic doses, albuterol, by inhibiting histamine release from mast cells, also reduces the mucus secretion, capillary leaking, and mucosal edema caused by an allergic response in the lungs.

Indications: Dyspnea - Uncertain Etiology (3B) Dyspnea - Asthma (3C) Dyspnea - Chronic Obstructive Pulmonary Disease (3D) Acute Allergic Reactions (8D) Bee/Wasp Stings (8F) Smoke Inhalation (12B)

**Contraindications:** Known hypersensitivity to albuterol. Albuterol should not be used if the sole etiology of dyspnea is strongly suspected to be CHF, as albuterol-induced tachycardia may worsen the compromised cardiac output in CHF.

**Pharmacokinetics:** Onset within 5 - 15 minutes; peak effect in 1 - 1.5 hours; duration of effect is up to 3 - 6 hours; half – life is less than 3 hours. Distribution: When inhaled, albuterol is distributed to muscle cells along the bronchial tree. Very little is systemically absorbed and distributed.

**Side Effects:** Tremors, anxiety, dizziness, headache, cough, reflex bronchospasm, palpitations, tachycardia, and hypertension.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16C:** Albuterol (Proventil<sup>®</sup>, Ventolin<sup>®</sup>)

Dosage:Dyspnea - Uncertain Etiology - Adult & Pediatric Weight ≥ 15kg (3B)Smoke Inhalation - Adult & Pediatric Weight ≥ 15kg (12B)5 mg nebulized, may repeat once

Dyspnea - Uncertain Etiology - Pediatric Weight < 15kg (3B) Smoke Inhalation - Pediatric Weight < 15kg (12B) 2.5 mg nebulized, may repeat once

Dyspnea - Asthma - Adult & Pediatric Weight  $\geq$  15kg (3C) Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D) Acute Allergic Reactions - Adult & Pediatric Weight  $\geq$  15kg (8D) Bee/Wasp Stings - Adult & Pediatric Weight  $\geq$  15kg (8F) 5 mg nebulized (with ipratropium bromide 0.5 mg), may repeat twice

Dyspnea - Asthma - Pediatric Weight < 15kg (3C) Acute Allergic Reactions - Pediatric Weight < 15kg (8D) Bee/Wasp Stings - Pediatric Weight < 15kg (8F) 2.5 mg nebulized (with ipratropium bromide 0.25 mg), may repeat twice

**How Supplied:** 2.5 mg/3 mL (0.083%) in nebulizer vials. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 16D – AMIODARONE (CORDARONE<sup>®</sup>, NEXTERONE<sup>®</sup>)

PARAMEDIC

**Class:** Class III Anti-Dysrhythmic (Vaughn William Classification)

Actions/Pharmacodynamics: Prolongs the cardiac action potential's refractory period, slowing conduction through the heart. Amiodarone also has secondary actions in the other three classifications of anti-dysrhythmics. Amiodarone blocks sodium channels (class I) which can prevent cardiac action potentials. It is a non-competitive anti-sympathetic (class II) which slows cardiac action potentials. Amiodarone also slows conduction through the cardiac atrioventricular (AV) node (class IV). In sum, all of these actions lead to slowing of conduction and prolongation of refractoriness in the cardiac conduction system.

Indications:	: Ventricular Fibrillation/Pulseless Ventricular Tachycardia (4G)	
	Tachycardia - Stable (5F)	
	Wide-Complex Tachycardia of Uncertain Type or	
	Monomorphic VentricularTachycardia (if heart rate $\geq$ 150 beats per minute with systolic BP $\geq$ 100 mmHg in adults)	
	Narrow-Complex Tachycardia (if heart rate ≥ 150 beats per minute with	
	systolic BP ≥ 100 mmHg in adults) ** <b>OLMC Order Only</b>	
	Tachycardia - Unstable (5G)	
	Post-Cardioverion of Ventricular Tachycardia	
	Premature Ventricular Contractions (5K)	
	Symptomatic Premature Ventricular Contractions (with BP < 100mmHg in adults due to frequent non-conducted ventricular impulses and in absence of 2nd/3rd degree AV blocks)	

**Contraindications:** 2nd/3rd degree AV blocks (may induce asystole) Bradycardia (may induce symptomatic hypotension)

**Pharmacokinetics:** Onset of action within 60 seconds after IV administration, with effects lasting up to 20-25 minutes.

**Side Effects:** Hypotension is the most common side effect, requiring treatment in less than 20% of patients (transient effect). Bradycardia and AV Block may also result, requiring treatment in less than 10% of patients (transient effect). In a very rare circumstance, as with all anti-dysrythmics which can have pro-dysrhythmic effects, torsades may result from excessive prolongation of the cardiac action potential. When indicated by protocol, the benefits of amiodarone administration exceed these risks of side effects.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16D:** Amiodarone (Cordarone<sup>®</sup>, Nexterone<sup>®</sup>), cont.

Dosage:

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) (refractory to initial defibrillation attempt)

300 mg IVP/IOP. Repeat at 150 mg IVP/IOP in 5 minutes to maximum cumulative dose of 450 mg. Epinephrine 1 mg (1:10,000) IVP/IOP is to be given with every amiodarone administration.

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G) (refractory to initial defibrillation attempts)

5 mg/kg IVP/IOP in single dose. Epinephrine 0.01 mg/kg (1:10,000, 0.1 mL/kg) IVP/IOP is to be given with every amiodarone administration.

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) (Successful conversion to sustained pulsatile rhythm)

150 mg (add to 100 ml NS and infuse over 10 minutes). If unable to establish IV access, then add 150 mg to 50 ml NS in a syringe and administer via IO over 10 minutes. IF maximum cumulative dose of 450 mg has not been achieved.

Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G) (post return of sustained spontaneous circulation)

Tachycardia - Stable - Pediatric (5F)

(wide-complex tachycardia of uncertain type or monomorphic ventricular tachycardia; narrow-complex tachycardia)

Tachycardia - Unstable - Pediatric (5G)

Premature Ventricular Contractions - Pediatric (5K)

\*\*OLMC Consult & Order Only

Tachycardia - Stable - Adult (5F)

(wide-complex tachycardia of uncertain type - standing order; monomorphic ventricular tachycardia - standing order; narrow complex - \*\*OLMC order only)

Tachycardia - Unstable - Adult (5G)

(post cardioversion of ventricular tachycardia)

#### Premature Ventricular Contractions - Adult (5K)

150 mg (add to 100 ml NS and infuse over 10 minutes). If unable to establish IV access, then add 150 mg to 50 ml NS in a syringe and administer via IO over 10 minutes.


How Supplied: 150 mg/3 mL in vial, ampule, or pre-filled syringe. 150 mg/100 mL pre-mixed infusion. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16E – ASPIRIN



Class: Anti-Platelet

**Actions/Pharmacodynamics:** Inhibits platelet aggregation (and thereby, further clot formation). This action results in an overall increase in survival from acute myocardial infarction.

 Indications: Chest Pain - Uncertain Etiology (5A) ≥ 35 years of age Acute Coronary Syndrome (5C)
 Contraindications: Active gastrointestinal bleeding History of aspirin allergy including angioedema and/or anaphylaxis History of asthma with aspirin-induced exacerbation

**Pharmacokinetics:** Absorption in stomach and small intestine, with onset of action within 30 minutes and duration of action for several hours.

**Side Effects:** Typically, none from single EMS dosing. Rare instances of nausea or allergic reaction could be encountered. Treat allergic reaction per Protocol 8D - Acute Allergic Reactions.

Dosage: Chest Pain - Uncertain Etiology - Adult (5A) Acute Coronary Syndrome - Adult (5C) 324 OR 325 mg chewed by patient (hold if taken 324+mg within 6 hours)

How Supplied: 81 mg tablets 325 mg tablets (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** Aspirin is indicated even if the patient is taking warfarin sodium (Coumadin<sup>®</sup>), clopidogrel (Plavix<sup>®</sup>), or other anticoagulant or antiplatelet agents on a daily basis.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16F – ATROPINE SULFATE** 

PARAMEDIC

**Class:** Parasympatholytic

Actions/Pharmacodynamics: Blocks parasympathetic impulses to the heart via the vagus nerve. Atropine increases the rate of cardiac sinoatrial (SA) node discharges, enhances conduction through the atrioventricular (AV) node, and by increasing heart rate, increases the cardiac output and blood pressure. Additionally, in the treatment of indicated poisonings (organophosphates) atropine reverses muscarinic effects of acetylcholine, including diaphoresis, diarrhea, urination, bronchorrhea (secretions from the lower respiratory tract), emesis, lacrimation (tearing), and salivation. Atropine produces dilation of pupils by blocking stimulation of the ciliary muscle surrounding the pupils.

Indications:	Bradycardia (5D) Poisonings – General Management (Organophosphate) (8A)
Contraindications:	None absolute in indicated situations.
Pharmacokinetics: 1 hour.	Typical onset within 60 seconds given IV. Effects can persist in excess of

**Side Effects:** Tachycardia (either supraventricular or ventricular), hypertension, palpitations, blurred vision due to pupillary dilation, photophobia, dry mouth.

Adult organophospate poisoning: 2 mg IVP/IOP/IM. Use IVP for more severe presentations. May repeat as often as every 3-5 minutes if symptoms progressive or persistent.

Dosage:Bradycardia – Symptomatic & Systolic BP < 100 mmHg<br/>(Sinus, First Degree, 2nd Degree Type I) - Adult (5D)<br/>In Non-Acute Coronary Syndrome, 0.5 mg IVP/IOP.<br/>May repeat every 5 minutes to cumulative maximum dose of 3 mg

Bradycardia - Symptomatic & Systolic BP < 70 + (2 x age in years) mmHg (Sinus, First Degree, 2nd Degree Type I) - Pediatric (5D) Unresponsive to Epinephrine, 0.02 mg/kg IVP/IOP; minimum dose 0.1 mg Max. single dose 0.5 mg May repeat once.

Poisonings – General Management (Organophosphate) – Adult (8A) 2 mg IVP/IOP/IM. Use IVP for more severe presentation. Repeat every 3-5 minutes if symptoms progressive.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 16F: Atropine Sulfate, cont.

#### Dosage, cont:

Poisonings – General Management (Organophosphate) – Pediatric (8A) 0.05 mg/kg IVP/IOP/IM. Use IVP for more severe presentation. Minimum dose 0.1 mg. Consult with OLMCP for repeat dosing needs.

How Supplied: 1 mg/10 mL prefilled syringe 1 mg/1 mL vial 0.25 mg/5 mL prefilled syringe for pediatric use (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# **16G – CALCIUM CHLORIDE**

#### PARAMEDIC

**Class:** Electrolyte

Actions/Pharmacodynamics: Calcium causes a significant increase in myocardial contractility and in ventricular automaticity. It is used as an antidote for some electrolyte imbalances (eg. stabilizing cardiac rhythm in the setting of hyperkalemia) and to minimize the side effects from calcium channel blocker overdose. The actions of calcium chloride are similar to those of calcium gluconate but, since it ionizes more readily, it is more potent than calcium gluconate.

Indications: Specific Causes of Cardiac Arrest (Hyperkalemia) (4I) Poisonings - General Management (Calcium Channel Blocker Overdose) (8A) Dialysis-Related Issues (Hyperkalemia) (9E) Crush Injury Syndrome (Hyperkalemia Prophylaxis) (10K)

**Contraindications:** Calcium chloride is contraindicated in ventricular fibrillation unless known hyperkalemia, in known hypercalcemia, and in suspected digitalis toxicity. It should be used with caution in patients taking digoxin as it may precipitate toxicity. Safe use in pregnancy and in children has not been established, though in indicated conditions, benefits outweigh risks.

**Pharmacokinetics:** Onset nearly immediate when given IVP/IOP. The peak effect time frame and duration of effect is not well established.

**Side Effects:** Paresthesias (tingling), syncope, sensations of heat waves (peripheral vasodilation), pain and burning at IV site, <u>skin necrosis and sloughing (with extravasation)</u>, hypotension, bradycardia, cardiac dysrhythmias, cardiac arrest.

Dosage: Specific Causes of Cardiac Arrest (Hyperkalemia) - Adult & Pediatric (4I)
 Poisonings - General Management (Calcium Channel Blocker Overdose) - Adult & Pediatric (8A)
 Dialysis-Related Issues (Hyperkalemia) - Adult & Pediatric (9E)
 Crush Injury Syndrome (Hyperkalemia Prophylaxis) - Adult & Pediatric (10K)
 10 mg/kg (10% solution) IVP/IOP, maximum dose of 1 gram


How Supplied: 1 gram in a 10 mL prefilled syringe (100 mg/mL) (Always check concentration and dose per container at time of patient medication administration)

**Special Comments:** Calcium chloride will interact with sodium bicarbonate and form a precipitate. Do not give both medications via the same vascular access line unless giving a copious flush of NS - approximately 50+ mL - between medications. In general, use an 18-20 gauge angiocatheter in a proximal IV site or use an IO line and test line patency before administration. In non-cardiac arrest or non-impending cardiac arrest settings, administer at 0.5 -1.0 mL per minute to reduce chances of venous irritation and extravasation.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Class: Carbohydrate

Actions/Pharmacodynamics: Dextrose is the principal form of glucose (sugar) used by the body to create energy and support critical metabolic processes. Since serious brain injury can occur in prolonged hypoglycemia, the timely administration of glucose is essential in treating hypoglycemia (blood glucose < 50 mg/dL). Dextrose 10% IVPB is the treatment of choice for hypoglycemic patients. Medical literature shows speed of hypoglycemia reversal to be near clinically equivalent when comparing D10 infusion wide open with D50 IVP. The lower concentration of D10 results in less extravasation tissue damage than D50. Dextrose 25% IV/IO should be considered second line treatment for hypoglycemic patients and Dextrose 50% IV/IO should be considered the third line treatment of choice for hypoglycemic patients with weight at or exceeding 25 kg.

Indications: Respiratory Arrest (3A) Specific Cause of Cardiac Arrest (4I) Altered Mental Status (6B) Seizure (6D) Syncope (6E) Dystonic Reaction (6F) Behavioral Disorder (7A) Dialysis -Related Issues (9E) Complications of Pregnancy (13D) For all listed situations, indication is hypoglycemia (blood glucose < 50 mg/dL).

**Contraindications:** Hyperglycemia (blood glucose > 100 mg/dL) Normoglycemia in the setting of suspected cerebral ischemia.

**Pharmacokinetics:** Onset within 60 seconds after IVP with peak effect and duration of action dependent upon degree and cause of hypoglycemia. Usual effective duration is more than 30 minutes. Medical literature shows speed of hypoglycemia reversal to be near clinically equivalent when comparing D10 infusion wide open with D50 IVP.

**Side Effects:** Warmth, pain, or burning at the injection site. D50 extravasation can cause tissue necrosis (requiring skin graft surgery), phlebitis, sclerosis, or thrombosis at the injection site.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 16H: Dextrose (50% as D50; 25% as D25; 10% as D10)

#### Dosage:

#### **Adult and Pediatric**

Dextrose 10% (D10) 5 mL/kg IVPB up to 250 mL Dextrose 25% (D25) 2 mL/kg IV/IO up to 100 mL (must be  $\geq$  1 year of age) Dextrose 50% (D50) 1 mL/kg IV/IO up to 50 mL (must be  $\geq$  25 kg)

#### **How Supplied:**

D10 - Premixed using 25 grams dextrose in 250 mL normal saline (0.1 gram/mL) D25 - Discard 25 mL of prefilled syringe of D50 – Draw up 25 mL of NS for a total of 50 mL (0.5 gram/mL) D50 - Prefilled syringes of D50 - 25 grams dextrose in 50 mL of water (0.5 gram/mL)

**Special Comments:** D50 should be administered using an infusing IV, **NOT** a saline lock. The tissue caustic nature of D50 can be decreased by performing a slow and non-forceful IV push through the side port of an IV line that is flowing with normal saline into the patient's vein. Because of the risk of extravasation and the consequences of local tissue damage from extravasation, neither D50 nor D25 should be administered through an external jugular IV. High concentrations of dextrose can lead to cerebral edema in younger/smaller pediatric patients. A repeat determination of blood glucose level is to be performed post D10, D25, or D50 administration

Given markedly low perfusing pressures, such as in cardiac arrest, utilize Dextrose 50% IV/IO.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16I – DIAZEPAM (VALIUM®)

#### PARAMEDIC

**Class:** Sedative; Anticonvulsant; Muscle Relaxant; Anxiolytic (Benzodiazepine)

Actions/Pharmacodynamics: Intermediate - acting benzodiazepine with central nervous system depressant, anticonvulsant, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain. Diazepam has considerably more muscle relaxant properties than midazolam, though no substantial amnestic effects as with midazolam.

Indications: Medication Assisted Intubation (2G) Post-intubation sedation - onset delay does not favor pre-intubation use Seizure (6D) (Midazolam preferred benzodiazepine due to faster onset of action) Dystonic Reactions (6F) Chemical Restraint (7C) (Midazolam preferred benzodiazepine due to faster onset of action) Poisonings - General Management (8A) Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis Head/Neck/Spine Injury (10A) Heat Illness (11A)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 3-5 minutes, IVP/IOP; 15-30 minutes IM with erratic absorption, mandating IM dosing only utilized as a last option in adults; peak effects in 15-45 minutes. Duration is 2+ hours IVP/IOP/IM; half – life can reach 20 – 50 hours.

**Side Effects:** Headache, euphoria, drowsiness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, hypotension, nausea, vomiting.

Dosage:Medication Assisted Intubation (Post Intubation Sedation) - Adult (2G)0.1 mg/kg to max 5 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

Seizure - Adult (6D) Head/Neck/Spine Injury - Adult (10A) Heat Illness - Adult (11A) 5 mg IVP/IOP or 10 mg IM for active seizure May repeat once in 5 minutes if still seizing.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16I: Diazepam (Valium<sup>®</sup>), cont.** 

#### Dosage, cont.:

Seizure - Pediatric (6D) Head/Neck/Spine Injury - Pediatric (10A) Heat Illness - Pediatric (11A) 0.1 mg/kg to max 5 mg IVP/IOP/IM for active seizure May repeat once in 5 minutes if still seizing.

**Dystonic Reactions - Adult (6F)** 5 mg IVP

**Dystonic Reactions - Pediatric (6F)** 0.1 mg/kg to max 5 mg IVP/IM

Chemical Restraint - Adult (7C) 5 mg IVP/IOP or 10 mg IM

Chemical Restraint - Pediatric (7C) 0.1 mg/kg to max 5 mg IVP/IOP/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A) 2.5 mg - 5 mg IVP

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

**How Supplied:** 10 mg/2 mL in vials, ampules, or pre-filled syringes. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16J – DILTIAZEM (CARDIZEM<sup>®</sup>)

PARAMEDIC

Class: Calcium Channel Blocker

Actions/Pharmacodynamics: Diltiazem is a slow calcium channel blocker with pharmacologic actions similar to those of verapamil. It inhibits calcium ion influx through slow channels into cells of myocardial and arterial smooth muscle (both coronary and peripheral blood vessels). As a result, intracellular calcium remains at sub-threshold levels insufficient to stimulate cell excitation and contraction. Diltiazem slows SA and AV node conduction (antidyshythmic effect) without affecting normal atrial action potential or intraventricular conduction.

Indications:	Tachycardia - Stable (5F) Sustained narrow-complex tachycardia > 150 bpm in adults with systolic BP ≥ 100 mmHg **OLMC Order Only
Contraindications:	Known hypersensitivity to diltiazem 2nd/3rd degree AV Blocks (may induce asystole) Known Wolff-Parkinson-White Syndrome (may increase heart rate) Known Sick Sinus Syndrome (may induce asystole) Hypotension Bradycardia

Safe use in pregnancy and in children has not been established. Use with caution in CHF (especially if patient is also receiving a beta-blocker), conduction abnormalities, renal or hepatic impairment and the elderly due to exaggerated degree of effect.

**Pharmacokinetics:** Onset is 3 minutes; peak effect in 7 minutes; duration is 1-3 hours; half-life is 2 hours.

**Side Effects:** Headache, fatigue, dizziness, dysrhythmias, 2nd/3rd degree AV block, bradycardia, CHF, hypotension, syncope, palpitations.

Dosage: Tachycardia - Stable - Adult (5F) Sustained narrow-complex tachycardia > 150 bpm in adults with systolic BP ≥ 100mmHg \*\*OLMC Order Only Usual adult dose is 0.25 mg/kg slow IVP over 2 minutes

**How Supplied:** 25 mg in 5 mL vial (5 mg/mL) (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 16K – DIPHENHYDRAMINE (BENADRYL®)

#### PARAMEDIC

Class: Antihistamine, Anticholinergic

Actions/Pharmacodynamics: Diphenhydramine competes for H1 – histamine receptor sites on effector cells, thus blocking histamine release. Histamine release creates some of the common signs and symptoms of an allergic response: pruritis (itching), mucus secretion, and capillary leaking, which contributes to the formation of urticaria (hives), erythematous skin, and mucosal edema. In the setting of a dystonic reaction, the balance of dopamine and choline must be changed within the brain. The most clinically feasible method of reversing a dystonic reaction, though inhibiting the enzyme acetylcholinesterase, is through the anti-cholinergic effect of a medication like diphenhydramine.

Indications: Dystonic Reactions (6F) Acute Allergic Reactions (8D) Bee/Wasp Stings (8F)

**Contraindications:** Known hypersensitivity to diphenhydramine. While rare, allergic reaction to diphenhydramine is possible and should be considered valid if stated or documented in a patient's medical history.

**Pharmacokinetics:** Onset within 15 – 30 minutes; duration is approximately 6 hours.

Side Effects: Drowsiness, dizziness, disturbed coordination.

Dosage: Dystonic Reactions - Adult (6F) Acute Allergic Reactions- Adult (8D) Bee/Wasp Stings - Adult (8F) 50 mg IM/IVP

> Dystonic Reactions - Pediatric (6F) Acute Allergic Reactions- Pediatric (8D) Bee/Wasp Stings - Pediatric (8F) 1 mg/kg IM/IVP to maximum of 50 mg

**How Supplied:** 50 mg/1 mL in vial, ampule, or pre-filled syringe. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16L – DOPAMINE (INTROPIN®)** 

PARAMEDIC

Class: Vasoconstrictor

Actions/Pharmacodynamics: Dose dependent. Higher doses (5+ mcg/kg/min) increasingly stimulate alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in system blood pressure. Concurrent beta receptor stimulation may produce increases in heart rate and mild bronchodilation. Lower doses (<5 mcg/kg/min), as may be encountered infrequently in interhospital transfers, produce mesenteric (intestinal) and renal vascular dilation to ensure continued perfusion to these organ systems in complicated medical illness that would otherwise sacrifice such circulation.

Indications: Dyspnea - Congestive Heart Failure (Cardiogenic Shock) (3E) Post Cardiac Arrest Treatment (Cardiogenic Shock) (4J) Acute Coronary Syndrome (Cardiogenic Shock) (5C) Sepsis (Septic Shock) (9B) Dialysis-Related Issues (9E) For all listed situations, indication is hypotension (adult = systolic < 100 mmHg) due to cardiogenic, septic, or neurogenic shock either refractory to intravascular fluid boluses or in which intravascular fluid bolusing is contraindicated (eg. pulmonary edema).

Contraindications: Hypertension

**Pharmacokinetics:** Onset of action within 5 minutes after IV/IO infusion initiated. Rapid metabolism, requiring ongoing IV/IO infusion to maintain clinical effects.

Side Effects: Palpitations, tachycardia, chest pain, and hypertension if not titrated.

 Dosage:
 Dyspnea - Congestive Heart Failure (Cardiogenic Shock) - Adult (3E)

 Post Cardiac Arrest Treatment (Cardiogenic Shock) - Adult (4J)

 Acute Coronary Syndrome (Cardiogenic Shock) - Adult (5C)

 Sepsis (Septic Shock) - Adult (9B)

 Dialysis-Related Issues - Adult (9E)

 For hypotension (shock) refractory to fluids or fluids contraindicated

 5 - 20 mcg/kg/minute - see dosage chart - titrate to a sys B/P ≥ 100 mmHg.

 Dyspnea - Congestive Heart Failure (Cardiogenic Shock) - Pediatric (3E)

 Post Cardiac Arrest Treatment (Cardiogenic Shock) - Pediatric (4.1)

Post Cardiac Arrest Treatment (Cardiogenic Shock) - Pediatric (4J) Sepsis (Septic Shock) - Pediatric (9B) Dialysis-Related Issues - Pediatric (9E) For hypotension (shock) refractory to fluids or fluids contraindicated \*\*OLMC Order Only.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16L: Dopamine (Intropin<sup>®</sup>), cont** 

#### Dopamine Infusion Adult Dosage Chart

Den	omino	Dose in mcg				
Бор	amine	5	10	15	20	
	40	8	15	23	30	
	50	9	19	28	38	-
	60	11	23	34	45	yln
	70	13	26	39	53	o u
	80	15	30	45	60	atio
	90	17	34	51	68	ntra
	100	19	38	56	75	cer
Patient Weight in Kilograms	110	21	41	62	83	loo
gra	120	23	45	68	90	5
<il><li></li></il>	130	24	49	73	98	bm
in k	140	26	53	79	105	00
ght	150	28	56	84	113	r 16
Veig	160	30	60	90	120	(foi
nt V	170	32	64	96	128	te
ttier	180	34	68	101	135	nu
Ра	190	36	71	107	143	/mi
	200	38	75	113	150	ips
	210	39	79	118	158	dr
	220	41	83	124	165	or
	230	43	86	129	173	/hr
	240	45	90	135	180	mL/hr or drips/minute (for 1600 mcg concentration only)
	250	47	94	141	188	-


How Supplied: 400 mg/10 mL vial to be mixed into 250 mL D5W. (1600 mcg/mL concentration) OR pre-mixed dopamine infusion at 1600 mcg/mL concentration. (Always check concentration and dose per container at time of patient medication administration)

**Special Comments:** Relative caution should be exercised prior to use in the setting of marked tachydysrhythmias, due to the potential for further increase in heart rates. In the setting of tachydysrhythmia-induced cardiogenic shock, treat per Protocol 5G - Tachycardia - Unstable. Ensure aggressive fluid resuscitation is accomplished (unless contraindicated) prior to dopamine use.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Class: Parasympatholytic & Cholinesterase Reactivator

#### Actions/Pharmacodynamics:

**Atropine** Blocks parasympathetic impulses to the heart via the vagus nerve. Atropine increases the rate of cardiac sinoatrial (SA) node discharges, enhances conduction through the atrioventricular (AV) node, and by increasing heart rate, increases the cardiac output and blood pressure. Additionally, in the treatment of indicated poisonings (organophosphates, nerve agents), atropine reverses muscarinic effects of acetylcholine, including diaphoresis, diarrhea, urination, bronchorrhea (secretions from the lower respiratory tract), emesis, lacrimation (tearing), and salivation. Atropine produces dilation of pupils by blocking stimulation of the ciliary muscle surrounding the pupils.

**Pralidoxime chloride** reactivates cholinesterase (mainly outside the central nervous system) which has been inactivated by an organophosphate pesticide. The destruction of accumulated acetylcholine can then proceed and neuromuscular junctions will regain function. Pralidoxime chloride has its most critical effect in reversing paralysis of the muscles of respiration. Because Pralidoxime Chloride is less effective in relieving depression of the respiratory center, atropine is always required concomitantly to block the effect of accumulated acetylcholine at the site. Pralidoxime Chloride is short acting and repeated doses may be needed, especially when there is evidence of continuing toxicity.

Indications: Nerve Agents (15E)

Contraindications: None

**Pharmacokinetics:** With IM autoinjector use in nerve agent poisoning, effects may not be observed for 3-5+ minutes. Beneficial effects can persist in excess of 1 hour.

**Side Effects:** Headache, dizziness, vision changes (blurry vision and photophobia) due to papillary dilation, loss of coordination, laryngospam, tachycardia, hypertension, palpitations, dry mouth.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions DuoDote<sup>®</sup> Autoinjector, cont. **PROTOCOL 16M:** Nerve Agents - Adult & Pediatric > 12 years of age (15E) Dosage: 2.1 mg atropine/ 600 mg pralidoxime IM May repeat every 5-15 minutes to cumulative maximum dose of 6.3 mg/1800 mg. In the setting of serious symptoms (cardiopulmonary distress), repeat doses in rapid succession. Nerve Agents - Pediatric  $\leq$  12 years of age (15E) \*\*OLMC Order Only Typical pediatric dose is 0.05 mg/kg atropine & 15 mg/kg pralidoxime IM per dose, max single dose of 2.1 mg atropine/600 mg pralidoxime DuoDote<sup>®</sup> autoinjector How Supplied: (Always check concentration and dose per container at time of patient medication administration)


**Special Comments:** Ideally, every public safety professional should have ready access to three DuoDote<sup>®</sup> autoinjectors for self/buddy use should emergent conditions warrant. In the setting of suspected/actual nerve agent exposure, administration of the DuoDote<sup>®</sup> autoinjector(s) must occur within minutes of exposure for clinically effective results.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 16N – EPINEPHRINE 1mg/mL (1:1000) & 0.1mg/mL (1:10,000)



IM Administration 1mg/mL (1:1000) Only – 8D 8E 8F

IM Administration 1mg/mL (1:1000) Only - 8D 8E 8F

IM Administration 1mg/mL (1:1000) Only - 3C 8D 8E 8F

Class: Vasoconstrictor, Bronchodilator (Catecholamine)

Actions/Pharmacodynamics: Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in systemic blood pressure. Stimulates beta-1 receptors in the myocardium, producing increases in heart rate, myocardial contraction, and as a result, cardiac output. Stimulates beta-2 receptors in the lower respiratory tract smooth musculature, producing bronchodilation.

Indications:	Dyspnea - Asthma (Severe & Refractory to Nebulization) (3C) Dyspnea – Croup (3C) Asystole (4F)
	Ventricular Fibrillation/Pulseless Ventricular Tachycardia (4G) Pulseless Electrical Activity (4H)
	Bradycardia (Pediatric) (5D) Acute Allergic Reactions (Anaphylaxis) (8D)
	Snakebites (Anaphylaxis) (8E) Bee/Wasp Stings (Anaphylaxis) (8F)

**Contraindications:** None absolute in indications above.

Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks.

**Pharmacokinetics:** Onset of action within 2 minutes after IVP/IOP; within 5-10 minutes after IM. Duration of effect ranges from 3-5 minutes after IVP/IOP to upwards of 30 minutes after IM.

**Side Effects:** Restlessness, anxiety, generalized tremors, headache, dizziness, chest pain, palpitations, hypertension, premature ventricular contractions, tachycardia.

#### Dosage: Dyspnea - Asthma (Severe & Refractory to Nebulization) - Adult (3C) 1mg/mL (1:1000) 0.3 mg IM

\*\*OLMC Order Required if pt  $\geq$  50 years old, heart illness history, or blood pressure > 140/90 mmHg.

Dyspnea - Asthma (Severe & Refractory to Nebulization) - Pediatric (3C) 1mg/mL (1:1000) 0.01 mg/kg (0.01 mL/kg) not to exceed 0.3 mg (0.3 mL) IM

\*\*OLMC Order required if heart illness history or blood pressure > 140/90 mmHg.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 16N: Epinephrine 1mg/mL (1:1000) & 0.1mg/mL (1:10,000), cont

#### Dosage, cont:

**Dyspnea – Croup – Pediatric (3M)** 1mg/mL (1:1000) 3mg/3mL via nebulizer

Asystole - Adult (4F) Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) Pulseless Electrical Activity - Adult (4H) 0.1mg/mL (1:10,000) 1 mg IVP/IOP Repeat every 3 - 5 minutes while resuscitating cardiac arrest

Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) 0.1mg/mL (1:10,000) 1 mg IVP/IOP Repeat every 3 - 5 minutes while resuscitating cardiac arrest, cumulative maximum 3mg

Asystole - Pediatric (4F) Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G) Pulseless Electrical Activity - Pediatric (4H) 0.1mg/mL (1:10,000) 0.01 mg/kg (0.1 mL/kg) IVP/IOP Repeat every 3 - 5 minutes while resuscitating cardiac arrest

Bradycardia - Symptomatic & Systolic BP < 70 + (2 x age in years) mmHg (Sinus, First Degree, 2nd Degree Type I) - Pediatric (5D) 0.1mg/mL (1:10,000) 0.01 mg/kg (0.1 mL/kg) IVP/IOP May repeat once.

Acute Allergic Reactions (Anaphylaxis) - Adult (8D) Snakebites (Anaphylaxis) - Adult (8E) Bee/Wasp Stings (Anaphylaxis) - Adult (8F) 1mg/mL (1:1000) 0.5 mg IM If anaphylaxis refractory to above IM dose: 0.1mg/mL (1:10,000) 1 mg slow IVP/IOP over 3 minutes

Acute Allergic Reactions (Anaphylaxis) - Pediatric (8D) Snakebites (Anaphylaxis) - Pediatric (8E) Bee/Wasp Stings (Anaphylaxis) - Pediatric (8F) 1mg/mL (1:1000) 0.15 mg IM dose for EMT 1mg/mL (1:1000) 0.01 mg/kg (0.01 mL/kg) not to exceed 0.3 mg (0.3 mL) IM If anaphylaxis refractory to above IM dose: 0.1mg/mL (1:10,000) 0.01 mg/kg slow IVP/IOP over 3 minutes

How Supplied: Epinephrine 1mg/mL (1:1000) in 1 mg/1mL ampules or 30 mg/30 mL vial (Always check concentration and dose per container at time of patient medication administration)


**Epinephrine 0.1mg/mL (1:10,000)** in 1 mg/10 mL prefilled syringes (Always check concentration and dose per container at time of patient medication administration)

**Special Comments: Be sure to administer correct concentration.** Pulsatile patients ages 35 years or greater, particularly those with known coronary artery disease, receiving epinephrine should have ECG monitoring initiated and continued as soon as an ECG monitor is available.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Class: Vasoconstrictor, Bronchodilator (Catecholamine)

Actions/Pharmacodynamics: Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in systemic blood pressure. Stimulates beta-1 receptors in the myocardium, producing increases in heart rate, myocardial contraction, and as a result, cardiac output. Stimulates beta-2 receptors in the lower respiratory tract smooth musculature, producing bronchodilation.

Indications: Dyspnea - Asthma (Severe - Refractory to Inhaler/Nebulization) (3C) Acute Allergic Reactions (Anaphylaxis) (8D) Snakebites (Anaphylaxis) (8E) Bee/Wasp Stings (Anaphylaxis) (8F)

**Contraindications:** None in indications above.

**Pharmacokinetics:** Onset of action within 5-10 minutes after IM administration. Duration of effect may range upwards of 30 minutes intramuscularly.

Adverse/Side Effects: Restlessness, anxiety, generalized tremors, headache, dizziness, chest pain, palpitations, hypertension, premature ventricular contractions, tachycardia. Pulsatile patients ages 35 years or greater, particularly those with known coronary artery disease, receiving epinephrine should have ECG monitoring initiated and continued as soon as an ECG monitor is available. Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks and should not deter clinically necessary usage.

Dosage: Dyspnea - Asthma (Severe - Refractory to Inhaler/Nebulization) - Adult (3C) Acute Allergic Reactions (Anaphylaxis) - Adult (8D) Snakebites (Anaphylaxis) - Adult (8E) Bee/Wasp Stings (Anaphylaxis) - Adult (8F) Adult Epinephrine Autoinjector (0.3 mg of Epinephrine 1mg/mL 1:1000) IM lateral thigh

\*\*OLMC Order required if  $pt \ge 50$  years old, heart illness history, or blood pressure > 140/90 mmHg.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 160:** Epinephrine Autoinjector (EpiPen<sup>®</sup>, Auvi-Q<sup>®</sup>)

Dosage, cont.:

Dyspnea- Asthma (Severe-Refractory to Inhaler/Nebulization)-Pediatric (3C) Acute Allergic Reactions (Anaphylaxis) - Pediatric (8D) Snakebites (Anaphylaxis) - Pediatric (8E) Bee/Wasp Stings (Anaphylaxis) - Pediatric (8F) Pediatric Epinephrine Autoinjector (0.15 mg of Epinephrine 1mg/mL 1:1000) IM lateral thigh

# \*\*OLMC Order required if heart illness history or blood pressure > 140/90 mmHg.

How Supplied: 0.3 mg Adult Epinephrine Autoinjector

0.15 mg Pediatric Epinephrine Autoinjector

(Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** For autoinjector medication administration, expose and wipe the midlateral thigh with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or an alcohol wipe. When handling the autoinjector for dosing, grasp the autoinjector with a fist, and remove the trigger safety cap. DO NOT place fingers or hand over the injection tip once the trigger safety cap is being removed.

Place the injection tip on the desired injection skin area and push the entire autoinjector into the thigh, using firm and continuous pressure, until a click is heard (patient will exhibit evidence of feeling spring-loaded needle activation) and hold in place for 10 seconds while medication is being delivered intramuscular.

Use caution when withdrawing the autoinjector to avoid needlestick injury. Dispose of whole autoinjector in a sharps container.

After autoinjector is complete, massage injection site for 15 to 30 seconds to improve epinephrine absorption.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16P – ETOMIDATE (AMIDATE<sup>®</sup>)** 

PARAMEDIC

**Class:** Sedative - Hypnotic (non-narcotic/opiate; non-benzodiazepine; non-barbiturate)

**Actions/Pharmacodynamics:** Etomidate is an intravenous hypnotic drug without analgesia. Etomidate is safe to use in patients with cardiac illness and patients with traumatic injuries. Etomidate has little to no effect upon myocardial metabolism, cardiac output, or peripheral circulation. Etomidate has been shown to reduce cerebral blood flow, cerebral oxygen consumption, and intracranial pressure – helpful in head injury situations.

Indications: Medication Assisted Intubation (2G)

**Contraindications:** Known hypersensitivity to etomidate.

**Pharmacokinetics:** Rapid onset of action, seen as desired sedation within as little as 10-15 seconds, but nearly always within less than 1 minute. Duration of action, based upon a standard dose of 0.3 mg/kg (70 kg adult dose of 20 mg) is 5-15 minutes.

**Side Effects:** 1) Transient skeletal muscle movements, called myoclonus, have been reported in 10-80% of patients. Most of these movements are mild to moderate in severity. Rarely, these movements are severe in motion and force, though transient. Most movements are bilateral and can involve any part of the body. Results of electroencephalographic studies taken during periods when these muscle movements were observed have failed to reveal true seizure activity. 2) Transient venous pain at injection site, due to propylene glycol, a solvent in Etomidate preparations. 3) Nausea and/or vomiting. 4) Very rarely, hypoventilation and apnea, though Etomidate generally preserves the baseline respiratory activity. 5) Very rarely, hypotension and when seen, usually is due to too rapid IVP administration.

Dosage:Medication Assisted Intubation - Adult (2G)0.3 mg/kg IVP/IOP over 15-30 seconds, given just prior to intubation.

**How Supplied:** 40 mg/20 mL (2 mg/mL) vial or pre-filled syringe (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** Repeated doses of Etomidate should be avoided to minimize its effect upon adrenal function. Repeated doses and continuous infusions of etomidate have been linked to adrenal suppression.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



#### PARAMEDIC

**Class:** Narcotic analgesic

Actions/Pharmacodynamics: Stimulates central nervous system opiate receptors, producing systemic analgesia. On a milligram weight basis, fentanyl is 50-100 times more potent than morphine. Its duration of action is shorter than morphine or hydromorphone. An IV dose of 100 mcg of fentanyl is roughly equivalent to an IV dose of 10 mg of morphine. Fentanyl has less emetic effects than other narcotic analgesics.

Indications:	Chest Pain – Uncertain Etiology (5A) Acute Coronary Syndrome (5C) Snakebites (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea (9A) Pain Management (Acute Onset &Chronic Type) (9D) Eye Injury (10B) Dental Injury/Pain (10C) Chest/Abdomen/Pelvis Injury (10D) Extremity injury/Amputation Injury (10G) Compartment Syndrome (10J) Crush Injury Syndrome (10K) Burns (10L) Lightning/Electrical Injury (11C) Pelvic Pain (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

Contraindications: Hypotension Respiratory Depression Minor Degrees of Pain Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP.

**Pharmacokinetics:** Onset of action nearly immediate after IV administration. Peak effects occur within 3 - 5 minutes. Duration of effect is 30 - 60 minutes, with a half-life of 6 - 8 hours.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 16Q: Fentanyl (Sublimaze®), cont.

Dosage: Chest Pain – Uncertain Etiology – Adult (5A) Acute Coronary Syndrome – Adult (5C) 0.5 mcg/kg slow IVP/IM/IN, maximum single dose of 50 mcg May repeat every 10 minutes to a maximum cumulative dose of 1.5 mcg/kg or 125 mcg, whichever is lesser

#### Snakebites – Adult (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A) Pain Management (Acute Onset &Chronic Type) – Adult (9D) Eye Injury – Adult (10B) Dental Injury/Pain – Adult (10C) Chest/Abdomen/Pelvis Injury – Adult (10D) Extremity/Amputation Injury – Adult (10G) Compartment Syndrome – Adult (10J) Crush Injury Syndrome – Adult (10K) Burns – Adult (10L) Lightning/Electrical Injury – Adult (11C) Pelvic Pain – Adult (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

1 mcg/kg slow IVP/IM/IN, maximum single dose of 100 mcg May repeat every 10 minutes to a maximum cumulative dose of 3 mcg/kg or 250 mcg, whichever is lesser

Extremity/Amputation Injury – Pediatric (10G) Burns – Pediatric (10L) 1mcg/kg up to 50 mcg per dose. Repeat dose(s) requires OLMC order.

Chest Pain – Uncertain Etiology – Pediatric (5A) Snakebites – Pediatric (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A) Pain Management (Acute Onset &Chronic Type) – Pediatric (9D) Eye Injury – Pediatric (10B) Dental Injury/Pain – Pediatric (10C) Chest/Abdomen/Pelvis Injury – Pediatric (10D) Compartment Syndrome – Pediatric (10J) Crush Injury Syndrome – Pediatric (10K) Lightning/Electrical Injury – Pediatric (11C) Pelvic Pain – Pediatric (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient \*\*OLMC Order Only – Typical dose is 1 mcg/kg up to 50 mcg per dose.


How Supplied: 100 mcg/2 mL (50 mcg/mL) ampule, vial, or pre-filled syringe 250 mcg/5 mL (50 mcg/mL) ampule or vial 500 mcg/10 mL (50 mcg/mL) vial (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions





#### Class: Hormone

Actions/Pharmacodynamics: Glucagon is a hormone produced in the pancreas. When released in times of hypoglycemia, it causes a breakdown of glycogen (stored in the liver) to glucose and inhibits the subsequent synthesis of glycogen from circulating glucose. Both actions increase the blood levels of glucose. Given via the IM route, it is a useful drug in hypoglycemia when IV access is unsuccessful. Glucagon also increases heart rate, myocardial contractility and improves AV conduction in a manner similar to that produced by catecholamines. Its actions are independent of beta blockade and therefore may be useful via IV/IO administration by paramedics for reversing cardiovascular collapse effects of suspected beta blocker toxicity.

Indications: Respiratory Arrest (3A) Specific Causes of Cardiac Arrest (4I) Altered Mental Status (6B) Seizure (6D) Syncope (6E) Dystonic Reactions (6F) Behavioral Disorder (7A) Poisonings – General Management (8A) Complications of Pregnancy (13D)

For all listed situations, indication is hypoglycemia (blood glucose <50 mg/dL) without ability to safely administer oral glucose (due to aspiration concern) and without ability to establish IV access in EMT-I85, AEMT, and Paramedic Scopes of Practice.

Additional indication for beta blocker toxicity with hypotension and bradycardia in Paramedic Scope of Practice.

#### Contraindications: None

**Pharmacokinetics:** Onset 5 - 20 minutes; peak effects in 30 minutes; duration is 1 - 1.5 hours.

Side Effects: Dizziness, headache, nausea/vomiting, hyperglycemia.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 16R: Glucagon, cont.

 Dosage:
 Respiratory Arrest – Adult & Pediatric weight ≥ 25 kg (3A)

 Specific Causes of Cardiac Arrest - Adult& Pediatric weight ≥ 25 kg (4I)

 Altered Mental Status – Adult & Pediatric weight ≥ 25 kg (6B)

 Seizure – Adult & Pediatric weight ≥ 25 kg (6D)

 Syncope – Adult & Pediatric weight ≥ 25 kg (6E)

 Dystonic Reactions – Adult & Pediatric weight ≥ 25 kg (6F)

 Behavioral Disorder – Adult & Pediatric weight ≥ 25 kg (7A)

 Poisonings – General Management – Adult & Pediatric weight ≥ 25 kg (13D)

 All indicate hypoglycemia without safe PO access and without IV access 1 mg IM

Respiratory Arrest – Pediatric weight < 25 kg (3A) Specific Causes of Cardiac Arrest– Pediatric weight < 25 kg (4I) Altered Mental Status – Pediatric weight < 25 kg (6B) Seizure – Pediatric weight < 25 kg (6D) Syncope – Pediatric weight < 25 kg (6E) Dystonic Reactions – Pediatric weight < 25 kg (6F) Behavioral Disorder – Pediatric weight < 25 kg (7A) Poisonings – General Management – Pediatric weight < 25 kg (8A) Complications of Pregnancy – Pediatric weight < 25 kg (13D) All indicate hypoglycemia without safe PO access and without IV access 0.5 mg IM

Specific Causes of Cardiac Arrest - Adult (4I) Poisonings – General Management - Adult(8A) Suspected beta blocker toxicity with arrest or hypotension/bradycardia (Paramedic only) 1 mg IVP/IOP; May be given IM if no IV access obtainable

Specific Causes of Cardiac Arrest - Pediatric (4I) Poisonings – General Management –Pediatric (8A) Suspected beta blocker toxicity with arrest or hypotension/bradycardia (Paramedic only)

0.5 mg IVP/IOP; May be given IM if no IV access obtainable

**How Supplied:** 1 mg dry powder in vial with 1 mL of diluting solute for reconstitution (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16S –	GLUCOSE	(ORAL)
-------	---------	--------

EMERGENCY MEDICAL RESPONDER
ЕМТ
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

Class: Carbohydrate

Actions/Pharmacodynamics: Increases blood sugar level.

Indications: Altered Mental Status (Hypoglycemia) (6B) Syncope (Hypoglycemia) (6E) Dystonic Reaction (Hypoglycemia) (6F) Behavioral Disorder (Hypoglycemia) (7A) Dialysis-Related Issues (Hypoglycemia) (9E) Complications of Pregnancy (Hypoglycemia) (13D)

**Contraindications:** Unconscious or semi–conscious and unable to follow simple commands. Care should be taken to prevent choking or aspiration of medication in semi–conscious patient.

**Pharmacokinetics:** Rapid oral absorption uptake to increase circulating blood sugar levels. Onset of effect within several minutes of oral dosing. Duration of effect up to 30+ minutes, but patient should be advised to consume complex carbohydrates within minutes of restoration of normal blood sugar, unless otherwise contraindicated.

Side Effects: None

Dosage: Altered Mental Status (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6B) Syncope (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6E) Dystonic Reaction (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6F) Behavioral Disorder (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (7A) Dialysis-Related Issues (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (9E) Complications of Pregnancy (Hypoglycemia) - Adult (13D) 15 grams (1 tube) PO or SL for blood glucose < 50 mg/dL</p>





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL16S: Glucose (Oral), cont.** 

#### Dosage, cont.

Altered Mental Status (Hypoglycemia) - Pediatric Weight < 25 kg (6B) Syncope (Hypoglycemia) - Pediatric Weight < 25 kg (6E) Dystonic Reaction (Hypoglycemia) - Pediatric Weight < 25 kg (6F) Behavioral Disorder (Hypoglycemia) - Pediatric Weight < 25 kg (7A) Dialysis-Related Issues (Hypoglycemia) - Pediatric Weight < 25 kg (9E) 7.5 grams (1/2 tube) PO or SL for blood glucose < 50 mg/dL

**How Supplied:** 15 grams of glucose for oral administration in a squeeze tube container. (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** Medical grade glucose should be utilized in place of sodas, candy, and other carbohydrate-heavy solid food. In many cases, the carbohydrate grams cannot be measured.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16T – HALOPERIDOL (HALDOL®)** 

#### PARAMEDIC

**Class:** Antipsychotic

**Therapeutic Action/Pharmacodynamics:** Haloperidol is a potent, long – acting antipsychotic agent. While its exact mechanism is unclear, it appears to block the dopamine receptors in the brain associated with mood and behavior. It exerts strong antiemetic effects and impairs central thermoregulation. It also produces weak central anticholinergic effects and transient orthostatic hypotension

**Indications:** Chemical Restraint (7C)

Contraindications: Known hypersensitivity Behavioral disorder etiology easily reversed (eg. hypoglycemia) Minor degrees of agitation Parkinson's disease Known seizure disorders (lowers seizure threshold)

CNS depressants, opiates, and alcohol may increase the CNS depression effect of haloperidol. Use with caution in elderly or debilitated patients due to exaggerated effect. Safe use in pregnancy has not been established, though in the indicated setting, benefit outweighs risks.

**Pharmacokinetics:** Onset is within 10-20 minutes IM; peak effect in 30-45 minutes; duration is 3+ hours, reported up to 35 hours.

**Side Effects:** CNS depression, seizure, dystonic reactions, dry mouth, blurry vision, bronchospasm, tachycardia, hypertension, hypotension, dysrhythmias, hyperpyrexia, diaphoresis, urinary retention.

Dosage:Chemical Restraint - Adult (7C)5 mg IM (use deep IM injection in large muscle - lateral thigh if possible)

#### Chemical Restraint - Pediatric (7C) \*\* OLMC Order Only

**How Supplied:** 5 mg/1 mL vial. (Always check concentration and dose per container at time of patient medication administration)

**Special Comments:** In emergency situations where the patient's behavior poses an immediate risk to rescuers and bystanders, the IM injection may be given through the patient's clothing to minimize risk of needlestick injuries to rescuers. Dystonic reactions are common with haloperidol; diphenhydramine should be readily available - see Protocol 6F - Dystonic Reactions.





16U - HYDRALAZINE (APRESOLINE®)

Protocol removed by the Medical Control Board





Approved 9/14/22, Effective 1/16/23 replaces all prior versions

## 16V – HYDROMORPHONE (DILAUDID®)

#### PARAMEDIC

**Class:** Narcotic analgesic

Actions/Pharmacodynamics: Stimulates central nervous system opiate receptors, producing systemic analgesia. Modest vasodilation effects increase peripheral venous capacitance, and reduce venous return, myocardial workload, and myocardial oxygen demand. Hydromorphone is roughly 10 times more potent than morphine. An IV dose of 1 mg of hydromorphone is equivalent to an IV dose of 10 mg of morphine.

Indications:	Snakebites (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea (9A) Pain Management (Acute Onset &Chronic Type) (9D) Eye Injury (10B) Dental Injury/Pain (10C) Chest/Abdomen/Pelvis Injury (10D) Extremity/Amputation Injury (10G) Compartment Syndrome (10J) Crush Injury Syndrome (10K) Burns (10L) Lightning/Electrical Injury (11C) Pelvic Pain (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

Contraindications:	Hypotension
	Respiratory Depression
	Minor Degrees of Pain
	Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP. Rapid IVP will lead to an accompanying histamine release, producing the nausea and/or vomiting often erroneously attributed to hydromorphone itself.

**Pharmacokinetics:** Onset of action within 5-10 minutes after IV administration. Duration of effect can reach 4 - 6 hours depending upon end-organ function.





Approved 9/14/22, Effective 1/16/23 replaces all prior versions

PROTOCOL 16V: Hydromorphone (Dilaudid<sup>®</sup>), cont.

Dosage: Snakebites – Adult (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A) Pain Management (Acute Onset & Chronic Type) – Adult (9D) Eye Injury – Adult (10B) Dental Injury/Pain – Adult (10C) Chest/Abdomen/Pelvis Injury – Adult (10D) Extremity/Amputation Injury – Adult (10G) Compartment Syndrome – Adult (10J) Crush Injury Syndrome – Adult (10K) Burns – Adult (10L) Lightning/Electrical Injury – Adult (11C) Pelvic Pain – Adult (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient. 0.5 - 1 mg slow IVPMay repeat every 10 minutes to a maximum cumulative dose of 2 mg Snakebites – Pediatric (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A) Pain Management (Acute Onset & Chronic Type) – Pediatric (9D) Eye Injury – Pediatric (10B) Dental Injury/Pain – Pediatric (10C) Chest/Abdomen/Pelvis Injury – Pediatric (10D) Extremity/Amputation Injury – Pediatric (10G) Compartment Syndrome – Pediatric (10J) Crush Injury Syndrome – Pediatric (10K) Burns – Pediatric (10L) Lightning/Electrical Injury – Pediatric (11C) Pelvic Pain – Pediatric (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient \*\*OLMC Order Only – Typical dose is 0.01 mg/kg up to 0.5 mg per dose.

**How Supplied:** 2 mg/1 mL vial or pre-filled syringe (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 16W – HYDROXOCOBALAMIN (CYANOKIT®)

ADVANCED EMT

PARAMEDIC

**Class:** Cyanide Antidote

Actions/Pharmacodynamics: Hydroxocobalamin binds cyanide, forming cyanocobalamin for urinary excretion.

**Indications:** Cyanide (12E)

**Contraindications:** None in the setting of suspected cyanide toxicity.

**Pharmacokinetics:** Near immediate onset of action following IVPB initiation. Effect is seen for hours, with duration of action seen predominantly in the first 24 hours following administration, but measurable for days.

**Side Effects:** Redness of skin and mucous membranes may be prominently noted. Additional side effects include headache, dizziness, restlessness, eye irritation, throat irritation, dyspnea, pulmonary edema, chest tightness, hypertension, tachycardia, palpitations, nausea, vomiting, diarrhea, abdominal pain, dysphagia, red urine, and hives.

Dosage: Cyanide - Adult (12E) 5 grams IVPB in 15 minutes

#### Cyanide - Pediatric (12E)

The pediatric dose is 70 mg/kg IVPB administered over 15 minutes. Safe use of CYANOKIT<sup>®</sup> has not been well established in children. However, if clinically indicated the benefits likely outweigh the risk.


How Supplied: CYANOKIT<sup>®</sup> preparations include either one glass vial containing 5 grams of hydroxocobalamin as a dark red crystalline powder for reconstitution with 200 mL normal saline or a set of two glass vials, each containing 2.5 grams of hydroxocobalamin as a dark red crystalline powder for reconstitution with 100 mL normal saline per vial. Follow full instructions accompanying CYANOKIT<sup>®</sup> for preparation and administration, including use of transfer spike for normal saline addition to the vial(s), rocking, but not shaking the vial for 60 seconds prior to administration, and administering the infusion from the vial(s). (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** Multiple drug-drug incompatibilities exist with hydroxocobalamin. Use a separate IV line for the administration of hydroxocobalamin.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



**Class:** Parasympatholytic Bronchodilator

Actions/Pharmacodynamics: Atrovent is an anticholinergic agent, chemically related to atropine. Given in a nebulized form, it acts directly on the smooth muscle of the bronchial tree by inhibiting acetylcholine at receptor sites. By blocking parasympathetic action, it dilates the bronchial smooth muscle and decreases secretions. It also abolishes the vagally mediated reflex bronchospasm caused by inhaled irritants such as smoke, dust, and cold air and by a range of inflammatory mediators such as histamine.

Indications: Dyspnea - Asthma (3C) Dyspnea - Chronic Obstructive Pulmonary Disease (3D) Acute Allergic Reactions (8D) Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Atrovent is contraindicated in patients with hypersensitivity to atropine. It should not be used as the sole pharmacologic treatment for acute bronchospasm. By protocol, atrovent is always administered in conjunction with albuterol.

**Pharmacokinetics:** Absorption: 10% of inhaled dose reaches lower airway; approximately 0.5% of dose is systemically absorbed; onset within 5-15 minutes; peak effect in 1.5 - 2 hours; duration of effect is up to 4 - 6 hours; half – life is 1.5 - 2 hours.

Side Effects: Cough, reflex bronchospasm, hoarseness, nasal/oral dryness, bitter taste.

Dosage:Dyspnea - Asthma - Adult & Pediatric weight ≥ 15 kg (3C)<br/>Acute Allergic Reactions - Adult & Pediatric weight ≥ 15 kg (8D)<br/>Bee/Wasp Stings - Adult & Pediatric weight ≥ 15 kg (8F)<br/>0.5 mg nebulized (with albuterol 5 mg)

**Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D)** 0.5 mg nebulized (with albuterol 5 mg), may repeat twice





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16X:** Ipratropium bromide (Atrovent<sup>®</sup>)

Dosage, cont.:

Dyspnea - Asthma - Pediatric weight < 15 kg (3C) Acute Allergic Reactions - Pediatric weight < 15 kg (8D) Bee/Wasp Stings - Pediatric weight < 15 kg (8F) 0.25 mg nebulized (with albuterol 2.5 mg)

**How Supplied:** 0.5 mg/2.5 mL nebulizer solution vials. (Always check concentration and dose per container at time of patient medication administration)






16Y – LABETALOL (NORMODYNE®, TRANDATE®)

Protocol removed by the Medical Control Board





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



Class: Intraosseous Local Anesthetic & Antidysrhythmic

**Therapeutic Actions/Pharmacodynamics:** As a local anesthetic, reduces nerve activation that carries painful stimulus from intraosseous fluid and/or medication administration. As an antidysrhythmic, suppresses ventricular automaticity, chemically converting ventricular tachycardia.

- Indications: Tachycardia Stable (5F) Wide complex tachycardia, refractory to amiodarone \*\*OLMC Order Only Vascular Access - Intraosseous (9I)
- **Contraindications:** Narrow complex tachycardia Second degree AV Block-Type II (Classic Type) Third degree AV Block (Complete Heart Block) Premature ventricular contractions with underlying bradycardias No indication for IO anesthetic (unresponsive patients)

Pharmacokinetics: Onset of action within 3 minutes IVP/IOP. Duration for 10-20 minutes.

**Side Effects:** None expected in indicated dosing. Erroneous use in high degree heart blocks can lead to complete ventricular suppression/cardiac arrest.

Dosage: Tachycardia - Stable - Wide Complex Tachycardia - Adult (5F) Refactory to Amiodarone Up to 1 mg/kg, slow IVP/IOP at < 50 mg/minute \*\*OLMC Order Only

> Tachycardia - Stable - Pediatric (5F) Consult with OLMCP for use and dosing.

Vascular Access - Intraosseous (Local Anesthetic) - Adult & Pediatric (9I) 1 mg/kg up to 40 mg IOP


**How Supplied:** 100 mg/5 mL (20 mg/mL of 2% lidocaine) prefilled syringe. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16AA - LIDOCAINE VISCOUS GEL (XYLOCAINE®)



**Class:** Topical Anesthetic

**Actions/Pharmacodynamics:** Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. In gel formulation, additional lubricant effect is possible.

Indications: Nasotracheal Intubation (2H).

**Contraindications:** Known hypersensitivity to local anesthetics, amide type.

**Pharmacokinetics:** Onset of action within 3 - 5 minutes.

**Side Effects:** None expected unless amide anesthetic allergy. In this specific setting, adverse experiences are generally systemic in nature. Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse.

- **Dosage:** Nasotracheal Intubation Adult (2H) Apply gel to the external surface of the endotracheal tube, primarily the distal parts near the balloon cuff and the balloon cuff itself just prior to intubation. Typical use is 1-2 mL of gel.
- **How Supplied:** 2% Viscous Gel (20 mg/mL) available in foil packs, tubes, pre-filled syringes for topical application, and bottles. (Always check concentration and dose per container at time of patient medication administration)

**Special Comments:** Care should be taken to avoid partially occluding the lumen of the endotracheal tube with gel. Do not use the gel to lubricate the endotracheal stylette. Avoid large bottles of lidocaine viscous gel. Attempts to use over multiple patients can result in gel contamination.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16BB – LORAZEPAM (ATIVAN®)

#### PARAMEDIC

**Class:** Sedative; Anticonvulsant; Muscle Relaxant; Anxiolytic (Benzodiazepine)

Actions/Pharmacodynamics: Long - acting benzodiazepine with central nervous system depressant, anticonvulsant, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain. Ativan has less muscle relaxant properties than diazepam, though no substantial amnestic effects as with midazolam.

Indications: Medication Assisted Intubation (2G)

Post-intubation sedation - onset delay does not favor pre-intubation use Seizure (6D)

(Midazolam preferred benzodiazepine due to faster onset of action) Dystonic Reactions (6F)

Chemical Restraint (7C)

(Midazolam preferred benzodiazepine due to faster onset of action) Poisonings - General Management (8A)

Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis Head/Neck/Spine Injury (10A)

(Midazolam preferred benzodiazepine due to faster onset of action) Heat Illness (11A)

(Midazolam preferred benzodiazepine due to faster onset of action)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 5-10 minutes, IVP/IOP; up to 30 minutes IM; peak effects in 2-3 hours. Duration is 3-6+ hours IVP/IOP/IM; half – life can reach 20 – 50 hours.

**Side Effects:** Headache, euphoria, drowsiness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, hypotension, nausea, vomiting.

**Dosage:** Medication Assisted Intubation (Post Intubation Sedation) - Adult (2G) 0.1 mg/kg to max 2 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

> Seizure - Adult (6D) Heat Illness - Adult (11A) 2 mg IVP/IOP/IM for active seizure May repeat once in 10 minutes if still seizing.





# Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16BB: Lorazepam (Ativan®), cont.**

#### Dosage, cont.:

Seizure - Pediatric (6D) Heat Illness - Pediatric (11A) 0.1 mg/kg to max 2 mg IVP/IOP/IM for active seizure May repeat once in 5 minutes if still seizing.

Dystonic Reactions - Adult (6F) 2 mg IVP/IM

**Dystonic Reactions - Pediatric (6F)** 0.1 mg/kg to max 2 mg IVP/IM

**Chemical Restraint - Adult (7C)** 2 mg IVP/IOP/IM May repeat once.

Chemical Restraint - Pediatric (7C) 0.1 mg/kg to max 2 mg IVP/IOP/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A) 1 -2 mg IVP/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

Head/Neck/Spine Injury - Adult (10A) 1 mg IVP/IM/IOP for active seizure. May repeat once in 5 minutes if still seizing.

# Head/Neck/Spine Injury - Pediatric (10A)

0.1 mg/kg IVP/IM/IOP for active seizure. May repeat once in 5 minutes if still seizing.

- **How Supplied:** 2 mg/1 mL or 4 mg/1 mL in vials, ampules, or pre-filled syringes. (Always check concentration and dose per container at time of patient medication administration)
- Special Comment: Lorazepam must be kept refrigerated.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## **16CC – MAGNESIUM SULFATE**

PARAMEDIC

**Class:** Electrolyte

**Therapeutic Actions/Pharmacodynamics:** As an antidysrhythmic, reverses low circulating magnesium levels associated with ventricular arrhythmias, particularly polymorphic ventricular tachycardia, commonly called Torsades de Pointes. It is the anticonvulsant of greatest benefit for eclampsia.

Indications: Dyspnea - Asthma (3C) Ventricular Fibrillation/Pulseless Ventricular Tachycardia (Torsades) (4G) Tachycardia - Stable (Torsades) (5F) Childbirth - Complicated (Eclampsia) (13B) Complications of Pregnancy (Eclampsia) (13D)

**Contraindications:** Hypotension or Known Renal Failure (when treating asthma)

**Pharmacokinetics:** Onset of action typically within 1-2 minutes after IVP/IOP. Effects persist for up to 30 minutes.

**Side Effects:** None expected in indicated dosing. High doses (exceeding 4-6 grams) may cause sedation, muscle weakness, depressed reflexes, hypotension, bradycardia, and respiratory depression.

**Dosage:** Dyspnea - Asthma - (Severe & Refractory to Nebulization) - Adult (3C) 1 gram (add to 100 ml NS and infuse over 10 minutes)

> Ventricular Fibrillation/Pulseless Ventricular Tachycardia (Torsades) - Adult (4G) 1 gram IVP/IOP

**Tachycardia - Stable (Torsades) - Adult (5F)** 1 gram slow IVP/IOP over 1 minute. May repeat once.

Tachycardia - Stable (Torsades) - Pediatric (5F) Consult with OLMCP for use and dosing.

## Childbirth - Complicated (Eclampsia) (13B) Complications of Pregnancy (Eclampsia) (13D)

1 gram IVP/IOP/IM. Reconstitute 1 gram with 2 ml NS and administer 1 mL IM via two unique injection sites if unable to establish IV/IO access. May repeat every 2-3 mins until seizure abates. Maximum cumulative dose is 4 grams.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 16CC: Magnesium Sulfate, cont.

How Supplied: 1 gram/2 mL (500 mg/mL in 50% solution) vials 5 grams/10 mL (500 mg/mL in a 50% solution) vials 5 grams/10 mL (500 mg/mL in a 50% solution) pre-filled syringes (Always check concentration and dose per container at time of patient medication administration





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## 16DD – METHYLPREDNISOLONE (SOLU-MEDROL<sup>®</sup>)

PARAMEDIC

Class: Steroid

Actions/Pharmacodynamics: Methylprednisolone is an intermediate-acting synthetic adrenal corticosteroid with glucocorticoid activity. It exerts anti-inflammatory effects in the setting of inflammatory-mediated illness.

Indications: Dyspnea - Asthma (3C) Dyspnea - Chronic Obstructive Pulmonary Disease (3D) Dyspnea – Croup (3M) Acute Allergic Reactions (8A) Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Known hypersensitivity to methylprednisolone. In the setting of anaphylaxis, the only true contraindication is prior severe allergy (anaphylaxis) caused by methylprednisolone.

**Pharmacokinetics:** Onset of action within 4 – 6 hours, may have effect in excess of 24 hours.

**Side Effects:** None expected immediately. May occasionally see any of the following effects with onset of action: euphoria, insomnia, confusion, psychosis, edema, hypertension, nausea/ vomiting, hyperglycemia.

Dosage: Dyspnea - Asthma - Adult (3C) Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D) Acute Allergic Reactions - Adult (8A) Bee/Wasp Stings - Adult (8F) 125 mg IVP. Give IM if no IV access obtainable.

> Dyspnea - Asthma - Pediatric (3C) Dyspnea - Croup - Pediatric (3M) Acute Allergic Reactions - Pediatric (8A) Bee/Wasp Stings - Pediatric (8F) 2 mg/kg not to exceed 125 mg IVP. Give IM if no IV access obtainable.

**How Supplied:** 125 mg Act-O-Vial<sup>™</sup> System (Single Dose Vial) (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16EE – MIDAZOLAM (VERSED®)

#### PARAMEDIC

**Class:** Sedative; Anticonvulsant; Amnestic; Muscle Relaxant, Anxiolytic (Benzodiazepine)

Actions/Pharmacodynamics: Short - acting benzodiazepine with central nervous system depressant, anticonvulsant, anterograde amnestic, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain.

Indications: Medication Assisted Intubation (Pre & Post Intubation Sedation) (2G) Post Cardiac Arrest Treatment (Hypothermia Induced Shivering Control) (4J) Transcutaneous Pacing (Sedation) (5E) Synchronized Cardioversion (Sedation) (5G) Seizure (6D) Dystonic Reactions (6F) Chemical Restraint (7C) Poisonings - General Management (8A) Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis Head/Neck/Spine Injury (10A) Heat Illness (11A)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 3-5 minutes, IVP/IOP; 6-14 minutes IN; up to 15 minutes IM (though clinically evident much faster); peak effects in 20-60 minutes. Duration is 2 hours IVP/IOP/IN; 1-6 hours IM; half – life is 1-4 hours.

**Side Effects:** Retrograde amnesia, headache, euphoria, drowsiness, weakness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, tachypnea, hypotension, nausea, vomiting.

**Dosage:** Medication Assisted Intubation (Pre & Post Intubation Sedation) - Adult (2G) 0.1 mg/kg to max 5 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

> Post Cardiac Arrest Treatment (Hypothermia Induced Shivering Control) -Adult & Pediatric (4J)

0.1 mg/kg to max 5 mg IVP/IOP

Transcutaneous Pacing (Sedation) - Adult (5E)

2 - 5 mg IVP based upon weight and hemodynamics (0.1 mg/kg to max 5 mg)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 16EE: Midazolam (Versed®), cont.** 

#### Dosage, cont.:

Synchronized Cardioversion (Sedation) - Adult (5G) 0.1 mg/kg to max 5 mg IVP/IOP/INP

Seizure - Adult (6D) Heat Illness - Adult (11A) 0.1 mg/kg to max 5 mg IM/IVP/IN/IOP for active seizure. May repeat once in 5 minutes if still seizing.

Seizure - Pediatric (6D) Head/Neck/Spine Injury - Pediatric (10A) Heat Illness - Pediatric (11A) 0.1 mg/kg to max 5 mg IM/IVP/IN/IOP for active seizure May repeat once in 5 minutes if still seizing.

**Dystonic Reactions - Adult (6F)** 2.5 mg IVP/IM/IN

**Dystonic Reactions - Pediatric (6F)** 0.1 mg/kg to max 2.5 mg IM/IVP/IN

**Chemical Restraint - Adult (7C)** 0.1 mg/kg to max 5 mg IM/IVP/IN/IOP. May repeat once.

Chemical Restraint - Pediatric (7C) 0.1 mg/kg to max 5 mg IM/IVP/IN/IOP

**Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A)** 0.1 mg/kg to max 5 mg IVP/IN/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

Head/Neck/Spine Injury - Adult (10A) 5 mg IM/IVP/IN/IOP for active seizure. May repeat once in 5 minutes if still seizing.

**How Supplied:** 5 mg/1 mL in vials, ampules, or pre-filled syringes. (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## **16FF – MORPHINE SULFATE**

#### PARAMEDIC

**Class:** Narcotic analgesic

**Actions/Pharmacodynamics:** Stimulates central nervous system opiate receptors, producing systemic analgesia. Modest vasodilation effects increase peripheral venous capacitance, and reduce venous return, myocardial workload, and myocardial oxygen demand.

Indications: Snakebites (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea (9A) Pain Management (Acute Onset &Chronic Type) (9D) Eye Injury (10B) Dental Injury/Pain (10C) Chest/Abdomen/Pelvis Injury (10D) Extremity/Amputation Injury (10G) Compartment Syndrome (10J) Crush Injury Syndrome (10K) Burns (10L) Lightning/Electrical Injury (11C) Pelvic Pain (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

Contraindications: Hypotension Respiratory Depression Minor Degrees of Pain Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP. Rapid IVP will lead to an accompanying histamine release, producing the nausea and/or vomiting often erroneously attributed to morphine itself.

**Pharmacokinetics:** Onset of action within 3-5 minutes after IV administration. Duration of effect can reach 4 hours depending upon end-organ function.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 16FF: Morphine Sulfate, cont.

Dosage: Snakebites – Adult (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A) Pain Management (Acute Onset & Chronic Type) – Adult (9D) Eye Injury – Adult (10B) Dental Injury/Pain – Adult (10C) Chest/Abdomen/Pelvis Injury – Adult (10D) Extremity/Amputation Injury – Adult (10G) Compartment Syndrome – Adult (10J) Crush Injury Syndrome – Adult (10K) Burns – Adult (10L) Lightning/Electrical Injury – Adult (11C) Pelvic Pain – Adult (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient. 2 – 4 mg slow IVP May repeat every 5 minutes to a maximum cumulative dose of 10 mg Snakebites – Pediatric (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A) Pain Management (Acute Onset & Chronic Type) – Pediatric (9D) Eye Injury – Pediatric (10B) Dental Injury/Pain – Pediatric (10C) Chest/Abdomen/Pelvis Injury – Pediatric (10D) Extremity/Amputation Injury – Pediatric (10G) Compartment Syndrome – Pediatric (10J) Crush Injury Syndrome – Pediatric (10K) Burns – Pediatric (10L) Lightning/Electrical Injury – Pediatric (11C) Pelvic Pain – Pediatric (13E) For all listed situations, indication is acute pain control in alert, hemodynamically stable patient **\*\*OLMC Order Only** – Typical dose is 0.1 mg/kg up to 2 mg per dose. **How Supplied:** 2 mg/1 mL pre-filled syringe 4 mg/1 mL vial, ampule, or pre-filled syringe


4 mg/1 mL vial, ampule, or pre-filled syringe 8 mg/1 mL pre-filled syringe 10 mg/1 mL vial 10 mg/10 mL vial (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16GG – NALOXONE (NARCAN®)** 



Class: Narcotic antagonist

Actions/Pharmacodynamics: The primary action of interest is reversal of respiratory depression associated with narcotic agents. Naloxone competes with and displaces narcotic substances from opiate receptors.

Respiratory Arrest (3A)
Specific Causes of Cardiac Arrest (4I)
Altered Mental Status (6B)
Syncope (6E)
Poisonings – General Management (8A)

**Contraindications:** Known or suspected narcotic substance use or abuse without cardiopulmonary compromise. Post-intubation in known or suspected narcotic substance use or abuse situations. Avoid whenever possible in known or suspected narcotic addicts. In these patients, use the smallest clinically effective dose possible (titrating administration slowly) to avoid acute narcotic withdrawal.

**Pharmacokinetics:** Onset of action within 2 minutes after IVP/IOP/IN administration with duration of effect up to 2 hours.

**Side Effects:** Agitation, anxiety, diaphoresis, tachycardia, nausea, vomiting, headache, hypertension, hypotension, seizures.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 16GG: Naloxone (Narcan<sup>®</sup>), cont.

Dosage:	Respiratory Arrest - Adult (3A) Specific Causes of Cardiac Arrest - Adult (4I) Altered Mental Status – Adult (6B) Syncope – Adult (6E) Poisonings – General Management – Adult (8A) In Apnea/Agonal Breathing, 2 mg IVP/IOP/IN. May repeat once to maximum cumulative dose of 4 mg.
	In Ineffective Breathing Activity, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 4 mg.
	Respiratory Arrest - Pediatric (3A) Specific Causes of Cardiac Arrest - Pediatric (4I) Altered Mental Status – Pediatric (6B) Syncope – Pediatric (6E) Poisonings – General Management – Pediatric (8A) In Apnea/Agonal Breathing, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 2 mg.
	In Ineffective Breathing Activity, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 2 mg.
How Supplied:	0.4 mg/1 mL vial 0.4 mg/1 mL prefilled syringe 2 mg/2 mL prefilled syringe 4 mg/10 mL vial (Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** In non-respiratory arrest or non-cardiac arrest situations, always titrate administration slowly, using the lowest clinically effective amount of naloxone possible to avoid inadvertent acute narcotic withdrawal and/or other side effects.

Naloxone should not be administered unless there is a known or suspected narcotic substance use or abuse.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 16HH – NITROGLYCERIN (NITROLINGUAL<sup>®</sup>, NITROMIST<sup>®,</sup> NITROSTAT<sup>®</sup>, NITROQUICK<sup>®</sup>, TRIDIL (IV INFUSION), NITRO-BID<sup>®</sup> - DERMAL)

EMERGENCY MEDICAL DISPATCHER	Sublingual Dosing - Own Self-Administration Phone Directive - 3E 5A 5C
EMERGENCY MEDICAL RESPONDER	Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C
ЕМТ	Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C
EMT-INTERMEDIATE 85	Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C
ADVANCED EMT	Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C
PARAMEDIC	

**Class:** Anti-Anginal, Vasodilator, Anti-Hypertensive (Nitrate)

Actions/Pharmacodynamics: Arterial and venous vasodilator through relaxing vascular smooth muscle. Reduces cardiac afterload resistance and cardiac preload volume respectively. Myocardial oxygen consumption/demand is decreased. Systemic blood pressure is decreased.

Indications: Dyspnea - Congestive Heart Failure (3E) Chest Pain - Uncertain Etiology (5A) Acute Coronary Syndrome (5C)

Contraindications: Hypotension Asymptomatic Hypertension Erectile Dysfunction Medications (\*\*Requires OLMC Order Only) Sildenafil (Viagra<sup>®</sup>) or Vardenafil (Levitra<sup>®</sup>) use within 24 hours Tadafil (Cialis<sup>®</sup>) use within 48 hours

**Pharmacokinetics:** Rapid vascular uptake within 3 minutes of sublingual dosing, with duration of effect up to 30 minutes. Rapid vascular effect within 1-3 minutes of intravenous dosing, with ongoing effect while continuous infusion. Vascular effect within 15-30 minutes of transdermal dosing, with ongoing effect while continued transdermal absorption.

**Side Effects:** The most serious side effect is hypotension, usually transient and responsive to supine positioning and intravenous fluid bolusing. Common, though non-serious, symptoms include: headache due to vasodilation, blurred vision, and dizziness. Paramedics should exercise caution when applying transdermal nitroglycerin ointment, avoiding contact with bare hands to avoid experiencing personal side effects, typically headache and dizziness.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## PROTOCOL 16HH: Nitroglycerin (Nitrolingual<sup>®</sup>, NitroMist<sup>®</sup>, NitroStat<sup>®</sup>, NitroQuick<sup>®</sup>, Tridil -Intravenous, Nitro-BID<sup>®</sup> - Transdermal), cont.

## Dosage: Dyspnea - Congestive Heart Failure - Adult (3E) Acute Coronary Syndrome - Adult (5C)

0.4 mg sublingual spray or tablet if systolic BP > 100 mmHg. Single dose unless by Paramedic. May repeat 0.4 mg sublingual spray or tablet every 5 minutes if systolic BP >100 mmHg until chest pain and/or respiratory distress resolves.

Following initial sublingual use, may utilize intravenous infusion start at 10 mcg/min, titrate slowly to effect. Maximum infusion rate without OLMC consult is 50 mcg/min.

Following initial sublingual use, may utilize transdermal application of 1½ inches ointment to chest wall.

#### Chest Pain - Uncertain Etiology - Adult (5A)

0.4 mg sublingual spray or tablet if systolic BP >100 mmHg. Single dose unless by Paramedic. If chest pain improved with initial dose, 0.4 mg sublingual spray or tablet every 5 minutes until chest pain and/or respiratory distress resolves.

Following initial sublingual use, may utilize intravenous infusion start at 10 mcg/min, titrate slowly to effect. Maximum infusion rate without OLMC consult is 50 mcg/min.

Following initial sublingual use, may utilize transdermal application of 1½ inches ointment to chest wall.

How Supplied:Metered dose spray 0.4 mg/spray.<br/>Tablets for sublingual absorption 0.4 mg.<br/>Intravenous infusion - Mix 50 mg into 250 mL D5W (200 mcg/mL)<br/>10 mcg/min using microdrip infusion set is 3 mL/hour rate<br/>20 mcg/min using microdrip infusion set is 6 mL/hour rate<br/>Transdermal ointment in 2% nitroglycerin concentration<br/>1½ inches = 22.5 mg of nitroglycerin<br/>(Always check concentration and dose per container at time of patient<br/>medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

## **16II – NOREPINEPHRINE (LEVOPHED®)**

#### PARAMEDIC

Class: Vasoconstrictor

Actions/Pharmacodynamics: Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increase in systemic blood pressure. Concurrent beta receptor stimulation may produce increases in heart rate and mild bronchodilation, though norepinephrine is a weaker beta stimulator than dopamine.

Indications:Dyspnea – Congestive Heart Failure (Cardiogenic Shock) (3E)<br/>Post Cardiac Arrest Treatment (Cardiogenic Shock) (4J)<br/>Acute Coronary Syndrome (Cardiogenic Shock) (5C)<br/>Sepsis (Septic Shock) (9B)<br/>Dialysis-Related Issues (9E)<br/>For all listed situations, indication is hypotension (adult = systolic < 100<br/>mmHg) due to cardiogenic, septic, or neurogenic shock either refractory to<br/>intravascular fluid boluses or in which intravascular fluid bolusing is<br/>contraindicated (eg. pulmonary edema).

Contraindications: Hypertension

**Pharmacokinetics:** Onset of action within 5 minutes after IV/IO infusion initiated. Rapid metabolism, requiring ongoing IV/IO infusion to maintain clinical effects.

**Side Effects:** Few, though at higher doses, symptoms may include headache, palpitations, tachycardia, chest pain, and eventual hypertension. Bradycardia can result reflexively from an increase in blood pressure.

Dosage:Dyspnea – Congestive Heart Failure (CHF) – Adult (3E)<br/>Post Cardiac Arrest Treatment - Cardiogenic Shock - Adult (4J)<br/>Acute Coronary Syndrome – Adult (5C)<br/>Sepsis - Septic Shock - Adult (9B)<br/>Dialysis-Related Issues - Adult (9E)<br/>For hypotension (shock) refractory to fluids or fluids contraindicated<br/>Start at 2-4 mcg/minute - see dosage chart - titrated to a systolic B/P ≥<br/>100 mmHg. Maximum infusion rate is 12 mcg/minute.

# Norepinephrine Infusion Adult Dosage Chart rates reflect using a microdrip (60 drops/mL) set:

mcg/min	2	3	4	5	6	7	8	9	10	11	12
drops/min	15	22	30	37	45	52	60	67	75	82	90





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

PROTOCOL 16II: Norepinephrine (Levophed®), cont.

- Dosage, cont.: Dyspnea Congestive Heart Failure (CHF) Pediatric (3E) Post Cardiac Arrest Treatment - Cardiogenic Shock - Pediatric (4J) Sepsis - Septic Shock - Pediatric (9B) Dialysis-Related Issues - Pediatric (9E) For hypotension (shock) refractory to fluids or fluids contraindicated \*\*OLMC Order Only
- How Supplied: 4 mg/4 mL ampule or vial. <u>Use only 2 mL in a 250 mL bag of D5W.</u> (8 mcg/mL concentration) (Always check concentration and dose per container at time of patient medication administration)

**Special Comments:** In the setting of tachydysrhythmia-induced cardiogenic shock, treat per Protocol 5G – Tachycardia - Unstable. Ensure aggressive fluid resuscitation is accomplished (unless contraindicated) prior to norepinephrine use.

Norepinephrine should be given into a large, patent vein. The vein of choice for EMS use is the antecubital vein, as this will decrease the risk of overlying skin necrosis. Do not administer norepinephrine through an IV in the hand or leg. These veins are more likely to be affected by vaso-occlusive diseases and more prone to ischemic complications. Administration through IO in the proximal tibia or humeral head is permitted.

If local extravasation occurs, notify the receiving physician of the following FDA advisement of antidote to extravasation ischemia:

"To prevent sloughing/necrosis in peripheral ischemic areas promptly use syringe w/ fine hypodermic needle to liberally infiltrate area w/ 10-15 mL saline solution containing 5-10 mg phentolamine; sympathetic blockade causes immediate conspicuous local hyperemic changes if area infiltrated within 12 hours."

Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks. Safety in pediatrics not firmly established and OLMC is to be consulted prior to pediatric usage.

Avoid mixing in normal saline, as NS promotes loss of potency through oxidation of norepinephrine.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 16JJ – ONDANSETRON (ZOFRAN®)

## PARAMEDIC

Class: Antiemetic

Actions/Pharmacodynamics: Ondansetron reduces the activity of the vagus nerve, which activates the vomiting center in the medulla oblongata, and also blocks serotonin receptors in the chemoreceptor trigger zone. It has little effect on vomiting caused by motion sickness.

Indications:	Snakebites (8E)
	Abdominal Pain/Nausea/Vomiting/Diarrhea (9A)
	Sepsis (9B)
	Pelvic Pain (13E)
	For all listed situations, indication is for active vomiting.

**Contraindications:** Known hypersensitivity to ondansetron Current use of Apomorphine (Apokyn<sup>®</sup>), an anti – parkinsonian drug

Use with caution with patients currently using medications which effect QT interval (eg. procainamide, amiodarone, tricyclic antidepressants, haloperidol)


**Side Effects:** Sedation, dystonic reactions (rare), hypotension, tachycardia, angina, torsades (rare).

Dosage:	Snakebites - Adult (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea - Adult (9A) Sepsis - Adult (9B) Pelvic Pain - Adult (13E) For all listed situations, indication is for active vomiting. 4 mg oral dissolving tablet on tongue, may repeat once in 10 minutes 4 mg slow IVP over 60 seconds, may repeat once in 10 minutes			
	Snakebites - Pediatric (8E) Abdominal Pain/Nausea/Vomiting/Diarrhea - Pediatric (9A) Sepsis - Pediatric (9B) Pelvic Pain - Pediatric (13E) For all listed situations, indication is for active vomiting. If age > 2 years, 4 mg oral dissolving tablet on tongue 0.1 mg/kg to max of 4 mg slow IVP over 60 seconds			
How Supplied:	4 mg/2 mL (2 mg/mL) vial. 4 mg rapid oral dissolving tablet (ODT) (Always check concentration and dose per container at time of patient medication administration)			





Approved 9/14/22, Effective 1/16/23, replaces all prior versions



**Class:** Topical Nasal Vasoconstrictor

Actions/Pharmacodynamics: Phenylephrine is a direct-acting sympathomimetic amine. It stimulates alpha receptors in the blood vessels of the nasal mucosa which causes their constriction, thereby decreasing the risk of subsequent nasal bleeding.

Indications:	Nasal Intubation (2H) Epistaxis (9C)			
Contraindications:	None in the indicated settings.			
Pharmacokinetics:	Onset of action is within seconds.			
Side Effects: Rare with single dose. It is rarely absorbed systemically from nasal instillation.				
Dosage:	Nasal Intubation - Adult (2H) 2 sprays in each nostril			
	<b>Epistaxis - Adult &amp; Pediatric (9C)</b> 2 - 4 sprays in affected nostril(s) for control of epistaxis (with compression of nose immediately after administration)			
How Supplied:	Phenylephrine Nasal Spray 1% solution, 15 mL squeeze bottle for single patient use only. (Always check concentration and dose per container at time of patient medication administration)			





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

16LL – PRALIDOXIME CHLORIDE (2PAM)

PARAMEDIC

Class: Cholinesterase Reactivator

Actions/Pharmacodynamics: Pralidoxime chloride reactivates cholinesterase (mainly outside the central nervous system) which has been inactivated by an organophosphate pesticide. The destruction of accumulated acetylcholine can then proceed and neuromuscular junctions will regain function. Pralidoxime chloride has its most critical effect in reversing paralysis of the muscles of respiration. Because Pralidoxime Chloride is less effective in relieving depression of the respiratory center, atropine is always required concomitantly to block the effect of accumulated acetylcholine at the site. Pralidoxime Chloride is short acting and repeated doses may be needed, especially when there is evidence of continuing toxicity.

**Indications:** Poisonings – General Management (8A)

Contraindications: None

**Pharmacokinetics:** With IM autoinjector use, effects may not be observed for up to 15 minutes. Beneficial effects can persist in excess of 1 hour.

**Side Effects:** Headache, dizziness, vision changes, loss of coordination, laryngospam, tachycardia, palpitations.

Dosage: Poisonings – General Management - Adult & Pediatric > 12 years of age (8A) 600 mg IM May repeat every 15 minutes to cumulative maximum dose of 1800 mg. In the setting of serious symptoms (cardiopulmonary distress), repeat doses in rapid succession.

#### Poisonings – General Management - Pediatric ≤ 12 years of age (8A) \*\*OLMC Order Only

Typical pediatric dose is 15 mg/kg IM per dose, max single dose 600 mg

**How Supplied:** 600 mg/2 mL autoinjector (Always check concentration and dose per container at time of patient medication administration)





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

**16MM – SODIUM BICARBONATE** 

PARAMEDIC

**Class:** Alkalinizing agent

Actions/Pharmacodynamics: Raises the pH of blood by buffering excess hydrogen ions that are present in acidotic states. The role of sodium bicarbonate is limited in cardiac arrest. Because ventilation is an effective tool in managing respiratory acidosis, sodium bicarbonate should rarely be administered for cardiac arrest, unless the arrest is suspected to be secondary to hyperkalemia or a tricyclic antidepressant over ingestion.

Indications: Specific Causes of Cardiac Arrest (Hyperkalemia) (4I) Poisonings – General Management (Tricyclic Antidepressant) (8A) Dialysis-Related Issues (Hyperkalemia) (9E) Crush Injury Syndrome (Hyperkalemia Prophylaxis) (10K)

Contraindications: Known metabolic alkalosis.

Pharmacokinetics: Onset of effect is observed within 3-5 minutes after IVP/IOP administration.

**Side Effects:** Sodium bicarbonate may inhibit oxygen release secondary to a shift in oxyhemoglobin saturation. It also may produce a paradoxical acidosis that can depress cerebral and cardiac function. Severe soft tissue damage can occur in extravasated administrations.

- Dosage: Specific Causes of Cardiac Arrest Hyperkalemia Adult & Pediatric (4I)
   Poisonings General Management Tricyclic Antidepressants Adult & Pediatric (8A)
   Dialysis-Related Issues Hyperkalemia Adult & Pediatric (9E)
   Crush Injury Syndrome Hyperkalemia Prophylaxis Adult & Pediatric (10K)
   1 mEq/kg IVP/IOP with maximum dose of 50mEq
- **How Supplied:** 50 mEq/50 mL (1 mEq/mL) prefilled syringe. (Always check concentration and dose per container at time of patient medication administration)


**Special Comment:** Do not administer with calcium chloride. A precipitate will form and obstruct the vascular access being utilized.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 16NN – CALCIUM GLUCONATE



Class: Elemental metabolite - calcium is the active component

**Actions/Pharmacodynamics:** In the setting of hydrofluoric acid burns, calcium gluconate topically applied to affected skin will allow for calcium to bind up the free fluoride ions, reducing pain caused by such ions. Binding the free fluoride ions reduces their impacts, specifically those associated with causing hyperkalemia, hypocalcemia, and hypomagnesemia.

**Indications:** Hydrofluoric Acid (8H)

**Contraindications:** Known hypercalcemia; effectively none in setting of hydrofluoric acid burn

**Pharmacokinetics:** Absorption transdermally, with onset of action within several minutes and duration of action up to several hours.


Side Effects: Typically none from EMS dosing.

- Dosage:Hydrofluoric Acid Adult & Pediatric (8H)Apply topically to exposed/affected burn on skin
- **How Supplied:** 2.5% gel in 25 gram tube (Always check concentration and dose per container at time of patient medication administration)
- **Special Comment:** To monitor pain relief from calcium gluconate gel absorption, paramedics should avoid concurrent administration of opiate/narcotic medications. When hand(s) are involved, a best practice is to place a liberal amount of the calcium gluconate gel in exam glove(s), placing the gel in the spaces for any affected fingers too, and then pulling the glove(s) onto the affected hand(s). Weaker concentrations of hydrofluoric acid may result in time lag of several hours from exposure to onset of burn pain. High concentrations of hydrofluoric acid will cause immediate burn pain.





Approved 5/10/23, Effective 7/1/23, New protocol issuance, no prior versions



Class: Steroid

**Actions/Pharmacodynamics:** Dexamethasone is a long-acting synthetic adrenal corticosteroid with glucocorticoid activity. It exerts anti-inflammatory effects in the setting of inflammatory-mediated illness.

Indications: Dyspnea - Asthma (3C) Dyspnea - Chronic Obstructive Pulmonary Disease (3D) Dyspnea – Croup (3M) Acute Allergic Reactions (8D) Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Known hypersensitivity to dexamethasone. In the setting of anaphylaxis, the only true contraindication is prior severe allergy (anaphylaxis) caused by dexamethasone.

**Pharmacokinetics:** Onset of action within 4-6 hours, may have effect for 4-5 days and reportedly up to as long as 10 days.

**Side Effects:** None expected immediately. May occasionally see any of the following effects with onset of action: euphoria, insomnia, confusion, psychosis, edema, hypertension, nausea/ vomiting, hyperglycemia.

Dosage: Dyspnea - Asthma - Adult (3C) Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D) Acute Allergic Reactions - Adult (8D) Bee/Wasp Stings - Adult (8F) 10 mg IVP. Give IM if no IV access obtainable.

> Dyspnea - Asthma - Pediatric (3C) Dyspnea - Croup - Pediatric (3M) Acute Allergic Reactions - Pediatric (8D) Bee/Wasp Stings - Pediatric (8F) 0.6 mg/kg not to exceed 10 mg IVP. Give IM if no IV access obtainable.


**How Supplied:** 10 mg/mL in a 1mL single-use vial. (Always check concentration and dose per container at time of patient medication administration)





Approved 5/10/23, Effective 7/1/23, New protocol issuance, no prior versions

## 16PP – LEVALBUTEROL (XOPENEX®)



Class: Sympathomimetic Bronchodilator

**Actions/Pharmacodynamics:** Levalbuterol is a relatively selective beta<sub>2</sub> adrenergic stimulant. Levalbuterol causes relaxation of the smooth muscles of the bronchial tree thus decreasing airway resistance, facilitating mucus drainage, and increasing vital capacity. As an isomer (a differing molecular structure of the same atoms) of albuterol, marketing of levalbuterol historically describes milder effects on beta<sub>1</sub> (heart) or alpha (peripheral vasculature) receptors than albuterol. This has not consistently been proven in clinical trials. In therapeutic doses, levalbuterol, by inhibiting histamine release from mast cells, also reduces the mucus secretion, capillary leaking, and mucosal edema caused by an allergic response in the lungs.

Indications: Dyspnea - Uncertain Etiology (3B) Dyspnea - Asthma (3C) Dyspnea - Chronic Obstructive Pulmonary Disease (3D) Acute Allergic Reactions (8D) Bee/Wasp Stings (8F) Smoke Inhalation (12B)

**Contraindications:** Known hypersensitivity to levalbuterol or albuterol. Levalbuterol should not be used if the sole etiology of dyspnea is strongly suspected to be CHF, as levalbuterol-induced tachycardia (even if milder than albuterol) may worsen the compromised cardiac output in CHF.

**Pharmacokinetics:** Onset within 5–15 minutes; peak effect in 1.5 hours; duration of effect is up to 5-8 hours; half-life is 3-4 hours. Distribution: When inhaled, levalbuterol is distributed to muscle cells along the bronchial tree. Very little is systemically absorbed and distributed.

**Side Effects:** Tremors, anxiety, dizziness, headache, cough, reflex bronchospasm, palpitations, tachycardia, and hypertension.





Approved 5/10/23, Effective 7/1/23, New protocol issuance, no prior versions

#### PROTOCOL 16PP: Levalbuterol (Xopenex®)

Dosage:Dyspnea - Uncertain Etiology - Adult & Pediatric Weight ≥ 15kg (3B)Smoke Inhalation - Adult & Pediatric Weight ≥ 15kg (12B)2.5 mg nebulized, may repeat once.

Dyspnea - Uncertain Etiology - Pediatric Weight < 15kg (3B) Smoke Inhalation - Pediatric Weight < 15kg (12B) 1.25 mg nebulized, may repeat once.


Dyspnea - Asthma - Adult & Pediatric Weight  $\geq$  15kg (3C) Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D) Acute Allergic Reactions - Adult & Pediatric Weight  $\geq$  15kg (8D) Bee/Wasp Stings - Adult & Pediatric Weight  $\geq$  15kg (8F) 2.5 mg nebulized (with ipratropium bromide 0.5 mg), may repeat twice.

Dyspnea - Asthma - Pediatric Weight < 15kg (3C) Acute Allergic Reactions - Pediatric Weight < 15kg (8D) Bee/Wasp Stings - Pediatric Weight < 15kg (8F) 1.25 mg nebulized (with ipratropium bromide 0.25 mg), may repeat twice.

**How Supplied:** 1.25 mg/3 mL or 1.25mg/0.5 mL in nebulizer vials. (Always check concentration and dose per container at time of patient medication administration)




Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination – Adult General Medical Patients** 






## Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination – Adult Cardiology Patients**




- Any complex of signs and symptoms consistent with acute coronary syndrome and cardiac decompensation, i.e., pulmonary edema, symptomatic cardiac dysrhythmia
- Priority II Adult Cardiology Patient
  - Example:
    - Cardiac patients with pre-existing condition requiring evaluation only




## Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination – Adult Stroke Patients**













Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination– Pediatric General Medical Patients** 






#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination – Pediatric Trauma Patients**





#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17A: Destination Determination – Neonatal Medical Patients**



#### Neonatal Priority Determination

#### Priority I - Unstable


- Cardiac or respiratory arrest
   Less than 35 weeks gestation at time of birth(estimated)
- $\square$  APGAR  $\leq$  5 at 5 minutes
- □ SpO2 less than 90% on oxygen
- Diagnosed genetic disorders

#### Priority II - Stable

- 35 weeks or later gestation at time of birth (estimated)
- □ APGAR > 5 at 5 minutes
- No immediate life threat identified



Approved 9/14/22, Effective 1/16/23, replaces all prior versions



		Burn Determination
•	Dete	rmination Criteria
		Burns with P1 or P2 trauma should be transported to the Trauma Center.
		Burns with P3 trauma can be transported to IBMC-NWE if closest facility
		In the Western Division burns should be transported to the closest appropriate burn capable destination.



# **PROTOCOL 17B, Table: Categorization of Hospitals** Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Categorized Hospitals—Tulsa (Levels of Emergency Services)

Hospital	General Medical	Adult Stroke	Trauma	Neonatal	Ped. Medical	Ped. Trauma	Cardiology	Burns	Heli. Pad	Hyperbaric Chamber	Level I Cardiac Arrest Center
Bailey Medical Center	IV	IV	IV	N/A	IV	IV			Yes		No
Hillcrest Medical Center	I	I	Ш	Ш	Ш	Ш	I	*	Yes		Yes
Hillcrest Hospital South	П	Ш	111	N/A	=	Ш	I		Yes		Yes
OSUMC	I	=	Ш	N/A	Ш	Ш	I		Yes	Yes	Yes
Saint Francis Hospital	I	I	Ш	I	I	Ш	I		Yes		Yes
Saint Francis South	ш	Ш	ш	Ш	ш	Ш	ш		Yes		No
Saint Francis Healthplex Glenpool	Ш	Ξ	IV	N/A	IV	IV	Ш		No		No
St. John Medical Center	I	I	Ш	I	IV	Ш	I		Yes		Yes
St. John Broken Arrow	IV	IV	IV	N/A	IV	IV	Ш		Yes		No
St. John Owasso	IV	IV	IV	Ш	IV	IV	Ш		Yes		No
St. John Sapulpa	IV	IV	IV	N/A	IV	IV	Ш		Yes		No

#### Categorized Hospitals--Oklahoma City (Levels of Emergency Services)

Hospital	General Medical	Adult Stroke	Trauma	Neonatal	Ped. Medical	Ped. Trauma	Cardiology	Burns	Heli. Pad	Hyperbaric Chamber	Level I Cardiac Arrest Center
Alliance Health Midwest City Hospital	Ш	ш	ш	N/A	ш	ш	Ш		Yes		Yes
The Children's Hospital	I	N/A	N/A	I	I	Ш	I	**	Yes		No
Community Hospital	IV	IV	IV	N/A	IV	IV			No		No
Integris Baptist Medical Center - Northwest Expressway (IBMC-NWE)	I	I	Ш	I	I	Ш	I	*	Yes	Yes	Yes
Integris Canadian Valley Hospital	Ш	Ш	ш	Ш	Ш	Ш	Ш		No		No
Integris Community Hospitals	111	Ш	IV	N/A	IV	IV	Ш		No		No
Integris Baptist Medical Center -Portland Avenue (IBMC-PA)	I	Ш	ш	N/A	ш	Ш	Ш		No		No
Integris Health Edmond	Ш	Ш	ш	N/A	Ш	Ш	I		Yes		Yes
Integris Southwest Medical Center	I	Ш	Ш	N/A	Ш	Ш	I		Yes		Yes
Mercy Hospital – Oklahoma City	П	I	Ш	П	Ш	Ш	Ш		Yes		No
Mercy I-35 (Free Standing ED)***	=	=	IV	N/A	IV	IV	Ξ		No		No
Norman Regional Hospital	Ш	=	Ш	N/A	Ш	Ш	=		Yes		No
Norman Regional HealthPlex	Ш	Ш	Ш	N/A	Ш	Ш	I		Yes		Yes
Norman Regional Moore	Ш	Ш	IV	N/A	Ш	Ш	Ш		No		No
OU Edmond	Ш	IV	ш	N/A	ш	ш	Ш		Yes		No
OK Heart Hospital North	NA	NA	NA	N/A	NA	NA	I		Yes		Yes
OK Heart Hospital South	NA	NA	NA	N/A	NA	NA	I		Yes		Yes
OU Medical Center	I	I	I	N/A	Ш	I	I	*	Yes		Yes
St. Anthony Hospital	ļ	I	Ш	П	Ш	Ш	I		Yes		Yes
St. Anthony Healthplexes (Free Standing EDs)***	ш	Ш	IV	N/A	IV	IV	Ш		No		No
OU Health Emergency Room & Urgent Care – Czech Hall (Free Standing ED)***	Ш	Ш	IV	N/A	IV	IV	ш		No		No

17B.1 Table: Categorization of Hospitals



PROTOCOL 17B, Table: Categorization of Hospitals

Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### Specialty Hospitals, Healthcare Facilities, and Additional Service Capabilities

Veterans Administration Hospital OKC Bone and Joint Hospital	Predominately a medical and surgical facility for the veteran population. The Veterans Administration Hospital is capable of managing patients with complex medical illnesses and non-Priority 1 traumatic injuries. Predominately an orthopedic referral facility; Level IV Trauma Center
OKC Oklahoma Heart Hospital (North & South Campus) OKC	Predominately a medical and surgical facility for Priority I and II assigned and unassigned patients with cardiac related symptoms.
OU Medical Center, (Dean McGee Eye Institute) OKC	OUMC is affiliated with Dean McGee Eye Institute. Adult Patients with isolated ocular trauma with loss of vision, change in the appearance of the eye, or severe ocular pain should be transported to OUMC for most expeditious access to ocular services.
OU Medical Center, OKC	Labor and Delivery Services should only receive pregnant women with an obstetrical complaint and a gestational period greater than 16 weeks.
McBride Clinic Orthopedic Hospital OKC	Predominately an orthopedic referral facility; Level IV Trauma Center
Level I Cardiac Arrest Center	Cardiac intervention capabilities including a Cardiac Cath Lab and an interventional cardiologist available 24 hours a day, seven days a week; a therapeutic hypothermia method to cool the patient for at least 12 hours after a cardiac arrest.
Center for Orthopedic Reconstruction & Excellence (CORE), Jenks	Predominately an orthopedic referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at CORE within the next 7 days or a surgery that was performed at CORE within the past 30 days. The patient's surgeon (or the call coverage surgeon) must be contacted and agree to accept the patient at CORE's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at CORE. The EMSA Communications Center will attempt to contact that surgeon/physician at CORE on a recorded line. If no answer from the surgeon/physician at CORE within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.
Oklahoma Surgical Hospital (OSH) Tulsa	Predominately a surgical referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at OSH within the next 7 days or a surgery that was performed at OSH within the past 30 days. The patient's surgeon (or the call coverage specialist partner) must be contacted and agree to accept the patient at OSH's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at OSH. The EMSA Communications Center will attempt to contact that surgeon/physician at OSH on a recorded line. If no answer from the surgeon/physician at OSH within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.



**PROTOCOL 17B, Table: Categorization of Hospitals** 

Approved 9/14/22, Effective 1/16/23, replaces all prior versions

Tulsa Spine & Specialty Hospital (TSSH)	Predominately an orthopedic & neurosurgical referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at Tulsa Spine & Select Specialty Hospital within the next 7 days or a surgery that was performed at Tulsa Spine & Select Specialty Hospital within the past 30 days. The patient's surgeon (or the call coverage surgeon) must be contacted and agree to accept the patient at Tulsa Spine & Select Specialty Hospital's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at TSSH. The EMSA Communications Center will attempt to contact that surgeon/physician at TSSH on a recorded line. If no answer from the surgeon/physician at TSSH within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.
Norman Regional HealthPlex	Norman Regional HealthPlex has Labor and Delivery services for patients in labor.
Integris Lakeside Women's Hospital OKC	Predominately a labor and delivery hospital for assigned patients
St. Anthony Healthplex, Saint Francis Healthplex- Glenpool, Mercy I-35, Integris Portland Hospital, OU Health Emergency Room & Urgent Care – Czech Hall	Typical emergency department capabilities exist, though no post- emergency department care (surgery, cardiac cath, inpatient care) is available on-site. These facilities should be bypassed for a hospital-based emergency department when the patient's symptoms, exam, and/or diagnostics such as 12-lead ECG indicate the patient most likely requires very urgent or emergent intervention by a specialty physician that is hospital-based (eg. cardiac cath, surgery). Examples of typical transports allowed include: minor head trauma with no or brief LOC; MVC or falls with low suspicion for internal injury and normal vital signs; minor isolated/closed orthopedic injury; epistaxis; respiratory infections; dental injury/illness; fever in pediatrics and young adult (without hypotension/suspected sepsis); chest pain in patients less than 35 years of age, without ST elevation or depression on 12-lead ECG, and without coronary disease history; HTN illness; abdominal pain with normal vital signs and suspected non-surgical cause; genitourinary illness (infections, kidney stones, vaginal bleeding non-pregnant), neurological illness (headaches, seizure (non- status) with seizure history), psychiatric illness, allergic reactions, minor burns, dermal rashes, and MCI "green" patients.



### **PROTOCOL 17B, Table: Categorization of Hospitals**

Approved 9/14/22, Effective 1/16/23, replaces all prior versions

Integris Community Hospital- (EMERUS) Council Crossing, Del City, Moore, OKC West.	Typical emergency department capabilities exist, with very limited post-emergency department adult-only inpatient care (no ICU, no surgery, no cardiac cath) available on-site. These facilities should be bypassed for a hospital-based emergency department when the patient's symptoms, exam, and/or diagnostics such as 12-lead ECG indicate the patient most likely requires very urgent or emergent intervention by a specialty physician that is hospital- based (eg. cardiac cath, surgery). Examples of typical transports allowed include: minor head trauma with no or brief LOC; MVC or falls with low suspicion for internal injury and normal vital signs; minor isolated/closed orthopedic injury; epistaxis; respiratory infections, including COPD or pneumonia that could require short term admission but not NIPPV/ICU care; dental injury/illness; fever in pediatrics and young adult (without hypotension/suspected sepsis); chest pain in patients less than 35 years of age, without ST elevation or depression on 12-lead ECG, and without coronary disease history; HTN illness; abdominal pain with normal vital signs and suspected non-surgical cause; prominent vomiting/diarrhea with suspected dehydration; genitourinary illness (infections, kidney stones, vaginal bleeding non-pregnant), neurological illness (headaches, seizure (non-status) with seizure history), psychiatric illness, allergic reactions, minor burns, dermal rashes, and MCI "green" patients.
St. John Medical Center Pediatric Capabilities	Internal medicine and ICU physicians will only treat patients 18 years of age and older. So, almost anyone under 18 years of age that, in the judgement of on-scene EMTs and Paramedics, will most likely require hospital inpatient admission and care beyond the emergency department should be taken to an alternative hospital destination. Many pediatric patients are successfully cared for with safe discharge home after emergency department-based care. Examples of such patients include non-toxic appearing febrile illness, febrile seizures that have resolved, seizures resolved prior to EMS arrival or with EMS care with a past medical history of seizure disorder, minor abdominal symptoms such as nausea/vomiting/diarrhea, lacerations without suspected underlying fracture(s), closed orthopedic injuries (strains, sprains, suspected simple fractures), and lower speed blunt trauma – motor vehicular, non-motorized scooters/bikes, and falls). Of note, at least one pediatric general surgeon, experienced in pediatric trauma care, two urologists doing pediatric surgeries, and multiple ear, nose, & throat surgeons doing pediatric surgeries are on the medical staff. You may encounter pediatric patients established with these surgeons and their families may understandably wish to continue utilizing St. John Medical Center for their child's specific surgical care. St. John Medical Center is a Level II Trauma Center by a definition established by the American Collee of Surgeons Committee on Trauma, and will accept trauma patients 15 years and older. When any doubt arises if St. John Medical Center is an appropriate hospital destination, immediately request an on-line clinical consult with an on-duty emergency physician at St. John Medical Center to review with them the current clinical situation.

#### **Special Considerations**

*	Burn Center. Burns associated with Priority I Trauma should be transported to Level I or II Trauma Centers
**	Pediatric Burn Center. Burns associated with Priority I Trauma should be transported to Level I or II Trauma Centers
***	See comments above for Freestanding EDs



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **PROTOCOL 17C: EMS Diversion from Hospitals**

In the event that a hospital's capability to safely provide the standard of care becomes compromised, one **temporary** action may be the EMS system suspends transports to that hospital's emergency department for a limited amount of time. While EMS patient diversion may occur, the Medical Control Board believes hospitals must continually strive to minimize these occurrences in frequency and in duration. Specifically, hospitals should not expect patient divert continuously more than 2 hours and/or more than 6 hours in any 24 hour period. In return for this professional and civic commitment, hospitals directly contribute to efforts to ensure that all EMS patients receive efficient out-of-hospital emergency medical response and care, including efficient ambulance transport, and timely emergency department physician evaluation and stabilization.

Hospitals may request to be placed on divert status by contacting the EMSA Communications Center. Divert status may be granted depending on the entire system status at the time the request is made. Alternatively, an EMSA Field Operations Supervisor may designate a hospital on divert status due to operational impacts placed on the EMS system (eg. prolonged bed waits).

Hospitals on divert will utilize EMSystem.com to reflect their type and time on divert status, including timely updates of status. Specific types (and triggers) of hospital-initiated EMS patient diversion include:

- 1. Emergency Department Divert\* applies to all illness and injury conditions\*\* \*\*\*.
  - a) Overcrowding secondary to unpredicted, sudden influx of critical care patients

\* ED divert is not granted to alleviate routine ED overcrowding and each hospital is expected to have a Divert Avoidance Policy when predictable levels of excess capacity need occur, including expeditious movement of admitted patients out of the ED, ancillary service optimization, and addressing crowding due to non-critical patients. The placement of a hospital on ED divert status is subject to the entire Regulated Service Area's system status at the time of hospital request.

\*\* For OU Medical Center in Oklahoma City, emergency department divert may be specified as medical only, trauma only, or complete.

\*\*\* For pediatric priority one trauma, those patients must go to OU Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa regardless of divert status. For pediatric priority one medical, those patients must go to a hospital with pediatric ICU capabilities, which includes OU Medical Center Children's or Baptist Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa.

- 2. Priority One Trauma Divert\* applies to priority 1 trauma conditions only\*\*.
  - a) ICU or recovery bed shortage creating an overload of critical surgical patients in surgery or the emergency department
  - b) Two or more active, unscheduled critical patients in surgery or emergency department
  - c) Loss of critical ancillary service (CT scanning, basic laboratory)



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **PROTOCOL 17C: EMS Diversion from Hospitals, cont.**

\*Priority One Trauma divert is not granted to alleviate routine bed or nurse staffing shortages. Expedited patient transfers to free needed beds and/or nursing callbacks to achieve needed specialty unit staffing levels should be utilized.

In the event of multiple unscheduled critical patient resuscitations/surgeries, a time estimate of stabilization and return to normal receiving capacity is to be communicated to EMSA dispatch at the time of divert status request.

\*\*For pediatric priority one trauma, those patients must go to OU Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa regardless of divert status.

3. CT Divert (Computerized Tomography Scanning Divert)

a) Loss of CT scanning ability (affecting trauma and medical receiving capability)

\*\*\* CT divert is not routinely granted to accommodate scheduled maintenance. Immediate repairs are to be initiated and a time estimate of return to normal capacity is to be communicated to EMSA dispatch at the time of divert status request.

- 4. Cath Lab Divert (Cardiac Catheterization Lab Divert)
  - a) Loss of Cath Lab operations (affecting STEMI receiving capability)

\*\*\* Cath Lab divert is not routinely granted to accommodate scheduled maintenance. Immediate repairs are to be initiated and a time estimate of return to normal capacity is to be communicated to EMSA dispatch at the time of divert status request.

Procedure:

- 1. Hospitals will request divert status by contacting the EMSA Communication Center.
- 2. Once divert conditions are met and approved, hospitals may enter their status in the EMSystem.com computer according to the following categories:
  - a) Tulsa:
    - 1) ED Divert
    - 2) Priority One Trauma
    - 3) CT Divert
    - 4) Cath Lab Divert
  - b) Oklahoma City:
    - 1) ED Divert
    - 2) Priority One Trauma
    - 3) CT Divert
    - 4) Cath Lab Divert



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 17C: EMS Diversion from Hospitals, cont.**

- 3. The following information on hospital diverts shall be displayed on the EMSystem.com computer:
  - a) Current hospital status
  - b) Type of divert
  - c) Time on divert or most recent update
  - d) Special comments

In accordance with the American College of Emergency Physicians Policy Statement on Ambulance Diversion, if the Chief Medical Officer or Chief Medical Offier's designee determines the <u>entire</u> system to be overloaded, all hospitals will be opened to receive EMS patients in accordance with these protocols. If hospitals request divert to the point that a given geographic area is essentially without a receiving hospital, or overload is created for that area, then all facilities within that geographic region will be opened to receive EMS patients in accordance with these protocols. At the discretion of the Chief Medical Officer or Chief Medical Officer's designee, a temporary rotation of hospitals on divert may be utilized as conditions allow.

A hospital-initiated request for ED Divert shall automatically expire 1 hour after being initially granted unless extenuating circumstances continue and a diversion extension is granted for an additional 1 hour. A verbal report on divert avoidance action will be requested and forwarded to an EMSA Field Operations Supervisor for approval prior to any extension being granted. At EMSA, Chief Medical Officer, or Chief Medical Officer's designee's discretion, an EMSA Field Supervisor may conduct an on-site consultation to determine if an extension of the divert status is justified, factoring concurrent system needs.

A hospital-initiated request for Priority One Trauma or CT Divert shall automatically expire 2 hours after being initially granted unless extenuating circumstances continue to prevail and a diversion extension is granted for an additionally defined period of hours.

When a hospital is on an MCB approved divert as defined above, all on-duty field personnel are to be notified in an expeditious manner and are expected to honor the diversion hospital's status (see exception next paragraph). Diversion status will be explained to the patient (or appropriate patient's representative) in order to allow for an informed alternative hospital destination decision. In the event of encode to a hospital in the midst of diversion request with EMSA Dispatch, the EMT or paramedic may continue to that hospital if an alternative hospital destination MCB approved divert status, an EMT or paramedic may override the hospital's divert status if transport to that hospital is required for life-saving, immediately needed patient stabilization.

When a hospital is on ED divert status only, all stable patients will be delivered to that hospital if there exists an established relationship with that hospital or a member of its medical staff. Established relationships include, but are not limited to, a previous admission to that hospital and/or a pre-existing doctor-patient relationship with a doctor on that hospital's medical staff.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **PROTOCOL 17C: EMS Diversion from Hospitals, cont.**

Questions that will assist Paramedics in determining an established patient include:

- Which hospital do you want to be transported to?
- Who is your primary physician?
- Which hospital has your physician told you to use for your care?
- Have you been an inpatient in a hospital and do you still go there for care?
- Have you recently been seen in a hospital emergency department for this problem?


In any instance that an EMSA ambulance transports an unscheduled patient for emergency medical care and arrives on hospital property, that hospital's Emergency Department must perform an emergency medical screening examination, even if on divert status. If further indicated treatment cannot be provided, it shall be the responsibility of that hospital to make arrangements for transfer of the patient to a more appropriate healthcare facility.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### **PROTOCOL 17C: EMS Diversion from Hospitals, cont.**

The following algorithm is to be used in conjunction with the preceding text of this protocol and not independently of the preceding text of this protocol.




Medical References:

"Ambulance Diversion. A Position Paper for the Standards and Clinical Practices Committee of the National Association of EMS Physicians." 1997; 1:100-3.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17D: "No Fly Zones"** 

### Western Division




• Service area within the boundaries of the red circle represents "No Fly" zone.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17D: "No Fly Zones," cont.** 

### Eastern Division



• Service area within the boundaries of the red circle represents "No Fly" zone.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### PROTOCOL 17E: Advanced Airway Management: Pediatric Oral Intubation

EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

Orotracheal intubation authorized for pediatric patients utilizing same protocols for adult patients.

#### Technique Comments:

- 1. Avoid hyperextension of neck during intubation attempts. This positioning compromises glottic visualization.
- 2. Endotracheal tube size can be determined using the formula 16 + age in years/4 or using a tube roughly the diameter of the patient's little finger, (5<sup>th</sup> digit).
- 3. The Flex-Guide is **<u>NOT</u>** compatible with pediatric endotracheal tubes.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 17F - MEDICATION-ASSISTED INTUBATION PEDIATRIC

#### TREATMENT PRIORITIES

1. Oxygenation/Ventilation support

#### EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL

RESPONDER EMT

EMT-INTERMEDIATE 85

ADVANCED EMT

PARAMEDIC

PA	RA	ME	D	С

MEDICATION-ASSISTED INTUBATION IF INDICATED FOLLOW PROTOCOL 2G – ORAL INTUBATION FOR TECHNIQUE & CONFIRMATION OF INTUBATION

> FOR FACILITATING ORAL INTUBATION: PEDIATRIC: ETOMIDATE 0.3 mg/kg IVP/IOP SINGLE DOSE OR

PEDIATRIC: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

FOR POST-ORAL INTUBATION SEDATION TO PREVENT EXTUBATION (IF INDICATED): PEDIATRIC: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

OR

PEDIATRIC: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

OR

PEDIATRIC: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 17G – CONFIRMATION OF ENDOTRACHEAL AIRWAY PLACEMENT PEDIATRIC


**EMT-INTERMEDIATE 85** 


#### ADVANCED EMT

PARAMEDIC

The following sequence is to be used (and its use documented) to verify and maintain correct endotracheal artificial airway placement without fail:

- 1. Visualization of endotracheal tube passage between vocal cords oral intubation only. (Figure 1)
- 2. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values and waveforms. (Figure 2)
- 3. Auscultation. Auscultate the epigastrium. (Figure 3) If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to midaxillary lines. If breath sounds are present on the right and absent on the left, this suggests a right mainstem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.










Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17G: Confirmation of Endotracheal Artificial Airway Placement –** 

### Pediatric

- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress/failure.
- 5. Secure the endotracheal tube with a tube holder and place a cervical collar. (Figure 4)



When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.

Upon delivery of the patient at treatment destination or at subsequent transport (eg. helicopter transport), a waveform capnograph will be obtained and documented after the patient has been physically transferred onto the destination's/subsequent transport's stretcher/bed/operating table to show confirmed, continued correct endotracheal tube placement at EMS transfer of patient care.




Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17H: Helmet Removal** 

ЕМТ
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

#### Motorcycle-style helmet comments:

While helmets offer protection for the head, they have not proven to reduce spine injuries. While their use is encouraged, helmets prevent airway access and complicate spinal immobilization. Because most full helmets do not hold the head firmly and also prevent cervical collar application, spinally immobilizing a helmeted patient does not result in effective cervical immobilization. Helmets must be removed prior to spinal immobilization on a long board to assure airway access and adequate spinal immobilization. In motocross events, look for neck braces and chest protectors that are attached by clasps and hinges that will also need to be removed.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17H: Helmet Removal, (cont.)** 

MOTORCYCLE-STYLE HELMET REMOVAL PROCEDURE (continued)

Step 6: After helmet removal, first EMT replaces hands on both sides of the head, resuming manual stabilization.



Step 7: Maintain manual stabilization until complete spinal immobilization is achieved.



#### Football helmet and pad set comments:

When removing football helmets, shoulder pad sets must be also be removed to avoid immobilizing the neck in a hyperextended position. In some instances, the face mask alone may need to be removed first, either for immediate airway interventions or to facilitate helmet removal. In all cases, the coach or athletic trainer may prove a good source of information regarding the exact equipment needed for removal. For instance, many recently manufactured football helmets have air bladder systems designed so the helmet tightly fits the head; the coach or athletic trainer will be best able to release these air bladders.

#### FOOTBALL HELMET FACE MASK REMOVAL PROCEDURE

Several different tools can be used to remove a football helmet face mask – the FM extractor, Trainer's Angel, knives, pruning shears, and PVC cutters. There are typically four plastic clips attached to the face mask and screwed into the helmet. A screwdriver should be utilized only as a last resort. Unscrewing these face mask clips may cause excessive head movement if the screws have been place for some time and are rusted. Medic shears and seatbelt cutters are not recommended as these tools have been shown to take excessive time to work.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17H: Helmet Removal, (cont.)** 

FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE

Step 1: Manually stabilize the head and spine. Remove the mouthpiece.



Step 2: Second EMT unfastens any straps while stabilization is maintained.



Step 3: Second EMT removes ear pads by unsnapping them from inside the shell.



Step 4: If fitted with air bladder system, deflate the liner through the valve as pictured by using the needle of the inflation system to release air pressure at inflation points.







Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17H: Helmet Removal, (cont.)** 

FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE (continued)

Step 5: Remove helmet utilizing technique for motorcyclestyle helmets.



Step 6: Maintain neutral alignment of the neck while the shoulder pads are removed.



Step 7: Cut jersey away. Unfasten or cut the shoulder pads straps and laces.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17H: Helmet Removal, (cont.)** 

FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE (continued)

Step 8: Laterally unfold shoulder pads and slide out toward the first EMT. A third and even fourth EMT may be needed to support the back.











- Techniques of Helmet Removal from Injured Patients, American College of Surgeons, Committee on Trauma, April 1997
- Training Medical Personnel in Techniques for Proper Motorcycle Helmet Removal, The Motorcycle Riders Foundation, September 2001
- Techniques and Equipment for Helmet Removal; Professional Sports Training, Green Bay Packers, EMSED.Com; November 2005
- Prehospital Emergency Care, 8<sup>th</sup> Edition, Copyright, July 2008



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### PROTOCOL 17I: Controlled Substance Handling & Documentation - Field Paramedics

#### EMT-PARAMEDIC

#### Indication:

Federal, State of Oklahoma, and Medical Control Board/Office of the Medical Director laws, regulations, and requirements for appropriate control of controlled substances. These procedures apply to all scheduled controlled substances: Class II - Fentanyl (Sublimaze) and Morphine Sulfate; Class IV - Diazepam (Valium) and Midazolam (Versed).

#### Authorized Handling, Inventory, & Custody:

- 1. While in field use inventory, only system-certified paramedics may access and handle controlled substances.
- At the start and end of every shift and at any time of resupply of controlled substance, direct inspection of each controlled substance container (e.g. vial, ampule, pre-filled syringe or cartridge) will be conducted for any signs of damage to the individually numbered and/or letter tamper-evident seals and overall container, recording of controlled substance containers present and/or missing, and such inspection shall be signed by the oncoming paramedic with an appropriate witness signature as well (e.g. off going paramedic if at shift change, authorized materials agent if at EMSA, supervising officer). Expiration dates are to be noted at these inspections. All such inspection/inventory shall be recorded in an apparatus specific controlled substance log book, itself having secured access.
   At the start and end of every shift, if the apparatus is dispatched to an incident prior to the
- At the start and end of every shift, if the apparatus is dispatched to an incident prior to the proper transfer of controlled substances to the oncoming paramedic, the paramedic with current documented custody must respond on the incident. At no time will transfer of controlled substances delay apparatus response or occur during an incident response.
- 4. In the event of tampered/damaged and/or unaccounted controlled substances at any inspection, all involved personnel will remain on-duty and the last authorized personnel will retain custody of the controlled substances until all discrepancies are immediately reported to the supervising EMS officer and an OMD Division Chief with sufficient resolution acceptable to both the EMS officer and OMD Division Chief.
- 5. In the event of expired controlled substances, the expired controlled substance will be removed from immediate patient use stock, reflected in the apparatus specific controlled substance log book and be secured, using a clear chain of custody per specific agency policy, until the expired controlled substance is in the secured custody of the agency's Controlled Substance Officer.
- 6. All completed pages in the apparatus specific controlled substance log book will be retained by the agency's Controlled Substance Officer in compiling an agency specific master log of controlled substance use and inventory.



#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17I: Controlled Substance Handling & Documentation - Field Paramedics** (cont.)

#### Storage for Immediate Patient Use:

- 1. All MCB-approved controlled substances will be maintained in locked, temperature-controlled locations on paramedic-staffed apparatus.
- 2. Securing of controlled substances will be primarily by mechanical lock.
- 3. Securing of controlled substances will be secondarily by consistent personal control of devices for accessing the controlled substance location on the apparatus. Paramedics are not to share individual access codes, keys, or other devices for access with anyone other than agency clinical leadership, Office of the Medical Director personnel, and/or law enforcement personnel conducting a formal inspection of controlled substances assigned to the individual paramedic/apparatus.
- 4. Securing of controlled substances will be by individually numbered and/or lettered tamper-evident seals (as approved and assigned by the Office of the Medical Director) that are uniquely assigned to each controlled substance container.
- 5. At any time the paramedic-staffed apparatus is taken out of service, the assigned paramedic at the time of such status change will maintain direct control of controlled substances until all assigned substances on that apparatus are secured within the station or central inventory as applicable based upon specific agency procedure.

#### Patient Administration

- 1. Paramedics may only administer a controlled substance in accordance with MCB treatment protocol(s) and/or a direct order from an on-line medical control physician.
- When a controlled substance is administered in patient care, the patient care record will contain at a minimum in relation to the controlled substance: date, time, incident number, medical condition being treated, patient name, physician ordering (if applicable), and name, dose, and route of controlled substance administered.
- 3. When a controlled substance is administered in patient care, the apparatus specific controlled substance log book will contain at a minimum in relation to the controlled substance: date, time, incident number, medical condition being treated, patient initials, physician ordering (if applicable), and name and dose of controlled substance administered. Additionally, any unused ("wasted") amount of controlled substance will be recorded by patient care incident.
- 4. Any partially unused amount of opened controlled substance will require the log book entry to bear the signature of two persons each attesting to the fact that the drug was properly disposed. One of two persons should be a physician, nurse, or the paramedic's partner (if unable to obtain nurse or physician's signature).
- 5. Any wholly unused amount of an opened controlled substance (e.g. vial seal opened but not administered to patient) will be denoted in both the apparatus specific controlled substance log book and an incident report that details the specifics of why the controlled substance was accessed but not administered to the patient (e.g. seizure abated prior to medication administration). The involved container of controlled substance will be transferred, maintaining a clear chain of custody, to the agency's Controlled Substance Officer or his/her designee.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17J: Seasonal Influenza Vaccine Administration** 

#### **EMT-PARAMEDIC**

#### Indications:

- 1. Request from employee of EMS Agency and/or Fire Department administering the vaccine.
- 2. Request from employee of the city, county, and/or regional governmental authority providing oversight of the EMS Agency and/or Fire Department administering the vaccine.
- 3. Timing of request by indicated personnel in 1 or 2 above within the seasonal influenza vaccination time period as authorized by the Chief Medical Officer (timing authorized may change from year to year)

### Contraindications:

- 1. Known hypersensitivity, including allergic reactions, to past seasonal influenza vaccine administration.
- 2. History of Guillain Barré syndrome onset within 6 weeks of a past seasonal influenza vaccine administration.
- 3. Known hypersensitivity, including allergic reactions, to eggs.
- 4. Active infection.
- 5. Close contact with an immune suppressed person requiring protective isolation.
- 6. Do not administer <u>a live</u>, <u>attenuated seasonal influenza vaccination (e.g. inhaled formulation)</u> to patients with any of the following characteristics:
  - a. Age 50 years or greater
  - b. COPD, including asthma
  - c. Heart disease
  - d. Vascular disease (excluding hypertension)
  - e. Renal disease
  - f. Hepatic disease
  - g. Neurologic/Neuromuscular disease, including cognitive impairment
  - h. Hematologic disease
  - i. Metabolic/Endocrine disease, including diabetes
  - j. Immune dysfunction, including that caused by HIV and related medications
  - k. Pregnancy



#### Approved 9/14/22, Effective 1/16/23, replaces all prior versions **PROTOCOL 17J: Seasonal Influenza Vaccine Administration (cont.)**

#### Procedure Comments:

- 1. Review all seasonal influenza vaccine manufacturer's instructions supplied with the vaccine.
- 2. The seasonal influenza vaccine must be stored per manufacturer's instructions.
- 3. Utilize a standardized seasonal influenza vaccination informed consent form.
- 4. Utilize a standardized seasonal influenza vaccination pre-screening questionnaire form.
- 5. Ensure appropriate medical equipment is present at the seasonal influenza vaccination site for treatment per protocol of allergic reaction.
- 6. Administer seasonal influenza vaccine per manufacturer's instructions proper dose, deltoid IM route (or inhaled route if using inhaled formulation), etc.
- 7. Briefly monitor the patient for any immediate allergic reaction.
- 8. Prior to patient leaving seasonal influenza vaccination site, ensure the following information is obtained and documented on a seasonal influenza vaccination form for each patient:
  - a. Contact information: work mailing address, work email (if applicable), work phone
  - b. This information is necessary if the seasonal influenza vaccination lot is found problematic (e.g. defective in immunity function) and patient notification is required.
- 9. Provide the patient with a standardized seasonal influenza vaccination post-vaccination information form.
- 10. A standard EMS Agency and/or Fire Department patient care record does NOT need to be generated, but the seasonal influenza vaccinating organization must maintain a log of all patient contacts associated with a seasonal influenza vaccination program. For each patient receiving a seasonal influenza vaccine administration, the following must be recorded:
  - a. date of seasonal influenza vaccine administration
  - b. the manufacturer and lot number of seasonal influenza vaccine administered
  - c. vaccination site and route (e.g. left deltoid IM)
  - d. name of paramedic administering the vaccination
- 11. Any and all adverse medical reactions to the administration of a seasonal influenza vaccine must be reported to the Chief Medical Officer or his/her designee within 24 hours. Upon the Chief Medical Officer's review, further reporting may be directed to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967.



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

# 17K – TRANEXAMIC ACID (TXA, CYCLOKAPRON)

#### PARAMEDIC

**Class:** Anti-Fibrinolytic

Actions/Pharmacodynamics: Promotes clot formation in the setting of massive hemorrhage.

**Indications:** Hemostatic Agents (10I)

Traumatic hemorrhagic shock less than 3 hours from injury with suspected need for massive blood transfusion (clinical evidence of marked blood loss – internal or external, sustained tachycardia and hypotension, see Protocol 10I for exact VS parameters by age group)

**Contraindications:** Non-hemorrhagic shock Non-traumatic hemorrhagic shock Hemorrhagic shock stabilized with other hemostatic agents/measures

**Pharmacokinetics:** Onset of action within 4 hours after IV administration, exact time of onset unclear and variable. Delayed effects up to 48 hours consistent with anti-inflammatory actions.

**Side Effects:** While a theoretical concern, TXA has not been shown to cause significant increase in deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke in published trials to date.

Dosage: Hemostatic Agents – Adult (10I) (Hemorrhagic shock as described above) 1 gram IVPB over 10 minutes. Administer in 100 mL or 250 mL NS.

> Hemostatic Agents – Pediatric Ages 10 and Above (10I) (Hemorrhagic shock as described above) 15 mg/kg up to 1 gram IVPB over 10 minutes. Administer in 100 mL or 250 mL NS.

**How Supplied:** 1 gram/10 mL vial or ampule (100 mg/mL) (Always check concentration and dose per container at time of patient medication administration)



Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### **17L - POSITIVE END EXPIRATORY PRESSURE (PEEP)**

A small amount of PEEP ranging between 5 and 10 cm/H<sub>2</sub>O prevents airway closure, increases the airway opening index and improves the efficiency of alveolar ventilation produced by chest compressions.

Indication: Any pediatric patient (Birth to 12 years of age) with an advanced airway.


Contraindication: Status Asthmaticus


Set PEEP device to 5 cm/H<sub>2</sub>O (Figure 1) and attach PEEP device to the Bag Valve Mask exhaust port (Figure 2). Attach Bag Valve Mask to endotracheal tube or supraglottic airway and provide ventilations per protocol 3A - Respiratory Arrest or 4A - Cardiac Arrest as indicated.

Rotate PEEP valve to increase pressure by 1 cm/H<sub>2</sub>0 (clockwise ¼ turn) every 2 minutes until SpO2  $\ge$  94%. Max PEEP 10 cm/H<sub>2</sub>O.

**Clinical Note**: If patient has a congenital cardiac anomaly or other known medical condition with baseline SpO2 <94% set PEEP device to 5 cm/H<sub>2</sub>O and titrate to upper limit of baseline SpO2.

Attach ResQPOD<sup>m</sup> to BVM if  $\geq$  12 years of age AND estimated patient wt  $\geq$  50 Kg.










Approved 9/114/22, Effective 1/16/23, replaces all prior versions



#### Indications:

Collection of evidentiary blood samples for assisting law enforcement officers in select situations where logistics would otherwise prove notably difficult (e.g. patient transport out of state, patient transport significant distance in state). Blood collected will be for the purpose of Blood Alcohol and/or Drug Content Analysis pursuant to Oklahoma Statutes Title 47. Motor Vehicle Chapter 67 - Chemical Tests Section 752 - Procedure for Blood Tests - Authorization - Liability for Withdrawal - Reports Cite as: 47 O.S. § 752 (OSCN 2022). 40 O.A.R 10-9-1 - Persons authorized to withdraw blood

#### Procedure by EMS Personnel:

- 1. At no time is patient care to be compromised for the purpose of blood sample collection for assisting law enforcement. Unstable patients may not have evidentiary blood samples drawn if treating EMS personnel believe such will compromise medical care. Unstable patients should be transported to the hospital, where blood collection can be performed by hospital-based personnel.
- 2. EMS personnel should not be requested for the sole purpose of collecting a blood sample under the Oklahoma Vehicle and Traffic Law if no obvious EMS medical care need exists. Any person contacted by EMS personnel under such circumstance is to be offered medical assessment, care, and transport. See also Protocol 14D: Informed Patient Consent/Refusal.
- 3. EMS personnel are allowed, but not required, to perform blood collection requested by a law enforcement officer and consented to by the patient. If on-scene disagreement occurs between EMS personnel and law enforcement officers specific to the immediacy of medical care and/or EMS transportation needs, provide care within MCB Treatment Protocols and contact OMD for on-line consultation. Such consultation may include discussion by OMD with the ranking law enforcement officer on scene and/or supervising an arrest (if applicable). Medical decisions are to be made by EMS personnel (which may include OMD consultation).
- 4. OMD/physician contact is not required for EMS personnel to collect a blood sample for the purpose of Blood Alcohol and/or Drug Content Analysis if requested by a law enforcement officer.
- 5. If a blood sample is collected by EMS personnel, it must be performed in the presence of a law enforcement officer. EMS personnel obtaining a blood sample must collect or immediately deposit the collected blood samples into 10 milliliter (mL) glass vacuum tubes labeled by the manufacturer as containing 100 milligrams (mg) of sodium fluoride and 20 milligrams (mg) of potassium oxalate. The vacuum tubes contained in the State of Oklahoma Blood Specimen Collection Kit meet these requirements.
- 6. In the process of obtaining a blood sample, do not use an alcohol containing skin prep over the venipuncture site. If starting an IV for fluids or medications, first obtain the blood samples in the tubes provided by the law enforcement officer before the IV line.



# EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/14/22, Effective 1/16/23, new interim guidance issuance

### **COVID-19 Vaccine Administration**

PARAMEDIC

#### Indications:

- 1. Vaccinating Paramedic has completed all required COVID-19 vaccination training requirements established by relevant public health authority (typically Oklahoma City County Health Department, Tulsa Health Department, or Oklahoma State Department of Health).
- Request for COVID-19 vaccination by anyone authorized by the relevant public health authority (typically Oklahoma City County Health Department, Tulsa Health Department, or Oklahoma State Department of Health) to receive COVID-19 vaccination. At Interim Guidance new issuance, the Pfizer/BioNTech COVID-19 vaccine is approved by the U.S. Food and Drug Administration (FDA) for individuals age 16 years and older. For the Moderna COVID-19 vaccine, FDA approval is for individuals age 18 years and older.
- 3. Timing of request above within a time period authorized by the Chief Medical Officer (timing at issuance is without limitation).

#### Contraindications:

 Per the Centers for Disease Control (CDC), history of severe allergic reaction (anaphylaxis) to any of the components of the vaccine. Check manufacturer listing of components of the specific vaccine intended for administration. Most anaphylaxis observed to date from COVID-19 vaccine is thought due to polyethylene glycol (PEG) which can be used as a thickener, softener, or moisture carrier in products such as toothpaste, shampoo, and laxatives.

Current observation in the United States indicates that anaphylaxis to COVID-19 vaccines is very rare. During December 14–23, 2020, monitoring by the Vaccine Adverse Event Reporting System detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million doses); 71% of these occurred within 15 minutes of vaccination. (source: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. ePub: 6 January 2021.)

#### Precaution Considerations that are NOT Contraindications:

- 1. Per the CDC, persons with moderate to severe acute illness (e.g., pneumonia with acute dyspnea) should be encouraged to recover from such illness and vaccination is recommended deferred until that time.
- 2. Per the CDC, history of severe allergic reaction (anaphylaxis) to another vaccine or injectable therapy.

Of note, the CDC vaccine safety team experts have shared that there are NO contraindications or precautions to getting the COVID-19 mRNA vaccines if allergic to food (including eggs or gelatin), pets, venoms, environmental agents, oral medications, or latex.



# EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/14/22, Effective 1/16/23, new interim guidance issuance

### COVID-19 Vaccine Administration (cont.)

### Procedure Comments:

- 1. Review all COVID-19 vaccine manufacturer's instructions supplied with the vaccine.
- 2. The COVID-19 vaccine must be stored and handled per manufacturer's instructions.
- 3. Utilize a standardized COVID-19 vaccination informed consent form available from the relevant public health authority.
- 4. Utilize a standardized COVID-19 vaccination pre-screening questionnaire form AND provide the patient a standardized pre-vaccination information sheet specific to the COVID-19 vaccine, which are both available from the relevant public health authority. It is federal law that anyone being vaccinated (or the legal guardian of the person being vaccinated) receive pre-vaccination information, typically called a Vaccine Information Statement (VIS), specific to the vaccine describing its risks and benefits. Review this information with the patient (or legal guardian) and give a copy of such to them for their personal records. Specific to the COVID-19 vaccines, the VIS is called "Fact Sheet for Recipients and Caregivers Emergency Use Authorization (EUA)."
- 5. Ensure appropriate medical equipment is present at the COVID-19 vaccination site for treatment per protocol of allergic reaction.
- 6. Administer COVID-19 vaccine per manufacturer's instructions dose, deltoid IM route, etc.
- 7. Monitor the patient for any immediate allergic reaction for a minimum of 15 minutes if no precaution considerations present. If precaution considerations are present, increase the minimum monitoring time to 30 minutes post-vaccination.
- 8. Prior to patient leaving the COVID-19 vaccination site, ensure the following information is obtained and documented on the COVID-19 vaccination form for each patient:
  - a. Contact information: preferred mailing address, preferred email (if applicable), preferred phone
  - b. This information is necessary if the COVID-19 vaccination lot is found problematic (e.g., defective in immunity function) and patient notification is required.
- 9. Provide the patient with a standardized CDC COVID-19 vaccination record card that has been completed by the vaccination team so the patient has a record of when vaccinated, what vaccine they received to include the specific manufacturer of it, the lot number of the vaccine received, and when the second dose (if applicable) should be scheduled. At present, the second dose for the Pfizer/BioNTech COVID-19 vaccine is 21 days after the first dose; the second dose for the Moderna COVID-19 vaccine is 28 days after the first dose. Patients are also to receive a standardized COVID-19 vaccination post-vaccination information form, including information about enrolling in the V-safe after vaccination health checker smartphone app. These information forms are available from the relevant public health authority.
- 10. A standard EMS Agency and/or Fire Department patient care record does NOT need to be generated, but the COVID-19 vaccinating organization must maintain a log of all patient contacts associated with a COVID-19 vaccination program. For each patient receiving a COVID-19 vaccine administration, the following must be recorded for EMS system and MCB/OMD availability:
  - a. date of COVID-19 vaccine administration
  - b. the manufacturer and lot number of COVID-19 vaccine administered
  - c. vaccination site and route (e.g., left deltoid IM)
  - d. name of Paramedic administering the vaccination



# EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/14/22, Effective 1/16/23, new interim guidance issuance

### COVID-19 Vaccine Administration (cont.)

Procedure Comments (cont.):


- 11. For each patient receiving a COVID-19 vaccine administration, the vaccination information must also be recorded into the Oklahoma State Immunization Information System (OSIIS). Information about OSIIS and recording information into it should be coordinated with the relevant public health authority.
- 12. Any and all adverse medical reactions to the administration of a COVID-19 vaccine must be reported to the Chief Medical Officer or his/her designee within 24 hours. Upon the Chief Medical Officer's review, further reporting may be directed to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967.





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

#### 170 – LOW TITER O+ WHOLE BLOOD(LTOWB) METROPOLITAN OKLAHOMA CITY



PARAMEDIC

Class: Blood Products

**Purpose**: Increase survival from traumatic hemorrhagic shock, factoring trauma patients who receive whole blood vs component therapy have many advantages, one of the most important being a reduction in 30-day mortality per published studies.

#### Actions/Pharmacodynamics:

Whole blood **provides red cells, stable clotting factors, and volume in each unit** that make it potentially beneficial in rapidly hemorrhaging patients.

#### Indications: Hemorrhagic Shock in Priority 1 Trauma Patients

- Males ≥15 years old/ Females ≥51 years old AND
- Systolic Blood Pressure < 70 mmHg OR
- Systolic Blood Pressure < 90 mmHg with Heart Rate ≥110 beats per min <u>OR</u>
- ETCO2 < 25 <u>OR</u>
- Witnessed traumatic arrest < 5 minutes prior to provider arrival and continuous CPR throughout downtime <u>OR</u>
- Post traumatic arrest/ ROSC obtained

#### For Hemorrhagic Shock in Priority 1 Geriatric Trauma Patients

• If age ≥ 65 years old <u>AND</u> Systolic Blood Pressure ≤ 100 with HR ≥100 beats per minute

#### **Contraindications and Precautions:**

- Ground level falls/found down
- Males less than 15 years old
- Females less than 51 years old
- Burns
- Religious objection to receiving whole blood





Approved 9/14/22, Effective 1/16/23, replaces all prior versions

### Protocol 17O: Low Titer O+ Whole Blood (LTOWB) Metropolitan Oklahoma City cont.'

**Side Effects:** Transfusion Reactions- Fever, chills, urticaria (hives), and itching. Respiratory distress, high fever, hypotension, and hemoglobinuria can indicate a more serious reaction.

Dosage: One unit of Low Titer O+ Whole Blood

**How Supplied:** One unit of Low Titer O+ Whole Blood contains approximately 500 ml of blood and is packaged by the Oklahoma Blood Institute.

#### Infusion Site Considerations

LTOWB requires an 18 gauge or larger IV/IO. IO transfusion is authorized but is less efficient than IV. The humeral neck is the most effective IO site if used for blood transfusion.

If TXA is needed it should be administered through a separate IV. This IV should be established in a different extremity than the one in which LTOWB is transfusing.

#### Procedure: Prepping Tubing and Disposable Unit for Whole Blood Administration

- Make certain that unused portion of the IV line is closed off.
- Attach the IV line to the Disposable Tubing Unit.
- Attach the Disposable Tubing Unit to the Blood Warmer.
- Attach Disposable Tubing Unit to the saline lock.
- Spike the 100 mL NS bag to appropriate port on the Blood Tubing.
- Spike the Whole Blood Bag to the appropriate port on the Blood Tubing.
- Prime the IV-line, Disposable Tubing Unit, and saline lock with saline prior to powering on the Blood Warmer.
- Turn Blood Warmer ON.
- Start infusion of LTOWB (do not wait for the blood to warm).
- Place LTOWB in the Pressure Bag and pump up the Pressure Bag.
- Use the hand pump built into the blood tubing for rapidly administering LTOWB.
- Once LTOWB infusion is complete, flush line with remaining saline from 100 mL bag.

\*\*Avoid excessive delays related to availability of LTOWB. Scene times may be delayed while starting LTOWB. However, there should not be a significant delay waiting on LTOWB to arrive on-scene. Consider intercept enroute to transition LTOWB case to transporting unit if time allows.

### **SECTION 18**

# RESERVED FOR AGENCY SPECIFIC USE PILOT PROGRAMS / RESEARCH

This page left intentionally blank.



<u>A</u>

B

EMS System for Metropolitan Oklahoma City and Tulsa 2023 Medical Control Board Treatment Protocols



#### ABBREVIATIONS

ABCs	AIRWAY, BREATHING, AND CIRCULATION
Abd	ABDOMEN
AC	ASSIST CONTROL (Mechanical Ventilation mode)
ACS	ACUTE CORONARY SYNDROME
AED	AUTOMATED EXTERNAL DEFIBRILLATOR
AEMT	ADVANCED EMERGENCY MEDICAL TECHNICIAN
АКА/ВКА	ABOVE-BELOW-KNEE AMPUTATION
ALTE	APPARENT LIFE THREATENING EVENT
AMI	ACUTE MYOCARDIAL INFARCTION
AMS	ALTERED MENTAL STATUS
AOS	ARRIVAL ON SCENE
ASA	ASPIRIN
ASAP	AS SOON AS POSSIBLE
AV	ATRIOVENTRICULAR
BiPAP	BI-LEVEL POSTIVE AIRWAY PRESSURE
BGL	BLOOD GLUCOSE
BP	BLOOD PRESSURE
BSA	BODY SURFACE AREA
BVM	BAG VALVE MASK





## <u>C</u>

D

CELSIUS
CERVICAL COLLAR
CIRCULATION, AIRWAY, AND BREATHING
CONGESTIVE HEART FAILURE
CENTIMETER
CENTRAL NERVOUS SYSTEM
CARBON MONOXIDE
CARBON DIOXIDE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CONTINUOUS POSITIVE AIRWAY PRESSURE
CARDIOPULMONARY RESUSCITATION
CLEAR TO AUSCULTATION
DEXTROSE 10%
DEXTROSE 25%
DEXTROSE 50%
DISCHARGE
DEFORMITIES, CONTUSIONS, ABRASIONS, PENETRATIONS, PARADOXICAL MOVEMENTS, BURNS, LACERATIONS, SWELLING
DIASYSTOLIC BLOOD PRESSURE
DECILITER

- DNI DO NOT INTUBATE
- DNR DO NOT RESUSCITATE





<u>D</u>		
	D.O.	DOCTOR OF OSTEOPATHY
<u>E</u>		
	ECG	ELECTROCARDIOGRAM
	ED	EMERGENCY DEPARTMENT
	EMD	EMERGENCY MEDICAL DISPATCHER
	EMR	EMERGENCY MEDICAL RESPONDER
	EMS	EMERGENCY MEDICAL SERVICES
	EMSA	EMERGENCY MEDICAL SERVICE AUTHORITY
	EMT	EMERGENCY MEDICAL TECHNICIAN
	EMT-I 85	EMERGENCY MEDICAL TECHNICIAN-INTERMEDIATE 1985
	EOC	EMERGENCY OPERATIONS CENTER
	ETA	ESTIMATED TIME OF ARRIVAL
	EtCO2	END-TIDAL CARBON DIOXIDE
	ETOH	ETHANOL
	ETT	ENDOTRACHEAL TUBE
<u>F</u>		
	F	FAHRENHEIT
	FD	FIRE DEPARTMENT
	FiO2	FRACTION OF INSPIRED OXYGEN
	FOS	FIELD OPERATIONS SUPERVISOR

FT FEET (in measurement)





<u>G</u>		
	GCS	GLASGOW COMA SCALE
<u>H</u>		
	НВО	HYPERBARIC OXYGEN
	HEMS	HELICOPTER EMERGENCY MEDICAL SERVICE
	HIV	HUMAN IMMUNODEFICIENCY VIRUS
	HR	HOUR
	HTN	HYPERTENSION
	НХ	HISTORY
Ī		
	IABP	INTRA-AORTIC BALLON PUMP
	ICD	IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
	ICS	INCIDENT COMMAND STRUCTURE
	ID	IDENTIFICATION
	I:E	INSPIRATORY TO EXPIRATORY RATIO
	IM	INTRAMUSCULAR
	IN	INTRANASAL
	ю	INTRAOSSEOUS
	IOP	INTRAOSSEOUS PUSH
	IOPB	INTRAOSSEOUS PIGGYBACK
	IV	INTRAVENOUS
	IVP	INTRAVENOUS PUSH
	IVPB	INTRAVENOUS PIGGYBACK





ī		
	J	JOULES
<u>K</u>		
	KCL	POTASSIUM CHLORIDE
	kg	KILOGRAM
L		
	L	LITER
	LA	LEFT ARM
	LAPSS	LOS ANGELES PREHOSPITAL STROKE SCALE
	LL	LEFT LEG
	LLE	LEFT LOWER EXTREMITY
	LLQ	LEFT LOWER QUADRANT
	LOC	LOSS OF CONSCIOUSNESS
	lpm	LITERS PER MINUTE
	LUE	LEFT UPPER EXTREMEITY
	LUQ	LEFT UPPER QUADRANT
<u>M</u>		
	mA	milliAmp
	MAX	MAXIMUM
	mcg	MICROGRAM
	МСВ	MEDICAL CONTROL BOARD
	MCI	MASS CASUALTY INCIDENT

M.D. MEDICAL DOCTOR





### M

<u>N</u>

<u>0</u>

mEq	MILLIEQUIVALENT
MERC	MEDICAL EMERGENCY RESPONSE CENTER
mg	MILLIGRAM
MI	MYOCARDIAL INFARCTION
MIN	MINUTE
mL	MILLILITER
mm	MILLIMETER
mmHg	MILLIMETERS OF MERCURY
MOI	MECHANISM OF INJURY
mph	MILES PER HOUR
NC	NASAL CANULA
NIPPV	NON-INVASIVE POSITIVE PRESSURE VENTILATION
NPA	NASAL PHARYNGEAL AIRWAY
NPO	NOTHING BY MOUTH
NRB	NON REBREATHER MASK
NS	NORMAL SALINE
NTG	NITROGLYCERIN
NVD	NAUSEA, VOMITING, DIARRHEA
02	OXYGEN
OD	OVERDOSE

- ODT ORAL DISOLVING TABLET





### <u>0</u>

<u>P</u>

OLMC	ON-LINE MEDICAL CONTROL
OLMCP	ON-LINE MEDICAL CONTROL PHYSICIAN
OMD	OFFICE OF THE MEDICAL DIRECTOR
OPA	ORAL PHARYNGEAL AIRWAY
OSDH	OKLAHOMA STATE DEPARTMENT OF HEALTH
O2 SAT	OXYGEN SATURATION
PD	POLCIE DEPARTMENT
PEA	PULSELESS ELECTRICAL ACTIVITY
PEEP	POSITIVE END-EXPIRATORY PRESSURE
PEP	POST-EXPOSURE PROPHYLAXIS
PICC	PERIPHERLLY INSERTED CENTRAL CATHETER
PMS	PULSE MOVEMENT SENSATION
РО	BY MOUTH
PRN	AS NEEDED
Psi	POUNDS PER SQUARE INCH
PS	PRESSURE SUPPORT (Mechanical Ventilation mode)
PSVT	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Pt	PATIENT
ΡΤΑ	PRIOR TO ARRIVAL
PVC	PREMATURE VENTRICULAR CONTRACTION
PERRLA	PUPILS EQUAL ROUND REACTIVE TO LIGHT ACCOMADATIONS





## <u>R</u>

<u>S</u>

RA	RIGHT ARM
REMSS	REGIONAL EMERGENCY MEDICAL SERVICE SYSTEM
RESP	RESPIRATIONS
RL	RIGHT LEG
RLE	RIGHT LOWER EXTREMITY
RLQ	RIGHT LOWER QUADRANT
RN	REGISTERED NURSE
ROSC	RETURN OF SPONTANEOUS CIRCULATION
RUE	RIGHT UPPER EXTREMITY
RUQ	RIGHT UPPER QUADRANT
SA	SINOATRIAL
SBP	SYSTOLIC BLOOD PRESSURE
SL	SUBLINGUAL
SOB	SHORTNESS OF BREATH
SpCO	CARBON MONOXIDE SATURATION OF ARTERIAL BLOOD
SpO2	OXYGEN SATURATION OF ARTERIAL BLOOD
STEMI	ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
SubQ	SUBCUTANEOUS

SYS BP SYSTOLIC BLOOD PRESSURE

ST SINUS TACHYCARDIA





# <u>T</u>

ТВ	TUBERCULOSIS
TBSA	TOTAL BODY SURFACE AREA
TCA	TRICYCLIC ANTIDEPRESSANT
TEMP	TEMPERATURE
THA	TOTAL HIP ARTHROPLASTY
ТКА	TOTAL KNEE ARTHROPLASTY
ТКО	TO KEEP OPEN
TREC	TRAUMA REFERRAL CENTER
ТХА	TRANEXAMIC ACID
VAD	VENTRICULAR ASSIST DEVICE
VF	VENTRICULAR FIBRILLATION
VS	VITAL SIGNS
VT	VENTRICULAR TACHYCARDIA

<u>W</u>

V

WO W	IDE OPEN (FLOW RATE)
------	----------------------

## INSTRUCTIONS Oklahoma State Department of Health Communicable Disease Risk Exposure Report

This report form was developed to initiate a system of notification for risk exposures occurring outside of a health care facility to health care workers, emergency responders, and funeral workers as specified by the Oklahoma State Department of Health OAC 310:555. This report and all information entered on it are to be held in strictest confidence to conform with 63 O.S. Supp. 2001, Section 1-502.1 et. seq.

Note: For questions regarding the handling of ODH Form 207, call 405/271-4636.

#### **PART I: Exposed Worker Section**

#### Questions 1-13 are to be completed by the exposed worker, immediately following the injury.

- 11: Describe exposure in detail. Include information regarding type of exposure, body part affected, type of body fluid involved, duration of exposure, etc.
- 13: List the facility where the source patient was taken. This will be the facility that is responsible for testing the source patient.

#### Questions 14-19 are to be completed by Employer's Designee, immediately following the injury.

#### Questions 20-22 are to be completed by a Licensed Health Care Professional. (MD, DO, RN, PA,).

Routing:

- A. If the Licensed Health Care Professional determines that the exposure does not have the potential for transmission of a communicable disease, the form should be returned to the Employer's Designee.
- B. If the exposure does have the potential for transmission of a communicable disease, the *Yellow* copy should be mailed *immediately* to the OSDH HIV/STD Service (use gray, self addressed, metered envelope).

The *Green* copy, a gray metered envelope and instruction page are to be delivered *immediately* to the designated person (usually the Infection Control Practitioner) at the health care facility to which the source patient was transported; to the attending physician, if the source patient was being cared for outside of a health care facility; to the health care provider who last had responsibility for the deceased source patient; or to the medical examiner.

#### PART II: Source Patient Health Care Provider Section

Questions 23-38 are to be completed by the Health Care Provider who is responsible for testing the source patient.

32. Rapid HIV testing has become a valuable tool used to quickly determine the need for initiation and/or continuation of PEP meds for the exposed person. When a rapid HIV test is performed on the source patient, communication of these results should not be delayed. The results should be **immediately** communicated to the physician/provider who is providing post-exposure counseling and follow up and is listed on page 1, q. 17-19.

Please note that as other source results become available, these should be released to the Provider listed on page 1, q. 17-19.

#### Routing:

A. The Health Care Provider should complete Part II and mail the completed green form to OSDH HIV/STD Service immediately using the gray, self-addressed, metered envelope.

#### PART II: Source Patient Health Care Provider Section (Please Print)

3. Date and time Con	nmunicable Disease Risk Exp	osure Report received: (Mo./Day/	Yr.)/ Time:	AM or PM (Circle One)
4. Person completin	g Part II:(Last)	(First)	(Title)	
5. Institution (name):		<u> </u>	Business Phone: ()	
ource Patient Inform				
	Day/Yr.)//			
	tient found to have any poten	tially communicable disease(s), suc	ch as hepatitis B, hepatitis C, HIV, TB, m	eningococcal disease, or
0. If yes, specify:				
1. Does the source p	atient have clinical evidence	of AIDS or symptoms of HIV infec	tion or acute retroviral syndrome?[]Yes;	🛛 No; 🛛 Unknown
ource Patient Test I	Results			
2. Rapid HIV test:	<b>Positive</b> ; <b>Negative</b> ;	Indeterminant Test Date	: (Mo./Day/Yr.)//	Not Done
Note: IMMEDIATEI hese are also to be re	Y report Rapid HIV results eleased to the Provider listed	by phone or fax to the Provider I on page 1, q. 17-19.	listed on page 1, q. 17-19. As other tes	t results become available,
3. HBsAg:	<b>Positive</b> ; <b>Negativ</b>	ve Test Date: (Mo/Day	/Yr.)/ ] Not	Done
4. anti-HCV:	[Positive; []Negativ			t Done
5. HIV:	_ , 0		: (Mo/Day/Yr.)/	<b>]</b> Not Done
			Test Date: (Mo./Day/Y	r.)//
			he exposed person's physician/provider	
	sed to Provider: (Mo/Day/Yt	)/ 38. Date mai	iled to OSDH: (Mo./Day/Yr.)/	/
When Part II is com	pleted, mail immediately to	the OSDH HIV/STD Service usin	ng the gray, self-addressed, metered env	/elope.
Part III: OSDH Sec		Densey Completing P		
Date Report Received	1: (Mo./Day/Yr.)/	/ Person Completing Pa	(Last) (First)	
OSDH Division:				
Follow-Up Action:				
	A ·			OSDH Form 2

07 11/03

#### **Communicable Disease Risk Exposure Report**

The filing of this report initiates a system of notification for risk exposures occurring outside of a health care facility to health care workers, emergency responders, and funeral workers as specified by the Oklahoma State Department of Health OAC 310:555. This report and all information entered on it are to be held in strictest confidence in conformance with 63 O.S. Supp. 2001, Section 1-502.1 et. seq.

PART I: Exposed Worker Section (Please Print)

1. Employee Name:(Last)		2. Birth date:/
	(First) (MI)	Mo. Day Yr.
3. Home Telephone: ()	4. Profession/Job Title:	
5. Employer/Company Name:		
6. Work Address/Telephone:(Street)	(City) (Zip)	()
7. Number of hepatitis B vaccinations previously rec	ceived: []None; []1; []2; []3	
8. Date of Exposure: (Mo./Day/Yr.)/	9. Time of Exposure:	AM or PM (Circle One)
10. Supervisor's Name/Telephone:		()
11. Description of Exposure:		
12. Source Patient Name:		
(Last) 13. Location of Source Patient (include name of faci		(M.I.)
(Last) 13. Location of Source Patient (include name of faci	lity, address and phone number):	
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve	lity, address and phone number): of this incident and verify that the appropriate for	llow-up (according to our agency Exposure Control
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure.	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure.	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure. 14	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to 15	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this 16
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure. 14. Name & Title (Print) Post-exposure counseling and follow-up will be provided	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to 15	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this 16 /
(Last) 13. Location of Source Patient (include name of faci  To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure. 14	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to 15 Gignature ded to this employee by: 18. () Provider's Telephone Number	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this 16/ 16/
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure. 14	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to 15 Gignature ded to this employee by: 18. () Provider's Telephone Number Cessional (MD, DO, RN, PA,)	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this 16/ Mo. Day Yr. 19. () Provider's Fax Number
(Last) 13. Location of Source Patient (include name of faci To Be Completed By Employer's Designee I have reviewed the circumstances and management Plan) is being attempted in order to identify or preve exposure. 14	lity, address and phone number): of this incident and verify that the appropriate for nt the transmission of communicable diseases to 15 Gignature ded to this employee by: 18. () Provider's Telephone Number Cessional (MD, DO, RN, PA,)	llow-up (according to our agency Exposure Control which the employee may be at risk as a result of this 16 / Mo. Day Yr 19. () Provider's Fax Number sure that has the potential for transmission of a

Note: If this exposure does not warrant medical follow-up, please return the form to the *Employer's Designee* and indicate to that individual why no follow-up is required.

If this is an exposure that warrants medical follow-up, the employer shall handle the report accordingly:

- A. Yellow copy to be mailed *Immediately* to the OSDH HIV/STD Service (use gray, self-addressed, metered envelope) at 1000 N.E. 10, OKC, Ok 73110
- B. Green copy, a gray metered envelope and instruction page to be delivered *immediately* to the designated person (usually the Infection Control Practitioner) at the location of the source patient.

### ADULT PRE-HOSPITAL

#### TRIAGE AND TRANSPORT GUIDELINES

Oklahoma Model Trauma Triage Algorithm

- Inability To Secure Airway
- Traumatic Arrest

YES

YES

YES

Go Directly to Nearest Appropriate Facility

#### **PRIORITY 1**

#### Physiological Compromise Criteria

- Hemodynamic Compromisel-Systolic BP < 90mmHg Or signs that should be considered include:
  - Sustained tachycardia
  - Cool diaphoretic skin
- \* Respiratory Compromise2- RR < 10 or > 29 breaths/minute
- or < 20 in infant < 1 yr
- Altered Mentation of trauma etiology3- GCS < 14</li>

#### NO V

#### Anatomical Injury

- · Penetrating injury of head, neck, chest/abdomen, or
- extremities proximal to elbow or knee
- Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to regional Burn Center. Burns >10% with significant trauma transport to trauma center.
- · Amputation above wrist or ankle
- · Paralysis or suspected spinal fracture w/neurological deficit

PRIORITY 2

- Flail chest
- Two or more obvious proximal long bone fractures [upper arm or thigh]
- Open or suspected depressed skull fracture
- Unstable pelvis or suspected unstable pelvic fracture
- Tender and/or distended abdomen
- · Crushed, degloved, or mangled extremity

#### NO

#### Initiate Trauma Treatment Protocol Activate Trauma System

**RAPID** transport to the designated Level I, II, or Regional Level III Trauma Center according to the Regional Trauma Plan but may be stabilized at a Level III or IV facility depending on location and time and distance to the higher level trauma center.

Air Rendezvous may be necessary considering time & distance constraints. If conditions do not permit air transport then consider ALS rendezvous. Stabilization may occur either in the field or at the nearest appropriate facility.

Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to regional Burn Center. Burns >10% with significant trauma transport to trauma center.

#### **Risk of Serious Injury - Single System Injury**

Patients with potentially time sensitive injuries due to a high energy event (positive mechanism of injury) or with a less severe single system injury, but currently with no physiological abnormalities or significant anatomical injury

- Ejection of the patient from an enclosed vehicle
   Auto/pedestrian or auto/bike or motorcycle crash
- Auto/pedestrian or auto/pike or motorcycle crash with significant impact (> 20 mph) with the patient thrown or run over by a vehicle
- Falls greater than 20 feet or distance 2-3 times height of patient
- Significant assault or altercations
- High risk auto crash5
- Neurology: Isolated head trauma with transient loss of consciousness or altered mental status but currently alert and oriented.

NO

- Orthopedic: Single proximal and distal extremity fractures (including open) from high energy event, isolated joint dislocations-knee, hip, elbow, shoulder without neurovascular deficits, and unstable joint (ligament) injuries without neurovascular deficits.
- Maxillofacial trauma: Facial lacerations; such as those requiring surgical repair, isolated open facial fractures or isolated orbit trauma with or without entrapments, or avulsed teeth

#### Initiate Trauma Treatment Protocol

#### PROMPT transport

to the designated Level III Trauma Center or higher depending on location according to the Regional Trauma Plan

Consider<sup>6</sup>

PRIORITY 3

- Co-morbid factors
- Gestalt-EMS clinical judgment

NO

TRANSPORT to either the closest Level IV Trauma Center or higher depending on location according to the Regional Trauma Plan or the facility of the patient's choice

YES

YES

PEDIATRIC (≤ 16YEARS) PRE-HOSPITAL

#### TRIAGE AND TRANSPORT GUIDELINES

Oklahoma Model Trauma Triage Algorithm

 Inability To Secure Airway Traumatic Arrest

# YES

YES

YES

Go Directly to Nearest Appropriate Facility

Initiate Trauma Treatment Protocol

RAPID transport to the designated Level I, II, or Regional Level III Trauma

a Level III or IV facility depending on location and time and distance to the

Air Rendezvous may be necessary considering time & distance

constraints. If conditions do not permit air transport consider ALS rendezvous. Stabilization may occur either in the field or at the nearest

Combination of burns > 10% or

significant burns involving face, airway, hands, feet or genitalia

to Hillcrest Burn Center or OUMC

Children's Hospital. Burns >10%

without significant trauma transport

with significant trauma transport to

Center according to the Regional Trauma Plan but may be stabilized at

Activate Trauma System

higher level trauma center.

appropriate facility.

trauma center.

YES

#### PRIORITY 1

#### **Physiological Compromise Criteria**

- Hemodynamic Compromise'-Systolic BP < 90mmHg</li> or other signs such as: - Sustained tachycardia - Cool diaphoretic skin
- Respiratory Compromise<sup>2</sup>- RR < 10 or > 29 breaths/ minute or < 20 in infant < 1 yr
- Altered Mentation of trauma etiology3- GCS < 14

#### Anatomical Injury

- · Penetrating injury of head, neck, chest/abdomen or
- extremities proximate below or knee Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to Hillorest Burn Center or OUMC Children's Hospital. Burns >10% with significant trauma transport to

NO

- trauma center.
- Amputation above wrist or ankle
- Paralysis or suspected spinal fracture w/neurological deficit · Flail chest
- Two or more obvious proximal long bone fractures (upper arm or thigh). Open or suspected depressed skull fracture
- Unstable pelvis or suspected unstable pelvis fracture
- Tender and/or distended abdomen Crushed, degloved, or mangled extremity

Pediatric Trauma Score <5

#### PRIORITY 2

#### **Risk of Serious Injury - Single System Injury**

Patients with potentially time sensitive injuries due to a high energy event (positive mechanism of injury) or with a less severe single system injury, but currently with no physiological abnormalities or significant anatomical injury

NO

- · Election of the patient from an enclosed vehicle
- Auto/pedestrian or auto/bike or motorcycle crash with significant impact (> 20 mph) with the patient thrown or run over by a vehicle
- Falls greater than 10 feet or distance 2-3 times height of patient
- Significant assault or altercations

PRIORITY 3

- · High risk auto crash
- Neurology: Isolated head trauma with transient loss of consciousness or altered mental status but currently alert and oriented.
- · Orthopedic: Single proximal and distal extremity fractures (including open) from high energy event, isolated joint dislocations-knee, hip, elbow, shoulder without neurovascular deficits, and unstable joint (ligament) injuries without neurovascular deficits.
  - Maxillofacial trauma: Facial lacerations: such as those requiring surgical repair, isolated open facial fractures or isolated orbit trauma with or without entrapments, or avulsed teeth

Pediatric Trauma Score 6-8

YES

NO

#### Initiate Trauma Treatment Protocol

#### **PROMPT** transport to the designated Level III Trauma Center or higher depending on location according to the Regional Trauma Plan

Consider<sup>a</sup>

- Co-morbid factors and Gestalt-EMS clinical judgment Pediatric Trauma Score 9-12

NO

TRANSPORT to either the closest Level IV Trauma Center or higher depending on location according to the Regional Trauma Plan or the facility of the patient's choice

#### 19C.2



## 100.3.17 Incident Scene Rehabilitation: (Rehab)

## 100.3.17.1 General:

No member will be permitted to continue emergency operations beyond safe levels of physical or mental endurance. The intent of rehab is to lessen the risk of injury that may result from extended field operations under adverse conditions. Rehab is implemented during hot or cold environmental temperature extremes, but may be used anytime at the direction of the IC.

## 100.3.17.2 Work-to-Rest Ratio:

The basic work-to-rest ratios are listed below. These ratios are considered minimum guidelines and can be adjusted for incident conditions.

Work:	After

- One 30-minute SCBA cylinder
- 20 minutes of intense work without SCBA

Rest: 10 minutes of self-rehabilitation (rest with hydration)

Work: After:

- Two 30-minute SCBA cylinders
- One 45/60-minute SCBA cylinder when encapsulating chemical protective clothing is worn
- 40 Minutes of intense work without SCBA
- Rest: 20 minutes of rest (with hydration) in a rehabilitation area

## 100.3.17.3 Ongoing Hydration: (Water)

Minimum of 2-4 oz. of water for every:

- 20 minutes during any type of firefighting
- 20 minutes during major medical or mass casualty incidents
- 15-30 minutes during Hazmat/special operations

## 100.3.17.4 Long Term Incident Hydration: (Diluted Sports Drink)

When the on-scene time exceeds two hours, members will be provided with sports drink diluted to half strength with water in place of water at the intervals indicated above.



# Section 100 - Incident Command/Management

## 100.3.17.5 Rehab Levels and Functions:

# 100.3.17.5.1 Self-Rehabilitation (Company/Crew Level Rehabilitation):

Self-rehabilitation occurs after short duration incidents and/or between trips to the Rehab Area. Company officers should ensure that fluids are available on their apparatus so that members can replace fluids (while changing SCBA cylinders, taking short breaks, etc.).

## 100.3.17.5.2 Formal Rehab (Rehab Group):

The Rehab group will be used to evaluate and assist personnel who could be suffering from the effects of sustained physical or mental exertion during emergency operations.

The rehab group provides a specific area where personnel will assemble to receive:

- A physical assessment
- Rest, hydration, and refreshments
- Medical evaluation and treatment of minor injuries
- Continual monitoring of physical condition
- Transportation for those requiring treatment at medical facilities
- Initial stress support assessment
- Reassignment

## 100.3.17.5.2.1 Rehab Group Resources and Capabilities:

When the IC implements the Rehab Group, the group supervisor should utilize any of the following resources that he/she deems appropriate:

- EMSA
- TFD Apparatus with Rehab Equipment
  - "? Air & Light Units
  - "? Hazmat
  - "? TFD Bus
- TFD Training Staff: The TFD Training Center maintains a cache of towels, buckets, and sports drink for Rehab. Additionally, the staff can bring the TFD Bus.
- TFD EMS Staff
- TFD ALS Capabilities
- TFD Fitness Staff
- MTTA Bus
- Any other resource necessary



# Section 100 - Incident Command/Management

The IC has the discretion to assign an appropriate person to the position of Rehab Group Supervisor. When assigning this position, the IC should consider the following personnel:

- TFD EMS Officer
- TFD Training Officer
- TFD Exercise Physiologist
- TFD Chief Officer or Company Officer
- EMSA Supervisor

## 100.3.17.5.2.2 Check-In Point:

This is the initial entry point. Rehab staff will take a pulse rate on all crew members.

- Any member who has a pulse rate greater than 120 will report directly to medical rehab. These members will be treated by advanced life support personnel in accordance with EMS protocols.
- All other members will report to the hydration and replenishment area.

## 100.3.17.5.2.3 Hydration and Replenishment Area:

During warm weather conditions, all personnel will remove coats, helmets, gloves, and protective hoods. Turnout pants should be removed or at least rolled down over the boots. Fluid and electrolyte replacement will be provided.

The following requirements pertain to the physical area used for Rehab:

- A key concept to abide by when establishing a Rehab Area is to set it up as close as safely possible to where firefighters are working.
- During hot temperature extremes, avoid placing personnel directly in an air conditioned environment. Provide a shaded area with air movement. Air and Light Units and Hazmat have canopies, fans and misters for this purpose. Hazmat also has tent capabilities. Rehab supervisors may also be able to secure areas that are close to the incident.



# Section 100 - Incident Command/Management

The following other requirements pertain to personnel assigned to the hydration and replenishment area:

- All personnel should spend a minimum of 20 minutes resting in this area.
- Personnel should consume a minimum of 10 ounces of water or other approved beverages while in this area.
- Personnel should place their arms into cool (not cold) water as they are resting (See Rehab Group Resources).
- Smoking is not permitted in this area.

## 100.3.17.5.2.4 Medical Rehab and Transport Area:

This Section is staffed by an ALS crew and at least one EMS transport vehicle. Personnel reporting here will receive evaluation and treatment per EMS protocols. The ALS crew in this area will pay close attention to the following:

- Pulse
- Pulse-ox
- Respiratory rate
- Blood pressure
- Body temperature
- Obvious injuries or illness

Any firefighters who receive IV fluids are considered to be in medical rehab and fall under EMS protocols. Additionally, those receiving IV fluids will be taken to the appropriate medical facility to obtain laboratory blood testing to ensure appropriate levels of hydration, electrolytes, and renal function.

## 100.3.17.5.2.5 Reassignment Area:

After the prescribed rehabilitation (minimum of 20 minutes for an initial cool down and evaluation period) members will be re-evaluated. Upon evaluation, the members will be triaged into one of the following groups:

- Return to duty adequately rehabbed and medically sound.
- Remove from duty evidence of an illness or injury; including any person with a pulse rate greater than 100.
- Transported to an appropriate medical facility for further evaluation and treatment of illness or injury; including any member who has a temperature greater than 101 °F (38 °C) or a blood pressure less than 100 (systolic).

Members who are transported to a medical facility should be accompanied by a department representative.



# Section 100 - Incident Command/Management

Crews authorized to return to duty will be released as intact crews and report to the Reassignment Area.

The rehab group supervisor will update the IC throughout the operation with pertinent information including the identities of companies in Rehab, the companies available for reassignment, and the status of injured personnel.

Company officers must keep crews intact and report to the proper sections in Rehab. The rehab group supervisor will direct the crew to the proper areas; however, it is the company officer's responsibility to make sure crew members receive refreshments, rest, and a medical clearance.



Section 100 - Incident Command/Management

# **REHABILITATION** ARM & HAND IMMERSION IN TAP WATER

A simple, safe and controlled method to reduce heat stress is hand and arm immersion into containers of standard tap water. Buckets for this procedure will be stored on Engines and specialized apparatus or staff positions.



#### STEP 1

<u>Remove the helmet, bunker coat, hood, pants and boots</u> when checked into Rehabilitation. The helmet, coat and hood tend to be naturally removed. Direction usually needs to be given to remove the pants and boots. <u>The removal of all gear</u> <u>is essential to obtain the desired cooling</u>.

<u>Filltwobucketswithtapwater</u> obtained from a garden hose, hose line from fire apparatus or connection to a fire hydrant. NOTE: If water is acquired through a fire pump, make certain that it has not been heated from the churn action of the fire pump.



DO NOT ADD ICE TO THE BUCKETS.



## STEP 2

Seat the person onto a bench type surface such as the tailboard of the apparatus or curb of the street. <u>Positionthebucketsoneithersideofthepersonatthesameelevationattheobjectusedasaseat</u>. Instruct the person to place both hands and arms into the water with the hands touching the bottom of the bucket. Ideally, the person should spread his/her fingers apart to maximize the exchange of heat.



## STEP 3

<u>The immersion process should be conducted forten</u> to twenty minutes. A similar process may be conducted with the feet for additional control of severe cases.

<u>Continuouslymonitorthemedicalconditionoftheperson</u> and frequently record vital signs. Provide medical care as needed.

<u>Also provide cool water or partial strength sports drinks</u>. Do <u>not</u> <u>provide hotor cold beverages</u> and avoid all fluids that contain caffeine.

## O/EMS-203 INCIDENT REHABILITATION

#### UPDATED 7/31/2019

No employee will operate at an emergency or non-emergency scene beyond a safe level of physical and mental endurance. These guidelines apply to all appropriate emergency incidents and training exercises where physical activity or exposure to extreme environmental conditions exists. Rehabilitation (Rehab) will be utilized to evaluate and assist personnel to avoid sustained physical exertion that can result in acute health detriments as well as to evaluate and assist personnel who may already be suffering from the effects of sustained physical exertion during emergency operations. Rehab will provide a specific area where personnel will assemble to receive:

- ✓ a physical assessment
- ✓ revitalization rest, refreshments, etc.
- treatment for physical and/or mental stress as well as physically induced injuries and/or illnesses
- ✓ close monitoring of physical condition
- ✓ transportation for those requiring treatment at medical facilities

#### RESPONSIBILITIES

The Incident Commander (IC) will consider the circumstances of each Incident and make necessary arrangements early in the Incident for rehabilitation of all personnel operating at the scene.

All Company Officers will maintain an awareness of the condition of each Fire Crew (Crew) member operating within their span of control.

It is the responsibility of each firefighter to advise their Company Officer when they believe that their level of fatigue or exposure to heat or cold is approaching a level that could affect themselves or their Crew in the operation in which they are involved.

#### **ESTABLISHMENT OF REHAB**

#### Responsibility

The Incident Commander will establish Rehab when conditions indicate it will be needed at an Incident or training evolution scene and will assign a Rehab Supervisor who reports to the Logistics Section Chief (if filled).

#### Location

The location for Rehab will normally be designated by the Incident Commander. If a specific location has not been designated, the Rehab Supervisor will select an appropriate location for the Rehab Area.

## **Rehab Area Site Characteristics**

- 1. The entry/exit will be marked with two traffic cones to indicate where all personnel will enter and exit Rehab Area.
- 2. Rehab Area should be far enough away from the scene that members may safely remove their Structural PPE and SCBA.
- 3. The Rehab Area should enable members to be free of exhaust fumes from fire apparatus, vehicles, or equipment
- 4. It should provide protection from the prevailing environmental conditions.
- 5. Misting and cooling equipment should be made available if heat stress could result from the incident operations and/or prevailing environmental conditions.
- 6. It should be large enough to accommodate multiple Crews.
- 7. It should be easily accessible to EMS personnel and Incident support agencies.
- 8. It should allow easy reentry into the emergency operation.
- 9. Rehab Area should be divided into four areas:
  - Rest Area (for immediate Rehab)
  - Ready Area (for rehabbed firefighters cleared by Rehab Supervisor)
  - Medical Evaluation Area
  - Medical Treatment Area

The staffing of Rehab Area will be determined by the Incident Commander taking into consideration the size and duration of the Incident/evolution.

## Staffing

Residential/Commercial Response: Rehab Area will be staffed using the initial responding Fire Companies unless in the judgment of the Incident Commander more resources are needed to adequately staff it.

Multiple Alarm: Rehab Area will be staffed by initial responding resources until such time as the additional Alarm support personnel arrive on the scene. The additional Alarm support personnel will report to the Incident Commander and could be assigned Rehab duties, if necessary, for existing personnel to be relieved.

## **REHAB GUIDELINES**

#### Establishment

Rehab should be considered by the Incident Commander during the size-up phase of an Incident. Climatic and environmental conditions for the Incident scene should not be the sole justification for establishing the location of Rehab Area. Any training or Incident activity which is large in size, long in duration, and/or labor intensive, will rapidly deplete the energy and strength of personnel and therefore merits consideration for establishing Rehab. When established, the Rehab Medical Evaluation Form will be used to document personnel in the Rehab Area (on FDWEB Forms).

### Accountability

All Crew members reporting to Rehab Area will check in with the Rehab Supervisor at the entry/exit point. Personnel leaving Rehab Area must check out through the Rehab Supervisor. Personnel assigned to Rehab Area must remain in Rehab for at least 10 minutes. During this time, the firefighter will be medically evaluated and be provided hydration. No firefighter should be reassigned to return to duty until cleared by the Rehab Supervisor.

The Rehab Supervisor will update the Incident Commander (or Logistics Section Chief, if filled) throughout the operation with pertinent information including: the Fire Companies in Rehab, the Fire Companies available for reassignment, and the status of any injured or ill personnel.

### Resources

The Rehab Supervisor will secure all necessary resources to adequately staff and supply the Rehab Area. The supplies should include the following items but should be adjusted as necessary for the Incident.

- 1. Hydration: water, activity beverage and ice
- 2. Nourishment: Red Cross can be used as a resource for food and nourishing drinks
- 3. Medical: at least one trauma kit, oxygen administration equipment, defibrillator with CO monitoring capability, and other equipment as needed
- 4. Other (as deemed by the Incident): fans, tarps, heaters, floodlights, blankets, and traffic cones (to mark the entry/exit of Rehab Area)

#### Hydration

A critical factor in the prevention of heat injury is the maintenance of water and electrolytes. Water must be replaced during exercise periods and at emergency incidents. Employees will rehydrate (at least eight ounces) while SCBA cylinders are being refilled. During heat stress, each employee should consume at least one quart (32 oz.) of water per hour. The rehydration fluid, if possible, should be an activity beverage administered cool. Rehydration is important even during cold weather operations where heat stress may occur during firefighting or other strenuous activity when Structural PPE is worn. Carbonated and caffeinated drinks should be avoided before and during emergency operations, because both interfere with the body's water conservation mechanisms.

## Nourishment

Food and nourishing drinks may be provided by the American Red Cross (or suitable alternative) at the scene of extended Incidents when units are engaged for three or more hours.

### Rest

Rest should not be less than ten minutes and may exceed an hour as determined by the Rehab Supervisor. Fire Companies released from the Rest Area of Rehab, will move to the Ready Area of Rehab to ensure that fatigued employees are not required to return to duty before they are rested, evaluated, and released by the Rehab Supervisor.

\*The Company Officer should additionally ensure that all personnel in the Fire Company appear fit to return to duty.

### MEDICAL TREATMENT AREA

All treatment should follow approved protocols. There is clear delineation between Medical Evaluation and Medical Treatment in Rehab. Documentation is to be kept separately. Although the same providers may do both, it makes logistical and operational sense to separate them into functional areas if possible.

If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Incident Commander for possible transport to the hospital.

## Measure the SpCO% with RAD-57 or LifePak 15

Figure 16 SpCO% > 3% with any of below signs or symptoms, treat per MCB protocol III.44 Monitoring of CO Poisoning.


#### **CO Poisoning Symptoms**

Flu-like symptoms	Abdominal pain
Fatigue	Headache
Dyspnea	Drowsiness
Chest pain	Dizziness
Palpitations	Weakness
Lethargy	Confusion
Confusion	Visual disturbances
Depression	Syncope
Impulsiveness	Seizures
Distractibility	Fecal incontinence
Hallucination	Urinary incontinence
Confabulation	Memory disturbances
Agitation	Gait disturbances
Nausea	Bizarre neurologic symptoms
Vomiting	Coma
Diarrhea	

#### **Firefighter Headaches**

While CO should always be considered a possible cause of headaches in working firefighters, there are more common causes which includes:

- > Tight helmet ratchet
- > Too heavy a helmet (especially leather)
- > Dehydration



#### MEDICAL TREATMENT AREA

All treatment should follow MCB approved protocols. There is clear delineation between medical monitoring and emergency medical treatment in rehab. Documentation is to be kept separately. Although the same providers may do both, it makes logistical and operational sense to separate them into functional areas if possible.

If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Medical Officer for possible transport to the hospital.

	Attachn	nent	4 - (	COM	PAN	Y C	HE	СК	IN /	CH	IEC	KO	UT	SH	EET	Г ( <b>F</b> I	RON	T S	IDF	E)			
	Transport Destination		-	-															-•				
	Transport Y/N																				I		
	Medical Complaints																						
	Cooling/ Heating Y/N																				Incident Number:	of	
ur at	Temp																				ncident	Page	
artmei ance Fo	CO Level							-				-									-		
ire Deg Surveill	Pulse Ox																						
na City F ledical S	Resp.																						
Oklahoma City Fire Department Incident Medical Surveillance Form	Heart Rate			_				_				-		_									
-	ВР																						
Jage	Time Vitals Taken																					Rehab Medic:_	
erse of this p	# SCBA Bottles Used																					Reha	
m are on rev	Time in / Time Out																						
for this for	# Times in Rehab																				S:		
***Instructions for this form are on reverse of this page	Name and Company			_																	Incident Address:	Date:	
-																					-7		
	Transport Destination														-								

#### Attachment A - COMPANY CHECK IN / CHECK OUT SHEET (BACK SIDE)

- Enter name of medic in rehab at bottom of form
- Enter the name and company of each person entering rehab
- Each time personnel enter rehab, re-enter them on the form. Be sure to record the number of times the person is rehabilatated
- Once in the medical evaluation area, heart rate should be measured for 30 seconds as early as possible in the rest period
- If employee's heart rate exceeds 110 beats per minute, an oral temperature should be taken
- If temperature exceeds 100.6°, no PPE should be worn
- If temperature is below 100.6° and heart rate remains above 110 beats per minute, rehab time should be increased
- Vitals should be taken every 5-10 minutes
- If employees SpCO level is >3% with any of the below signs or symptoms, treat per MCB protocol III.44 Monitoring of CO Poisoning

	Signs of CO Poisi	oning	Heat Str	ess Symptoms	Cold Stress Symptoms				
Flu like symptoms	Fatigue	Dyspnea	nausea	shortness of breath	headache	low or absent blood pressure			
Chest Pain	Palpitations	Lethargy	flushed skin	weakness	mental confusion	slow pupil response			
Confusion	Depression	Impulsiveness	cramping	exhaustion	numbness	muscle rigidity or stiff posture			
Abd pain	Headache	Drowsiness	headache mental	seizures	waxy/pale skin	blistered skin			
Weakness	Confusion	Visual Disturbances	confusion	sunburn	dehydration				
Syncope Agitation	Seizures Nausea	Hallucination Vomiting	rapid heartbeat	absence of sweating					
Diarrhea	Incontinence	Memory disturbances							
Gait disturbances	Neurologic symptoms	Coma							

#### Work-to-Rest Ratio

	At least 10 minutes of self-rehabilitation (rest with hydration ) as a company or
Up to one 30 minute SCBA cylinder	crew
	At least 10 minutes of self-rehabilitation (rest with hydration ) as a company or
20 min of intense work without SCBA	crew


(When encapsulating chemical protective clothing is	worn)
Up to two 30-minute SCBA cylinders	At least 20 minutes of rest (with hydration) in rehabilitation area
One 45-minute SCBA cylinder	At least 20 minutes of rest (with hydration) in rehabilitation area
One 60-minute SCBA cylinder	At least 20 minutes of rest (with hydration) in rehabilitation area
40 minutes of of work without SCBA	At least 20 minutes of rest (with hydration) in rehabilitation area

# If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Medical Officer for possible transport to the hospital

Office of the Medical Director – EMS System for Metropolitan Oklahoma City & Tulsa Approved by: Jeffrey M. Goodloe, MD, NREMT-P, FACEP, Medical Director Effective: 1/16/2023; CQI data collection procedure



#### TRANSMITTING CARDIAC ARREST MONITOR DATA ADULT & PEDIATRIC



Indications:

1. Cardiac Arrest, regardless of etiology.

Contraindications:

None

Technique (LifePak® 15):

To transmit the cardiac arrest data for resuscitation CQI:

- In the **OPTIONS** window select Patient, scroll down to Incident and place the last five digits of the RUN number of the cardiac arrest into the **OPTIONS/PATIENT/INCIDENT** window. (Figure 1)
- In the TRANSMIT window, Report selection MUST be "All" when transmitting data from the LifePak to CodeSTAT or your Electronic Health Care Record. Any other selection will not transmit a complete data PCO file for analytics. (Figure 2)
- 3. In the TRANSMIT window, select SITE. (Figure 3)
- 4. In the SITE window, select CODE STAT. (Figure 4)
- 5. In the **TRANSMIT** window, select **SEND**. (Figure 5)
- 6. The LifePak<sup>®</sup>15 should connect to the selected destination.
- 7. Once the transmission is completed a transaction message is automatically printed.
- 8. If the transmission fails, make additional attempts at transmission until successful. If unsuccessful, contact the Clinical Officer of the Day or Supervisor.









